The consensus molecular subtypes of colorectal cancer

Citation Report

#	Article	IF	Citations
2	An integrated gene expression analysis approach. , 2015, , .		1
3	Integrating tumor microenvironment with cancer molecular classifications. Genome Medicine, 2015, 7, 115.	3.6	2
4	Integrating Colon Cancer Microarray Data: Associating Locus-Specific Methylation Groups to Gene Expression-Based Classifications. Microarrays (Basel, Switzerland), 2015, 4, 630-646.	1.4	3
5	BCL9/9L-Î²-catenin Signaling is Associated With Poor Outcome in Colorectal Cancer. EBioMedicine, 2015, 2, 1932-1943.	2.7	58
7	The Prognostic Yield of Biomarkers Harvested in Chemotherapy-Naive stage II Colon Cancer: Can We Separate the Wheat from the Chaff?. Molecular Medicine, 2016, 22, 271-273.	1.9	3
8	Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening. ELife, 2016, 5, .	2.8	191
9	Prediction of biological behavior and prognosis of colorectal cancer patients by tumor MSI/MMR in the Chinese population. OncoTargets and Therapy, 2016, Volume 9, 7415-7424.	1.0	28
10	Immunological Landscape and Clinical Management of Rectal Cancer. Frontiers in Immunology, 2016, 7, 61.	2.2	14
11	The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. Frontiers in Immunology, 2016, 7, 621.	2.2	132
12	Cytokine-Induced Modulation of Colorectal Cancer. Frontiers in Oncology, 2016, 6, 96.	1.3	181
13	Colorectal Choriocarcinoma in a Patient with Probable Lynch Syndrome. Frontiers in Oncology, 2016, 6, 252.	1.3	5
14	Clinicopathologic and Molecular Features of Colorectal Adenocarcinoma with Signet-Ring Cell Component. PLoS ONE, 2016, 11, e0156659.	1.1	25
15	Wnt disruption in colorectal polyps - the traditional serrated adenoma enters the fray. Journal of Pathology, 2016, 239, 387-390.	2.1	7
16	DNA methylation based biomarkers in colorectal cancer: A systematic review. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1866, 106-120.	3.3	84
17	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 2016, 27, 1386-1422.	0.6	2,545
18	TGFÎ² signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype. EMBO Molecular Medicine, 2016, 8, 745-760.	3.3	119
19	H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-Î²-Catenin Signaling in Colorectal Cancer. EBioMedicine, 2016, 13, 113-124.	2.7	106
20	Management ofBRAF-mutant metastatic colorectal cancer. Colorectal Cancer, 2016, 5, 131-133.	0.8	2

#	Article	IF	Citations
21	Silencing speckle-type POZ protein by promoter hypermethylation decreases cell apoptosis through upregulating Hedgehog signaling pathway in colorectal cancer. Cell Death and Disease, 2016, 7, e2569-e2569.	2.7	40
22	A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC. Nature Communications, 2016, 7, 11743.	5.8	170
23	Pan-cancer subtyping in a 2D-map shows substructures that are driven by specific combinations of molecular characteristics. Scientific Reports, 2016, 6, 24949.	1.6	21
24	Targeting the Microenvironment in Advanced Colorectal Cancer. Trends in Cancer, 2016, 2, 495-504.	3.8	80
25	OncoScape: Exploring the cancer aberration landscape by genomic data fusion. Scientific Reports, 2016, 6, 28103.	1.6	10
26	Spectrum of Gene Mutations in Colorectal Cancer. Cancer Journal (Sudbury, Mass), 2016, 22, 149-155.	1.0	22
27	Biomarker in Colorectal Cancer. Cancer Journal (Sudbury, Mass), 2016, 22, 156-164.	1.0	35
28	Differential Radiographic Appearance ofBRAFV600Eâ€"Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1536-1543.	2.3	17
29	Immunotherapy Progress in Mismatch Repairâ€"Deficient Colorectal Cancer and Future Therapeutic Challenges. Cancer Journal (Sudbury, Mass), 2016, 22, 190-195.	1.0	20
31	Improving definition of the term â€œsynchronous liver metastasesâ€•from colorectal cancer. Hepatobiliary and Pancreatic Diseases International, 2016, 15, 458-460.	0.6	6
32	Favorable prognosis in colorectal cancer patients with co-expression of c-MYC and ÃŸ-catenin. BMC Cancer, 2016, 16, 730.	1.1	42
33	Gene Signature in Sessile Serrated Polyps Identifies Colon Cancer Subtype. Cancer Prevention Research, 2016, 9, 456-465.	0.7	40
34	HIC1 Expression Distinguishes Intestinal Carcinomas Sensitive to Chemotherapy. Translational Oncology, 2016, 9, 99-107.	1.7	7
35	A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during Tumorigenesis. Cell Stem Cell, 2016, 18, 827-838.	5.2	593
36	Colorectal cancer: how to teach an old drug new tricks. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 384-385.	8.2	1
37	Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications. Expert Review of Clinical Pharmacology, 2016, 9, 1091-1108.	1.3	9
38	Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer. Clinical Cancer Research, 2016, 22, 4095-4104.	3.2	135
39	A multidimensional network approach reveals microRNAs as determinants of the mesenchymal colorectal cancer subtype. Oncogene, 2016, 35, 6026-6037.	2.6	49

#	Article	IF	Citations
40	Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer. Current Colorectal Cancer Reports, 2016, 12, 141-150.	1.0	40
41	Chances, risks and limitations of neoadjuvant therapy in surgical oncology. Innovative Surgical Sciences, 2016, 1, 3-11.	0.4	6
42	Major milestones in translational oncology. BMC Medicine, 2016, 14, 110.	2.3	15
43	Colorectal Cancer Subtypes: Developmental Origin and Microenvironmental Regulation. Trends in Cancer, 2016, 2, 505-518.	3.8	51
44	Multi-omics landscapes of colorectal cancer subtypes discriminated by an individualized prognostic signature for 5-fluorouracil-based chemotherapy. Oncogenesis, 2016, 5, e242-e242.	2.1	17
46	PTEN mRNA expression is less pronounced in left- than right-sided colon cancer: a retrospective observational study. BMC Cancer, 2016, 16, 366.	1.1	18
47	Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. The Lancet Gastroenterology and Hepatology, 2016, 1, 207-216.	3.7	227
48	Drug repurposing for glioblastoma based on molecular subtypes. Journal of Biomedical Informatics, 2016, 64, 131-138.	2.5	29
49	mRNA expression profiles of colorectal liver metastases as a novel biomarker for early recurrence after partial hepatectomy. Molecular Oncology, 2016, 10, 1542-1550.	2.1	9
50	A new simple morphology–based risk score is prognostic in stage I/II colon cancers. Cancer Medicine, 2016, 5, 1492-1501.	1.3	3
51	Clinical Implications and Future Perspectives of Circulating Tumor Cells and Biomarkers in Clinical Outcomes of Colorectal Cancer. Translational Oncology, 2016, 9, 340-347.	1.7	32
52	Higher Order Chromatin Modulator Cohesin SA1 Is an Early Biomarker for Colon Carcinogenesis: Race-Specific Implications. Cancer Prevention Research, 2016, 9, 844-854.	0.7	11
53	Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer. Expert Opinion on Emerging Drugs, 2016, 21, 267-282.	1.0	7
55	Olfactomedin 1 negatively regulates <scp>NF–κB</scp> signalling and suppresses the growth and metastasis of colorectal cancer cells. Journal of Pathology, 2016, 240, 352-365.	2.1	31
56	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With _RAS_ and _BRAF_ Wild-Type Metastatic Colorectal Cancer. Oncologist, 2016, 21, 988-994.	1.9	94
57	Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer. Gastroenterology, 2016, 151, 961-972.	0.6	41
58	Molecular Pathology: A Requirement for Precision Medicine in Cancer. Oncology Research and Treatment, 2016, 39, 804-810.	0.8	24
59	Targeted Treatment of Esophagogastric Cancer. Oncology Research and Treatment, 2016, 39, 788-794.	0.8	2

#	Article	IF	Citations
60	Long-Term Culture of Intestinal Cell Progenitors: An Overview of Their Development, Application, and Associated Technologies. Current Pathobiology Reports, 2016, 4, 209-219.	1.6	3
61	Molecular or Metabolic Reprograming: What Triggers Tumor Subtypes?. Cancer Research, 2016, 76, 5195-5200.	0.4	41
62	Differential protein abundance of a basolateral MCT1 transporter in the human gastrointestinal tract. Cell Biology International, 2016, 40, 1303-1312.	1.4	11
63	A potential role for CCN2/CTGF in aggressive colorectal cancer. Journal of Cell Communication and Signaling, 2016, 10, 223-227.	1.8	27
65	A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets. Cancer Letters, 2016, 382, 203-214.	3.2	99
66	The Iron y of Tumor-Induced Inflammation. Cell Metabolism, 2016, 24, 368-369.	7.2	3
67	Assessment of clinically related outcomes and biomarker analysis for translational integration in colorectal cancer (ACROBATICC): study protocol for a population-based, consecutive cohort of surgically treated colorectal cancers and resected colorectal liver metastasis. Journal of Translational Medicine, 2016, 14, 192.	1.8	15
68	LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer. Acta OncolÃ³gica, 2016, 55, 1425-1433.	0.8	8
71	Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence. British Journal of Cancer, 2016, 115, 1565-1574.	2.9	34
72	Colon cancer subtypes: concordance, effect on survival and selection of the most representative preclinical models. Scientific Reports, 2016, 6, 37169.	1.6	23
73	Molecular Classification of Colon Cancer: Perspectives for Personalized Adjuvant Therapy. Current Colorectal Cancer Reports, 2016, 12, 296-302.	1.0	1
74	The mPower study, Parkinson disease mobile data collected using ResearchKit. Scientific Data, 2016, 3, 160011.	2.4	439
75	Big Dataâ€"Led Cancer Research, Application, and Insights. Cancer Research, 2016, 76, 6167-6170.	0.4	7
76	Molecular Triage Trials in Colorectal Cancer. Cancer Journal (Sudbury, Mass), 2016, 22, 218-222.	1.0	0
77	Adjuvant Therapy for Colon Cancer. JAMA Oncology, 2016, 2, 1133.	3.4	8
78	Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes. JAMA Oncology, 2016, 2, 1162.	3.4	140
79	Embracing an integromic approach to tissue biomarker research in cancer: Perspectives and lessons learned. Briefings in Bioinformatics, 2017, 18, bbw044.	3.2	9
80	Optimizing adjuvant therapy and survivorship care of stage III colon cancer. Future Oncology, 2016, 12, 2021-2035.	1.1	12

#	Article	IF	Citations
81	Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer. Current Treatment Options in Oncology, 2016, 17, 41.	1.3	33
82	Molecular pathological classification of colorectal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 125-134.	1.4	276
83	Tumor Microenvironment in Gene Signatures: Critical Biology or Confounding Noise?. Clinical Cancer Research, 2016, 22, 3989-3991.	3.2	12
84	The clinical utility of molecular genetic cancer profiling. Expert Review of Molecular Diagnostics, 2016, 16, 827-838.	1.5	6
85	Gut macrophage phenotype is dependent on the tumor microenvironment in colorectal cancer. Clinical and Translational Immunology, 2016, 5, e76.	1.7	34
86	Phase 2 Trial of Metformin Combined With 5-Fluorouracil in Patients With Refractory Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2016, 15, 321-328.e1.	1.0	59
87	Promoter methylation of ITF2, but not APC, is associated with microsatellite instability in two populations of colorectal cancer patients. BMC Cancer, 2016, 16, 113.	1.1	7
88	Stromal VCAN expression as a potential prognostic biomarker for disease recurrence in stage II–III colon cancer. Carcinogenesis, 2016, 37, 878-887.	1.3	43
89	SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing <i>MGMT</i>-Methylated Colorectal Cancer. Clinical Cancer Research, 2016, 22, 6266-6277.	3.2	22
90	Algorithmic methods to infer the evolutionary trajectories in cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E4025-34.	3.3	80
91	Targeting the serrated pathway of colorectal cancer with mutation in BRAF. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1866, 51-63.	3.3	8
92	Molecular Taxonomy and Tumourigenesis of Colorectal Cancer. Clinical Oncology, 2016, 28, 73-82.	0.6	5
93	The development of new agents and molecular classifications. Nature Reviews Clinical Oncology, 2016, 13, 69-70.	12.5	21
94	Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. Clinical Cancer Research, 2016, 22, 4057-4066.	3.2	433
95	Collagen-rich stroma in aggressive colon tumors induces mesenchymal gene expression and tumor cell invasion. Oncogene, 2016, 35, 5263-5271.	2.6	87
96	Acute Respiratory Distress: From syndrome to disease. Medicina Intensiva (English Edition), 2016, 40, 169-175.	0.1	11
97	Distrés respiratorio agudo: del síndrome a la enfermedad. Medicina Intensiva, 2016, 40, 169-175.	0.4	31
98	High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine. Familial Cancer, 2016, 15, 405-412.	0.9	105

#	Article	IF	Citations
99	Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. Clinical Gastroenterology and Hepatology, 2016, 14, 651-658.	2.4	99
100	DNA-Guided Precision Medicine for Cancer: A Case of Irrational Exuberance?. Cancer Discovery, 2016, 6, 130-132.	7.7	44
101	Molecular classification of gastric cancer. Annals of Oncology, 2016, 27, 763-769.	0.6	215
102	Are Gene Signatures Ready for Use in the Selection of Patients for Adjuvant Treatment?. Current Colorectal Cancer Reports, 2016, 12, 18-26.	1.0	1
103	Understanding Epigenetics: an Alternative Mechanism of Colorectal Carcinogenesis. Current Colorectal Cancer Reports, 2016, 12, 113-122.	1.0	7
104	MicroRNA *MIR21* (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival. Clinical Cancer Research, 2016, 22, 3841-3848.	3.2	53
105	*BRAF*â€ˆ*V600E* Mutant Colorectal Cancer Subtypes Based on Gene Expression. Clinical Cancer Research, 2017, 23, 104-115.	3.2	167
106	Bringing 3D tumor models to the clinic â€" predictive value for personalized medicine. Biotechnology Journal, 2017, 12, 1600295.	1.8	35
107	Endometrial Cancer Risk Factors, Hormone Receptors, and Mortality Prediction. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 727-735.	1.1	42
109	Immunotherapy and patients treated for cancer with microsatellite instability. Bulletin Du Cancer, 2017, 104, 42-51.	0.6	64
110	Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. Critical Reviews in Oncology/Hematology, 2017, 110, 106-116.	2.0	33
111	Near future of tumor immunology: Anticipating resistance mechanisms to immunotherapies, a big challenge for clinical trials. Human Vaccines and Immunotherapeutics, 2017, 13, 1109-1111.	1.4	7
112	Translating genomic profiling to gastrointestinal cancer treatment. Future Oncology, 2017, 13, 919-934.	1.1	7
113	Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis. Clinical Colorectal Cancer, 2017, 16, e153-e163.	1.0	110
114	Determinants of metastatic competency in colorectal cancer. Molecular Oncology, 2017, 11, 97-119.	2.1	180
115	First-line therapy for mCRC â€" the influence of primary tumour location on the therapeutic algorithm. Nature Reviews Clinical Oncology, 2017, 14, 113-113.	12.5	35
116	Translational research in surgical oncology. British Journal of Surgery, 2017, 104, 491-492.	0.1	4
117	DNA profiling of tumor buds in colorectal cancer indicates that they have the same mutation profile as the tumor from which they derive. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 341-346.	1.4	14

#	Article	IF	Citations
118	Identification of miRNA-mRNA Modules in Colorectal Cancer Using Rough Hypercuboid Based Supervised Clustering. Scientific Reports, 2017, 7, 42809.	1.6	13
119	In reply to 'Hynes <i>etÂal</i>. Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage <scp>II</scp>/<scp>III</scp> colon cancer in a large populationâ€based studyâ€™. Histopathology, 2017, 71, 326-327.	1.6	2
120	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. , 2017, 174, 145-172.		22
121	Targeting TGF-Î² Signaling in Cancer. Trends in Cancer, 2017, 3, 56-71.	3.8	697
122	Liquid Biopsies in Colorectal Cancer: Monitoring Genetic Heterogeneity. Trends in Cancer, 2017, 3, 166-168.	3.8	6
123	Molecular Stratification of Colorectal Cancer: Moving from the Laboratory to Clinical Practice. Current Colorectal Cancer Reports, 2017, 13, 81-90.	1.0	0
124	Tumor-Initiating Cells: a criTICal review of isolation approaches and new challenges in targeting strategies. Molecular Cancer, 2017, 16, 40.	7.9	64
125	BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?. Current Treatment Options in Oncology, 2017, 18, 9.	1.3	51
126	Gastric Cancer Genomics: Advances and FutureÂDirections. Cellular and Molecular Gastroenterology and Hepatology, 2017, 3, 211-217.	2.3	60
127	Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. European Journal of Cancer, 2017, 76, 68-75.	1.3	65
128	Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naÃ¯ve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic ColorectalÂCancer. Clinical Colorectal Cancer, 2017, 16, 158-163.	1.0	13
129	Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage <scp>II</scp>/<scp>III</scp> colon cancer in a large populationâ€based study. Histopathology, 2017, 71, 12-26.	1.6	48
130	The loss-of-function mutations and down-regulated expression of ASB3 gene promote the growth and metastasis of colorectal cancer cells. Chinese Journal of Cancer, 2017, 36, 11.	4.9	23
131	BCL-2 system analysis identifies high-risk colorectal cancer patients. Gut, 2017, 66, 2141-2148.	6.1	40
132	Colorectal cancer cells use the negative feedback regulators of WNT signalling to activate epithelialâ€"mesenchymal transition pathways. Gut, 2017, 66, 563-564.	6.1	15
133	MicroRNAs in the etiology of colorectal cancer: pathways and clinical implications. DMM Disease Models and Mechanisms, 2017, 10, 197-214.	1.2	113
134	Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies. Current Oncology Reports, 2017, 19, 19.	1.8	98
135	Multicenter fresh frozen tissue sampling in colorectal cancer: does the quality meet the standards for state of the art biomarker research?. Cell and Tissue Banking, 2017, 18, 425-431.	0.5	13

#	Article	IF	Citations
136	Hypermutated Colorectal Cancer and Neoantigen Load. , 2017, , 187-215.		3
137	QMC-PCRx: a novel method for rapid mutation detection. Journal of Clinical Pathology, 2017, 70, 702-711.	1.0	2
138	Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nature Communications, 2017, 8, 14262.	5.8	260
139	Embryonic origin of primary colon cancer predicts survival in patients undergoing ablation for colorectal liver metastases. European Journal of Surgical Oncology, 2017, 43, 1040-1049.	0.5	18
140	Sidedness is prognostic in locoregional colon cancer: an analysis of 9509 Australian patients. BMC Cancer, 2017, 17, 251.	1.1	34
141	Molecular subtypes in cancers of the gastrointestinal tract. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 333-342.	8.2	99
142	Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. Annals of Oncology, 2017, 28, 958-968.	0.6	107
143	Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Annals of Oncology, 2017, 28, 1713-1729.	0.6	654
144	Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer. British Journal of Cancer, 2017, 116, 1444-1450.	2.9	46
145	What We Know About Stage II and III Colon Cancer: Itâ€™s Still Not Enough. Targeted Oncology, 2017, 12, 265-275.	1.7	25
146	Colorectal cancer subtypes: Translation to routine clinical pathology. Cancer Treatment Reviews, 2017, 57, 1-7.	3.4	36
147	Treatment decisions in metastatic colorectal cancer â€" Beyond first and second line combination therapies. Cancer Treatment Reviews, 2017, 59, 54-60.	3.4	99
148	The genetics and molecular biology of colonic neoplasia. Current Opinion in Gastroenterology, 2017, 33, 47-52.	1.0	4
149	Minimum Volume Discussion in the Treatment of Colon and Rectal Cancer: A Review of the Current Status and Relevance of Surgeon and Hospital Volume regarding Result Quality and the Impact on Health Economics. Visceral Medicine, 2017, 33, 140-147.	0.5	12
150	Molecular-Subtype-Specific Biomarkers Improve Prediction of Prognosis in Colorectal Cancer. Cell Reports, 2017, 19, 1268-1280.	2.9	79
151	Gallstone Disease and Cancer Risk: Finding the Bug in the System. Gastroenterology, 2017, 152, 1825-1828.	0.6	14
153	The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. European Journal of Cancer, 2017, 70, 87-98.	1.3	436
154	Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity. Gastroenterology, 2017, 153, 1082-1095.	0.6	55

#	Article	IF	Citations
155	TGFβ pathway limits dedifferentiation following WNT and MAPK pathway activation to suppress intestinal tumourigenesis. Cell Death and Differentiation, 2017, 24, 1681-1693.	5.0	48
156	Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer. Cancer, 2017, 123, 3513-3523.	2.0	50
157	Adenylate kinase hCINAP determines self-renewal of colorectal cancer stem cells by facilitating LDHA phosphorylation. Nature Communications, 2017, 8, 15308.	5.8	52
159	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 2392.	3.8	670
160	The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. British Journal of Cancer, 2017, 117, 315-321.	2.9	19
161	Statistical contributions to bioinformatics: Design, modelling, structure learning and integration. Statistical Modelling, 2017, 17, 245-289.	0.5	15
162	Downregulation of serum metabolite GTA-446 as a novel potential marker for early detection of colorectal cancer. British Journal of Cancer, 2017, 117, 227-232.	2.9	12
163	The role of hERG1 ion channels in epithelial-mesenchymal transition and the capacity of riluzole to reduce cisplatin resistance in colorectal cancer cells. Cellular Oncology (Dordrecht), 2017, 40, 367-378.	2.1	29
164	Challenges behind proving efficacy of adjuvant chemotherapy after preoperative chemoradiation for rectal cancer. Lancet Oncology, The, 2017, 18, e354-e363.	5.1	89
165	Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. British Journal of Cancer, 2017, 117, 203-209.	2.9	38
166	Standardising RNA profiling based biomarker application in cancer—The need for robust control of technical variables. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 258-272.	3.3	16
168	Flow Cytometric Methods for Circulating Tumor Cell Isolation and Molecular Analysis. Advances in Experimental Medicine and Biology, 2017, 994, 105-118.	0.8	4
169	Early detection: the impact of genomics. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 165-173.	1.4	10
170	Role of TGF-β in metastatic colon cancer: it is finally time for targeted therapy. Cell and Tissue Research, 2017, 370, 29-39.	1.5	80
171	Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification. Nature Communications, 2017, 8, 15657.	5.8	70
172	Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer. Nature Communications, 2017, 8, 15107.	5.8	213
173	Genetic and epigenetic markers in colorectal cancer screening: recent advances. Expert Review of Molecular Diagnostics, 2017, 17, 665-685.	1.5	22
174	A Novel Diagnostic Tool for Selecting Patients With Mesenchymal-Type Colon Cancer Reveals Intratumor Subtype Heterogeneity. Journal of the National Cancer Institute, 2017, 109, .	3.0	30

#	Article	IF	Citations
175	Multiple Roles of APC and its Therapeutic Implications in Colorectal Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	254
176	Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes. Clinical Cancer Research, 2017, 23, 6002-6011.	3.2	26
177	Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency. Critical Reviews in Oncology/Hematology, 2017, 113, 242-248.	2.0	68
178	A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic *BRAF*-Mutant Colorectal Cancer. Cancer Discovery, 2017, 7, 610-619.	7.7	194
179	PSMB8 as a Candidate Marker of Responsiveness to Preoperative Radiation Therapy in Rectal Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1164-1173.	0.4	26
180	Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies. Seminars in Cancer Biology, 2017, 44, 153-169.	4.3	68
181	Methylation of WNT target genes AXIN2 and DKK1 as robust biomarkers for recurrence prediction in stage II colon cancer. Oncogenesis, 2017, 6, e308-e308.	2.1	26
182	CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification. Annals of Oncology, 2017, 28, 1032-1035.	0.6	43
183	Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. Nature Reviews Clinical Oncology, 2017, 14, 562-576.	12.5	150
184	Update on cholangiocarcinoma: potential impact of genomic studies on clinical management. Zeitschrift Fur Gastroenterologie, 2017, 55, 575-581.	0.2	25
185	Sessile Serrated Polyps and Colon Cancer Prevention. Cancer Prevention Research, 2017, 10, 270-278.	0.7	31
186	Immunotherapy for colorectal cancer: where are we heading?. Expert Opinion on Biological Therapy, 2017, 17, 709-721.	1.4	85
187	Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Annals of Oncology, 2017, 28, 1023-1031.	0.6	174
188	Molecular subtypes of colorectal cancers determined by <scp>PCR</scp>â€based analysis. Cancer Science, 2017, 108, 427-434.	1.7	13
189	Image-based surrogate biomarkers for molecular subtypes of colorectal cancer. Bioinformatics, 2017, 33, 2002-2009.	1.8	18
190	Drug Resistance Mechanisms in Colorectal Cancer Dissected with Cell Typeâ€"Specific Dynamic Logic Models. Cancer Research, 2017, 77, 3364-3375.	0.4	101
192	Oncogenic *Kras* drives invasion and maintains metastases in colorectal cancer. Genes and Development, 2017, 31, 370-382.	2.7	137
193	Bone morphogenetic protein and Notch signalling crosstalk in poorâ€prognosis, mesenchymalâ€subtype colorectal cancer. Journal of Pathology, 2017, 242, 178-192.	2.1	36

#	Article	IF	Citations
194	CD95 ligand induces senescence in mismatch repair-deficient human colon cancer via chronic caspase-mediated induction of DNA damage. Cell Death and Disease, 2017, 8, e2669-e2669.	2.7	10
195	Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors. Nature Genetics, 2017, 49, 708-718.	9.4	849
196	Clinical relevance of colorectal cancer molecular subtypes. Critical Reviews in Oncology/Hematology, 2017, 109, 9-19.	2.0	109
197	From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nature Reviews Clinical Oncology, 2017, 14, 235-246.	12.5	466
198	Current and future biomarkers in the treatment of colorectal cancer. Acta Clinica Belgica, 2017, 72, 103-115.	0.5	30
199	Association of DNA Mismatch Repair and Mutations in *BRAF* and *KRAS* With Survival After Recurrence in Stage III Colon Cancers. JAMA Oncology, 2017, 3, 472.	3.4	82
201	ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice. Nature Genetics, 2017, 49, 296-302.	9.4	260
202	Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nature Reviews Cancer, 2017, 17, 79-92.	12.8	686
203	Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair. Clinical Colorectal Cancer, 2017, 16, 228-239.	1.0	40
204	Different in vivo and in vitro transformation of intestinal stem cells in mismatch repair deficiency. Oncogene, 2017, 36, 2750-2761.	2.6	12
205	Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. European Journal of Cancer, 2017, 86, 305-317.	1.3	22
206	Molecular Profiling in Colon Cancer: Where Are We Now?. Current Colorectal Cancer Reports, 2017, 13, 362-369.	1.0	0
207	Molecular stratification of colorectal cancer populations and its use in directing precision medicine. Expert Review of Precision Medicine and Drug Development, 2017, 2, 205-215.	0.4	3
208	Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients. Cancer Genetics, 2017, 218-219, 51-57.	0.2	14
210	Cell plasticity in epithelial homeostasis and tumorigenesis. Nature Cell Biology, 2017, 19, 1133-1141.	4.6	170
211	EGFR pathway subgroups in Chilean colorectal cancer patients, detected by mutational and expression profiles, associated to different clinicopathological features. Tumor Biology, 2017, 39, 101042831772451.	0.8	11
212	Rectal Cancer in Asian vs. Western Countries: Why the Variation in Incidence?. Current Treatment Options in Oncology, 2017, 18, 64.	1.3	74
213	Loss of Myosin Vb in colorectal cancer is a strong prognostic factor for disease recurrence. British Journal of Cancer, 2017, 117, 1689-1701.	2.9	58

#	Article	IF	Citations
214	A Blueprint to Advance Colorectal Cancer Immunotherapies. Cancer Immunology Research, 2017, 5, 942-949.	1.6	63
215	Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency. European Journal of Cancer, 2017, 86, 266-274.	1.3	65
216	The colorectal cancer immune microenvironment and approach to immunotherapies. Future Oncology, 2017, 13, 1633-1647.	1.1	76
217	Search for Master Regulators in Walking Cancer Pathways. Methods in Molecular Biology, 2017, 1613, 161-191.	0.4	4
218	Genomic Determinants of Protein Abundance Variation in Colorectal Cancer Cells. Cell Reports, 2017, 20, 2201-2214.	2.9	95
219	Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine. European Journal of Cancer, 2017, 84, 290-303.	1.3	112
220	Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer. Scientific Reports, 2017, 7, 11590.	1.6	173
221	Complete sequence-based pathway analysis by differential on-chip DNA and RNA extraction from a single cell. Scientific Reports, 2017, 7, 11030.	1.6	16
222	Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. Cancer Treatment Reviews, 2017, 60, 109-119.	3.4	45
223	Colorectal cancer: epigenetic alterations and their clinical implications. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 439-448.	3.3	48
224	Tailored Treatment of Colorectal Cancer: Surgical, Molecular, and Genetic Considerations. Clinical Medicine Insights: Oncology, 2017, 11, 117955491769076.	0.6	31
226	A Novel Statistical Method to Diagnose, Quantify and Correct Batch Effects in Genomic Studies. Scientific Reports, 2017, 7, 10849.	1.6	32
227	Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. Lancet Respiratory Medicine,the, 2017, 5, 816-826.	5.2	381
228	Towards personalized medicine of colorectal cancer. Critical Reviews in Oncology/Hematology, 2017, 118, 70-78.	2.0	42
229	Universal testing of colorectal cancer for deficient mismatch repair â€•a new era has arrived. Colorectal Disease, 2017, 19, 801-802.	0.7	0
230	DNA and Histone Methylation in Colon Cancer. Cancer Drug Discovery and Development, 2017, , 461-487.	0.2	0
231	Genomic and transcriptomic heterogeneity of colorectal tumours arising in Lynch syndrome. Journal of Pathology, 2017, 243, 242-254.	2.1	69
232	PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer. Lancet Oncology, The, 2017, 18, 1141-1142.	5.1	29

#	ARTICLE	IF	CITATIONS
233	Editorial: Use of Gene Expression Profiles to Distinguish Molecular Subtypes in Colorectal Cancer: Progression Toward Primetime. Journal of the National Cancer Institute, 2017, 109, .	3.0	2
234	BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives. Annals of Oncology, 2017, 28, 2648-2657.	0.6	227
235	The immune contexture in cancer prognosis and treatment. Nature Reviews Clinical Oncology, 2017, 14, 717-734.	12.5	1,590
236	Looking for the Good, Bad and the Ugly rectal cancers of the twenty-first centuryâ€¦ or â€œHow to avoid tears when peeling onionsâ€• Techniques in Coloproctology, 2017, 21, 577-579.	0.8	3
237	Lymphangiogenic Gene Expression Is Associated With Lymph Node Recurrence and Poor Prognosis After Partial Hepatectomy for Colorectal Liver Metastasis. Annals of Surgery, 2017, 266, 765-771.	2.1	27
238	Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancerâ€"A definite conclusion?. Seminars in Oncology, 2017, 44, 129-131.	0.8	3
239	Whose side are you on?. Annals of Oncology, 2017, 28, 1685-1686.	0.6	1
240	Recent developments in the treatment of metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2017, 9, 551-564.	1.4	82
241	Inflammation and Colorectal Cancer. Current Colorectal Cancer Reports, 2017, 13, 341-351.	1.0	111
242	The utilization of multidisciplinary tumor boards (MDT) in clinical routine: results of a health care research study focusing on patients with metastasized colorectal cancer. International Journal of Colorectal Disease, 2017, 32, 1463-1469.	1.0	23
243	Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. European Journal of Cancer, 2017, 84, 69-80.	1.3	212
244	TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer. OncoImmunology, 2017, 6, e1356143.	2.1	79
245	Defining key concepts of intestinal and epithelial cancer biology through the use of mouse models. Carcinogenesis, 2017, 38, 953-965.	1.3	5
246	Simple classifiers for molecular subtypes of colorectal cancer. Arab Journal of Gastroenterology, 2017, 18, 191-200.	0.4	3
247	Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. Cell Reports, 2017, 21, 2458-2470.	2.9	148
248	CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models. Scientific Reports, 2017, 7, 16618.	1.6	229
249	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. ESMO Open, 2017, 2, e000241.	2.0	10
251	Pharmacoproteomic characterisation of human colon and rectal cancer. Molecular Systems Biology, 2017, 13, 951.	3.2	44

#	Article	IF	Citations
252	Histopathological and genotypic characterization of metastatic colorectal carcinoma with PD‑L1 (CD274) expression: Possible roles of tumour micro environmental factors for CD274 expression. Journal of Pathology: Clinical Research, 2017, 3, 268-278.	1.3	18
253	Beyond cancer genes: colorectal cancer as robust intrinsic states formed by molecular interactions. Open Biology, 2017, 7, 170169.	1.5	17
254	Percolation transition of cooperative mutational effects in colorectal tumorigenesis. Nature Communications, 2017, 8, 1270.	5.8	28
255	The current value of determining the mismatch repair status of colorectal cancer: A rationale for routine testing. Critical Reviews in Oncology/Hematology, 2017, 116, 38-57.	2.0	99
256	Targeting metabolic reprogramming in KRAS-driven cancers. International Journal of Clinical Oncology, 2017, 22, 651-659.	1.0	102
257	Neoadjuvant chemotherapy affects molecular classification of colorectal tumors. Oncogenesis, 2017, 6, e357-e357.	2.1	35
258	Exo70 is an independent prognostic factor in colon cancer. Scientific Reports, 2017, 7, 5039.	1.6	9
259	Biomarkers that Predict Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. Current Colorectal Cancer Reports, 2017, 13, 276-283.	1.0	0
260	Immune checkpoint inhibitors for patients with colorectal cancer: mismatch repair deficiency and perspectives. Colorectal Cancer, 2017, 6, 23-31.	0.8	1
261	The potential role of platelets in the consensus molecular subtypes of colorectal cancer. Cancer and Metastasis Reviews, 2017, 36, 273-288.	2.7	37
262	Comprehensive analysis of copy number aberrations in microsatellite stable colon cancer in view of stromal component. British Journal of Cancer, 2017, 117, 421-431.	2.9	125
263	Refining prognosis in early-stage colorectal cancer: one or multiple genes at a time?. Annals of Oncology, 2017, 28, 1686-1688.	0.6	2
264	Spectral clustering using Nyström approximation for the accurate identification of cancer molecular subtypes. Scientific Reports, 2017, 7, 4896.	1.6	2
265	Pan-cancer EMT-signature identifies RBM47 down-regulation during colorectal cancer progression. Scientific Reports, 2017, 7, 4687.	1.6	77
266	Intestinal lymphatic vasculature: structure, mechanisms and functions. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 510-526.	8.2	163
267	Multilevel genomics of colorectal cancers with microsatellite instability—clinical impact of JAK1 mutations and consensus molecular subtype 1. Genome Medicine, 2017, 9, 46.	3.6	71
268	Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT). BMC Cancer, 2017, 17, 282.	1.1	13
269	Quantitative evaluation and reversion analysis of the attractor landscapes of an intracellular regulatory network for colorectal cancer. BMC Systems Biology, 2017, 11, 45.	3.0	27

#	Article	IF	Citations
270	The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases. Clinical Epigenetics, 2017, 9, 46.	1.8	15
271	Analysis of the DNA methylation level of cancer-related genes in colorectal cancer and the surrounding normal mucosa. Clinical Epigenetics, 2017, 9, 55.	1.8	35
272	Immune therapy in colorectal cancer. Colorectal Cancer, 2017, 6, 1-10.	0.8	3
273	Genomic profiling of colorectal cancers and the future of personalized treatment. Colorectal Cancer, 2017, 6, 11-22.	0.8	1
274	Friend or foe?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1867, 1-18.	3.3	54
275	Heterogeneity of colorectal cancer risk by tumour characteristics: Large prospective study of <scp>UK</scp> women. International Journal of Cancer, 2017, 140, 1082-1090.	2.3	37
276	Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. JAMA Oncology, 2017, 3, 774.	3.4	221
277	Transforming Growth Factor Î² Superfamily Signaling inÂDevelopment of Colorectal Cancer. Gastroenterology, 2017, 152, 36-52.	0.6	181
278	Using Big Data to Discover Diagnostics and Therapeutics forÂGastrointestinal and Liver Diseases. Gastroenterology, 2017, 152, 53-67.e3.	0.6	61
279	Patient selection for the surgical treatment of resectable colorectal liver metastases. Journal of Surgical Oncology, 2017, 115, 213-220.	0.8	14
280	Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer. Indian Journal of Surgical Oncology, 2017, 8, 580-590.	0.3	2
281	Primary Tumor Sidedness as Prognostic and Predictive Biomarker in Metastatic Colorectal Cancer. JAMA Oncology, 2017, 3, 165.	3.4	10
282	Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i>Wild-Type Metastatic Colorectal Cancer. JAMA Oncology, 2017, 3, 194.	3.4	555
283	Fatty acid-binding protein 1 is preferentially lost in microsatellite instable colorectal carcinomas and is immune modulated via the interferon Î³ pathway. Modern Pathology, 2017, 30, 123-133.	2.9	18
284	Signal Transduction and Activator of Transcription-3 (STAT3) in Patients with Colorectal Cancer: Associations with the Phenotypic Features of the Tumor and Host. Clinical Cancer Research, 2017, 23, 1698-1709.	3.2	38
285	Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry. Clinical Cancer Research, 2017, 23, 387-398.	3.2	128
286	Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. Therapeutic Advances in Medical Oncology, 2017, 9, 106-126.	1.4	36
287	Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching. British Journal of Cancer, 2017, 116, 58-65.	2.9	124

#	ARTICLE	IF	CITATIONS
288	Germline miRNA DNA variants and the risk of colorectal cancer by subtype. Genes Chromosomes and Cancer, 2017, 56, 177-184.	1.5	7
289	Wnt signaling in cancer. Oncogene, 2017, 36, 1461-1473.	2.6	1,975
290	A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer. Clinical Cancer Research, 2017, 23, 1200-1212.	3.2	21
291	Perineural Invasion is a Major Prognostic and Predictive Factor of Response to Adjuvant Chemotherapy in Stage I–II Colon Cancer. Annals of Surgical Oncology, 2017, 24, 1077-1084.	0.7	51
292	Lifestyle, Diet, and Colorectal Cancer Risk According to (Epi)genetic Instability: Current Evidence and Future Directions of Molecular Pathological Epidemiology. Current Colorectal Cancer Reports, 2017, 13, 455-469.	1.0	91
294	Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2017, 28, iv22-iv40.	0.6	1,126
296	Inter-patient and Intra-tumor Heterogeneity in the Sensitivity to Tumor-targeted Immunity in Colorectal Cancer. Japanese Journal of Clinical Immunology, 2017, 40, 54-59.	0.0	12
297	Bioinformatics Approaches to Profile the Tumor Microenvironment for Immunotherapeutic Discovery. Current Pharmaceutical Design, 2017, 23, 4716-4725.	0.9	11
299	The Epigenomics of Embryonic Pathway Signaling in Colorectal Cancer. Frontiers in Pharmacology, 2017, 8, 267.	1.6	23
300	Current and future biomarkers in colorectal cancer. Annals of Gastroenterology, 2017, 30, 613-621.	0.4	88
301	Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer. International Journal of Molecular Sciences, 2017, 18, 1632.	1.8	46
302	Cancer Epigenetics. , 2017, , 519-534.		2
303	An integrated lncRNA, microRNA and mRNA signature to improve prognosis prediction of colorectal cancer. Oncotarget, 2017, 8, 85463-85478.	0.8	33
304	Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications. International Journal of Molecular Sciences, 2017, 18, 2229.	1.8	105
305	Precision Nutrition for Targeting Lipid Metabolism in Colorectal Cancer. Nutrients, 2017, 9, 1076.	1.7	37
306	Immunotherapy for Colorectal Cancer. Cancers, 2017, 9, 50.	1.7	125
307	MYC Deregulation in Primary Human Cancers. Genes, 2017, 8, 151.	1.0	281
308	Clinical Significance and Prognostic Relevance of Microsatellite Instability in Sporadic Colorectal Cancer Patients. International Journal of Molecular Sciences, 2017, 18, 107.	1.8	62

#	ARTICLE	IF	CITATIONS
309	Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer. International Journal of Molecular Sciences, 2017, 18, 573.	1.8	130
310	Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy. International Journal of Molecular Sciences, 2017, 18, 1240.	1.8	38
311	Role of Type I and II Interferons in Colorectal Cancer and Melanoma. Frontiers in Immunology, 2017, 8, 878.	2.2	60
312	Signal Transduction Networks Analysis: The Reverse Phase Protein Array. , 2017, , .		0
313	Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future. BioMed Research International, 2017, 2017, 1-10.	0.9	6
314	Patterns of Sociodemographic and Clinicopathologic Characteristics of Stages II and III Colorectal Cancer Patients by Age: Examining Potential Mechanisms of Young-Onset Disease. Journal of Cancer Epidemiology, 2017, 2017, 1-10.	0.5	20
316	Recent advances in computational epigenetics. Advances in Genomics and Genetics, 2017, Volume 8, 1-12.	0.8	3
317	Activation of the mTOR Pathway by Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastasis. PLoS ONE, 2017, 12, e0169439.	1.1	28
318	The Influence of BRAF and KRAS Mutation Status on the Association between Aspirin Use and Survival after Colon Cancer Diagnosis. PLoS ONE, 2017, 12, e0170775.	1.1	23
319	Syndecan-1 deficiency promotes tumor growth in a murine model of colitis-induced colon carcinoma. PLoS ONE, 2017, 12, e0174343.	1.1	28
320	High mRNA expression of splice variant SYK short correlates with hepatic disease progression in chemonaive lymph node negative colon cancer patients. PLoS ONE, 2017, 12, e0185607.	1.1	14
321	Clinical baseline and prognostic difference of platelet lymphocyte ratio (PLR) in right-sided and let-sided colon cancers. BMC Cancer, 2017, 17, 873.	1.1	13
322	Proteomic profiling identifies markers for inflammation-related tumorâ€"fibroblast interaction. Clinical Proteomics, 2017, 14, 33.	1.1	17
323	The prognostic value of lymph node yield in the earliest stage of colorectal cancer: a multicenter cohort study. BMC Medicine, 2017, 15, 129.	2.3	23
324	Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies. Molecular Cancer, 2017, 16, 116.	7.9	232
326	Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer. BMC Gastroenterology, 2017, 17, 121.	0.8	12
327	Recent Advances in the Use of Molecular Biomarkers in Colorectal Cancer. Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research, 2017, 11, .	0.1	0
328	Comprehensive investigation of a novel differentially expressed lncRNA expression profile signature to assess the survival of patients with colorectal adenocarcinoma. Oncotarget, 2017, 8, 16811-16828.	0.8	95

#	Article	IF	Citations
329	Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget, 2017, 8, 86356-86368.	0.8	147
330	Precision Medicine: Where have we reached and where are we headed?. Sultan Qaboos University Medical Journal, 2017, 17, e255-258.	0.3	13
331	AF1q Mediates Tumor Progression in Colorectal Cancer by Regulating AKT Signaling. International Journal of Molecular Sciences, 2017, 18, 987.	1.8	10
332	Molecular Subtyping of Pancreatic Cancer: Translating Genomics and Transcriptomics into the Clinic. Journal of Cancer, 2017, 8, 513-522.	1.2	36
333	Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.8	110
334	To Treat or Not to Treat: Adjuvant Therapy for Stage II Colon Cancer in the Era of Precision Oncology. Journal of Oncology Practice, 2017, 13, 242-244.	2.5	3
335	Not All BRAF-Mutant Metastatic Colorectal Cancers Are Identical: Distinct Clinical Consequences of non-V600BRAF Mutations. Journal of Clinical Oncology, 2017, 35, 2598-2599.	0.8	4
336	Personalizing Adjuvant Therapy for Stage II/III Colorectal Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 232-245.	1.8	10
337	Clinico-pathological and oncological differences between right and left-sided colon cancer (stages) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.1	14
338	GSK-3β inhibitor 6-bromo-indirubin-3′-oxime promotes both adhesive activity and drug resistance in colorectal cancer cells. International Journal of Oncology, 2017, 51, 1821-1830.	1.4	16
339	Molecular landscape and sub-classification of gastrointestinal cancers: a review of literature. Journal of Gastrointestinal Oncology, 2017, 8, 379-386.	0.6	19
340	Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment. Journal of Gastrointestinal Oncology, 2017, 8, 405-417.	0.6	17
341	Should cT2 esophageal cancer get neoadjuvant treatment before surgery?. Journal of Thoracic Disease, 2017, 9, 2819-2823.	0.6	6
342	Next generation sequencing identifies 'interactome' signatures in relapsed and refractory metastatic colorectal cancer. Journal of Gastrointestinal Oncology, 2017, 8, 20-31.	0.6	14
343	Prognostic gene expression profiling in esophageal cancer: a systematic review. Oncotarget, 2017, 8, 5566-5577.	0.8	36
345	Difference between right-sided and left-sided colorectal cancers: from embryology to molecular subtype. Expert Review of Anticancer Therapy, 2018, 18, 351-358.	1.1	60
346	The tumour–stroma ratio in colon cancer: the biological role and its prognostic impact. Histopathology, 2018, 73, 197-206.	1.6	97
347	Genetic Mechanisms of Immune Evasion in Colorectal Cancer. Cancer Discovery, 2018, 8, 730-749.	7.7	367

#	Article	IF	Citations
348	CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. Annals of Oncology, 2018, 29, 1227-1234.	0.6	63
349	Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer. Clinical Cancer Research, 2018, 24, 3867-3877.	3.2	47
350	Prospective patient stratification into robust cancer‐cell intrinsic subtypes from colorectal cancer biopsies. Journal of Pathology, 2018, 245, 19-28.	2.1	49
351	Extracellular Matrix Remodeling in Intestinal Homeostasis and Disease. Advances in Stem Cells and Their Niches, 2018, 2, 99-140.	0.1	5
352	Atezolizumab for the treatment of colorectal cancer: *the latest evidence and clinical potential*. Expert Opinion on Biological Therapy, 2018, 18, 449-457.	1.4	25
353	Results and challenges of immune checkpoint inhibitors in colorectal cancer. Expert Opinion on Biological Therapy, 2018, 18, 561-573.	1.4	58
354	Hakai overexpression effectively induces tumour progression and metastasis in vivo. Scientific Reports, 2018, 8, 3466.	1.6	27
355	Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer. Current Treatment Options in Oncology, 2018, 19, 11.	1.3	3
356	The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic *BRAF* Mutant Colorectal Cancer. Molecular Cancer Therapeutics, 2018, 17, 1280-1290.	1.9	17
357	Colorectal cancer spheroid biobanks: multi-level approaches to drug sensitivity studies. Cell Biology and Toxicology, 2018, 34, 459-469.	2.4	14
358	FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer. Medicine (United States), 2018, 97, e0097.	0.4	7
359	Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis. Expert Review of Anticancer Therapy, 2018, 18, 339-349.	1.1	6
360	The impact of primary tumour location in patients undergoing hepatic resection for colorectal liver metastasis. European Journal of Surgical Oncology, 2018, 44, 771-777.	0.5	36
361	Genomics and emerging biomarkers for immunotherapy of colorectal cancer. Seminars in Cancer Biology, 2018, 52, 189-197.	4.3	112
362	TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor *CD274* (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. OncoImmunology, 2018, 7, e1442999.	2.1	53
363	Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature Medicine, 2018, 24, 541-550.	15.2	3,421
364	High microRNA-28-5p expression in colorectal adenocarcinoma predicts short-term relapse of node-negative patients and poor overall survival of patients with non-metastatic disease. Clinical Chemistry and Laboratory Medicine, 2018, 56, 990-1000.	1.4	28
365	Strategy to targeting the immune resistance and novel therapy in colorectal cancer. Cancer Medicine, 2018, 7, 1578-1603.	1.3	23

#	Article	IF	Citations
366	"Are There New Chemotherapy Drugs Behind the Corner?", 2018, , 355-358.		0
367	Are There Biochemical and Molecular Biological Factors to Distinguish the Rectal Cancer by the Colon Cancer?. , 2018, , 503-507.		0
368	Concise Review: Aggressive Colorectal Cancer: Role of Epithelial Cell Adhesion Molecule in Cancer Stem Cells and Epithelial-to-Mesenchymal Transition. Stem Cells Translational Medicine, 2018, 7, 495-501.	1.6	59
369	An integrated flow cytometry-based platform for isolation and molecular characterization of circulating tumor single cells and clusters. Scientific Reports, 2018, 8, 5035.	1.6	63
370	Is primary sidedness a prognostic factor in patients with resected colon cancer liver metastases (CLM)?. Journal of Surgical Oncology, 2018, 117, 858-863.	0.8	20
371	Clinical importance of DNA repair in sporadic colorectal cancer. Critical Reviews in Oncology/Hematology, 2018, 126, 168-185.	2.0	11
372	Impact of histological subtype on the prognosis of patients undergoing surgery for colon cancer. Journal of Surgical Oncology, 2018, 117, 1355-1363.	0.8	26
374	MEG3 Activated by Vitamin D Inhibits Colorectal Cancer Cells Proliferation and Migration via Regulating Clusterin. EBioMedicine, 2018, 30, 148-157.	2.7	67
375	Gambogic Acid Efficiently Kills Stem-Like Colorectal Cancer Cells by Upregulating ZFP36 Expression. Cellular Physiology and Biochemistry, 2018, 46, 829-846.	1.1	20
376	The Intestinal Microbiota in Colorectal Cancer. Cancer Cell, 2018, 33, 954-964.	7.7	543
378	Immunohistochemistry testing for mismatch repair deficiency in Stage 2 colon cancer: A cohort study of two cancer centres. International Journal of Surgery, 2018, 51, 71-75.	1.1	6
379	Tumour spheres with inverted polarity drive the formation of peritoneal metastases in patients with hypermethylated colorectal carcinomas. Nature Cell Biology, 2018, 20, 296-306.	4.6	88
380	Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Modern Pathology, 2018, 31, 947-955.	2.9	56
381	Correlation of immunohistochemical mismatch repair protein status between colorectal carcinoma endoscopic biopsy and resection specimens. Journal of Clinical Pathology, 2018, 71, 631-636.	1.0	23
382	TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature, 2018, 554, 538-543.	13.7	1,296
383	Inhibition of <scp>DDR</scp> 1–<scp>BCR</scp> signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer. EMBO Molecular Medicine, 2018, 10, .	3.3	82
384	miR-508 Defines the Stem-like/Mesenchymal Subtype in Colorectal Cancer. Cancer Research, 2018, 78, 1751-1765.	0.4	30
385	RNF6 Promotes Colorectal Cancer by Activating the Wnt/β-Catenin Pathway via Ubiquitination of TLE3. Cancer Research, 2018, 78, 1958-1971.	0.4	67

#	ARTICLE	IF	CITATIONS
386	Correlation between circulating endothelial progenitor cells and serum carcinoembryonic antigen level in colorectal cancer. Acta Biochimica Et Biophysica Sinica, 2018, 50, 307-312.	0.9	5
387	PPARÎ³-activation increases intestinal M1 macrophages and mitigates formation of serrated adenomas in mutant <i>KRAS</i> mice. OncoImmunology, 2018, 7, e1423168.	2.1	12
388	Intratumoral morphological heterogeneity can be an indicator of genetic heterogeneity in colorectal cancer. Experimental and Molecular Pathology, 2018, 104, 76-81.	0.9	6
389	Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer. British Journal of Surgery, 2018, 105, e110-e120.	0.1	49
390	Feature specific quantile normalization enables cross-platform classification of molecular subtypes using gene expression data. Bioinformatics, 2018, 34, 1868-1874.	1.8	53
391	Clinicopathological, genomic and immunological factors in colorectal cancer prognosis. British Journal of Surgery, 2018, 105, e99-e109.	0.1	39
392	Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases. British Journal of Surgery, 2018, 105, e204-e211.	0.1	65
393	The role of tumor angiogenesis as a therapeutic target in colorectal cancer. Expert Review of Anticancer Therapy, 2018, 18, 251-266.	1.1	41
394	Mesenchymal stem cells over-expressing cxcl12 enhance the radioresistance of the small intestine. Cell Death and Disease, 2018, 9, 154.	2.7	13
395	Tumor Heterogeneity in Colorectal Cancer: What Do We Know So Far?. Pathobiology, 2018, 85, 72-84.	1.9	110
396	STAT1 is a sexâ€specific tumor suppressor in colitisâ€associated colorectal cancer. Molecular Oncology, 2018, 12, 514-528.	2.1	29
397	The Cdx2 homeobox gene suppresses intestinal tumorigenesis through nonâ€"cell-autonomous mechanisms. Journal of Experimental Medicine, 2018, 215, 911-926.	4.2	33
398	Epigenetic and epitranscriptomic changes in colorectal cancer: Diagnostic, prognostic, and treatment implications. Cancer Letters, 2018, 419, 84-95.	3.2	52
399	Outcome in colorectal cancerâ€"tumour, stroma and so much more. Annals of Oncology, 2018, 29, 534-535.	0.6	2
400	Network science in clinical trials: A patient-centered approach. Seminars in Cancer Biology, 2018, 52, 135-150.	4.3	9
401	Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK). Digestive and Liver Disease, 2018, 50, 305-307.	0.4	13
402	Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clinical Cancer Research, 2018, 24, 1344-1354.	3.2	414
403	Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. Gut, 2018, 67, 179-193.	6.1	73

#	Article	IF	Citations
404	Impact of oncogenic pathways on evasion of antitumour immune responses. Nature Reviews Cancer, 2018, 18, 139-147.	12.8	506
405	Appendiceal goblet cell carcinoids and adenocarcinomas ex-goblet cell carcinoid are genetically distinct from primary colorectal-type adenocarcinoma of the appendix. Modern Pathology, 2018, 31, 829-839.	2.9	44
406	Proteome Heterogeneity in Colorectal Cancer. Proteomics, 2018, 18, 1700169.	1.3	13
407	Iron therapy as treatment of anemia: A potentially detrimental and hazardous strategy in colorectal cancer patients. Medical Hypotheses, 2018, 110, 110-113.	0.8	23
408	Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models. Cell Death and Differentiation, 2018, 25, 616-633.	5.0	137
409	The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine. Cancer, 2018, 124, 1650-1659.	2.0	32
410	Phenotypic characteristics of colorectal cancer in BRCA1/2 mutation carriers. European Journal of Human Genetics, 2018, 26, 382-386.	1.4	11
411	Colorectal Cancer Disparity in African Americans. American Journal of Pathology, 2018, 188, 291-303.	1.9	115
412	Prognostic markers for colorectal cancer: estimating ploidy and stroma. Annals of Oncology, 2018, 29, 616-623.	0.6	56
413	High-Dimensional Profiling of Tumor-Specific Immune Responses: Asking T Cells about What They â€œSeeâ€ in Cancer. Cancer Immunology Research, 2018, 6, 2-9.	1.6	15
414	Quantitative translational modeling to facilitate preclinical to clinical efficacy & toxicity translation in oncology. Future Science OA, 2018, 4, FSO306.	0.9	26
415	Effect of long non-coding RNA Gas5 on proliferation, migration, invasion and apoptosis of colorectal cancer HT-29 cell line. Cancer Cell International, 2018, 18, 4.	1.8	33
416	Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nature Communications, 2018, 9, 1793.	5.8	188
417	Variability and Reproducibility of 3rd-generation dual-source dynamic volume perfusion CT Parameters in Comparison to MR-perfusion Parameters in Rectal Cancer. Scientific Reports, 2018, 8, 6868.	1.6	6
418	Immunotherapy of Colon Cancer. Oncology Research and Treatment, 2018, 41, 282-285.	0.8	33
419	<scp>G</scp>ene expression differences among different <scp>MSI</scp> statuses in colorectal cancer. International Journal of Cancer, 2018, 143, 1731-1740.	2.3	137
420	The Secretion of miR-200s by a PKCÎ¶/ADAR2 Signaling Axis Promotes Liver Metastasis in Colorectal Cancer. Cell Reports, 2018, 23, 1178-1191.	2.9	53
421	BRAF-mutant colorectal cancer, a different breed evolving. Expert Review of Molecular Diagnostics, 2018, 18, 499-512.	1.5	19

#	Article	IF	Citations
422	Evaluation of Cancer-Associated DNA Copy Number Events in Colorectal (Advanced) Adenomas. Cancer Prevention Research, 2018, 11, 403-412.	0.7	15
423	Turning Cold Tumors Hot by Blocking TGF-Î². Trends in Cancer, 2018, 4, 335-337.	3.8	26
425	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell, 2018, 33, 721-735.e8.	7.7	396
426	SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases. European Journal of Surgical Oncology, 2018, 44, 684-692.	0.5	61
427	Clinical Trials and Progress in Metastatic Colon Cancer. Surgical Oncology Clinics of North America, 2018, 27, 349-365.	0.6	64
428	Cell Line Models of Molecular Subtypes of Colorectal Cancer. Methods in Molecular Biology, 2018, 1765, 3-26.	0.4	6
429	Classification of Colorectal Cancer in Molecular Subtypes by Immunohistochemistry. Methods in Molecular Biology, 2018, 1765, 179-191.	0.4	31
430	Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview. Methods in Molecular Biology, 2018, 1765, 281-297.	0.4	12
431	NF-Î°B pathways in the development and progression of colorectal cancer. Translational Research, 2018, 197, 43-56.	2.2	164
432	Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis. Lancet Oncology, The, 2018, 19, 629-638.	5.1	172
433	Genome, transcriptome and proteome: the rise of omics data and their integration in biomedical sciences. Briefings in Bioinformatics, 2018, 19, 286-302.	3.2	498
434	Left Versus Right: Does Location Matter for Refractory Metastatic Colorectal Cancer Patients in Phase 1 Clinical Trials?. Journal of Gastrointestinal Cancer, 2018, 49, 283-287.	0.6	3
435	Targeting the tumor microenvironment as a potential therapeutic approach in colorectal cancer: Rational and progress. Journal of Cellular Physiology, 2018, 233, 2928-2936.	2.0	35
436	Microbial Interactions and Interventions in Colorectal Cancer. Microbiology Spectrum, 2017, 5, .	1.2	35
437	Intratumoral stromal morphometry predicts disease recurrence but not response to 5â€‘fluorouracilâ€”results from the <scp>QUASAR</scp> trial of colorectal cancer. Histopathology, 2018, 72, 391-404.	1.6	16
438	Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative. Acta OncolÃ³gica, 2018, 57, 195-202.	0.8	55
439	The human <i>PKP2</i>/plakophilinâ€‘2 gene is induced by Wnt/Î²â€‘catenin in normal and colon cancerâ€‘associated fibroblasts. International Journal of Cancer, 2018, 142, 792-804.	2.3	26
440	Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study. Clinical Colorectal Cancer, 2018, 17, e69-e76.	1.0	44

#	ARTICLE	IF	CITATIONS
441	The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors. Journal of the National Cancer Institute, 2018, 110, 68-77.	3.0	89
442	Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. Clinical Colorectal Cancer, 2018, 17, 73-79.	1.0	17
443	Proteomics for early detection of colorectal cancer: recent updates. Expert Review of Proteomics, 2018, 15, 55-63.	1.3	18
444	KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer. Clinical Cancer Research, 2018, 24, 224-233.	3.2	101
445	Genome-wide association study identified copy number variants associated with sporadic colorectal cancer risk. Journal of Medical Genetics, 2018, 55, 181-188.	1.5	12
446	Genomic profiling of intestinalâ€type sinonasal adenocarcinoma reveals subgroups of patients with distinct clinical outcomes. Head and Neck, 2018, 40, 259-273.	0.9	22
447	DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies. Oncogene, 2018, 37, 566-577.	2.6	65
448	Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to KÃ¶hne Prognostic Category and BRAF Mutation Status. Clinical Colorectal Cancer, 2018, 17, 50-57.e8.	1.0	6
449	Staging the tumor and staging the host: A two centre, two country comparison of systemic inflammatory responses of patients undergoing resection of primary operable colorectal cancer. American Journal of Surgery, 2018, 216, 458-464.	0.9	21
450	Clinicopathological and molecular implications of aberrant thyroid transcription factorâ€1 expression in colorectal carcinomas: an immunohistochemical analysis of 1319 cases using three different antibody clones. Histopathology, 2018, 72, 423-432.	1.6	13
451	Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies. Cancer Immunology, Immunotherapy, 2018, 67, 981-988.	2.0	89
452	Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clinical Cancer Research, 2018, 24, 1062-1072.	3.2	225
453	Colorectal Cancers Developed from Proximal and Distal Tumor Location Belong to theÂDistinct Genetic Entity and Show Different Oncologic Behavior. Current Human Cell Research and Applications, 2018, , 81-91.	0.1	0
454	Tumor Budding and PDC Grade Are Stage Independent Predictors of Clinical Outcome in Mismatch Repair Deficient Colorectal Cancer. American Journal of Surgical Pathology, 2018, 42, 60-68.	2.1	34
456	Multispectral imaging reveals hyper active TGF-Î² signaling in colorectal cancer. Cancer Biology and Therapy, 2018, 19, 105-112.	1.5	28
457	Molecular profiling and genomeâ€wide analysis based on somatic copy number alterations in advanced colorectal cancers. Molecular Carcinogenesis, 2018, 57, 451-461.	1.3	13
458	Integrated Molecular Characterization of the Lethal Pediatric Cancer Pancreatoblastoma. Cancer Research, 2018, 78, 865-876.	0.4	25
459	Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology). British Journal of Cancer, 2018, 118, 629-633.	2.9	18

#	Article	IF	Citations
460	Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. Clinical Cancer Research, 2018, 24, 794-806.	3.2	177
461	Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. Cancer Treatment Reviews, 2018, 63, 48-60.	3.4	134
462	Ribosome biogenesis in cancer: new players and therapeutic avenues. Nature Reviews Cancer, 2018, 18, 51-63.	12.8	524
463	Experimental study of delivery of humidified-warm carbon dioxide during open abdominal surgery. British Journal of Surgery, 2018, 105, 597-605.	0.1	13
464	Molecular Markers and Mutational Analysis. , 2018, , 295-312.		1
465	Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Seminars in Cancer Biology, 2018, 52, 117-124.	4.3	302
466	Regulatory T-cell Genes Drive Altered Immune Microenvironment in Adult Solid Cancers and Allow for Immune Contextual Patient Subtyping. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 103-112.	1.1	27
467	Decoding colorectal cancer epigenomics. Cancer Genetics, 2018, 220, 49-76.	0.2	42
468	Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I—Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications. Archives of Pathology and Laboratory Medicine, 2018, 142, 17-25.	1.2	34
469	Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With<i>RAS</i>and<i>BRAF</i>Mutational Status. JAMA Oncology, 2018, 4, e173695.	3.4	55
470	Primary Tumor Location and Survival in the General Population With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, e201-e206.	1.0	17
471	The predictive value of primary tumor location in patients with metastatic colorectal cancer: A systematic review. Critical Reviews in Oncology/Hematology, 2018, 121, 1-10.	2.0	45
472	Characterization of genetic intratumor heterogeneity in colorectal cancer and matching patient—derived spheroid cultures. Molecular Oncology, 2018, 12, 132-147.	2.1	49
473	Proteomic Characterization of Transcription and Splicing Factors Associated with a Metastatic Phenotype in Colorectal Cancer. Journal of Proteome Research, 2018, 17, 252-264.	1.8	28
474	Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. Gut, 2018, 67, 1484-1492.	6.1	59
475	Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer. Oncotarget, 2018, 9, 18698-18711.	0.8	127
476	Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 231-238.	1.8	46
477	Transcriptional Subtyping and CD8 Immunohistochemistry Identifies Patients With Stage II and III Colorectal Cancer With Poor Prognosis Who Benefit From Adjuvant Chemotherapy. JCO Precision Oncology, 2018, 2018, 1-15.	1.5	45

#	Article	IF	Citations
478	DLAD4U: deriving and prioritizing disease lists from PubMed literature. BMC Bioinformatics, 2018, 19, 495.	1.2	2
479	Biomarkers in colorectal cancer: Current clinical utility and future perspectives. World Journal of Clinical Cases, 2018, 6, 869-881.	0.3	100
480	Subject level clustering using a negative binomial model for small transcriptomic studies. BMC Bioinformatics, 2018, 19, 474.	1.2	8
481	Low prevalence of deficient mismatch repair (dMMR) protein in locally advanced rectal cancers (LARC) and treatment outcomes. Journal of Gastrointestinal Oncology, 2018, 10, 19-29.	0.6	12
482	The growing role of precision and personalized medicine for cancer treatment. Technology, 2018, 06, 79-100.	1.4	237
483	Comprehensive and critical evaluation of individualized pathway activity measurement tools on pan-cancer data. Briefings in Bioinformatics, 2018, , .	3.2	14
484	UEG Week 2018 Poster Presentations. United European Gastroenterology Journal, 2018, 6, A135.	1.6	27
485	Practice-changing updates in the adjuvant and metastatic setting. Nature Reviews Clinical Oncology, 2018, 15, 77-78.	12.5	29
486	Therapeutic efficacy of systemic therapy for colorectal peritoneal carcinomatosis: surgeon's perspective. Pleura and Peritoneum, 2018, 3, 20180102.	0.5	20
487	Challenges in Stratifying the Molecular Variability of Patient-Derived Colon Tumor Xenografts. BioMed Research International, 2018, 2018, 1-9.	0.9	18
488	MiR-192, miR-200c and miR-17 are fibroblast-mediated inhibitors of colorectal cancer invasion. Oncotarget, 2018, 9, 35559-35580.	0.8	26
489	Outcomes of Chemotherapy for Microsatellite Instable–High Metastatic Colorectal Cancers. JCO Precision Oncology, 2018, 2, 1-10.	1.5	15
490	Rates of metachronous adenoma after curative resection for left-sided or right-sided colon cancer. Intestinal Research, 2018, 16, 619-627.	1.0	3
491	Recent advances in understanding colorectal cancer. F1000Research, 2018, 7, 1528.	0.8	14
492	Systematic identification of mutations and copy number alterations associated with cancer patient prognosis. ELife, 2018, 7, .	2.8	126
493	Significance of Tumor Microenvironment Scoring and Immune Biomarkers in Patient Stratification and Cancer Outcomes. , 0, , .		11
494	Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer. Current Drug Targets, 2018, 19, 1731-1737.	1.0	12
496	Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features. Gastroenterology, 2018, 155, 1999-2013.e3.	0.6	347

#	Article	IF	Citations
497	Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patientsâ€"Analysis of the Phase III AIO KRK-0207 Trial. Frontiers in Oncology, 2018, 8, 474.	1.3	13
498	Integrative Molecular Tumor Classification: A Pathologist's View. , 2018, , 279-279.		0
499	Epigenetic Regulation by lncRNAs: An Overview Focused on UCA1 in Colorectal Cancer. Cancers, 2018, 10, 440.	1.7	44
500	Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology. Npj Precision Oncology, 2018, 2, 25.	2.3	36
501	Colorectal Cancer and Metabolism. Current Colorectal Cancer Reports, 2018, 14, 226-241.	1.0	88
502	Gene expression analyses identify a relationship between stanniocalcin 2 and the malignant behavior of colorectal cancer. OncoTargets and Therapy, 2018, Volume 11, 7155-7168.	1.0	7
503	Gene expression profiles in genome instability-based classes of colorectal cancer. BMC Cancer, 2018, 18, 1265.	1.1	12
504	Targeting Colon Cancers with Mutated BRAF and Microsatellite Instability. Advances in Experimental Medicine and Biology, 2018, 1110, 7-21.	0.8	6
505	<scp>TGF</scp>Î²1â€"induced cell motility but not cell proliferation is mediated through Cten in colorectal cancer. International Journal of Experimental Pathology, 2018, 99, 323-330.	0.6	13
506	Targeting KRAS Mutant CMS3 Subtype by Metabolic Inhibitors. Advances in Experimental Medicine and Biology, 2018, 1110, 23-34.	0.8	7
507	Targeting PTEN in Colorectal Cancers. Advances in Experimental Medicine and Biology, 2018, 1110, 55-73.	0.8	24
508	Impact of the Microenvironment on Tumour Budding in Colorectal Cancer. Advances in Experimental Medicine and Biology, 2018, 1110, 101-111.	0.8	6
509	Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All. Advances in Experimental Medicine and Biology, 2018, 1110, 113-131.	0.8	19
510	Targeted Therapy of Colorectal Cancer Subtypes. Advances in Experimental Medicine and Biology, 2018, , .	0.8	0
511	Colorectal Cancer Subtypes â€" The Current Portrait. Advances in Experimental Medicine and Biology, 2018, 1110, 1-6.	0.8	2
512	Wnt Signalling-Targeted Therapy in the CMS2 Tumour Subtype: A New Paradigm in CRC Treatment?. Advances in Experimental Medicine and Biology, 2018, 1110, 75-100.	0.8	7
513	How the<i>BRAF</i>V600E Mutation Defines a Distinct Subgroup of Colorectal Cancer: Molecular and Clinical Implications. Gastroenterology Research and Practice, 2018, 2018, 1-14.	0.7	34
514	Survival marker genes of colorectal cancer derived from consistent transcriptomic profiling. BMC Genomics, 2018, 19, 857.	1.2	48

#	Article	IF	Citations
515	Single-cell multiomics sequencing and analyses of human colorectal cancer. Science, 2018, 362, 1060-1063.	6.0	256
516	Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?. International Journal of Molecular Sciences, 2018, 19, 3733.	1.8	147
517	Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream. Cancer Management and Research, 2018, Volume 10, 5895-5908.	0.9	18
518	Clinical Proteomics in Colorectal Cancer, a Promising Tool for Improving Personalised Medicine. Proteomes, 2018, 6, 49.	1.7	31
519	AACR White Paper: Shaping the Future of Cancer Prevention â€" A Roadmap for Advancing Science and Public Health. Cancer Prevention Research, 2018, 11, 735-778.	0.7	36
520	Molecular and Immunohistochemical Markers with Prognostic and Predictive Significance in Liver Metastases from Colorectal Carcinoma. International Journal of Molecular Sciences, 2018, 19, 3014.	1.8	12
521	Positive Caricature Transcriptomic Effects Associated with Broad Genomic Aberrations in Colorectal Cancer. Scientific Reports, 2018, 8, 14826.	1.6	14
522	Analysis of cell proliferation and tissue remodelling uncovers a KLF4 activity score associated with poor prognosis in colorectal cancer. British Journal of Cancer, 2018, 119, 855-863.	2.9	11
523	Continuity of transcriptomes among colorectal cancer subtypes based on meta-analysis. Genome Biology, 2018, 19, 142.	3.8	20
524	CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway. Clinical Epigenetics, 2018, 10, 120.	1.8	41
525	Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTALÂand COIN-B trials in the ARCAD database. European Journal of Cancer, 2018, 103, 205-213.	1.3	13
526	A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy. Cancers, 2018, 10, 355.	1.7	22
527	Exome scale map of genetic alterations promoting metastasis in colorectal cancer. BMC Genetics, 2018, 19, 85.	2.7	22
528	The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial. Annals of Oncology, 2018, 29, 2240-2246.	0.6	113
529	Profiles of alternative splicing in colorectal cancer and their clinical significance: A study based on large-scale sequencing data. EBioMedicine, 2018, 36, 183-195.	2.7	123
530	HCCDB: A Database of Hepatocellular Carcinoma Expression Atlas. Genomics, Proteomics and Bioinformatics, 2018, 16, 269-275.	3.0	218
531	Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. Nature Communications, 2018, 9, 4112.	5.8	55
532	Genome-Wide Network-Based Analysis of Colorectal Cancer Identifies Novel Prognostic Factors and an Integrative Prognostic Index. Cellular Physiology and Biochemistry, 2018, 49, 1703-1716.	1.1	52

#	Article	IF	Citations
533	Heterogeneity in Colorectal Primary Tumor and Synchronous Liver Metastases. Russian Journal of Genetics, 2018, 54, 698-702.	0.2	2
534	Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysis. World Journal of Surgical Oncology, 2018, 16, 200.	0.8	3
535	Anti-metastatic effect of metformin via repression of interleukin 6-induced epithelial–mesenchymal transition in human colon cancer cells. PLoS ONE, 2018, 13, e0205449.	1.1	25
536	Cancers du côlon : prise en charge moléculaire. Revue Francophone Des Laboratoires, 2018, 2018, 40-45.	0.0	1
537	Distinct microbes, metabolites, and ecologies define the microbiome in deficient and proficient mismatch repair colorectal cancers. Genome Medicine, 2018, 10, 78.	3.6	107
538	Molecular characterization of breast and lung tumors by integration of multiple data types with functional sparse-factor analysis. PLoS Computational Biology, 2018, 14, e1006520.	1.5	13
539	Combined Inactivation of TP53 and MIR34A Promotes Colorectal Cancer Development and Progression in Mice Via Increasing Levels of IL6R and PAI1. Gastroenterology, 2018, 155, 1868-1882.	0.6	39
540	Association analysis using somatic mutations. PLoS Genetics, 2018, 14, e1007746.	1.5	8
541	An Analysis of Relationship Between RAS Mutations and Prognosis of Primary Tumour Resection for Metastatic Colorectal Cancer Patients. Cellular Physiology and Biochemistry, 2018, 50, 768-782.	1.1	6
542	ALDH1A1 expression is associated with poor differentiation, 'right-sidedness' and poor survival in human colorectal cancer. PLoS ONE, 2018, 13, e0205536.	1.1	29
543	Assessment of Nuclear ZEB2 as a Biomarker for Colorectal Cancer Outcome and TNM Risk Stratification. JAMA Network Open, 2018, 1, e183115.	2.8	24
544	Microbiome and Colorectal Cancer. Current Colorectal Cancer Reports, 2018, 14, 217-225.	1.0	5
545	A novel gene-pair signature for relapse-free survival prediction in colon cancer. Cancer Management and Research, 2018, Volume 10, 4145-4153.	0.9	6
546	Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data. British Journal of Cancer, 2018, 119, 1244-1251.	2.9	57
547	Genetic and immunological biomarkers predict metastatic disease recurrence in stage III colon cancer. BMC Cancer, 2018, 18, 998.	1.1	14
548	Quantitative assessment of cell population diversity in single-cell landscapes. PLoS Biology, 2018, 16, e2006687.	2.6	40
549	Dissecting cancer heterogeneity based on dimension reduction of transcriptomic profiles using extreme learning machines. PLoS ONE, 2018, 13, e0203824.	1.1	14
550	ARHGEF7 promotes metastasis of colorectal adenocarcinoma by regulating the motility of cancer cells. International Journal of Oncology, 2018, 53, 1980-1996.	1.4	16

#	Article	IF	Citations
551	Ap4 is rate limiting for intestinal tumor formation by controlling the homeostasis of intestinal stem cells. Nature Communications, 2018, 9, 3573.	5.8	18
552	Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy. PLoS ONE, 2018, 13, e0203051.	1.1	35
553	Evolving Tissue and Circulating Biomarkers as Prognostic and Predictive Tools in Colorectal Cancer. Current Colorectal Cancer Reports, 2018, 14, 138-151.	1.0	0
554	Proliferative and Invasive Colorectal Tumors in Pet Dogs Provide Unique Insights into Human Colorectal Cancer. Cancers, 2018, 10, 330.	1.7	21
555	Clinicopathological and Molecular Specificities of Inflammatory Bowel Disease–Related Colorectal Neoplastic Lesions: The Role of Inflammation. Journal of Crohn's and Colitis, 2018, 12, 1486-1498.	0.6	18
556	Are Colon and Rectal Cancer Two Different Tumor Entities? A Proposal to Abandon the Term Colorectal Cancer. International Journal of Molecular Sciences, 2018, 19, 2577.	1.8	134
557	Integration of large-scale multi-omic datasets: A protein-centric view. Current Opinion in Systems Biology, 2018, 11, 74-81.	1.3	5
558	Microbial exposure and human health. Current Opinion in Microbiology, 2018, 44, 79-87.	2.3	32
559	Differential Regulation of Methylation-Regulating Enzymes by Senescent Stromal Cells Drives Colorectal Cancer Cell Response to DNA-Demethylating Epi-Drugs. Stem Cells International, 2018, 2018, 1-11.	1.2	6
560	CpG Island Methylator Phenotype and Methylation of Wnt Pathway Genes Together Predict Survival in Patients with Colorectal Cancer. Yonsei Medical Journal, 2018, 59, 588.	0.9	24
561	Rationale for the use of metronomic chemotherapy in gastrointestinal cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 1451-1463.	0.9	5
562	Impact of Primary Tumor Localization on the Efficacy of Bevacizumab in Metastatic Colorectal Cancer. Anticancer Research, 2018, 38, 5539-5546.	0.5	11
563	Report from the 19th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Winnipeg, Manitoba; 29–30 September 2017. Current Oncology, 2018, 25, 275-284.	0.9	3
564	Stem cell functionality is microenvironmentally defined during tumour expansion and therapy response in colon cancer. Nature Cell Biology, 2018, 20, 1193-1202.	4.6	138
565	Recurrence Risk After Up-to-Date Colon Cancer Staging, Surgery, and Pathology: Analysis of the Entire Swedish Population. Diseases of the Colon and Rectum, 2018, 61, 1016-1025.	0.7	127
566	Mutations, Differential Gene Expression, and Chimeric Transcripts in Esophageal Squamous Cell Carcinoma Show High Heterogeneity. Translational Oncology, 2018, 11, 1283-1291.	1.7	7
567	Microbial Interactions and Interventions in Colorectal Cancer. , 2018, , 99-130.		1
568	Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis. Clinical and Translational Oncology, 2018, 20, 1422-1429.	1.2	6

#	Article	IF	Citations
569	Right Versus Left Colon Cancer: Resectable and Metastatic Disease. Current Treatment Options in Oncology, 2018, 19, 31.	1.3	21
570	Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. Nature Communications, 2018, 9, 1978.	5.8	177
571	Clinicopathological and molecular differences between right-sided and left-sided colorectal cancer in Japanese patients. Japanese Journal of Clinical Oncology, 2018, 48, 609-618.	0.6	40
572	The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study. International Journal of Colorectal Disease, 2018, 33, 1115-1124.	1.0	55
573	Colorectal Cancer: Why Does Side Matter?. Drugs, 2018, 78, 789-798.	4.9	41
574	Tumor-Infiltrating Lymphocytes and Colorectal Cancer Survival in African American and Caucasian Patients. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 755-761.	1.1	22
575	Itraconazole targets cell cycle heterogeneity in colorectal cancer. Journal of Experimental Medicine, 2018, 215, 1891-1912.	4.2	54
576	The protective role of all-transretinoic acid (ATRA) against colorectal cancer development is achieved via increasing miR-3666 expression and decreasing E2F7 expression. Biomedicine and Pharmacotherapy, 2018, 104, 94-101.	2.5	35
577	Aurora kinase A (AURKA) interaction with Wnt and Ras-MAPK signalling pathways in colorectal cancer. Scientific Reports, 2018, 8, 7522.	1.6	38
578	Host MICA Polymorphism as a Potential Predictive Marker in Response to Chemotherapy for Colorectal Liver Metastases. Digestive Diseases, 2018, 36, 437-445.	0.8	2
579	Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. The Lancet Gastroenterology and Hepatology, 2018, 3, 635-643.	3.7	60
580	Polypeptideâ€‘GalNAcâ€‘T6 expression predicts better overall survival in patients with colon cancer. Oncology Letters, 2018, 16, 225-234.	0.8	3
581	Serum heat shock protein 90α have an advantage in diagnosis of colorectal cancer at early stage. Biomarkers in Medicine, 2018, 12, 881-890.	0.6	23
582	P1 promoter-driven HNF4α isoforms are specifically repressed by β-catenin signaling in colorectal cancer cells. Journal of Cell Science, 2018, 131, .	1.2	22
583	Association of microRNA-7 and its binding partner CDR1-AS with the prognosis and prediction of 1st-line tamoxifen therapy in breast cancer. Scientific Reports, 2018, 8, 9657.	1.6	32
584	Cetuximab improves AZD6244 antitumor activity in colorectal cancer HT29 cells in vitro and in nude mice by attenuating HER3/Akt pathway activation. Oncology Letters, 2018, 16, 326-334.	0.8	5
585	Consensus molecular subtype classification of colorectal adenomas. Journal of Pathology, 2018, 246, 266-276.	2.1	60
586	Shortening adjuvant chemotherapy in stage III colon cancer: are we ready for a change?. ESMO Open, 2018, 3, e000392.	2.0	0

#	Article	IF	Citations
587	One-carbon metabolism biomarkers and genetic variants in relation to colorectal cancer risk by KRAS and BRAF mutation status. PLoS ONE, 2018, 13, e0196233.	1.1	9
588	Manic Fringe deficiency imposes Jagged1 addiction to intestinal tumor cells. Nature Communications, 2018, 9, 2992.	5.8	23
589	polyClustR: defining communities of reconciled cancer subtypes with biological and prognostic significance. BMC Bioinformatics, 2018, 19, 182.	1.2	1
590	Gene length corrected trimmed mean of M-values (GeTMM) processing of RNA-seq data performs similarly in intersample analyses while improving intrasample comparisons. BMC Bioinformatics, 2018, 19, 236.	1.2	105
591	Characterization and In Vivo Validation of a Three-Dimensional Multi-Cellular Culture Model to Study Heterotypic Interactions in Colorectal Cancer Cell Growth, Invasion and Metastasis. Frontiers in Bioengineering and Biotechnology, 2018, 6, 97.	2.0	30
592	Colorectal Cancer, Pathology and Genetics. , 2018, , 428-428.		0
593	Vitamin D and Colon Cancer. , 2018, , 837-862.		6
594	Prognostic value of total number of lymph nodes retrieved differs between left-sided colon cancer and right-sided colon cancer in stage III patients with colon cancer. BMC Cancer, 2018, 18, 558.	1.1	27
595	miR-155 Is Downregulated in Familial Adenomatous Polyposis and Modulates WNT Signaling by Targeting AXIN1 and TCF4. Molecular Cancer Research, 2018, 16, 1965-1976.	1.5	17
596	Colorectal cancer immunotherapy. Rad Hrvatske Akademije Znanosti I Umjetnosti Medicinske Znanosti, 2018, 533, 127-138.	0.1	0
597	Rimonabant Kills Colon Cancer Stem Cells without Inducing Toxicity in Normal Colon Organoids. Frontiers in Pharmacology, 2017, 8, 949.	1.6	33
598	From Chemotherapy to Combined Targeted Therapeutics: In Vitro and in Vivo Models to Decipher Intra-tumor Heterogeneity. Frontiers in Pharmacology, 2018, 9, 77.	1.6	21
599	SCF/c-KIT Signaling Increased Mucin2 Production by Maintaining Atoh1 Expression in Mucinous Colorectal Adenocarcinoma. International Journal of Molecular Sciences, 2018, 19, 1541.	1.8	10
600	Annexin A2 overexpression associates with colorectal cancer invasiveness and TGF-ÃŸ induced epithelial mesenchymal transition via Src/ANXA2/STAT3. Scientific Reports, 2018, 8, 11285.	1.6	57
601	Cancerâ€associated thrombosis: The search for the holy grail continues. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 622-629.	1.0	21
602	Does the site of primary colorectal cancer influence the outcome after resection of isolated liver metastases?. Digestive and Liver Disease, 2018, 50, 1088-1092.	0.4	13
603	Increased Levels of Oxidative Damage in Liver Metastases Compared with Corresponding Primary Colorectal Tumors. American Journal of Pathology, 2018, 188, 2369-2377.	1.9	14
604	Effects of CDX2 on prognosis and chemotherapy responsiveness in mismatch repair-deficient colorectal cancer. BJS Open, 2018, 2, 456-463.	0.7	11

#	Article	IF	Citations
605	An increased number of negative lymph nodes is associated with a higher immune response and longer survival in colon cancer patients. Cancer Management and Research, 2018, Volume 10, 1597-1604.	0.9	18
606	An Integrated Approach for Identifying Molecular Subtypes in Human Colon Cancer Using Gene Expression Data. Genes, 2018, 9, 397.	1.0	6
607	Molecular Epidemiology and Cancer Risk â˜†. , 2018, , 487-487.		0
608	Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy. Frontiers in Oncology, 2018, 8, 107.	1.3	24
609	The Application of Gene Expression Profiling in Predictions of Occult Lymph Node Metastasis in Colorectal Cancer Patients. Biomedicines, 2018, 6, 27.	1.4	19
610	Colorectal Cancers: An Update on Their Molecular Pathology. Cancers, 2018, 10, 26.	1.7	128
611	Teaming Up for Trouble: Cancer Cells, Transforming Growth Factor-Î²1 Signaling and the Epigenetic Corruption of Stromal NaÃ¯ve Fibroblasts. Cancers, 2018, 10, 61.	1.7	30
612	TGF-Î² in T Cell Biology: Implications for Cancer Immunotherapy. Cancers, 2018, 10, 194.	1.7	132
613	Biobanks in personalized medicine. Expert Review of Precision Medicine and Drug Development, 2018, 3, 265-273.	0.4	6
614	The Rac1 splice form Rac1b favors mouse colonic mucosa regeneration and contributes to intestinal cancer progression. Oncogene, 2018, 37, 6054-6068.	2.6	14
615	Consensus on Molecular Subtypes of High-Grade Serous Ovarian Carcinoma. Clinical Cancer Research, 2018, 24, 5037-5047.	3.2	93
616	Colorectal Cancer: Genetic Abnormalities, Tumor Progression, Tumor Heterogeneity, Clonal Evolution and Tumor-Initiating Cells. Medical Sciences (Basel, Switzerland), 2018, 6, 31.	1.3	167
617	Probing the colorectal cancer proteome for biomarkers: Current status and perspectives. Journal of Proteomics, 2018, 187, 93-105.	1.2	46
618	Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials. British Journal of Cancer, 2018, 119, 303-312.	2.9	29
619	Targeted therapy for metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2018, 18, 991-1006.	1.1	44
620	Organoids Provide an Important Window on Inflammation in Cancer. Cancers, 2018, 10, 151.	1.7	27
621	Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. Critical Reviews in Oncology/Hematology, 2018, 130, 13-26.	2.0	34
622	The TGFÎ²-signaling pathway and colorectal cancer: associations between dysregulated genes and miRNAs. Journal of Translational Medicine, 2018, 16, 191.	1.8	35

#	ARTICLE	IF	CITATIONS
623	Advantage of <i>HSP110</i> (T17) marker inclusion for microsatellite instability (MSI) detection in colorectal cancer patients. Oncotarget, 2018, 9, 28691-28701.	0.8	46
624	Mechanistic Insights into Colorectal Cancer Phenomics from Fundamental and Organotypic Model Studies. American Journal of Pathology, 2018, 188, 1936-1948.	1.9	7
625	Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. Clinical Colorectal Cancer, 2018, 17, e699-e709.	1.0	34
626	Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes. BMC Cancer, 2018, 18, 603.	1.1	63
627	Using patient-derived xenograft models of colorectal liver metastases to predict chemosensitivity. Journal of Surgical Research, 2018, 227, 158-167.	0.8	8
628	Molecular Basis of Colorectal Cancer: Tumor Biology. , 2018, , 23-34.		0
629	MicroRNA-181a promotes angiogenesis in colorectal cancer by targeting SRCIN1 to promote the SRC/VEGF signaling pathway. Cell Death and Disease, 2018, 9, 438.	2.7	78
630	Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie). BMC Cancer, 2018, 18, 11.	1.1	14
631	A role for endothelial nitric oxide synthase in intestinal stem cell proliferation and mesenchymal colorectal cancer. BMC Biology, 2018, 16, 3.	1.7	27
632	HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors. Breast Cancer Research, 2018, 20, 8.	2.2	44
633	Molecular subtyping of nasopharyngeal carcinoma (NPC) and a microRNA-based prognostic model for distant metastasis. Journal of Biomedical Science, 2018, 25, 16.	2.6	38
634	<i>Fusobacterium nucleatum</i> Infection in Colorectal Cancer: Linking Inflammation, DNA Mismatch Repair and Genetic and Epigenetic Alterations. Journal of the Anus, Rectum and Colon, 2018, 2, 37-46.	0.4	48
635	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet, The, 2018, 391, 2128-2139.	6.3	1,487
636	Integrated analysis highlights APC11 protein expression as a likely new independent predictive marker for colorectal cancer. Scientific Reports, 2018, 8, 7386.	1.6	12
637	DNA methylation-mediated repression of miR-181a/135a/302c expression promotes the microsatellite-unstable colorectal cancer development and 5-FU resistance via targeting PLAG1. Journal of Genetics and Genomics, 2018, 45, 205-214.	1.7	30
638	Profiles of immune infiltration in colorectal cancer and their clinical significant: A gene expression‐based study. Cancer Medicine, 2018, 7, 4496-4508.	1.3	194
639	Overexpression of UQCRC2 is correlated with tumor progression and poor prognosis in colorectal cancer. Pathology Research and Practice, 2018, 214, 1613-1620.	1.0	24
640	Itraconazole perturbs colorectal cancer dormancy through SUFU-mediated WNT inhibition. Molecular and Cellular Oncology, 2018, 5, e1494950.	0.3	11

#	Article	IF	Citations
641	Eastern Canadian Colorectal Cancer Consensus Conference 2017. Current Oncology, 2018, 25, 262-274.	0.9	4
642	Genetic and epigenetic alterations of colorectal cancer. Intestinal Research, 2018, 16, 327.	1.0	100
643	Nomogram Predicting Survival After Recurrence in Patients With Stage I to III Colon Cancer: A Nationwide Multicenter Study. Diseases of the Colon and Rectum, 2018, 61, 1053-1062.	0.7	30
644	Prognostic and predictive biomarkers in nonmetastatic colorectal cancers. Future Oncology, 2018, 14, 2097-2102.	1.1	4
645	Molecular Variances Between Right- and Left-sided Colon Cancers. Current Colorectal Cancer Reports, 2018, 14, 152-158.	1.0	5
646	Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX. Clinical Cancer Research, 2018, 24, 6204-6211.	3.2	61
647	Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2. Annals of Oncology, 2018, 29, 2061-2067.	0.6	35
648	Epithelialâ€toâ€mesenchymal transition signature assessment in colorectal cancer quantifies tumour stromal content rather than true transition. Journal of Pathology, 2018, 246, 422-426.	2.1	25
650	Sensitivity of Colorectal Cancer to Arginine Deprivation Therapy is Shaped by Differential Expression of Urea Cycle Enzymes. Scientific Reports, 2018, 8, 12096.	1.6	55
651	The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 2018, 19, 2298.	1.8	4
652	Patient Similarity Networks for Precision Medicine. Journal of Molecular Biology, 2018, 430, 2924-2938.	2.0	93
653	Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients. Neoplasia, 2018, 20, 678-686.	2.3	7
654	The Human Transcriptome. , 2018, , 135-164.		4
655	Cancer Stemness, Immune Cells, and Epithelialâ€"Mesenchymal Transition Cooperatively Predict Prognosis in Colorectal Carcinoma. Clinical Colorectal Cancer, 2018, 17, e579-e592.	1.0	24
656	Noninferiority of three monthsversussix months of oxaliplatinâ€based adjuvant chemotherapy for resected colon cancer. How shouldIDEAfindings affect clinical practice?. International Journal of Cancer, 2018, 143, 2342-2350.	2.3	7
657	Cell-of-Origin DNA Methylation Signatures Are Maintained during Colorectal Carcinogenesis. Cell Reports, 2018, 23, 3407-3418.	2.9	66
658	A feasibility study of colorectal cancer diagnosis via circulating tumor DNA derived CNV detection. PLoS ONE, 2018, 13, e0196826.	1.1	22
659	Prognostic, predictive, and pharmacogenomic assessments of <scp>CDX</scp>2 refine stratification of colorectal cancer. Molecular Oncology, 2018, 12, 1639-1655.	2.1	40

#	ARTICLE	IF	CITATIONS
660	Oncogenic BRAF^{V600E} drives expression of MGL ligands in the colorectal cancer cell line HT29 through <i>N</i>-acetylgalactosamine-transferase 3. Biological Chemistry, 2018, 399, 649-659.	1.2	16
661	Hypoxic tumor microenvironment activates GLI2 via HIF-1Î± and TGF-Î²2 to promote chemoresistance in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5990-E5999.	3.3	203
662	Telomere length alterations in microsatellite stable colorectal cancer and association with the immune response. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 2992-3000.	1.8	7
663	Molecular landscape of esophageal cancer: implications for early detection and personalized therapy. Annals of the New York Academy of Sciences, 2018, 1434, 342-359.	1.8	56
664	Roles for AXL and MERTK in Resistance to Cytotoxic and Targeted Therapies. , 2019, , 61-85.		1
665	Liver Resection for Colorectal Hepatic Metastases after Systemic Chemotherapy and Selective Internal Radiation Therapy with Yttrium-90 Microspheres: A Systematic Review. Digestive Surgery, 2019, 36, 273-280.	0.6	10
666	Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities. Seminars in Cancer Biology, 2019, 55, 37-52.	4.3	125
667	The landscape of genomic copy number alterations in colorectal cancer and their consequences on gene expression levels and disease outcome. Molecular Aspects of Medicine, 2019, 69, 48-61.	2.7	40
668	Genomic profiles of colorectal carcinoma with liver metastases and newly identified fusion genes. Cancer Science, 2019, 110, 2973-2981.	1.7	23
669	Association of Epigenetic Clock with Consensus Molecular Subtypes and Overall Survival of Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1720-1724.	1.1	37
670	Colorectal cancer cells respond differentially to autophagy inhibition in vivo. Scientific Reports, 2019, 9, 11316.	1.6	43
671	Epigenetics and Common Non Communicable Disease. Advances in Experimental Medicine and Biology, 2019, 1121, 7-20.	0.8	10
672	Genome-wide mapping of DNA-binding sites identifies stemness-related genes as directly repressed targets of SNAIL1 in colorectal cancer cells. Oncogene, 2019, 38, 6647-6661.	2.6	24
673	Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types. Nature Communications, 2019, 10, 3574.	5.8	111
674	Stochastic block models with multiple continuous attributes. Applied Network Science, 2019, 4, .	0.8	29
675	Novel reference genes in colorectal cancer identify a distinct subset of high stage tumors and their associated histologically normal colonic tissues. BMC Medical Genetics, 2019, 20, 138.	2.1	16
676	The Intricate Interplay between Epigenetic Events, Alternative Splicing and Noncoding RNA Deregulation in Colorectal Cancer. Cells, 2019, 8, 929.	1.8	28
677	Epigenome Mapping Identifies Tumor-Specific Gene Expression in Primary Rectal Cancer. Cancers, 2019, 11, 1142.	1.7	10

#	Article	IF	Citations
678	DeepCC: a novel deep learning-based framework for cancer molecular subtype classification. Oncogenesis, 2019, 8, 44.	2.1	138
679	Epigenetic Biomarkers and Their Therapeutic Applications in Colorectal Cancer. , 2019, , .		0
680	The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer. EBioMedicine, 2019, 46, 94-104.	2.7	24
681	Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses. Npj Breast Cancer, 2019, 5, 21.	2.3	43
682	Molecular Approaches to Metastatic Colorectal Cancer: Better Diagnosis â€" Better Treatment?. Visceral Medicine, 2019, 35, 259-265.	0.5	5
683	Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. Clinical Cancer Research, 2019, 25, 6243-6259.	3.2	42
684	Assessing the consequences of decentralizing biomedical research. Big Data and Society, 2019, 6, 205395171985385.	2.6	6
685	Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 364.	3.5	63
686	Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains. Oncogene, 2019, 38, 6109-6122.	2.6	20
687	Adjuvant chemotherapy in resected colon cancer: When, how and how long?. Surgical Oncology, 2019, 30, 100-107.	0.8	58
688	Neutrophil-related Variables Have Different Prognostic Effect Based on Primary Tumor Location in Patients With Metastatic Colorectal Cancer Receiving Chemotherapy. Clinical Colorectal Cancer, 2019, 18, e343-e348.	1.0	5
689	Cell Line Derived Xenograft Mouse Models Are a Suitable in vivo Model for Studying Tumor Budding in Colorectal Cancer. Frontiers in Medicine, 2019, 6, 139.	1.2	24
690	Roles of exosomes in metastatic colorectal cancer. American Journal of Physiology - Cell Physiology, 2019, 317, C869-C880.	2.1	28
691	External validation of molecular subtype classifications of colorectal cancer based on microsatellite instability, CIMP, BRAF and KRAS. BMC Cancer, 2019, 19, 681.	1.1	18
692	Immune cell concentrations among the primary tumor microenvironment in colorectal cancer patients predicted by clinicopathologic characteristics and blood indexes. , 2019, 7, 179.		58
693	Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A. EBioMedicine, 2019, 45, 139-154.	2.7	36
694	Identification of anticancer drugs to radiosensitise BRAF-wild-type and mutant colorectal cancer. Cancer Biology and Medicine, 2019, 16, 234.	1.4	4
695	Expression Profiling Reveals Involvement of WNT Pathway in the Malignant Progression of Sessile Serrated Adenomas. American Journal of Pathology, 2019, 189, 1732-1743.	1.9	3

#	Article	IF	Citations
696	Metagenomics and transcriptomics data from human colorectal cancer. Scientific Data, 2019, 6, 116.	2.4	7
697	Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. Cancer Cell, 2019, 36, 35-50.e9.	7.7	179
698	Prognostic and predictive markers in liver limited stage IV colorectal cancer. European Journal of Surgical Oncology, 2019, 45, 2251-2256.	0.5	23
699	Connections between the cell cycle, cell adhesion and the cytoskeleton. Philosophical Transactions of the Royal Society B: Biological Sciences, 2019, 374, 20180227.	1.8	102
700	Cancer-associated fibroblastsâ€"heroes or villains?. British Journal of Cancer, 2019, 121, 293-302.	2.9	155
701	<p>Integrated assessment of PD-L1 expression and molecular classification facilitates therapy selection and prognosis prediction in gastric cancer</p>. Cancer Management and Research, 2019, Volume 11, 6397-6410.	0.9	13
702	Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients. Frontiers in Oncology, 2019, 9, 723.	1.3	13
703	Subtyping of microsatellite instability-high colorectal cancer. Cell Communication and Signaling, 2019, 17, 79.	2.7	42
704	The Molecular Hallmarks of the Serrated Pathway in Colorectal Cancer. Cancers, 2019, 11, 1017.	1.7	115
705	Importance of genetic screens in precision oncology. ESMO Open, 2019, 4, e000505.	2.0	10
706	The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. Drugs, 2019, 79, 1375-1394.	4.9	48
707	Correlation between circulating endothelial progenitor cells and serum carcinoembryonic antigen level in colorectal cancer. Acta Biochimica Et Biophysica Sinica, 2019, 51, 1304-1304.	0.9	1
708	Intestinal PPARÎ± Protects Against Colon Carcinogenesis via Regulation of Methyltransferases DNMT1 and PRMT6. Gastroenterology, 2019, 157, 744-759.e4.	0.6	111
709	Molecular targeted therapy of <i>BRAF</i>-mutant colorectal cancer. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985649.	1.4	72
710	Genomics and metagenomics of colorectal cancer. Journal of Gastrointestinal Oncology, 2019, 10, 1164-1170.	0.6	28
711	Intercellular Transfer of Oncogenic KRAS via Tunneling Nanotubes Introduces Intracellular Mutational Heterogeneity in Colon Cancer Cells. Cancers, 2019, 11, 892.	1.7	43
712	Evolving neoantigen profiles in colorectal cancers with DNA repair defects. Genome Medicine, 2019, 11, 42.	3.6	42
713	Integrating proteomics and transcriptomics for the identification of potential targets in early colorectal cancer. International Journal of Oncology, 2019, 55, 439-450.	1.4	15

#	Article	IF	Citations
714	Mucin 16 and kallikrein 13 as potential prognostic factors in colon cancer: Results of an oncological 92-multiplex immunoassay. Tumor Biology, 2019, 41, 101042831986072.	0.8	11
715	<scp>ROCK</scp> 2 inhibition triggers the collective invasion of colorectal adenocarcinomas. EMBO Journal, 2019, 38, e99299.	3.5	48
716	Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer:<i>Post hoc</i>Analysis of the MOSAIC and PETACC-8 Trials. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1153-1161.	1.1	14
717	An updated review of microsatellite instability in the era of next-generation sequencing and precision medicine. Seminars in Oncology, 2019, 46, 261-270.	0.8	52
718	Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab. Expert Opinion on Biological Therapy, 2019, 19, 1247-1263.	1.4	29
719	Clinical Application of Next-Generation Sequencing as A Liquid Biopsy Technique in Advanced Colorectal Cancer: A Trick or A Treat?. Cancers, 2019, 11, 1573.	1.7	17
720	Insulin-Like Growth Factor 2 (IGF2) Signaling in Colorectal Cancerâ€"from Basic Research to Potential Clinical Applications. International Journal of Molecular Sciences, 2019, 20, 4915.	1.8	49
721	Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer. BMC Cancer, 2019, 19, 964.	1.1	20
722	Gender medicine and oncology: report and consensus of an ESMO workshop. Annals of Oncology, 2019, 30, 1914-1924.	0.6	120
723	Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients. Cancers, 2019, 11, 1540.	1.7	19
724	Human Colorectal Cancer from the Perspective of Mouse Models. Genes, 2019, 10, 788.	1.0	26
725	The role of <i>Fusobacterium nucleatum</i> in colorectal cancer: from carcinogenesis to clinical management. Chronic Diseases and Translational Medicine, 2019, 5, 178-187.	0.9	69
726	The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents. Anticancer Research, 2019, 39, 5645-5652.	0.5	9
727	WNT/Î²-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment. Frontiers in Immunology, 2019, 10, 2293.	2.2	165
728	<p>An immune-related gene pairs signature predicts overall survival in serous ovarian carcinoma</p>. OncoTargets and Therapy, 2019, Volume 12, 7005-7014.	1.0	27
729	Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution. Critical Reviews in Oncology/Hematology, 2019, 143, 153-163.	2.0	49
730	BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights. International Journal of Molecular Sciences, 2019, 20, 5369.	1.8	88
731	A multi-modal data resource for investigating topographic heterogeneity in patient-derived xenograft tumors. Scientific Data, 2019, 6, 253.	2.4	7

#	ARTICLE	IF	CITATIONS
732	Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. International Journal of Molecular Sciences, 2019, 20, 5452.	1.8	53
733	The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications. European Journal of Cancer, 2019, 123, 118-129.	1.3	50
734	Radiomics features on radiotherapy treatment planning CT can predict patient survival in locally advanced rectal cancer patients. Scientific Reports, 2019, 9, 15346.	1.6	29
735	Visualization of epithelial-mesenchymal transition in an inflammatory microenvironmentâ€"colorectal cancer network. Scientific Reports, 2019, 9, 16378.	1.6	29
736	Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status. , 2019, 7, 297.		24
737	Serrated Colorectal Cancer: The Road Less Travelled?. Trends in Cancer, 2019, 5, 742-754.	3.8	32
738	Colorectal cancer-associated microbiota contributes to oncogenic epigenetic signatures. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 24285-24295.	3.3	139
739	DNA repair capacity and response to treatment of colon cancer. Pharmacogenomics, 2019, 20, 1225-1233.	0.6	11
740	Intestinal microbiota and colorectal carcinoma: Implications for pathogenesis, diagnosis, and therapy. EBioMedicine, 2019, 48, 648-655.	2.7	72
741	Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients. Scientific Reports, 2019, 9, 15365.	1.6	54
742	Proteomic Analysis of Primary Colon Cancer and Synchronous Solitary Liver Metastasis. Cancer Genomics and Proteomics, 2019, 16, 583-592.	1.0	26
743	Primary adenocarcinoma of the bladder lacks mismatch repair deficiency and demonstrates PD-L1 expression in tumor-infiltrating immune cells, with implications in both diagnosis and therapeutics. Human Pathology, 2019, 94, 58-63.	1.1	6
744	SWATHâ€"based proteomics reveals processes associated with immune evasion and metastasis in poor prognosis colorectal tumours. Journal of Cellular and Molecular Medicine, 2019, 23, 8219-8232.	1.6	15
745	Bergamottin exerts anticancer effects on human colon cancer cells via induction of apoptosis, G2/M cell cycle arrest and deactivation of the Ras/Raf/ERK signalling pathway. Archives of Medical Science, 2019, , .	0.4	2
746	Colorectal cancer. Lancet, The, 2019, 394, 1467-1480.	6.3	2,462
747	Appraisal of Prognostic Interaction between Sidedness and Mucinous Histology in Colon Cancer: A Population-Based Study Using Inverse Probability Propensity Score Weighting. Journal of Cancer, 2019, 10, 388-396.	1.2	4
748	Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon. Cell Death and Disease, 2019, 10, 818.	2.7	12
750	Post-transcriptional Regulation of Colorectal Cancer: A Focus on RNA-Binding Proteins. Frontiers in Molecular Biosciences, 2019, 6, 65.	1.6	39

#	Article	IF	Citations
751	Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 713-732.	8.2	1,399
752	Gut Microbiome: A Promising Biomarker for Immunotherapy in Colorectal Cancer. International Journal of Molecular Sciences, 2019, 20, 4155.	1.8	83
753	Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer. Annals of Oncology, 2019, 30, 1622-1629.	0.6	150
754	Expressions of 10 genes as candidate predictors of recurrence in stageï¿½III colon cancer patients receiving adjuvant oxaliplatinâ€‘based chemotherapy. Oncology Letters, 2019, 18, 1388-1394.	0.8	9
755	Advances in Molecular Subclassification of Colorectal Cancer. , 2019, , .		0
756	Proteome-transcriptome alignment of molecular portraits achieved by self-contained gene set analysis: Consensus colon cancer subtypes case study. PLoS ONE, 2019, 14, e0221444.	1.1	1
757	Intratumoural-infiltrating CD4â€‰+â€‰and FOXP3â€‰+â€‰T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer. British Journal of Cancer, 2019, 121, 659-665.	2.9	84
758	Comprehensive intra-individual genomic and transcriptional heterogeneity: Evidence-based Colorectal Cancer Precision Medicine. Cancer Treatment Reviews, 2019, 80, 101894.	3.4	37
759	Wnt Signaling in Cancer: Not a Binary ON:OFF Switch. Cancer Research, 2019, 79, 5901-5906.	0.4	50
760	CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer. British Journal of Cancer, 2019, 121, 593-599.	2.9	24
761	Identification of modules and functional analysis in CRC subtypes by integrated bioinformatics analysis. PLoS ONE, 2019, 14, e0221772.	1.1	6
762	The Crohn's-Like Lymphoid Reaction to Colorectal Cancer-Tertiary Lymphoid Structures With Immunologic and Potentially Therapeutic Relevance in Colorectal Cancer. Frontiers in Immunology, 2019, 10, 1884.	2.2	42
764	Is the tumour microenvironment a critical prognostic factor in early-stage colorectal cancer?. Annals of Oncology, 2019, 30, 1538-1540.	0.6	4
765	Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research. Cancers, 2019, 11, 1321.	1.7	34
766	The Dual Roles of the Atypical Protein Kinase Cs in Cancer. Cancer Cell, 2019, 36, 218-235.	7.7	58
767	Terminology, Molecular Features, Epidemiology, and Management of Serrated Colorectal Neoplasia. Gastroenterology, 2019, 157, 949-966.e4.	0.6	213
768	Negative Hyperselection of Patients With *RAS* and *BRAF* Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. Journal of Clinical Oncology, 2019, 37, 3099-3110.	0.8	65
769	Clinical and immune profiling for cancer of unknown primary site. , 2019, 7, 251.		26

#	Article	IF	Citations
770	Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis. Cancer Cell, 2019, 36, 319-336.e7.	7.7	278
771	Proteomics analysis of the matrisome from MC38 experimental mouse liver metastases. American Journal of Physiology - Renal Physiology, 2019, 317, G625-G639.	1.6	7
772	Peripheral Innate Lymphoid Cells Are Increased in First Line Metastatic Colorectal Carcinoma Patients: A Negative Correlation With Th1 Immune Responses. Frontiers in Immunology, 2019, 10, 2121.	2.2	35
773	Mutation profiling of cancer drivers in Brazilian colorectal cancer. Scientific Reports, 2019, 9, 13687.	1.6	31
774	Colon Cancer: Epithelial Notch Signaling Recruits Neutrophils to Drive Metastasis. Cancer Cell, 2019, 36, 213-214.	7.7	23
775	A prognostic index based on an eleven gene signature to predict systemic recurrences in colorectal cancer. Experimental and Molecular Medicine, 2019, 51, 1-12.	3.2	21
776	Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer. International Journal of Molecular Sciences, 2019, 20, 4624.	1.8	5
777	Involvement of MAF1ï¿½homolog, negative regulator of RNA polymeraseï¿½III in colorectal cancer progression. International Journal of Oncology, 2019, 54, 1001-1009.	1.4	7
778	Hope4Genes: a Hopfield-like class prediction algorithm for transcriptomic data. Scientific Reports, 2019, 9, 337.	1.6	24
779	A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer. Cancers, 2019, 11, 147.	1.7	15
780	Back to the Colorectal Cancer Consensus Molecular Subtype Future. Current Gastroenterology Reports, 2019, 21, 5.	1.1	50
781	Integrating clinical, molecular, proteomic and histopathological data within the tissue context: tissunomics. Histopathology, 2019, 75, 4-19.	1.6	8
782	JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 28.	3.5	24
783	Predicting survival from colorectal cancer histology slides using deep learning: A retrospective multicenter study. PLoS Medicine, 2019, 16, e1002730.	3.9	563
784	Landscape of Big Medical Data: A Pragmatic Survey on Prioritized Tasks. IEEE Access, 2019, 7, 15590-15611.	2.6	2
785	Combination therapies with HSP90 inhibitors against colorectal cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 240-247.	3.3	81
786	<p>A novel LARCassigner3 classification predicts outcomes in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy: a retrospective training and validation analysis</p>. Cancer Management and Research, 2019, Volume 11, 4153-4170.	0.9	2
787	Targeted next generation sequencing reveals a common genetic pathway for colorectal cancers with chromosomal instability and those with microsatellite and chromosome stability. Pathology Research and Practice, 2019, 215, 152445.	1.0	3

#	Article	IF	Citations
788	Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Medicine, 2019, 11, 34.	3.6	732
789	Targeted Gene Sequencing Panels: Applicability for Neoantigen Profiling of Colon and Rectal Adenocarcinoma. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2019, 13, 146-153.	0.2	1
790	Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report. BMC Cancer, 2019, 19, 567.	1.1	15
791	Towards the Integration of Metabolic Network Modelling and Machine Learning for the Routine Analysis of High-Throughput Patient Data. Computational Biology, 2019, , 401-424.	0.1	0
792	InÂvivo effects of chemotherapy on oncogenic pathways in colorectal cancer. Cancer Science, 2019, 110, 2529-2539.	1.7	13
793	c-Myb and its Effector COX-2 as an Indicator Associated with Prognosis and Therapeutic Outcome in Colorectal Cancer. Journal of Cancer, 2019, 10, 1601-1610.	1.2	3
794	Mechanisms of immunogenicity in colorectal cancer. British Journal of Surgery, 2019, 106, 1283-1297.	0.1	32
795	Locally advanced rectal cancer transcriptomic-based secretome analysis reveals novel biomarkers useful to identify patients according to neoadjuvant chemoradiotherapy response. Scientific Reports, 2019, 9, 8702.	1.6	14
796	Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repairâ€"Deficient Colorectal Cancer. Cancer Immunology Research, 2019, 7, 1230-1236.	1.6	59
797	Analysis of the transcriptomic features of microsatellite instability subtype colon cancer. BMC Cancer, 2019, 19, 605.	1.1	10
798	Transcriptomic Differences between Primary Colorectal Adenocarcinomas and Distant Metastases Reveal Metastatic Colorectal Cancer Subtypes. Cancer Research, 2019, 79, 4227-4241.	0.4	48
799	Circulating Tumor DNA Analysis: Clinical Implications for Colorectal Cancer Patients. A Systematic Review. JNCI Cancer Spectrum, 2019, 3, pkz042.	1.4	22
800	Role of Brutonâ€™s Tyrosine Kinase in Stage III Colorectal Cancer. Cancers, 2019, 11, 880.	1.7	11
801	Oct4 Gene Expression in Primary Colorectal Cancer Promotes Liver Metastasis. Stem Cells International, 2019, 2019, 1-10.	1.2	27
802	Decoding Metastatic Colorectal Cancer to Improve Clinical Decision Making. Journal of Clinical Oncology, 2019, 37, 1847-1850.	0.8	5
803	A Cancer Stem Cell Perspective on Minimal Residual Disease in Solid Malignancies. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 31-49.	0.1	1
804	Clinicopathological and biomolecular characteristics of stage IIB/IIC and stage IIIA colon cancer: Insight into the survival paradox. Journal of Surgical Oncology, 2019, 120, 423-430.	0.8	19
805	Identifying Epistasis in Cancer Genomes: A Delicate Affair. Cell, 2019, 177, 1375-1383.	13.5	81

#	Article	IF	Citations
806	Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment. Cell Death and Disease, 2019, 10, 415.	2.7	121
807	Vitamin D and Wnt3A have additive and partially overlapping modulatory effects on gene expression and phenotype in human colon fibroblasts. Scientific Reports, 2019, 9, 8085.	1.6	23
808	A Hybrid Neural Network Approach for Lung Cancer Classification with Gene Expression Dataset and Prior Biological Knowledge. Lecture Notes in Computer Science, 2019, , 279-293.	1.0	3
809	Colorectal Adenocarcinoma, Not Just One Disease. Cellular and Molecular Gastroenterology and Hepatology, 2019, 8, 293-294.	2.3	0
810	Histomorphological and molecular profiling: friends not foes! Morpho€molecular analysis reveals agreement between histological and molecular profiling. Histopathology, 2019, 75, 694-703.	1.6	7
812	Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy. Molecular Aspects of Medicine, 2019, 69, 123-129.	2.7	30
813	Building a collaboration to improve surgical research through EORTC/ESSO 1409-CLIMB study: A prospective liver metastasis database with an integrated quality assurance program. European Journal of Surgical Oncology, 2019, 45, 1870-1875.	0.5	4
814	Ingestion of Non-digestible Carbohydrates From Plant-Source Foods and Decreased Risk of Colorectal Cancer: A Review on the Biological Effects and the Mechanisms of Action. Frontiers in Nutrition, 2019, 6, 72.	1.6	35
815	Tumor sidedness is not an independent prognostic marker of colorectal cancer patients undergoing curative resection: A retrospective cohort study. PLoS ONE, 2019, 14, e0218207.	1.1	6
816	Complexity and integration. A philosophical analysis of how cancer complexity can be faced in the era of precision medicine. European Journal for Philosophy of Science, 2019, 9, 1.	0.6	6
817	Analysis of risk factors for colon cancer progression . OncoTargets and Therapy, 2019, Volume 12, 3991-4000.	1.0	8
818	Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches. Journal of the National Cancer Institute, 2019, 111, 1131-1141.	3.0	116
819	Colorectal Cancer Research: A State of theÂArt. Hot Topics in Acute Care Surgery and Trauma, 2019, , 1-13.	0.1	1
820	Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies. Cancer Letters, 2019, 458, 123-135.	3.2	40
821	Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes. Scientific Reports, 2019, 9, 7665.	1.6	36
822	Differential colorectal cancer genomics between east and west. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 811-812.	1.4	0
823	Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors. Clinical Cancer Research, 2019, 25, 5250-5259.	3.2	46
824	Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy. BMC Cancer, 2019, 19, 421.	1.1	2

#	Article	IF	Citations
825	Histopathology of Early Mucosal Neoplasias: Morphologic Carcinogenesis in the GI Tract. , 2019, , 25-45.		0
826	Molecular classification of colorectal cancer using the gene expression profile of tumor samples. Experimental Biology and Medicine, 2019, 244, 1005-1016.	1.1	5
827	The role of mSEPT9 in screening, diagnosis, and recurrence monitoring of colorectal cancer. BMC Cancer, 2019, 19, 450.	1.1	82
828	Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 207-215.	1.8	17
829	Control of Tyrosine Kinase Signalling by Small Adaptors in Colorectal Cancer. Cancers, 2019, 11, 669.	1.7	7
830	Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy. Cancer Medicine, 2019, 8, 3120-3130.	1.3	2
831	The expression of long-chain non-coding RNA DMTF1v4 in colorectal cancer tissue and its relationship with clinicopathological features. European Journal of Inflammation, 2019, 17, 205873921984554.	0.2	0
832	UBN2 promotes tumor progression via the Ras/MAPK pathway and predicts poor prognosis in colorectal cancer. Cancer Cell International, 2019, 19, 126.	1.8	13
833	Consequences of a high incidence of microsatellite instability and <i>BRAFâ€‹</i>mutated tumors: A populationâ€‹based cohort of metastatic colorectal cancer patients. Cancer Medicine, 2019, 8, 3623-3635.	1.3	40
834	Integrated molecular and clinical staging defines the spectrum of metastatic cancer. Nature Reviews Clinical Oncology, 2019, 16, 581-588.	12.5	52
835	Emerging Roles of C-Myc in Cancer Stem Cell-Related Signaling and Resistance to Cancer Chemotherapy: A Potential Therapeutic Target Against Colorectal Cancer. International Journal of Molecular Sciences, 2019, 20, 2340.	1.8	165
836	An Ensemble Strategy to Predict Prognosis in Ovarian Cancer Based on Gene Modules. Frontiers in Genetics, 2019, 10, 366.	1.1	5
837	Genetics of rectal cancer and novel therapies: primer for radiologists. Abdominal Radiology, 2019, 44, 3743-3750.	1.0	10
838	Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer. Frontiers in Oncology, 2019, 9, 396.	1.3	135
839	Accurate differential analysis of transcription factor activity from gene expression. Bioinformatics, 2019, 35, 5018-5029.	1.8	3
840	Integrative Genome-Scale DNA Methylation Analysis of a Large and Unselected Cohort Reveals 5 Distinct Subtypes of Colorectal Adenocarcinomas. Cellular and Molecular Gastroenterology and Hepatology, 2019, 8, 269-290.	2.3	42
841	Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities. Cell, 2019, 177, 1035-1049.e19.	13.5	498
842	The Status and Impact of Clinical Tumor Genome Sequencing. Annual Review of Genomics and Human Genetics, 2019, 20, 413-432.	2.5	20

#	ARTICLE	IF	CITATIONS
843	Human Gut-Associated Natural Killer Cells in Health and Disease. Frontiers in Immunology, 2019, 10, 961.	2.2	101
844	Oncogenic KRAS Drives Immune Suppression in Colorectal Cancer. Cancer Cell, 2019, 35, 535-537.	7.7	14
845	Parsimonious Gene Correlation Network Analysis (PGCNA): a tool to define modular gene co-expression for refined molecular stratification in cancer. Npj Systems Biology and Applications, 2019, 5, 13.	1.4	22
846	Gene Expression Signature in Surgical Tissues and Endoscopic Biopsies Identifies High-Risk T1 Colorectal Cancers. Gastroenterology, 2019, 156, 2338-2341.e3.	0.6	37
847	A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer. Clinical Cancer Research, 2019, 25, 4431-4442.	3.2	40
848	State of the Art and Future Direction for the Analysis of Cell-Free Circulating DNA. , 2019, , 133-188.		2
849	Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. Cancer Treatment Reviews, 2019, 76, 22-32.	3.4	224
850	RNAMethyPro: a biologically conserved signature of N6-methyladenosine regulators for predicting survival at pan-cancer level. Npj Precision Oncology, 2019, 3, 13.	2.3	23
851	DNA methylation and chromatin modifiers in colorectal cancer. Molecular Aspects of Medicine, 2019, 69, 73-92.	2.7	34
852	Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival. JCO Precision Oncology, 2019, 3, 1-16.	1.5	30
853	A Machine Learning Platform to Optimize the Translation of Personalized Network Models to the Clinic. JCO Clinical Cancer Informatics, 2019, 3, 1-17.	1.0	4
854	Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies. Lancet Oncology, The, 2019, 20, e274-e283.	5.1	42
855	Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). Journal of Clinical Oncology, 2019, 37, 1876-1885.	0.8	169
856	Atlas Drugged. Cell, 2019, 177, 803-805.	13.5	1
857	Low tumour PPM1H indicates poor prognosis in colorectal cancer via activation of cancer-associated fibroblasts. British Journal of Cancer, 2019, 120, 987-995.	2.9	9
858	Transforming Growth Factor-Î² Signaling in Immunity and Cancer. Immunity, 2019, 50, 924-940.	6.6	1,360
859	Repurposing EGFR Inhibitor Utility in Colorectal Cancer in Mutant <i>APC</i> and <i>TP53</i> Subpopulations. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1141-1152.	1.1	15
860	Differences in gene expression profiling and biomarkers between histological colorectal carcinoma subsets from the serrated pathway. Histopathology, 2019, 75, 496-507.	1.6	6

#	ARTICLE	IF	CITATIONS
861	Improvement of Metastatic Colorectal Cancer Patient Survival: Single Institution Experience. Cancers, 2019, 11, 369.	1.7	4
862	Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy. BMC Cancer, 2019, 19, 255.	1.1	16
863	Adjuvant Chemotherapy of Locally Advanced Colon Cancer: Final Results of a Randomized Trial Comparing 5-Fluorouracil and Folinic Acid with Folfiri. Visceral Medicine, 2019, 35, 124-132.	0.5	3
864	Does Sidedness Matter in Unresectable Colorectal Cancer?. Annals of Surgical Oncology, 2019, 26, 1588-1591.	0.7	1
865	Combined Menin and EGFR Inhibitors Synergize to Suppress Colorectal Cancer via EGFR-Independent and Calcium-Mediated Repression of SKP2 Transcription. Cancer Research, 2019, 79, 2195-2207.	0.4	19
866	Role of SCFAs in gut microbiome and glycolysis for colorectal cancer therapy. Journal of Cellular Physiology, 2019, 234, 17023-17049.	2.0	116
867	Response to preoperative chemotherapy: impact of change in total burden score and mutational tumor status on prognosis of patients undergoing resection for colorectal liver metastases. Hpb, 2019, 21, 1230-1239.	0.1	14
868	Immunotherapy in colorectal cancer: rationale, challenges and potential. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 361-375.	8.2	1,039
869	Paracrine Induction of Epithelial-Mesenchymal Transition Between Colorectal Cancer Cells and its Suppression by a p53/miR-192/215/NID1 Axis. Cellular and Molecular Gastroenterology and Hepatology, 2019, 7, 783-802.	2.3	19
870	Clinical and Molecular Comparative Study of Colorectal Cancer Based on Age-of-onset and Tumor Location: Two Main Criteria for Subclassifying Colorectal Cancer. International Journal of Molecular Sciences, 2019, 20, 968.	1.8	27
871	Systematic Review of the Prognostic Role of the Immune System After Surgery of Colorectal Liver Metastases. Frontiers in Oncology, 2019, 9, 148.	1.3	11
872	KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell, 2019, 35, 559-572.e7.	7.7	353
873	Colonic CD90+ Crypt Fibroblasts Secrete Semaphorins to Support Epithelial Growth. Cell Reports, 2019, 26, 3698-3708.e5.	2.9	74
874	Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nature Communications, 2019, 10, 1333.	5.8	125
875	The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer. Journal of Cancer, 2019, 10, 1611-1615.	1.2	7
876	A robust panel based on tumour microenvironment genes for prognostic prediction and tailoring therapies in stage Iâ€"III colon cancer. EBioMedicine, 2019, 42, 420-430.	2.7	46
877	Mouse Model of Mutated in Colorectal Cancer Gene Deletion Reveals Novel Pathways in Inflammation and Cancer. Cellular and Molecular Gastroenterology and Hepatology, 2019, 7, 819-839.	2.3	11
878	Clinical implications of the genetics of sporadic colorectal cancer. ANZ Journal of Surgery, 2019, 89, 1224-1229.	0.3	25

#	Article	IF	Citations
880	Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. Clinical Colorectal Cancer, 2019, 18, 116-124.	1.0	7
881	Clinical and molecular characterization of early‐onset colorectal cancer. Cancer, 2019, 125, 2002-2010.	2.0	212
882	Colon Cancer Tumor Location Defined by Gene Expression May Disagree With Anatomic Tumor Location. Clinical Colorectal Cancer, 2019, 18, 149-158.	1.0	7
883	New insights into niclosamide action: autophagy activation in colorectal cancer. Biochemical Journal, 2019, 476, 779-781.	1.7	13
884	Impact of laterality and mucinous histology on relapse-free and overall survival in a registry-based colon cancer series. Scientific Reports, 2019, 9, 3668.	1.6	7
885	<p>Claudin gene expression profiles and clinical value in colorectal tumors classified according to their molecular subtype</p>. Cancer Management and Research, 2019, Volume 11, 1337-1348.	0.9	39
886	Novel Molecular Characterization of Colorectal Primary Tumors Based on miRNAs. Cancers, 2019, 11, 346.	1.7	22
887	Clinical characteristics and prognosis of different primary tumor location in colorectal cancer: a population-based cohort study. Clinical and Translational Oncology, 2019, 21, 1524-1531.	1.2	32
888	Proteomic studies of bone and skeletal health outcomes. Bone, 2019, 126, 18-26.	1.4	10
889	Phenotypic heterogeneity of 2D organoid reflects clinical tumor characteristics. Biochemical and Biophysical Research Communications, 2019, 513, 332-339.	1.0	6
890	High Expression of LTBP2 Contributes to Poor Prognosis in Colorectal Cancer Patients and Correlates with the Mesenchymal Colorectal Cancer Subtype. Disease Markers, 2019, 2019, 1-9.	0.6	6
891	Assessing reproducibility of matrix factorization methods in independent transcriptomes. Bioinformatics, 2019, 35, 4307-4313.	1.8	23
892	The CIMP-high phenotype is associated with energy metabolism alterations in colon adenocarcinoma. BMC Medical Genetics, 2019, 20, 52.	2.1	20
893	Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. ESMO Open, 2019, 4, e000489.	2.0	14
894	RNA sequencing reveals <i>PNN</i> and <i>KCNQ1OT1</i> as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy. International Journal of Cancer, 2019, 145, 2580-2593.	2.3	26
895	Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures. PLoS Genetics, 2019, 15, e1008076.	1.5	59
896	Chasing the FOXO3: Insights into Its New Mitochondrial Lair in Colorectal Cancer Landscape. Cancers, 2019, 11, 414.	1.7	19
897	Stem cells in homeostasis and cancer of the gut. Molecular Cancer, 2019, 18, 66.	7.9	44

#	Article	IF	Citations
899	Targeting Receptor Kinases in Colorectal Cancer. Cancers, 2019, 11, 433.	1.7	48
900	Meta-analysis of the molecular associations of mucinous colorectal cancer. British Journal of Surgery, 2019, 106, 682-691.	0.1	54
901	The role of inherited genetic variants in colorectal polyposis syndromes. Advances in Genetics, 2019, 103, 183-217.	0.8	10
902	Prognostic implications of a molecular classifier derived from whole‑exome sequencing in nasopharyngeal carcinoma. Cancer Medicine, 2019, 8, 2705-2716.	1.3	13
903	Immunologic Biomarkers and Biomarkers for Immunotherapies in Gastrointestinal Cancer. Visceral Medicine, 2019, 35, 3-10.	0.5	11
904	Early-stage serrated adenocarcinomas are divided into several molecularly distinct subtypes. PLoS ONE, 2019, 14, e0211477.	1.1	2
905	Co-expression of cytokeratin and vimentin in colorectal cancer highlights a subset of tumor buds and an atypical cancer-associated stroma. Human Pathology, 2019, 87, 18-27.	1.1	28
906	Context matters—consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials. Annals of Oncology, 2019, 30, 520-527.	0.6	80
907	Immunophenotypes of pancreatic ductal adenocarcinoma: Meta‑analysis of transcriptional subtypes. International Journal of Cancer, 2019, 145, 1125-1137.	2.3	30
908	Meeting report from the joint IARC–NCI international cancer seminar series: a focus on colorectal cancer. Annals of Oncology, 2019, 30, 510-519.	0.6	42
909	Systems analysis identifies potential target genes to overcome cetuximab resistance in colorectal cancer cells. FEBS Journal, 2019, 286, 1305-1318.	2.2	31
910	Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancer. Molecular Cancer, 2019, 18, 19.	7.9	31
911	Cancer epigenetics in solid organ tumours: A primer for surgical oncologists. European Journal of Surgical Oncology, 2019, 45, 736-746.	0.5	16
912	Prognostic Value of Primary Tumor Sidedness for Unresectable Stage IV Colorectal Cancer: A Retrospective Study. Annals of Surgical Oncology, 2019, 26, 1358-1365.	0.7	27
913	The expression of brown fat‑associated proteins in colorectal cancer and the relationship of uncoupling protein 1 with prognosis. International Journal of Cancer, 2019, 145, 1138-1147.	2.3	16
914	Programmed Death Ligand-1 expression in stage II colon cancer - experiences from a nationwide populationbased cohort. BMC Cancer, 2019, 19, 142.	1.1	24
915	PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways. Cancer Letters, 2019, 450, 1-13.	3.2	126
916	Neurotrophins and their involvement in digestive cancers. Cell Death and Disease, 2019, 10, 123.	2.7	39

#	Article	IF	Citations
917	Oncologic Effects of Primary Tumor-Sidedness on Patients with Stages 1â€"3 Colon Cancer: A Meta-Analysis. Annals of Surgical Oncology, 2019, 26, 1366-1375.	0.7	9
918	Clinical Implications of Mismatch Repair Status in Patients With High-risk Stage II Colon Cancer. In Vivo, 2019, 33, 649-657.	0.6	9
919	Ten Thousand Consecutive Gastrectomies for Gastric Cancer: Perspectives of a Master Surgeon. Yonsei Medical Journal, 2019, 60, 235.	0.9	11
920	Differential genomic destabilisation in human cells with pathogenic MSH2 mutations introduced by genome editing. Experimental Cell Research, 2019, 377, 24-35.	1.2	12
921	Radiogenomic Analysis of F-18-Fluorodeoxyglucose Positron Emission Tomography and Gene Expression Data Elucidates the Epidemiological Complexity of Colorectal Cancer Landscape. Computational and Structural Biotechnology Journal, 2019, 17, 177-185.	1.9	51
922	Cancer-associated fibroblasts in gastrointestinal cancer. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 282-295.	8.2	371
924	Human colon organoids reveal distinct physiologic and oncogenic Wnt responses. Journal of Experimental Medicine, 2019, 216, 704-720.	4.2	49
925	RAC1B: A Rho GTPase with Versatile Functions in Malignant Transformation and Tumor Progression. Cells, 2019, 8, 21.	1.8	35
926	DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers. Gastroenterology, 2019, 156, 890-903.	0.6	48
927	Right versus left sided metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survival. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 136-143.	0.7	12
929	Report from the 20th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; 28â€"29 September 2018. Current Oncology, 2019, 26, 773-784.	0.9	1
930	Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer. ESMO Open, 2019, 4, e000523.	2.0	11
931	Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics. Molecular Cancer Therapeutics, 2019, 18, 1852-1862.	1.9	22
932	Molecular pathology. , 2019, , 395-433.		0
933	Mucinous adenocarcinoma of the colon and rectum: A genomic analysis. Journal of Surgical Oncology, 2019, 120, 1427-1435.	0.8	22
934	Mapping the Mutation Landscape of Colorectal Cancer. American Journal of the Medical Sciences, 2019, 358, 313-314.	0.4	1
935	Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes. Annals of Oncology, 2019, 30, 1682-1685.	0.6	17
936	Implication of Microsatellite Instability Pathway in Outcome of Colon Cancer in Moroccan Population. Disease Markers, 2019, 2019, 1-10.	0.6	8

#	Article	IF	Citations
937	Tumorheterogenität des kolorektalen Karzinoms: Was wir bisher wissen. Karger Kompass Onkologie, 2019, 6, 76-88.	0.0	0
938	Elevated Microsatellite Alterations at Selected Tetranucleotides (EMAST) Is Not Attributed to MSH3 Loss in Stage I-III Colon cancer: An Automated, Digitalized Assessment by Immunohistochemistry of Whole Slides and Hot Spots. Translational Oncology, 2019, 12, 1583-1588.	1.7	7
939	Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4. Genome Medicine, 2019, 11, 87.	3.6	44
940	DNA methylation instability by BRAF-mediated TET silencing and lifestyle-exposure divides colon cancer pathways. Clinical Epigenetics, 2019, 11, 196.	1.8	22
941	Comparisons of cancer-associated fibroblasts in the intratumoral stroma and invasive front in colorectal cancer. Medicine (United States), 2019, 98, e15164.	0.4	50
942	Development and Characterization of a Genetic Mouse Model of KRAS Mutated Colorectal Cancer. International Journal of Molecular Sciences, 2019, 20, 5677.	1.8	3
943	Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. Annals of Oncology, 2019, 30, 1796-1803.	0.6	136
944	Transforming Growth Factor-β Signaling Pathway in Colorectal Cancer and Its Tumor Microenvironment. International Journal of Molecular Sciences, 2019, 20, 5822.	1.8	147
945	Methods for a similarity measure for clinical attributes based on survival data analysis. BMC Medical Informatics and Decision Making, 2019, 19, 195.	1.5	6
946	Bulk and Single-Cell Next-Generation Sequencing: Individualizing Treatment for Colorectal Cancer. Cancers, 2019, 11, 1809.	1.7	17
947	DAPK1 loss triggers tumor invasion in colorectal tumor cells. Cell Death and Disease, 2019, 10, 895.	2.7	41
948	The integrative knowledge base for miRNA-mRNA expression in colorectal cancer. Scientific Reports, 2019, 9, 18065.	1.6	15
949	Molecular subtyping improves prognostication of Stage 2 colorectal cancer. BMC Cancer, 2019, 19, 1155.	1.1	13
950	Newly Developed CK1-Specific Inhibitors Show Specifically Stronger Effects on CK1 Mutants and Colon Cancer Cell Lines. International Journal of Molecular Sciences, 2019, 20, 6184.	1.8	12
952	Pharmacological Inhibition of TFF3 Enhances Sensitivity of CMS4 Colorectal Carcinoma to 5-Fluorouracil through Inhibition of p44/42 MAPK. International Journal of Molecular Sciences, 2019, 20, 6215.	1.8	14
953	Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression. Journal of Experimental and Clinical Cancer Research, 2019, 38, 492.	3.5	28
954	CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal Carcinoma. American Journal of Surgical Pathology, 2019, 43, 1473-1482.	2.1	25
955	RAS, Cellular Plasticity, and Tumor Budding in Colorectal Cancer. Frontiers in Oncology, 2019, 9, 1255.	1.3	47

#	ARTICLE	IF	CITATIONS
956	Human epidermal growth factor receptor 2-positive digestive tumors. Current Opinion in Oncology, 2019, 31, 354-361.	1.1	4
957	Gel-Based Proteomics of Clinical Samples Identifies Potential Serological Biomarkers for Early Detection of Colorectal Cancer. International Journal of Molecular Sciences, 2019, 20, 6082.	1.8	7
958	Promising Colorectal Cancer Biomarkers for Precision Prevention and Therapy. Cancers, 2019, 11, 1932.	1.7	26
959	Dietary Factors in the Control of Gut Homeostasis, Intestinal Stem Cells, and Colorectal Cancer. Nutrients, 2019, 11, 2936.	1.7	25
960	Current and Emerging Biomarkers in Metastatic Colorectal Cancer. Current Oncology, 2019, 26, 7-15.	0.9	31
961	Capturing colorectal cancer inter€tumor heterogeneity in patient€derived xenograft (PDX) models. International Journal of Cancer, 2019, 144, 366-371.	2.3	32
962	Correlations between the Recurrence Patterns and Sizes of Lateral Pelvic Lymph Nodes before and after Chemoradiotherapy in Patients with Lower Rectal Cancer. Oncology, 2019, 96, 33-43.	0.9	7
963	Dedifferentiation process driven by TGF-beta signaling enhances stem cell properties in human colorectal cancer. Oncogene, 2019, 38, 780-793.	2.6	78
964	Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression. Modern Pathology, 2019, 32, 306-313.	2.9	31
965	Immune Checkpoint Inhibitors in Gastrointestinal Malignancies. , 2019, , 77-101.		0
966	The location of the primary colon cancer has no impact on outcomes in patients undergoing cytoreductive surgery for peritoneal metastasis. Surgery, 2019, 165, 476-484.	1.0	11
967	Activation of AZIN1 RNA editing is a novel mechanism that promotes invasive potential of cancer-associated fibroblasts in colorectal cancer. Cancer Letters, 2019, 444, 127-135.	3.2	40
968	Integrative molecular analysis of colorectal cancer and gastric cancer: What have we learnt?. Cancer Treatment Reviews, 2019, 73, 31-40.	3.4	15
969	Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. European Journal of Cancer, 2019, 107, 100-114.	1.3	12
970	Inter€and intra€tumoural heterogeneity in cancer€associated fibroblasts of human pancreatic ductal adenocarcinoma. Journal of Pathology, 2019, 248, 51-65.	2.1	215
971	CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer. Oncology, 2019, 96, 156-163.	0.9	6
972	Cancer stem cells in relation to treatment. Japanese Journal of Clinical Oncology, 2019, 49, 232-237.	0.6	10
973	A practical guide to biomarkers for the evaluation of colorectal cancer. Modern Pathology, 2019, 32, 1-15.	2.9	63

#	Article	IF	Citations
974	Current synthetic pharmacotherapy for treatment-resistant colorectal cancer: when urgent action is required. Expert Opinion on Pharmacotherapy, 2019, 20, 523-534.	0.9	3
975	Immune cell infiltration as a biomarker for the diagnosis and prognosis of stage I–III colon cancer. Cancer Immunology, Immunotherapy, 2019, 68, 433-442.	2.0	209
977	Clinical epigenetics: seizing opportunities for translation. Nature Reviews Genetics, 2019, 20, 109-127.	7.7	353
978	Butyrate-Induced *In Vitro* Colonocyte Differentiation Network Model Identifies *ITGB1, SYK, CDKN2A, CHAF1A,* and *LRP1* as the Prognostic Markers for Colorectal Cancer Recurrence. Nutrition and Cancer, 2019, 71, 257-271.	0.9	6
979	Immunological differences between colorectal cancer and normal mucosa uncover a prognostically relevant immune cell profile. OncoImmunology, 2019, 8, e1537693.	2.1	38
980	Circulating DNA and Protein Biomarkers for the Treatment of Metastatic Colorectal Cancer with Tyrosine Kinase Inhibitors. , 2019, , 271-285.		1
981	Rationale for Immunotherapy in Gastrointestinal Malignancies. , 2019, , 287-297.		1
982	Long noncoding RNA *MIR31HG* is a *bona fide* prognostic marker with colorectal cancer cell–intrinsic properties. International Journal of Cancer, 2019, 144, 2843-2853.	2.3	33
983	Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. Clinical Colorectal Cancer, 2019, 18, e117-e129.	1.0	53
984	miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis. Translational Oncology, 2019, 12, 282-291.	1.7	14
985	WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clinical Cancer Research, 2019, 25, 3074-3083.	3.2	435
986	Brain metastases. Nature Reviews Disease Primers, 2019, 5, 5.	18.1	579
987	Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting. Translational Oncology, 2019, 12, 502-512.	1.7	14
988	A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer. Anticancer Research, 2019, 39, 245-252.	0.5	3
989	Cellular Target of a Rhodium Metalloinsertor is the DNA Base Pair Mismatch. Chemistry - A European Journal, 2019, 25, 3014-3019.	1.7	9
990	Metabolic factors and the risk of colorectal cancer by KRAS and BRAF mutation status. International Journal of Cancer, 2019, 145, 327-337.	2.3	17
991	Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 463-474.	1.4	16
992	Distinct Prognosis of High Versus Mid/Low Rectal Cancer: a Propensity Score–Matched Cohort Study. Journal of Gastrointestinal Surgery, 2019, 23, 1474-1484.	0.9	13

#	ARTICLE	IF	CITATIONS
993	Marine omegaâ€3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance). International Journal of Cancer, 2019, 145, 380-389.	2.3	22
994	Targeting Angiogenesis in Colorectal Carcinoma. Drugs, 2019, 79, 63-74.	4.9	42
995	CD44v6 engages in colorectal cancer progression. Cell Death and Disease, 2019, 10, 30.	2.7	85
996	Right or Left Primary Site of Colorectal Cancer: Outcomes From the Molecular Analysis of the AGITG MAX Trial. Clinical Colorectal Cancer, 2019, 18, 141-148.	1.0	19
997	Whole Genome Sequencing Analysis of a Stage IV Colon Cancer Patient with a 10-Year Disease-Free Survival following Systemic Chemotherapy/Bevacizumab. Case Reports in Gastroenterology, 2019, 12, 729-736.	0.3	1
998	Identification of a 6-gene signature predicting prognosis for colorectal cancer. Cancer Cell International, 2019, 19, 6.	1.8	69
999	The forkhead-box family of transcription factors: key molecular players in colorectal cancer pathogenesis. Molecular Cancer, 2019, 18, 5.	7.9	106
1000	The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness. Clinical Epigenetics, 2019, 11, 4.	1.8	41
1001	Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy. Journal of Cellular Physiology, 2019, 234, 5601-5612.	2.0	7
1002	NSAIDs and Colorectal Cancer Phenotypes: What Now?. Journal of the National Cancer Institute, 2019, 111, 440-441.	3.0	3
1003	Strategies for targeting energy metabolism in Kirsten rat sarcoma viral oncogene homolog â€mutant colorectal cancer. Journal of Cellular Biochemistry, 2019, 120, 1106-1121.	1.2	0
1004	Smoking and Risk of Colorectal Cancer Sub-Classified by Tumor-Infiltrating T Cells. Journal of the National Cancer Institute, 2019, 111, 42-51.	3.0	30
1005	Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency. Bulletin Du Cancer, 2019, 106, 137-142.	0.6	22
1006	Predictive Biomarkers and Targeted Therapies in Colorectal Cancer. , 2019, , 423-430.		2
1007	Molecular Testing in Colorectal Carcinoma. , 2019, , 299-309.		0
1008	Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer. Oncogene, 2019, 38, 2305-2319.	2.6	41
1009	Mutant p53 in colon cancer. Journal of Molecular Cell Biology, 2019, 11, 267-276.	1.5	170
1010	Prognostic significance of microsatelliteâ€instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy. International Journal of Cancer, 2019, 144, 1697-1703.	2.3	51

#	Article	IF	Citations
1011	Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repairâ€"Deficient Colon Cancers: Implications for Prognosis. Clinical Cancer Research, 2019, 25, 125-133.	3.2	57
1012	Association of IL-36Î³ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer. Cancer Immunology, Immunotherapy, 2019, 68, 109-120.	2.0	59
1013	New Breeding Techniques: Detection and Identification of the Techniques andÂDerived Products. , 2019, , 320-336.		3
1014	Extent of enhancement on multiphase contrast-enhanced CT images is a potential prognostic factor of stage Iâ€"III colon cancer. European Radiology, 2019, 29, 1114-1123.	2.3	8
1015	Small RNA sequencing of sessile serrated polyps identifies microRNA profile associated with colon cancer. Genes Chromosomes and Cancer, 2019, 58, 23-33.	1.5	11
1016	Fusion Kinases Identified by Genomic Analyses of Sporadic Microsatellite Instabilityâ€"High Colorectal Cancers. Clinical Cancer Research, 2019, 25, 378-389.	3.2	49
1017	Associations Between Molecular Classifications of Colorectal Cancer and Patient Survival: A Systematic Review. Clinical Gastroenterology and Hepatology, 2019, 17, 402-410.e2.	2.4	44
1018	Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes. Gut, 2019, 68, 465-474.	6.1	52
1019	Molecular subtyping of cancer: current status and moving toward clinical applications. Briefings in Bioinformatics, 2019, 20, 572-584.	3.2	91
1020	Checkpoints and beyond â€" Immunotherapy in colorectal cancer. Seminars in Cancer Biology, 2019, 55, 78-89.	4.3	38
1021	Metastatic Profile of Colorectal Cancer: Interplay Between Primary Tumor Location and KRAS Status. Journal of Surgical Research, 2020, 246, 325-334.	0.8	15
1022	Metabolic pathways regulating colorectal cancer initiation and progression. Seminars in Cell and Developmental Biology, 2020, 98, 63-70.	2.3	203
1023	MCNF: A Novel Method for Cancer Subtyping by Integrating Multi-Omics and Clinical Data. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2020, 17, 1682-1690.	1.9	10
1024	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. European Urology, 2020, 77, 420-433.	0.9	741
1025	The molecular biology of pancreatic neuroendocrine neoplasms: Challenges and translational opportunities. Seminars in Cancer Biology, 2020, 61, 132-138.	4.3	16
1026	Influence of the Gut Microbiome, Diet, and Environment on Risk of Colorectal Cancer. Gastroenterology, 2020, 158, 322-340.	0.6	408
1027	Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant. Oncogene, 2020, 39, 987-1003.	2.6	24
1028	Comparison of short- and long-term outcomes between anatomical subtypes of resected biliary tract cancer in a Western high-volume center. Hpb, 2020, 22, 405-414.	0.1	12

#	ARTICLE	IF	CITATIONS
1029	*PIK3CA* mutation and clinicopathological features of colorectal cancer: a systematic review and Meta-Analysis. Acta Oncolª³gica, 2020, 59, 66-74.	0.8	27
1030	Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer. Pharmacogenomics Journal, 2020, 20, 136-158.	0.9	15
1031	Pathways of Colorectal Carcinogenesis. Gastroenterology, 2020, 158, 291-302.	0.6	241
1032	Colon cancer therapy by focusing on colon cancer stem cells and their tumor microenvironment. Journal of Cellular Physiology, 2020, 235, 4153-4166.	2.0	92
1033	Tumor Liquid Biopsies. Recent Results in Cancer Research, 2020, , .	1.8	11
1034	The missing heritability of familial colorectal cancer. Mutagenesis, 2020, 35, 221-231.	1.0	29
1035	RNA sequencing for research and diagnostics in clinical oncology. Seminars in Cancer Biology, 2020, 60, 311-323.	4.3	56
1036	The inhibitory receptor CD94/NKG2A on CD8+ tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE/Î²2m overexpression. Modern Pathology, 2020, 33, 468-482.	2.9	44
1037	Separation of Low- Versus High-grade Crohnâ€™s Disease-associated Small Bowel Carcinomas is Improved by Invasive Front Prognostic Marker Analysis. Journal of Crohn's and Colitis, 2020, 14, 295-302.	0.6	14
1038	High-dimensional cytometric analysis of colorectal cancer reveals novel mediators of antitumour immunity. Gut, 2020, 69, 691-703.	6.1	92
1039	Impact of primary tumor location on patterns of recurrence and survival of patients undergoing resection of liver metastases from colon cancer. Hpb, 2020, 22, 116-123.	0.1	16
1040	Molecular Genetics and the Role of Molecularly Targeted Agents in Metastatic Colorectal Carcinoma. Journal of Gastrointestinal Cancer, 2020, 51, 387-400.	0.6	6
1041	Reply. Clinical Gastroenterology and Hepatology, 2020, 18, 520-521.	2.4	0
1042	Biomarker-guided therapy for colorectal cancer: strength in complexity. Nature Reviews Clinical Oncology, 2020, 17, 11-32.	12.5	195
1043	Prognostic and predictive enrichment in sepsis. Nature Reviews Nephrology, 2020, 16, 20-31.	4.1	182
1044	Immunologic and immunogenomic aspects of tumor progression. Seminars in Cancer Biology, 2020, 60, 249-261.	4.3	35
1045	Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer. Modern Pathology, 2020, 33, 483-495.	2.9	9
1046	Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers. Journal of Gastroenterology, 2020, 55, 15-26.	2.3	115

#	Article	IF	Citations
1047	Elevated Microsatellite Alterations at Selected Tetranucleotides (EMAST) in Colorectal Cancer is Associated with an Elderly, Frail Phenotype and Improved Recurrence-Free Survival. Annals of Surgical Oncology, 2020, 27, 1058-1067.	0.7	14
1048	Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients. Journal of Cancer Research and Clinical Oncology, 2020, 146, 493-501.	1.2	7
1049	CrossICC: iterative consensus clustering of cross-platform gene expression data without adjusting batch effect. Briefings in Bioinformatics, 2020, 21, 1818-1824.	3.2	8
1050	Prognostic significance of body mass index and prognostic nutritional index in stage II/III gastric cancer. European Journal of Surgical Oncology, 2020, 46, 620-625.	0.5	43
1051	Colorectal cancer peritoneal metastases: Biology, treatment and next steps. European Journal of Surgical Oncology, 2020, 46, 675-683.	0.5	5
1052	Highâ€risk Stage III colon cancer patients identified by a novel fiveâ€gene mutational signature are characterized by upregulation of ILâ€23A and gut bacterial translocation of the tumor microenvironment. International Journal of Cancer, 2020, 146, 2027-2035.	2.3	43
1053	Small-bowel carcinomas associated with celiac disease: transcriptomic profiling shows predominance of microsatellite instability-immune and mesenchymal subtypes. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 711-723.	1.4	13
1054	Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. European Urology, 2020, 77, 434-435.	0.9	3
1055	Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancer. Cancer Letters, 2020, 469, 246-255.	3.2	12
1056	The Immunoscore: Colon Cancer and Beyond. Clinical Cancer Research, 2020, 26, 332-339.	3.2	255
1057	SNAIL1 employs Î²â€Cateninâ€LEF1 complexes to control colorectal cancer cell invasion and proliferation. International Journal of Cancer, 2020, 146, 2229-2242.	2.3	32
1058	Therapeutic Targeting of the Colorectal Tumor Stroma. Gastroenterology, 2020, 158, 303-321.	0.6	51
1059	A pre-existing population of ZEB2+ quiescent cells with stemness and mesenchymal features dictate chemoresistance in colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2020, 39, 2.	3.5	56
1060	Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. Oncologist, 2020, 25, 404-413.	1.9	25
1061	Lysine-Specific Demethylase 1 Mediates AKT Activity and Promotes Epithelial-to-Mesenchymal Transition in <i>PIK3CA</i>-Mutant Colorectal Cancer. Molecular Cancer Research, 2020, 18, 264-277.	1.5	29
1062	Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma. Hepatology, 2020, 72, 965-981.	3.6	159
1063	Lymphocyte-C-reactive Protein Ratio as Promising New Marker for Predicting Surgical and Oncological Outcomes in Colorectal Cancer. Annals of Surgery, 2020, 272, 342-351.	2.1	167
1064	Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?. Clinical and Translational Radiation Oncology, 2020, 21, 5-10.	0.9	8

#	ARTICLE	IF	CITATIONS
1065	WNT and Î²-Catenin in Cancer: Genes and Therapy. Annual Review of Cancer Biology, 2020, 4, 177-196.	2.3	39
1066	Delta peritoneal cancer index (Î"PCI): A new dynamic prognostic parameter for survival in patients with colorectal peritoneal metastases. European Journal of Surgical Oncology, 2020, 46, 590-599.	0.5	5
1067	Neutrophils suppress tumorâ€infiltrating T cells in colon cancer via matrix metalloproteinaseâ€mediated activation of <scp>TGF</scp> Î². EMBO Molecular Medicine, 2020, 12, e10681.	3.3	100
1068	Identification of Distinct Immune Subtypes in Colorectal Cancer Based on the Stromal Compartment. Frontiers in Oncology, 2019, 9, 1497.	1.3	38
1069	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. Clinical Cancer Research, 2020, 26, 1372-1384.	3.2	66
1070	Molecular Pathology of Colorectal Cancer. Advances in Anatomic Pathology, 2020, 27, 20-26.	2.4	68
1071	miR-181a-2* expression is different amongst carcinomas from the colorectal serrated route. Mutagenesis, 2020, 35, 233-241.	1.0	5
1072	PRDM14 promotes malignant phenotype and correlates with poor prognosis in colorectal cancer. Clinical and Translational Oncology, 2020, 22, 1126-1137.	1.2	8
1073	Whole-Slide Image Analysis Reveals Quantitative Landscape of Tumorâ€"Immune Microenvironment in Colorectal Cancers. Clinical Cancer Research, 2020, 26, 870-881.	3.2	37
1074	STAT3 activation through IL-6/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis. Gut, 2020, 69, 1269-1282.	6.1	181
1075	The impact of postoperative inflammation on recurrence in patients with colorectal cancer. International Journal of Clinical Oncology, 2020, 25, 602-613.	1.0	43
1076	Molecular Pathway Analysis Indicates a Distinct Metabolic Phenotype in Women With Right-Sided Colon Cancer. Translational Oncology, 2020, 13, 42-56.	1.7	14
1077	Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. Targeted Oncology, 2020, 15, 11-24.	1.7	65
1079	Role of the NF-Î°B signaling pathway in the pathogenesis of colorectal cancer. Gene, 2020, 726, 144132.	1.0	129
1080	Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Science Translational Medicine, 2020, 12, .	5.8	260
1081	Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC). Diagnostics, 2020, 10, 9.	1.3	24
1082	Gene Copy Number and Post-Transductional Mechanisms Regulate TRAP1 Expression in Human Colorectal Carcinomas. International Journal of Molecular Sciences, 2020, 21, 145.	1.8	3
1083	Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 111-130.	8.2	449

#	Article	IF	Citations
1084	Increased RAB31 Expression in Cancer-Associated Fibroblasts Promotes Colon Cancer Progression Through HGF-MET Signaling. Frontiers in Oncology, 2020, 10, 1747.	1.3	16
1085	Transcriptomic Profiling for the Autophagy Pathway in Colorectal Cancer. International Journal of Molecular Sciences, 2020, 21, 7101.	1.8	6
1086	Clinical, Pathology, Genetic, and Molecular Features of Colorectal Tumors in Adolescents and Adults 25 Years or Younger. Clinical Gastroenterology and Hepatology, 2021, 19, 1642-1651.e8.	2.4	8
1087	The impact of ARID1A mutation on molecular characteristics in colorectal cancer. European Journal of Cancer, 2020, 140, 119-129.	1.3	37
1088	Identification of stool miR-135b-5p as a non-invasive diaognostic biomarker in later tumor stage of colorectal cancer. Life Sciences, 2020, 260, 118417.	2.0	24
1089	Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial. JCO Precision Oncology, 2020, 4, 1152-1162.	1.5	6
1090	Genetic Alterations of Metastatic Colorectal Cancer. Biomedicines, 2020, 8, 414.	1.4	27
1091	Landscape of Genome-Wide DNA Methylation of Colorectal Cancer Metastasis. Cancers, 2020, 12, 2710.	1.7	18
1092	Promising Applications of Tumor Spheroids and Organoids for Personalized Medicine. Cancers, 2020, 12, 2727.	1.7	72
1093	Illuminating Colorectal Cancer Genomics by Next-Generation Sequencing. , 2020, , .		0
1094	An Introduction to the Current Management of Colorectal Cancer in the Era of Personalized Oncology. , 2020, , 1-27.		0
1095	Molecular Insights Into Colorectal Carcinoma. Archives of Medical Research, 2020, 51, 839-844.	1.5	13
1096	Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer. ESMO Open, 2020, 5, e000847.	2.0	21
1097	Impact of Polypharmacy for Chronic Ailments in Colon Cancer Patients: A Review Focused on Drug Repurposing. Cancers, 2020, 12, 2724.	1.7	5
1098	DNA methylation events in transcription factors and gene expression changes in colon cancer. Epigenomics, 2020, 12, 1593-1610.	1.0	13
1099	Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Targeted Oncology, 2020, 15, 743-750.	1.7	25
1100	Real-world Data for High-risk Stage II Colorectal Cancer â€" The Role of Tumor Side in the Adjuvant Setting. Clinical Colorectal Cancer, 2020, 20, e100-e108.	1.0	1
1101	Profiling of Tumor Microenvironment Components Identifies Five Stroma-Related Genes with Prognostic Implications in Colorectal Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2022, 37, 882-892.	0.7	13

#	Article	IF	Citations
1102	Identification of ATP8B1 as a Tumor Suppressor Gene for Colorectal Cancer and Its Involvement in Phospholipid Homeostasis. BioMed Research International, 2020, 2020, 1-16.	0.9	8
1103	De novo colorectal cancer after liver and kidney transplantationâ€"Microenvironment disturbance. Transplantation Reports, 2020, 5, 100057.	0.3	1
1104	The Wnt Signalling Pathway: A Tailored Target in Cancer. International Journal of Molecular Sciences, 2020, 21, 7697.	1.8	101
1105	Tn Antigen Expression Contributes to an Immune Suppressive Microenvironment and Drives Tumor Growth in Colorectal Cancer. Frontiers in Oncology, 2020, 10, 1622.	1.3	41
1106	Artificial intelligence quantified tumour-stroma ratio is an independent predictor for overall survival in resectable colorectal cancer. EBioMedicine, 2020, 61, 103054.	2.7	76
1107	Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188447.	3.3	97
1108	An update on colorectal cancer microenvironment, epigenetic and immunotherapy. International Immunopharmacology, 2020, 89, 107041.	1.7	45
1109	Gut microbiome alters functions of mutant p53 to promote tumorigenesis. Signal Transduction and Targeted Therapy, 2020, 5, 232.	7.1	4
1110	A Wnt-Induced Phenotypic Switch in Cancer-Associated Fibroblasts Inhibits EMT in Colorectal Cancer. Cancer Research, 2020, 80, 5569-5582.	0.4	64
1111	Optimized lowâ€dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment. Molecular Oncology, 2020, 14, 2894-2919.	2.1	20
1112	Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia. British Journal of Cancer, 2020, 123, 1280-1288.	2.9	45
1113	Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial). Clinical Cancer Research, 2020, 26, 5887-5894.	3.2	44
1114	Exploring and modelling colon cancer inter-tumour heterogeneity: opportunities and challenges. Oncogenesis, 2020, 9, 66.	2.1	52
1115	Spatial domain analysis predicts risk of colorectal cancer recurrence and infers associated tumor microenvironment networks. Nature Communications, 2020, 11, 3515.	5.8	24
1116	Combinatorial Immunotherapies for Metastatic Colorectal Cancer. Cancers, 2020, 12, 1875.	1.7	19
1117	CELLector: Genomics-Guided Selection of Cancer InÂVitro Models. Cell Systems, 2020, 10, 424-432.e6.	2.9	35
1118	Tumour budding, poorly differentiated clusters, and T-cell response in colorectal cancer. EBioMedicine, 2020, 57, 102860.	2.7	31
1119	In vivo anticancer activity of a rhodium metalloinsertor in the HCT116 xenograft tumor model. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 17535-17542.	3.3	15

#	ARTICLE	IF	CITATIONS
1120	Effect of preoperative chemoradiotherapy on the immunological status of rectal cancer patients. Journal of Radiation Research, 2020, 61, 766-775.	0.8	17
1121	The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer. Annals of Oncology, 2020, 31, 1135-1147.	0.6	58
1122	Personalised mapping of tumour development in synchronous colorectal cancer patients. Npj Genomic Medicine, 2020, 5, 27.	1.7	4
1123	Challenges and shifting treatment strategies in the surgical treatment of locally advanced rectal cancer. Annals of Gastroenterological Surgery, 2020, 4, 379-385.	1.2	8
1124	A novel mesenchymalâ€associated transcriptomic signature for riskâ€stratification and therapeutic response prediction in colorectal cancer. International Journal of Cancer, 2020, 147, 3250-3261.	2.3	6
1125	Prognostic impact of primary tumor location in Stage III colorectal cancer-right-sided colon versus left-sided colon versus rectum: a nationwide multicenter retrospective study. Journal of Gastroenterology, 2020, 55, 958-968.	2.3	42
1127	Recurrence Risk after Radical Colorectal Cancer Surgeryâ€"Less Than before, But How High Is It?. Cancers, 2020, 12, 3308.	1.7	25
1128	Not All Wnt Activation Is Equal: Ligand-Dependent versus Ligand-Independent Wnt Activation in Colorectal Cancer. Cancers, 2020, 12, 3355.	1.7	29
1129	Dysregulated PDGFR alphaÂexpression andÂnovel somatic mutations in colorectal cancer: association to RAS wild type status and tumorÂsize. Journal of Translational Medicine, 2020, 18, 440.	1.8	6
1130	A Detailed Flow Cytometric Analysis of Immune Activity Profiles in Molecular Subtypes of Colorectal Cancer. Cancers, 2020, 12, 3440.	1.7	9
1131	ActualizaciÃ³n en cÃ¡ncer colorrectal hereditario y su impacto en salud pÃºblica. Revista Facultad De Medicina, 2020, 68, .	0.0	0
1132	Identification of Two Novel Circular RNAs Deriving from BCL2L12 and Investigation of Their Potential Value as a Molecular Signature in Colorectal Cancer. International Journal of Molecular Sciences, 2020, 21, 8867.	1.8	24
1133	BRAF: A Two-Faced Janus. Cells, 2020, 9, 2549.	1.8	23
1134	The Role of BRAF in Metastatic Colorectal Carcinomaâ€"Past, Present, and Future. International Journal of Molecular Sciences, 2020, 21, 9001.	1.8	8
1135	Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant. Cell Death and Disease, 2020, 11, 1020.	2.7	15
1136	Prognostic Factors Involved in the Epithelialâ€"Mesenchymal Transition Process in Colorectal Cancer Have a Preponderant Role in Oxidative Stress: A Systematic Review and Meta-Analysis. Cancers, 2020, 12, 3330.	1.7	5
1137	Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clinical Colorectal Cancer, 2021, 20, 137-147.e1.	1.0	17
1138	Neurotensin pathway in digestive cancers and clinical applications: an overview. Cell Death and Disease, 2020, 11, 1027.	2.7	25

#	Article	IF	Citations
1139	Supervised clustering of high-dimensional data using regularized mixture modeling. Briefings in Bioinformatics, 2021, 22, .	3.2	5
1140	Angiogenesis-Related Functions of Wnt Signaling in Colorectal Carcinogenesis. Cancers, 2020, 12, 3601.	1.7	32
1141	Gastrointestinal adenocarcinoma analysis identifies promoter methylation-based cancer subtypes and signatures. Scientific Reports, 2020, 10, 21234.	1.6	10
1142	Major Histocompatibility Complex Genes as Therapeutic Opportunity for Immune Cold Molecular Cancer Subtypes. Journal of Immunology Research, 2020, 2020, 1-9.	0.9	2
1143	Metabolism-Associated Molecular Classification of Colorectal Cancer. Frontiers in Oncology, 2020, 10, 602498.	1.3	16
1144	Tn Antigen Expression Defines an Immune Cold Subset of Mismatch-Repair Deficient Colorectal Cancer. International Journal of Molecular Sciences, 2020, 21, 9081.	1.8	4
1145	Establishment of an immune-related gene pair model to predict colon adenocarcinoma prognosis. BMC Cancer, 2020, 20, 1071.	1.1	9
1146	Next-generation diagnostics for precision oncology: Preanalytical considerations, technical challenges, and available technologies. Seminars in Cancer Biology, 2022, 84, 3-15.	4.3	12
1147	Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers. Frontiers in Oncology, 2020, 10, 566511.	1.3	202
1148	TCox: Correlation-Based Regularization Applied to Colorectal Cancer Survival Data. Biomedicines, 2020, 8, 488.	1.4	4
1149	The human transcriptome: implications for understanding, diagnosing, and treating human disease. , 2020, , 113-138.		0
1150	TGFâ€Î²â€induced IGFBPâ€3 is a key paracrine factor from activated pericytes that promotes colorectal cancer cell migration and invasion. Molecular Oncology, 2020, 14, 2609-2628.	2.1	18
1151	In Silico Drug Repositioning Using Omics Data: The Potential and Pitfalls. , 2020, , 929-947.		0
1152	ColoType: a forty gene signature for consensus molecular subtyping of colorectal cancer tumors using whole-genome assay or targeted RNA-sequencing. Scientific Reports, 2020, 10, 12123.	1.6	22
1153	Cancer-associated fibroblasts of colorectal cancer and their markers: updates, challenges and translational outlook. Future Oncology, 2020, 16, 2329-2344.	1.1	13
1154	Identification of the HT-29 cell line as a model for investigating MCT1 transporters in sigmoid colon adenocarcinoma. Biochemical and Biophysical Research Communications, 2020, 529, 218-223.	1.0	2
1155	Systems analysis of protein signatures predicting cetuximab responses in <scp><i>KRAS</i></scp>, <scp><i>NRAS</i></scp>, <scp><i>BRAF</i></scp> and <scp><i>PIK3CA</i></scp> wildâ€type patientâ€derived xenograft models of metastatic colorectal cancer. International Journal of Cancer, 2020, 147, 2891-2901.	2.3	5
1156	Are Epithelial Ovarian Cancers of the Mesenchymal Subtype Actually Intraperitoneal Metastases to the Ovary?. Frontiers in Cell and Developmental Biology, 2020, 8, 647.	1.8	13

#	Article	IF	Citations
1157	Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer and Metastasis Reviews, 2020, 39, 1029-1038.	2.7	149
1158	Pan-cancer image-based detection of clinically actionable genetic alterations. Nature Cancer, 2020, 1, 789-799.	5.7	343
1159	Cellular Immunoprofile of Peritoneal Environment During a HIPEC Procedure. Annals of Surgical Oncology, 2020, 27, 5005-5013.	0.7	7
1160	Src Family Tyrosine Kinases in Intestinal Homeostasis, Regeneration and Tumorigenesis. Cancers, 2020, 12, 2014.	1.7	16
1161	Distant Metastasis in Colorectal Cancer Patientsâ€"Do We Have New Predicting Clinicopathological and Molecular Biomarkers? A Comprehensive Review. International Journal of Molecular Sciences, 2020, 21, 5255.	1.8	38
1162	Extracellular Granzyme A Promotes Colorectal Cancer Development by Enhancing Gut Inflammation. Cell Reports, 2020, 32, 107847.	2.9	34
1163	Comprehensive Analysis of LincRNAs in Classical and Basal-Like Subtypes of Pancreatic Cancer. Cancers, 2020, 12, 2077.	1.7	6
1164	Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. British Journal of Cancer, 2020, 123, 1262-1270.	2.9	18
1165	Signatures of co-deregulated genes and their transcriptional regulators in colorectal cancer. Npj Systems Biology and Applications, 2020, 6, 23.	1.4	20
1166	MicroRNAs and Apoptosis in Colorectal Cancer. International Journal of Molecular Sciences, 2020, 21, 5353.	1.8	59
1167	Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093608.	1.4	37
1169	Clinical development of therapies targeting TGFÎ²: current knowledge and future perspectives. Annals of Oncology, 2020, 31, 1336-1349.	0.6	157
1170	The Temperature-Dependent Effectiveness of Platinum-Based Drugs Mitomycin-C and 5-FU during Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Cell Lines. Cells, 2020, 9, 1775.	1.8	38
1171	Human Tumor-Infiltrating MAIT Cells Display Hallmarks of Bacterial Antigen Recognition in Colorectal Cancer. Cell Reports Medicine, 2020, 1, 100039.	3.3	32
1172	Immune Cell Associations with Cancer Risk. IScience, 2020, 23, 101296.	1.9	6
1173	Construction and optimization of gene expression signatures for prediction of survival in two-arm clinical trials. BMC Bioinformatics, 2020, 21, 333.	1.2	3
1174	Saffron Crudes and Compounds Restrict MACC1-Dependent Cell Proliferation and Migration of Colorectal Cancer Cells. Cells, 2020, 9, 1829.	1.8	12
1175	Immune-Modulating Effects of Conventional Therapies in Colorectal Cancer. Cancers, 2020, 12, 2193.	1.7	5

#	Article	IF	Citations
1176	S-Adenosylmethionine Treatment of Colorectal Cancer Cell Lines Alters DNA Methylation, DNA Repair and Tumor Progression-Related Gene Expression. Cells, 2020, 9, 1864.	1.8	16
1177	Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+T cell. World Journal of Surgical Oncology, 2020, 18, 196.	0.8	7
1178	The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy. Immunotherapy, 2020, 12, 1083-1100.	1.0	27
1179	Pre-Existing Tumoral B Cell Infiltration and Impaired Genome Maintenance Correlate with Response to Chemoradiotherapy in Locally Advanced Rectal Cancer. Cancers, 2020, 12, 2227.	1.7	14
1180	Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial. European Journal of Cancer, 2020, 137, 250-259.	1.3	15
1181	Delivery of Personalized Care for Locally Advanced Rectal Cancer: Incorporating Pathological, Molecular Genetic, and Immunological Biomarkers Into the Multimodal Paradigm. Frontiers in Oncology, 2020, 10, 1369.	1.3	13
1182	YAP/TAZ Signalling in Colorectal Cancer: Lessons from Consensus Molecular Subtypes. Cancers, 2020, 12, 3160.	1.7	15
1183	Pathologic evolution-related Gene Analysis based on both single-cell and bulk transcriptomics in Colorectal Cancer. Journal of Cancer, 2020, 11, 6861-6873.	1.2	5
1184	Tumor-Associated Neutrophils and Macrophagesâ€"Heterogenous but Not Chaotic. Frontiers in Immunology, 2020, 11, 553967.	2.2	53
1185	The tumor immune microenvironment transcriptomic subtypes of colorectal cancer for prognosis and development of precise immunotherapy. Gastroenterology Report, 2020, 8, 381-389.	0.6	14
1186	A Middle-Out Modeling Strategy to Extend a Colon Cancer Logical Model Improves Drug Synergy Predictions in Epithelial-Derived Cancer Cell Lines. Frontiers in Molecular Biosciences, 2020, 7, 502573.	1.6	13
1187	Germline Profiling and Molecular Characterization of Early Onset Metastatic Colorectal Cancer. Frontiers in Oncology, 2020, 10, 568911.	1.3	17
1188	A third Notch in colorectal cancer progression and metastasis. Journal of Experimental Medicine, 2020, 217, .	4.2	8
1189	The clinical and immune features of CD14 in colorectal cancer identified via large-scale analysis. International Immunopharmacology, 2020, 88, 106966.	1.7	5
1190	Resident Memory T Cells in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1273, 39-68.	0.8	3
1191	Integration of Online Omics-Data Resources for Cancer Research. Frontiers in Genetics, 2020, 11, 578345.	1.1	50
1192	AKT-dependent NOTCH3 activation drives tumor progression in a model of mesenchymal colorectal cancer. Journal of Experimental Medicine, 2020, 217, .	4.2	48
1193	NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer. Cancer Genetics, 2020, 248-249, 1-10.	0.2	7

#	ARTICLE	IF	CITATIONS
1194	Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated â€" NIVACOR trial (GOIRC-03-2018). BMC Cancer, 2020, 20, 822.	1.1	13
1195	Evaluation of Prognostic Factors for Survival in Transverse Colon Cancer. Cancers, 2020, 12, 2457.	1.7	3
1196	Development and validation of a RNA binding protein gene pair-associated prognostic signature for prediction of overall survival in hepatocellular carcinoma. BioMedical Engineering OnLine, 2020, 19, 68.	1.3	9
1197	Treating Colorectal Cancer with Immunotherapy: Implications for Single Versus Combination Therapy. Current Colorectal Cancer Reports, 2020, 16, 107-117.	1.0	2
1198	Insights into the Role of microRNAs in Colorectal Cancer (CRC) Metabolism. Cancers, 2020, 12, 2462.	1.7	16
1199	The DNA Glycosylase NEIL2 Suppresses Fusobacterium-Infection-Induced Inflammation and DNA Damage in Colonic Epithelial Cells. Cells, 2020, 9, 1980.	1.8	28
1200	Interconnectivity between molecular subtypes and tumor stage in colorectal cancer. BMC Cancer, 2020, 20, 850.	1.1	14
1201	Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer. Oncologist, 2020, 25, e1968-e1979.	1.9	17
1202	FUT9-Driven Programming of Colon Cancer Cells towards a Stem Cell-Like State. Cancers, 2020, 12, 2580.	1.7	15
1203	Adjuvant Chemotherapy for Stage III Colon Cancer. Cancers, 2020, 12, 2679.	1.7	44
1204	Immune-related gene signature in predicting prognosis of early-stage colorectal cancer patients. European Journal of Surgical Oncology, 2020, 46, e62-e70.	0.5	7
1205	Integrated Omics of Metastatic Colorectal Cancer. Cancer Cell, 2020, 38, 734-747.e9.	7.7	144
1206	Investigation of colorectal cancer in accordance with consensus molecular subtype classification. Annals of Gastroenterological Surgery, 2020, 4, 528-539.	1.2	30
1207	CD8$^+$ tumorâ€infiltrating lymphocytes within the primary tumor of patients with synchronous *de novo* metastatic colorectal carcinoma do not track with survival. Clinical and Translational Immunology, 2020, 9, e1155.	1.7	8
1208	Association of mismatch repair status with survival and response to neoadjuvant chemo(radio)therapy in rectal cancer. Npj Precision Oncology, 2020, 4, 26.	2.3	18
1209	Amphiregulin Expression Is a Predictive Biomarker for *EGFR* Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials. Clinical Cancer Research, 2020, 26, 6559-6567.	3.2	17
1210	Roles of IL-1 in Cancer: From Tumor Progression to Resistance to Targeted Therapies. International Journal of Molecular Sciences, 2020, 21, 6009.	1.8	85
1211	Gut Î³Î´ T cells as guardians, disruptors, and instigators of cancer. Immunological Reviews, 2020, 298, 198-217.	2.8	28

#	Article	IF	Citations
1212	A specific microRNA profile as predictive biomarker for systemic treatment in patients with metastatic colorectal cancer. Cancer Medicine, 2020, 9, 7558-7571.	1.3	9
1213	The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study. Journal of Gastrointestinal Cancer, 2021, 52, 932-939.	0.6	1
1214	Bacteria-related changes in host DNA methylation and the risk for CRC. Gut Microbes, 2020, 12, 1800898.	4.3	9
1215	Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer. Targeted Oncology, 2020, 15, 567-577.	1.7	14
1216	Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. Journal of Clinical Oncology, 2020, 38, 3638-3651.	0.8	130
1217	Predictive values of colon microbiota in the treatment response to colorectal cancer. Pharmacogenomics, 2020, 21, 1045-1059.	0.6	4
1218	Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib. Molecular Cancer Therapeutics, 2020, 19, 2146-2154.	1.9	18
1219	Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 21598-21608.	3.3	46
1220	Improving clinical management of colon cancer through CONNECTION, a nation-wide colon cancer registry and stratification effort (CONNECTION II trial): rationale and protocol of a single arm intervention study. BMC Cancer, 2020, 20, 776.	1.1	9
1221	Oncogenic Features in Histologically Normal Mucosa: Novel Insights Into Field Effect From a Mega-Analysis of Colorectal Transcriptomes. Clinical and Translational Gastroenterology, 2020, 11, e00210.	1.3	12
1222	ERK1/2 Signaling Induces Upregulation of ANGPT2 and CXCR4 to Mediate Liver Metastasis in Colon Cancer. Cancer Research, 2020, 80, 4668-4680.	0.4	35
1223	Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482094877.	1.4	45
1224	Molecular Pathogenesis and Classification of Colorectal Carcinoma. Current Colorectal Cancer Reports, 2020, 16, 97-106.	1.0	12
1225	Comparative Study of Organoids from Patient-Derived Normal and Tumor Colon and Rectal Tissue. Cancers, 2020, 12, 2302.	1.7	37
1226	Serrated lesions: who, what, when, where, why, and how?. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1851-1852.	1.4	1
1227	A new fat-dissociation method to detect lymph nodes in colorectal cancer: a prospective randomized study. Scientific Reports, 2020, 10, 20205.	1.6	5
1228	DEAD-box RNA helicase protein DDX21 as a prognosis marker for early stage colorectal cancer with microsatellite instability. Scientific Reports, 2020, 10, 22085.	1.6	12
1229	APC and AXIN2 Are Promising Biomarker Candidates for the Early Detection of Adenomas and Hyperplastic Polyps. Cancer Informatics, 2020, 19, 117693512097238.	0.9	1

#	Article	IF	Citations
1230	The epigenetic regulator Mll1 is required for Wnt-driven intestinal tumorigenesis and cancer stemness. Nature Communications, 2020, 11, 6422.	5.8	38
1231	Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota. Frontiers in Immunology, 2020, 11, 600886.	2.2	43
1232	Indoleamine 2, 3-Dioxygenase 1 and CD8 Expression Profiling Revealed an Immunological Subtype of Colon Cancer With a Poor Prognosis. Frontiers in Oncology, 2020, 10, 594098.	1.3	11
1233	Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer. Cancers, 2020, 12, 3828.	1.7	19
1234	Prognostic and Predictive Cross-Roads of Microsatellite Instability and Immune Response to Colon Cancer. International Journal of Molecular Sciences, 2020, 21, 9680.	1.8	17
1235	BRAFV600E mutation impinges on gut microbial markers defining novel biomarkers for serrated colorectal cancer effective therapies. Journal of Experimental and Clinical Cancer Research, 2020, 39, 285.	3.5	14
1236	Cell-Free DNA-Methylation-Based Methods and Applications in Oncology. Biomolecules, 2020, 10, 1677.	1.8	31
1237	Emerging Role and Therapeutic Potential of lncRNAs in Colorectal Cancer. Cancers, 2020, 12, 3843.	1.7	29
1238	Identification of Potential Hub Genes Related to Diagnosis and Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma via Integrated Bioinformatics Analysis. BioMed Research International, 2020, 2020, 1-19.	0.9	29
1239	Immune Adaptation of Colorectal Cancer Stem Cells and Their Interaction With the Tumor Microenvironment. Frontiers in Oncology, 2020, 10, 588542.	1.3	15
1240	Precision medicine for adjuvant chemotherapy of resected colorectal cancer. Annals of Gastroenterological Surgery, 2020, 4, 635-645.	1.2	5
1241	Biophysical and Epigenetic Regulation of Cancer Stemness, Invasiveness, and Immune Action. Current Tissue Microenvironment Reports, 2020, 1, 277-300.	1.3	7
1242	TGFÎ²-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts. Nature Communications, 2020, 11, 6315.	5.8	106
1243	Epigenetically regulated gene expression profiles reveal four molecular subtypes with prognostic and therapeutic implications in colorectal cancer. Briefings in Bioinformatics, 2021, 22, .	3.2	20
1244	Intestinal region-specific Wnt signalling profiles reveal interrelation between cell identity and oncogenic pathway activity in cancer development. Cancer Cell International, 2020, 20, 578.	1.8	8
1245	The impact of mismatch repair status to the preoperative staging of colon cancer: implications for clinical management. Colorectal Cancer, 2020, 9, CRC20.	0.8	3
1246	BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. Cancers, 2020, 12, 3236.	1.7	23
1248	Single-cell genomic profile-based analysis of tissue differentiation in colorectal cancer. Science China Life Sciences, 2021, 64, 1311-1325.	2.3	4

#	ARTICLE	IF	CITATIONS
1249	Analysis of Spatial Organization of Suppressive Myeloid Cells and Effector T Cells in Colorectal Cancer—A Potential Tool for Discovering Prognostic Biomarkers in Clinical Research. Frontiers in Immunology, 2020, 11, 550250.	2.2	15
1250	Silencing of Long Noncoding RNA LINC00346 Inhibits the Tumorigenesis of Colorectal Cancer Through Targeting MicroRNA-148b . OncoTargets and Therapy, 2020, Volume 13, 3247-3257.	1.0	7
1251	Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. Cancers, 2020, 12, 1214.	1.7	26
1252	The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer. Clinical Cancer Research, 2020, 26, 4313-4325.	3.2	22
1253	Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy. Clinical Cancer Research, 2020, 26, 3662-3670.	3.2	107
1254	Hunting for the Holy Grail in Colorectal Cancer. Gastroenterology, 2020, 158, 2047-2049.	0.6	0
1255	The role of epithelial–mesenchymal transition markers in the prediction of lymph node metastases in colorectal cancer. Biomarkers in Medicine, 2020, 14, 417-420.	0.6	0
1256	Harnessing stemness and PD-L1 expression by AT-rich interaction domain-containing protein 3B in colorectal cancer. Theranostics, 2020, 10, 6095-6112.	4.6	18
1257	Reduction of Liver Metastasis Stiffness Improves Response to Bevacizumab in Metastatic Colorectal Cancer. Cancer Cell, 2020, 37, 800-817.e7.	7.7	179
1258	Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer. Journal of Pathology: Clinical Research, 2020, 6, 283-296.	1.3	17
1259	Functional Interplay Between Collagen Network and Cell Behavior Within Tumor Microenvironment in Colorectal Cancer. Frontiers in Oncology, 2020, 10, 527.	1.3	36
1260	Revolutionizing the landscape of colorectal cancer treatment: The potential role of immune checkpoint inhibitors. International Journal of Cancer, 2020, 147, 2996-3006.	2.3	36
1261	Epithelial-to-mesenchymal transition is a prognostic marker for patient outcome in advanced stage HNSCC patients treated with chemoradiotherapy. Radiotherapy and Oncology, 2020, 147, 186-194.	0.3	12
1262	Plasma protein expression differs between colorectal cancer patients depending on primary tumor location. Cancer Medicine, 2020, 9, 5221-5234.	1.3	8
1263	Predictive and patient-monitoring biomarkers: precision in the management of colorectal cancer. Biomarkers in Medicine, 2020, 14, 335-339.	0.6	2
1264	Colorectal signet ring cell carcinoma: advancing research in a rare cancer. Future Oncology, 2020, 16, 1161-1163.	1.1	4
1265	WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. Cancers, 2020, 12, 1319.	1.7	10
1266	Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy. Frontiers in Immunology, 2020, 11, 1052.	2.2	55

#	Article	IF	Citations
1267	Clinical Multigene Panel Sequencing Identifies Distinct Mutational Association Patterns in Metastatic Colorectal Cancer. Frontiers in Oncology, 2020, 10, 560.	1.3	12
1268	Integrative multi-omics analysis of a colon cancer cell line with heterogeneous Wnt activity revealed RUNX2 as an epigenetic regulator of EMT. Oncogene, 2020, 39, 5152-5164.	2.6	33
1269	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. European Journal of Cancer, 2020, 135, 78-88.	1.3	10
1270	Zeb2 drives invasive and microbiota-dependent colon carcinoma. Nature Cancer, 2020, 1, 620-634.	5.7	29
1271	Leveraging Gene Expression Subgroups to Classify DLBCL Patients and Enrich for Clinical Benefit to a Novel Agent. Blood, 2020, 135, 1008-1018.	0.6	12
1272	Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment. Molecules, 2020, 25, 2614.	1.7	30
1273	A comprehensive overview of promising biomarkers in stage II colorectal cancer. Cancer Treatment Reviews, 2020, 88, 102059.	3.4	12
1274	Integrated analysis identifies an immune-based prognostic signature for the mesenchymal identity in colorectal cancer. Medicine (United States), 2020, 99, e20617.	0.4	3
1275	Eotaxins and Their Receptor in Colorectal Cancerâ€"A Literature Review. Cancers, 2020, 12, 1383.	1.7	18
1276	Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives. Cancer Treatment Reviews, 2020, 88, 102030.	3.4	44
1277	A TGFÎ²-Dependent Stromal Subset Underlies Immune Checkpoint Inhibitor Efficacy in DNA Mismatch Repairâ€"Deficient/Microsatellite Instability-High Colorectal Cancer. Molecular Cancer Research, 2020, 18, 1402-1413.	1.5	20
1278	Serrated adenomas with a BRAF mutation in a young patient with familial adenomatous polyposis. International Journal of Colorectal Disease, 2020, 35, 1967-1972.	1.0	0
1279	TRF2 and VEGF-A: an unknown relationship with prognostic impact on survival of colorectal cancer patients. Journal of Experimental and Clinical Cancer Research, 2020, 39, 111.	3.5	14
1280	BRAF Mutated Colorectal Cancer: New Treatment Approaches. Cancers, 2020, 12, 1571.	1.7	44
1281	Artificial Intelligence and Mechanistic Modeling for Clinical Decision Making in Oncology. Clinical Pharmacology and Therapeutics, 2020, 108, 471-486.	2.3	50
1282	Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update. Expert Review of Molecular Diagnostics, 2020, 20, 653-664.	1.5	7
1283	<p>Gene Expression Signature to Predict Prognosis and Adjuvant Chemosensitivity of Colorectal Cancer Patients</p>. Cancer Management and Research, 2020, Volume 12, 3301-3310.	0.9	9
1284	Identification of Early Warning Signals at the Critical Transition Point of Colorectal Cancer Based on Dynamic Network Analysis. Frontiers in Bioengineering and Biotechnology, 2020, 8, 530.	2.0	7

#	Article	IF	Citations
1285	AGA Clinical Practice Update on Young Adult–Onset Colorectal Cancer Diagnosis and Management: Expert Review. Clinical Gastroenterology and Hepatology, 2020, 18, 2415-2424.	2.4	24
1286	Development and validation of an individualized gene expression-based signature to predict overall survival in metastatic colorectal cancer. Annals of Translational Medicine, 2020, 8, 96-96.	0.7	6
1287	Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. Frontiers in Immunology, 2020, 11, 369.	2.2	291
1288	Single Cell Transcriptome in Colorectal Cancer—Current Updates on Its Application in Metastasis, Chemoresistance and the Roles of Circulating Tumor Cells. Frontiers in Pharmacology, 2020, 11, 135.	1.6	33
1289	Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected. Clinical Colorectal Cancer, 2020, 19, e110-e116.	1.0	20
1290	<p>Perioperative Circulating Tumor DNA in Colorectal Liver Metastases: Concordance with Metastatic Tissue and Predictive Value for Tumor Burden and Prognosis</p>. Cancer Management and Research, 2020, Volume 12, 1621-1630.	0.9	20
1291	Biology and Therapeutic Targets of Colorectal Serrated Adenocarcinoma; Clues for a Histologically Based Treatment against an Aggressive Tumor. International Journal of Molecular Sciences, 2020, 21, 1991.	1.8	6
1292	Mismatch Repair–Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. Clinical Cancer Research, 2020, 26, 3271-3279.	3.2	118
1293	<scp>KCML</scp> : a machine-learning framework for inference of multi-scale gene functions from genetic perturbation screens. Molecular Systems Biology, 2020, 16, e9083.	3.2	11
1294	Comprehensive landscape of immune-checkpoints uncovered in clear cell renal cell carcinoma reveals new and emerging therapeutic targets. Cancer Immunology, Immunotherapy, 2020, 69, 1237-1252.	2.0	22
1295	Tumor Plasticity and Resistance to Immunotherapy. Trends in Cancer, 2020, 6, 432-441.	3.8	88
1296	Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study. Gut, 2020, 69, 681-690.	6.1	79
1297	New genetic variations discovered in KRAS wild-type cetuximab resistant chinese colorectal cancer patients. Molecular Carcinogenesis, 2020, 59, 478-491.	1.3	10
1298	Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1321-1334.	1.2	6
1299	Sex Differences in Colon Cancer Metabolism Reveal A Novel Subphenotype. Scientific Reports, 2020, 10, 4905.	1.6	41
1300	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. Expert Review of Anticancer Therapy, 2020, 20, 251-270.	1.1	4
1301	Prevalence and Clinical Features of Sessile Serrated Polyps: A Systematic Review. Gastroenterology, 2020, 159, 105-118.e25.	0.6	48
1302	Comprehensive review of targeted therapy for colorectal cancer. Signal Transduction and Targeted Therapy, 2020, 5, 22.	7.1	853

#	Article	IF	Citations
1303	Immunogenic cell death in colon cancer prevention and therapy. Molecular Carcinogenesis, 2020, 59, 783-793.	1.3	65
1304	A longitudinal study of prediagnostic metabolic biomarkers and the risk of molecular subtypes of colorectal cancer. Scientific Reports, 2020, 10, 5336.	1.6	7
1305	Personalized Medicineâ€"Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer. Cancers, 2020, 12, 812.	1.7	30
1306	Tumor Microenvironment. Cancer Treatment and Research, 2020, , .	0.2	12
1307	TGF-beta: a master immune regulator. Expert Opinion on Therapeutic Targets, 2020, 24, 427-438.	1.5	101
1308	The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma. BioDrugs, 2020, 34, 349-362.	2.2	33
1309	Similarities in the General Chemical Composition of Colon Cancer Cells and Their Microvesicles Investigated by Spectroscopic Methods-Potential Clinical Relevance. International Journal of Molecular Sciences, 2020, 21, 1826.	1.8	4
1310	Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. Journal of Hepatology, 2020, 73, 315-327.	1.8	164
1311	Comprehensive transcriptome profiling of Taiwanese colorectal cancer implicates an ethnic basis for pathogenesis. Scientific Reports, 2020, 10, 4526.	1.6	9
1312	c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors. Cancers, 2020, 12, 638.	1.7	52
1313	Mechanistic and Functional Shades of Mucins and Associated Glycans in Colon Cancer. Cancers, 2020, 12, 649.	1.7	37
1314	A reference profile-free deconvolution method to infer cancer cell-intrinsic subtypes and tumor-type-specific stromal profiles. Genome Medicine, 2020, 12, 24.	3.6	34
1315	Syntenin-1 promotes colorectal cancer stem cell expansion and chemoresistance by regulating prostaglandin E2 receptor. British Journal of Cancer, 2020, 123, 955-964.	2.9	14
1316	Improved Outcome Prediction for Appendiceal Pseudomyxoma Peritonei by Integration of Cancer Cell and Stromal Transcriptional Profiles. Cancers, 2020, 12, 1495.	1.7	6
1317	RNA processing genes characterize RNA splicing and further stratify colorectal cancer. Cell Proliferation, 2020, 53, e12861.	2.4	4
1318	Methylation-Based Therapies for Colorectal Cancer. Cells, 2020, 9, 1540.	1.8	29
1319	Standard therapies: solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer. OncoImmunology, 2020, 9, 1773205.	2.1	3
1320	Personalized Adjuvant Treatment of Colon Cancer. Visceral Medicine, 2020, 36, 397-406.	0.5	6

#	Article	IF	Citations
1321	Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC). Frontiers in Oncology, 2020, 10, 964.	1.3	11
1322	Metabolomic Markers of Colorectal Tumor With Different Clinicopathological Features. Frontiers in Oncology, 2020, 10, 981.	1.3	15
1323	Index of Cancer-Associated Fibroblasts Is Superior to the Epithelialâ€"Mesenchymal Transition Score in Prognosis Prediction. Cancers, 2020, 12, 1718.	1.7	18
1324	KRAS Status is Associated with Metabolic Parameters in Metastatic Colorectal Cancer According to Primary Tumour Location. Pathology and Oncology Research, 2020, 26, 2537-2548.	0.9	7
1325	Galgo: a bi-objective evolutionary meta-heuristic identifies robust transcriptomic classifiers associated with patient outcome across multiple cancer types. Bioinformatics, 2020, 36, 5037-5044.	1.8	1
1326	High Expression of FAP in Colorectal Cancer Is Associated With Angiogenesis and Immunoregulation Processes. Frontiers in Oncology, 2020, 10, 979.	1.3	50
1327	Role of Inflammation in Pathophysiology of Colonic Disease: An Update. International Journal of Molecular Sciences, 2020, 21, 4748.	1.8	19
1328	The MLH1 polymorphism rs1800734 and risk of endometrial cancer with microsatellite instability. Clinical Epigenetics, 2020, 12, 102.	1.8	8
1329	Genomic and Transcriptomic Characterisation of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. Cancers, 2020, 12, 1808.	1.7	13
1331	Expression of the Serrated Markers Annexin A10 or Gremlin1 in Colonic Adenocarcinomas: Morphology and Prognostic Values. Pathology and Oncology Research, 2020, 26, 2509-2521.	0.9	1
1332	Multi-omics analysis to identify driving factors in colorectal cancer. Epigenomics, 2020, 12, 1633-1650.	1.0	10
1333	IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma. , 2020, 8, e000285.		95
1334	Combination of preoperative tumour markers and lymphovascular invasion with TNM staging as a cost and labour efficient subtyping of colorectal cancer. Scientific Reports, 2020, 10, 10238.	1.6	8
1335	Wnt-driven LARGE2 mediates laminin-adhesive O-glycosylation in human colonic epithelial cells and colorectal cancer. Cell Communication and Signaling, 2020, 18, 102.	2.7	10
1336	Detection of Human papillomavirus and the role of p16INK4a in colorectal carcinomas. PLoS ONE, 2020, 15, e0235065.	1.1	10
1337	Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study. Modern Pathology, 2020, 33, 2626-2636.	2.9	17
1338	Characterization of Chilean patients with sporadic colorectal cancer according to the three main carcinogenic pathways: Microsatellite instability, CpG island methylator phenotype and Chromosomal instability. Tumor Biology, 2020, 42, 101042832093849.	0.8	8
1339	Organoid technology and applications in cancer immunotherapy and precision medicine. Current Opinion in Biotechnology, 2020, 65, 242-247.	3.3	23

#	ARTICLE	IF	CITATIONS
1340	Association of Tumor Budding With Immune Evasion Pathways in Primary Colorectal Cancer and Patient-Derived Xenografts. Frontiers in Medicine, 2020, 7, 264.	1.2	10
1341	Resectability and Ablatability Criteria for the Treatment of Liver Only Colorectal Metastases: Multidisciplinary Consensus Document from the COLLISION Trial Group. Cancers, 2020, 12, 1779.	1.7	50
1342	Microsatellite Instability Correlated Inflammatory Markers and their Prognostic Value in the Rectal Cancer Following Neoadjuvant Chemoradiotherapy: A Hypothesis-generating Study. In Vivo, 2020, 34, 2119-2126.	0.6	7
1343	Evaluation of an aldo-keto reductase gene signature with prognostic significance in colon cancer via activation of epithelial to mesenchymal transition and the p70S6K pathway. Carcinogenesis, 2020, 41, 1219-1228.	1.3	14
1344	Identification of Genes Related to Clinicopathological Characteristics and Prognosis of Patients with Colorectal Cancer. DNA and Cell Biology, 2020, 39, 690-699.	0.9	21
1345	Improving prediction performance of colon cancer prognosis based on the integration of clinical and multi-omics data. BMC Medical Informatics and Decision Making, 2020, 20, 22.	1.5	20
1346	Organoid models of gastrointestinal cancers in basic and translational research. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 203-222.	8.2	108
1347	<i>BRAF</i>-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. Clinical Cancer Research, 2020, 26, 2466-2476.	3.2	39
1348	Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1. Genes, 2020, 11, 226.	1.0	11
1349	Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. Cancer Cell, 2020, 37, 371-386.e12.	7.7	68
1350	EMT transcription factor ZEB1 alters the epigenetic landscape of colorectal cancer cells. Cell Death and Disease, 2020, 11, 147.	2.7	58
1351	Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high concordance between existing classification systems. Scientific Reports, 2020, 10, 337.	1.6	46
1352	Immunogenomic pathways associated with cytotoxic lymphocyte infiltration and survival in colorectal cancer. BMC Cancer, 2020, 20, 124.	1.1	8
1353	Caveolin-1 Promotes Chemoresistance of Gastric Cancer Cells to Cisplatin by Activating WNT/Î²-Catenin Pathway. Frontiers in Oncology, 2020, 10, 46.	1.3	30
1354	Tumor proportion in colon cancer: results from a semiautomatic image analysis approach. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 185-193.	1.4	9
1355	Microsatellite Stable Colorectal Cancer With an Immunogenic Phenotype: Challenges in Diagnosis and Treatment. Clinical Colorectal Cancer, 2020, 19, 123-131.	1.0	3
1356	High mutational concordance between primary colorectal tumors and associated pulmonary metastases. Journal of Surgical Oncology, 2020, 121, 984-989.	0.8	1
1357	Adjuvant therapy for colorectal cancer in 2020: has anything changed this millennium?. Annals of Oncology, 2020, 31, 447-448.	0.6	2

#	ARTICLE	IF	CITATIONS
1358	Association Between Molecular Subtypes of Colorectal Tumors and Patient Survival, Based on Pooled Analysis of 7 International Studies. Gastroenterology, 2020, 158, 2158-2168.e4.	0.6	34
1359	Dual targeting of TGF-Î² and PD-L1 via a bifunctional anti-PD-L1/TGF-Î²RII agent: status of preclinical and clinical advances. , 2020, 8, e000433.		166
1360	EPDR1 up-regulation in human colorectal cancer is related to staging and favours cell proliferation and invasiveness. Scientific Reports, 2020, 10, 3723.	1.6	13
1361	Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?. Gastroenterology Report, 2020, 8, 11-24.	0.6	68
1362	Tumors of theÂGastrointestinal System Including the Pancreas. , 2020, , 691-870.		0
1363	Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434â€"5. European Urology, 2020, 77, 436-438.	0.9	1
1364	Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial. British Journal of Cancer, 2020, 122, 957-962.	2.9	4
1365	DNMT3B Oncogenic Activity in Human Intestinal Cancer Is Not Linked to CIMP or BRAFV600E Mutation. IScience, 2020, 23, 100838.	1.9	4
1366	PDâ€1/PDâ€L1â€dependent immune response in colorectal cancer. Journal of Cellular Physiology, 2020, 235, 5461-5475.	2.0	86
1367	Cell-Selective Cytotoxicity of a Fluorescent Rhodium Metalloinsertor Conjugate Results from Irreversible DNA Damage at Base Pair Mismatches. Biochemistry, 2020, 59, 717-726.	1.2	10
1368	Precision Therapy in RAS Mutant Colorectal Cancer. Gastroenterology, 2020, 158, 806-811.	0.6	29
1369	Pembrolizumab for the treatment of colorectal cancer. Expert Opinion on Biological Therapy, 2020, 20, 219-226.	1.4	21
1370	Molecular profiling for precision cancer therapies. Genome Medicine, 2020, 12, 8.	3.6	447
1371	Bidirectional tumor/stroma crosstalk promotes metastasis in mesenchymal colorectal cancer. Oncogene, 2020, 39, 2453-2466.	2.6	18
1372	A framework for advancing our understanding of cancer-associated fibroblasts. Nature Reviews Cancer, 2020, 20, 174-186.	12.8	2,012
1373	Cancer Stem Cell Marker DCLK1 Correlates with Tumorigenic Immune Infiltrates in the Colon and Gastric Adenocarcinoma Microenvironments. Cancers, 2020, 12, 274.	1.7	53
1374	Modeling rectal cancer to advance neoadjuvant precision therapy. International Journal of Cancer, 2020, 147, 1405-1418.	2.3	25
1375	Microsatellite instability in Costa Rican patients with colorectal adenocarcinoma and its association with overall survival and response to fluoropyrimidine-based chemotherapy. Cancer Epidemiology, 2020, 65, 101680.	0.8	6

#	ARTICLE	IF	CITATIONS
1376	Zebrafish Avatars towards Personalized Medicineâ€"A Comparative Review between Avatar Models. Cells, 2020, 9, 293.	1.8	47
1377	Role of Rad51 and DNA repair in cancer: A molecular perspective. , 2020, 208, 107492.		64
1378	An Exon Signature to Estimate the Tumor Mutational Burden of Right-sided Colon Cancer Patients. Journal of Cancer, 2020, 11, 883-892.	1.2	5
1379	Latency and interval therapy affect the evolution in metastatic colorectal cancer. Scientific Reports, 2020, 10, 581.	1.6	6
1380	Proteomic investigations into resistance in colorectal cancer. Expert Review of Proteomics, 2020, 17, 49-65.	1.3	8
1381	Tumor Sidedness Is Associated with Survival in Patients with Synchronous Colorectal Peritoneal Carcinomatosis. Oncology, 2020, 98, 230-236.	0.9	3
1382	Identification of microenvironmentâ€related genes with prognostic value in clear cell renal cell carcinoma. Journal of Cellular Biochemistry, 2020, 121, 3606-3615.	1.2	8
1383	Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions. BioMed Research International, 2020, 2020, 1-24.	0.9	38
1384	Oncomir MicroRNA-346 Is Upregulated in Colons of Patients With Primary Sclerosing Cholangitis. Clinical and Translational Gastroenterology, 2020, 11, e00112.	1.3	8
1385	Predictive value of serum and tissue carcinoembryonic antigens for radiologic response and oncologic outcome of rectal cancer. Pathology Research and Practice, 2020, 216, 152834.	1.0	7
1386	The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer. Cancer Cell International, 2020, 20, 30.	1.8	63
1387	Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges. Cancers, 2020, 12, 319.	1.7	141
1388	A Network-Based Approach for Identification of Subtype-Specific Master Regulators in Pancreatic Ductal Adenocarcinoma. Genes, 2020, 11, 155.	1.0	8
1389	RHBDD2 overexpression promotes a chemoresistant and invasive phenotype to rectal cancer tumors via modulating UPR and focal adhesion genes. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165810.	1.8	7
1390	Identifying Molecular Biomarkers for Diseases With Machine Learning Based on Integrative Omics. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2021, 18, 2514-2525.	1.9	20
1392	Molecular description of <scp>ANGPT2</scp> associated colorectal carcinoma. International Journal of Cancer, 2020, 147, 2007-2018.	2.3	15
1394	Structure of the Mucosal and Stool Microbiome in Lynch Syndrome. Cell Host and Microbe, 2020, 27, 585-600.e4.	5.1	40
1395	Imaging and clinical correlates with regorafenib in metastatic colorectal cancer. Cancer Treatment Reviews, 2020, 86, 102020.	3.4	9

#	ARTICLE	IF	CITATIONS
1396	Precision medicine and management of rheumatoid arthritis. Journal of Autoimmunity, 2020, 110, 102405.	3.0	56
1397	Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nature Medicine, 2020, 26, 566-576.	15.2	736
1398	Risk Factor Profiles Differ for Cancers of Different Regions of the Colorectum. Gastroenterology, 2020, 159, 241-256.e13.	0.6	64
1399	Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity. , 2020, 8, e000326.		54
1400	Integrative analyses of molecular pathways and key candidate biomarkers associated with colorectal cancer. Cancer Biomarkers, 2020, 27, 555-568.	0.8	7
1401	CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. Frontiers in Immunology, 2020, 11, 508.	2.2	58
1402	Mapping the spreading routes of lymphatic metastases in human colorectal cancer. Nature Communications, 2020, 11, 1993.	5.8	68
1403	A Validation Study for Recurrence Risk Stratification of Stage II Colon Cancer Using the 55-Gene Classifier. Oncology, 2020, 98, 534-541.	0.9	8
1404	Clinical Significance of a Gene Signature Generated from Tumor Budding Grade in Colon Cancer. Annals of Surgical Oncology, 2020, 27, 4044-4054.	0.7	14
1405	Canonical BMP Signaling Executes Epithelial-Mesenchymal Transition Downstream of SNAIL1. Cancers, 2020, 12, 1019.	1.7	17
1406	MethCORR modelling of methylomes from formalin-fixed paraffin-embedded tissue enables characterization and prognostication of colorectal cancer. Nature Communications, 2020, 11, 2025.	5.8	5
1407	Mitochondrial Respiration in KRAS and BRAF Mutated Colorectal Tumors and Polyps. Cancers, 2020, 12, 815.	1.7	15
1408	Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance). Annals of Oncology, 2020, 31, 487-494.	0.6	36
1409	Gastrointestinal tissue‐based molecular biomarkers: a practical categorisation based on the 2019 World Health Organization classification of epithelial digestive tumours. Histopathology, 2020, 77, 340-350.	1.6	26
1410	The role of mouse models in colorectal cancer research—The need and the importance of the orthotopic models. Animal Models and Experimental Medicine, 2020, 3, 1-8.	1.3	29
1411	Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis. International Journal of Cancer, 2020, 147, 2303-2315.	2.3	14
1412	Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer. Cancer Immunology, Immunotherapy, 2020, 69, 1627-1637.	2.0	16
1413	Characterization of a p53/miR-34a/CSF1R/STAT3 Feedback Loop in Colorectal Cancer. Cellular and Molecular Gastroenterology and Hepatology, 2020, 10, 391-418.	2.3	64

#	Article	IF	Citations
1414	PathME: pathway based multi-modal sparse autoencoders for clustering of patient-level multi-omics data. BMC Bioinformatics, 2020, 21, 146.	1.2	38
1415	Right and left-sided colon cancers - specificity of molecular mechanisms in tumorigenesis and progression. BMC Cancer, 2020, 20, 317.	1.1	51
1416	Role of FOXO3A in Trastuzumab Combination Chemotherapy in Esophageal Squamous Cell Carcinoma. Anticancer Research, 2020, 40, 1921-1930.	0.5	1
1417	The DNA hypermethylation phenotype of colorectal cancer liver metastases resembles that of the primary colorectal cancers. BMC Cancer, 2020, 20, 290.	1.1	13
1418	Metastatic colorectal cancer prior to expanded RAS assessment: evidence from long-term outcome analysis of a real-life cohort within a dedicated colorectal cancer unit. World Journal of Surgical Oncology, 2020, 18, 65.	0.8	0
1419	Hypoxia and Macrophages Act in Concert Towards a Beneficial Outcome in Colon Cancer. Cancers, 2020, 12, 818.	1.7	9
1420	Immunotherapy in Metastatic Colorectal Cancer: Could the Latest Developments Hold the Key to Improving Patient Survival?. Cancers, 2020, 12, 889.	1.7	20
1421	Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?. Cancer Treatment Reviews, 2020, 86, 102023.	3.4	34
1422	Colorectal cancer cell lines show striking diversity of their O-glycome reflecting the cellular differentiation phenotype. Cellular and Molecular Life Sciences, 2021, 78, 337-350.	2.4	34
1423	Regression on imperfect class labels derived by unsupervised clustering. Briefings in Bioinformatics, 2021, 22, 2012-2019.	3.2	1
1424	Stereotactic ablative radiotherapy for colorectal cancer liver metastasis. Seminars in Cancer Biology, 2021, 71, 21-32.	4.3	14
1425	Normal tissue content impact on the GBM molecular classification. Briefings in Bioinformatics, 2021, 22, .	3.2	4
1426	Gut microbiota contributes towards immunomodulation against cancer: New frontiers in precision cancer therapeutics. Seminars in Cancer Biology, 2021, 70, 11-23.	4.3	26
1427	Integrating Multidimensional Data for Clustering Analysis With Applications to Cancer Patient Data. Journal of the American Statistical Association, 2021, 116, 14-26.	1.8	7
1428	Identifying mismatch repairâ€deficient colon cancer: nearâ€perfect concordance between immunohistochemistry and microsatellite instability testing in a large, populationâ€based series. Histopathology, 2021, 78, 401-413.	1.6	55
1429	Effect of primary colorectal cancer tumor location on survival after pulmonary metastasectomy. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 296-305.	0.4	22
1430	Disparate and Alarming Impact of Gastrointestinal Cancers in Young Adult Patients. Annals of Surgical Oncology, 2021, 28, 785-796.	0.7	3
1431	Recent Advances in Digestive Tract Tumors: Updates From the 5th Edition of the World Health Organization â€œBlue Bookâ€. Archives of Pathology and Laboratory Medicine, 2021, 145, 607-626.	1.2	17

#	ARTICLE	IF	CITATIONS
1432	Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage IIâ€"III colon cancer. Modern Pathology, 2021, 34, 161-170.	2.9	9
1433	Genomic profile and immune contexture in colorectal cancerâ€"relevance for prognosis and immunotherapy. Clinical and Experimental Medicine, 2021, 21, 195-204.	1.9	5
1434	Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning. Gut, 2021, 70, 544-554.	6.1	148
1435	In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer. Clinical Cancer Research, 2021, 27, 288-300.	3.2	13
1436	Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma. Clinical Cancer Research, 2021, 27, 1162-1173.	3.2	13
1437	Tumor Sidedness, Recurrence, and Survival After Curative Resection of Localized Colon Cancer. Clinical Colorectal Cancer, 2021, 20, e53-e60.	1.0	24
1438	Prognostic Impact of Primary Side and RAS/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases. Annals of Surgical Oncology, 2021, 28, 3332-3342.	0.7	19
1439	An appraisal of emerging second line therapies for metastatic colorectal cancer. Expert Review of Gastroenterology and Hepatology, 2021, 15, 165-179.	1.4	2
1440	Current Microsatellite Instability Testing in Management of Colorectal Cancer. Clinical Colorectal Cancer, 2021, 20, e12-e20.	1.0	32
1441	Mutations and mechanisms of WNT pathway tumour suppressors in cancer. Nature Reviews Cancer, 2021, 21, 5-21.	12.8	235
1442	Aggressive recurrences determine oncologic outcomes after resection of liver metastases from primary right colon cancer: Results of a case-control study. European Journal of Surgical Oncology, 2021, 47, 834-841.	0.5	2
1443	Tumor-derived mutations in postoperative plasma of colorectal cancer with microsatellite instability. Translational Oncology, 2021, 14, 100945.	1.7	1
1444	A genomeâ€wide study of the relationship between chromosomal abnormalities and gene expression in colorectal tumors. Genes Chromosomes and Cancer, 2021, 60, 250-262.	1.5	13
1445	Early Adaptation of Colorectal Cancer Cells to the Peritoneal Cavity Is Associated with Activation of â€œStemnessâ€•Programs and Local Inflammation. Clinical Cancer Research, 2021, 27, 1119-1130.	3.2	8
1446	Tumorâ€only sequencing for oncology management: Germlineâ€focused analysis and implications. Genes Chromosomes and Cancer, 2021, 60, 352-357.	1.5	4
1447	Clinical Validation of a Machine-learningâ€"derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. Clinical Cancer Research, 2021, 27, 1174-1183.	3.2	28
1448	The Balance of Stromal BMP Signaling Mediated by GREM1 and ISLR Drives Colorectal Carcinogenesis. Gastroenterology, 2021, 160, 1224-1239.e30.	0.6	76
1449	Rising incidence of early-onset colorectal cancer â€" a call to action. Nature Reviews Clinical Oncology, 2021, 18, 230-243.	12.5	276

#	ARTICLE	IF	CITATIONS
1450	Stromal SOX2 Upregulation Promotes Tumorigenesis through the Generation of a SFRP1/2-Expressing Cancer-Associated Fibroblast Population. Developmental Cell, 2021, 56, 95-110.e10.	3.1	50
1451	RNA N6-Methyladenosine Methyltransferase METTL3 Facilitates Colorectal Cancer by Activating the m6A-GLUT1-mTORC1 Axis and Is a Therapeutic Target. Gastroenterology, 2021, 160, 1284-1300.e16.	0.6	161
1452	Multiâ€omics integration identifies a selective vulnerability of colorectal cancer subtypes to <scp>YM155</scp>. International Journal of Cancer, 2021, 148, 1948-1963.	2.3	11
1453	Heterogeneous distribution of <i>Fusobacterium nucleatum</i> in the progression of colorectal cancer. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1869-1876.	1.4	18
1455	The Role of <i>Fusobacterium nucleatum</i> in Colorectal Carcinogenesis. Pathobiology, 2021, 88, 127-140.	1.9	15
1456	Identification of Two Subgroups of FOLFOX Resistance Patterns and Prediction of FOLFOX Response in Colorectal Cancer Patients. Cancer Investigation, 2021, 39, 62-72.	0.6	5
1457	MNK Inhibition Sensitizes <i>KRAS</i>-Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression. Cancer Discovery, 2021, 11, 1228-1247.	7.7	45
1458	The atypical cadherin MUCDHL antagonizes colon cancer formation and inhibits oncogenic signaling through multiple mechanisms. Oncogene, 2021, 40, 522-535.	2.6	7
1459	Inducible mouse models of colon cancer for the analysis of sporadic and inflammation-driven tumor progression and lymph node metastasis. Nature Protocols, 2021, 16, 61-85.	5.5	46
1460	Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1. Clinical Colorectal Cancer, 2021, 20, 84-95.e8.	1.0	15
1461	Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. Clinical Cancer Research, 2021, 27, 120-130.	3.2	21
1462	Reduction of derived neutrophil-to-lymphocyte ratio after four weeks predicts the outcome of patients receiving second-line chemotherapy for metastatic colorectal cancer. Cancer Immunology, Immunotherapy, 2021, 70, 1115-1125.	2.0	4
1463	Towards multi-omics characterization of tumor heterogeneity: a comprehensive review of statistical and machine learning approaches. Briefings in Bioinformatics, 2021, 22, .	3.2	19
1464	New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients. Expert Review of Gastroenterology and Hepatology, 2021, 15, 65-79.	1.4	4
1465	Tumour budding in solid cancers. Nature Reviews Clinical Oncology, 2021, 18, 101-115.	12.5	166
1466	Molecular subtypes of colorectal cancer: AnÂemerging therapeutic opportunity for personalized medicine. Genes and Diseases, 2021, 8, 133-145.	1.5	71
1467	Die Rolle von zytoreduktiver Chirurgie und HIPEC beim Kolonkarzinom. , 2021, , 451-464.		0
1468	The Infiltration Pattern of Microenvironmental Cells and Different Immune Escape Mechanisms in Colorectal Cancer. SSRN Electronic Journal, 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
1469	Onco-ontogeny recapitulates phylogeny â€" a consideration. Oncogene, 2021, 40, 1542-1550.	2.6	1
1470	Tumor Profiling at the Service of Cancer Therapy. Frontiers in Oncology, 2020, 10, 595613.	1.3	9
1472	Efficacy and side effects of immune checkpoint inhibitors in the treatment of colorectal cancer. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110020.	1.4	11
1473	Metastatic colorectal cancer cells maintain the TGFÎ² program and use TGFBI to fuel angiogenesis. Theranostics, 2021, 11, 1626-1640.	4.6	45
1474	Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. Cancer Treatment and Research Communications, 2021, 27, 100328.	0.7	70
1475	The 2019 World Health Organization Classification of appendiceal, colorectal and anal canal tumours: an update and critical assessment. Pathology, 2021, 53, 454-461.	0.3	55
1476	A STING-related prognostic score predicts high-risk patients of colorectal cancer and provides insights into immunotherapy. Annals of Translational Medicine, 2021, 9, 14-14.	0.7	14
1477	Adenylosuccinate lyase is oncogenic in colorectal cancer by causing mitochondrial dysfunction and independent activation of NRF2 and mTOR-MYC-axis. Theranostics, 2021, 11, 4011-4029.	4.6	19
1478	High-Density, Targeted Monitoring of Tyrosine Phosphorylation Reveals Activated Signaling Networks in Human Tumors. Cancer Research, 2021, 81, 2495-2509.	0.4	41
1479	Neoadjuvant immunotherapy in primary and metastatic colorectal cancer. British Journal of Surgery, 2021, 108, 1417-1425.	0.1	57
1480	Prediction of clinical prognosis in cutaneous melanoma using an immune-related gene pair signature. Bioengineered, 2021, 12, 1803-1812.	1.4	6
1481	Exploration of the relationship between tumor mutation burden and immune infiltrates in colon adenocarcinoma. International Journal of Medical Sciences, 2021, 18, 685-694.	1.1	4
1482	Deep Tumor Profiling for Molecular Tumor Boards. , 2021, , 352-360.		0
1484	MethCORR infers gene expression from DNA methylation and allows molecular analysis of ten common cancer types using fresh-frozen and formalin-fixed paraffin-embedded tumor samples. Clinical Epigenetics, 2021, 13, 20.	1.8	0
1485	Modeling colorectal cancers using multidimensional organoids. Advances in Cancer Research, 2021, 151, 345-383.	1.9	3
1486	Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy. Advances in Cancer Research, 2021, 151, 231-304.	1.9	8
1488	Hedgehog Signaling in Colorectal Cancer: All in the Stroma?. International Journal of Molecular Sciences, 2021, 22, 1025.	1.8	17
1489	A signature of 13 autophagyâ€related gene pairs predicts prognosis in hepatocellular carcinoma. Bioengineered, 2021, 12, 697-707.	1.4	10

#	ARTICLE	IF	CITATIONS
1490	A 3D View of Colorectal Cancer Models in Predicting Therapeutic Responses and Resistance. Cancers, 2021, 13, 227.	1.7	48
1491	Expression of Thomsen–Friedenreich Antigen in Colorectal Cancer and Association with Microsatellite Instability. International Journal of Molecular Sciences, 2021, 22, 1340.	1.8	1
1492	A comparative prognostic performance of definitions of Crohn-like lymphoid reaction in colorectal carcinoma. Journal of Pathology and Translational Medicine, 2021, 55, 53-59.	0.4	0
1493	Stromal WNTer Keeps the Tumor Cold and Drives Metastasis. Developmental Cell, 2021, 56, 3-4.	3.1	2
1494	ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin. Nature Biotechnology, 2021, 39, 586-598.	9.4	81
1495	HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy. Cellular and Molecular Immunology, 2021, 18, 556-565.	4.8	55
1496	Molecular correlates of immune cytolytic subgroups in colorectal cancer by integrated genomics analysis. NAR Cancer, 2021, 3, zcab005.	1.6	9
1497	Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin. PLoS ONE, 2021, 16, e0245581.	1.1	8
1498	Artificial Intelligence for Histology-Based Detection of Microsatellite Instability and Prediction of Response to Immunotherapy in Colorectal Cancer. Cancers, 2021, 13, 391.	1.7	49
1499	The Caspase-1/IL-18 Axis of the Inflammasome in Tumor Cells: A Modulator of the Th1/Tc1 Response of Tumor-Infiltrating T Lymphocytes in Colorectal Cancer. Cancers, 2021, 13, 189.	1.7	8
1500	Prognostic value of the PrP^C-ILK-IDO1 axis in the mesenchymal colorectal cancer subtype. OncoImmunology, 2021, 10, 1940674.	2.1	11
1501	ELF3 Overexpression as Prognostic Biomarker for Recurrence of Stage II Colorectal Cancer. In Vivo, 2021, 35, 191-201.	0.6	6
1502	Hereditäre Aspekte des Kolonkarzinoms. , 2021, , 121-135.		0
1504	PPARγ induces PD-L1 expression in MSS+ colorectal cancer cells. OncoImmunology, 2021, 10, 1906500.	2.1	15
1505	Mapping of colorectal carcinoma diseases with activation of Wnt/beta-catenin signalling pathway using hierarchical clustering approach. Journal of Clinical Pathology, 2022, 75, 168-175.	1.0	1
1506	Immune Cell Infiltration of the Primary Tumor Microenvironment Predicted the Treatment Outcome of Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients. Frontiers in Oncology, 2020, 10, 581051.	1.3	8
1507	Cancer-Associated Fibroblasts and T Cells: From Mechanisms to Outcomes. Journal of Immunology, 2021, 206, 310-320.	0.4	35
1508	Systems biology and molecular characterization of subtypes to guide targeted therapies in gastric cancer. , 2021, , 259-288.		0

#	Article	IF	Citations
1509	Current Achievements and Applications of Transcriptomics in Personalized Cancer Medicine. International Journal of Molecular Sciences, 2021, 22, 1422.	1.8	64
1510	Impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in CRC cases. PLoS Genetics, 2021, 17, e1009113.	1.5	7
1511	Tumor immune infiltration estimated from gene expression profiles predicts colorectal cancer relapse. OncoImmunology, 2021, 10, 1862529.	2.1	9
1512	Chromosome 20q11.21 Amplifications in Colorectal Cancer. Cancer Genomics and Proteomics, 2021, 18, 487-496.	1.0	11
1513	Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study. Clinical Cancer Research, 2021, 27, 2159-2167.	3.2	9
1514	Immunomodulatory nanomedicine for colorectal cancer treatment: a landscape to be explored?. Biomaterials Science, 2021, 9, 3228-3243.	2.6	6
1515	Immunotherapy in colorectal cancer. Advances in Cancer Research, 2021, 151, 137-196.	1.9	18
1516	Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis. Computational and Structural Biotechnology Journal, 2021, 19, 949-960.	1.9	111
1517	Identifying Stage II Colorectal Cancer Recurrence Associated Genes by Microarray Meta-Analysis and Building Predictive Models with Machine Learning Algorithms. Journal of Oncology, 2021, 2021, 1-13.	0.6	2
1518	Identification of an immune overdrive high-risk subpopulation with aberrant expression of FOXP3 and CTLA4 in colorectal cancer. Oncogene, 2021, 40, 2130-2145.	2.6	15
1520	A universal molecular prognostic score for gastrointestinal tumors. Npj Genomic Medicine, 2021, 6, 6.	1.7	6
1521	Precision Medicine and Public Health: New Challenges for Effective and Sustainable Health. Journal of Personalized Medicine, 2021, 11, 135.	1.1	27
1522	Understanding cellâ€cell communication and signaling in the colorectal cancer microenvironment. Clinical and Translational Medicine, 2021, 11, e308.	1.7	52
1523	Interplay of stromal tumor-infiltrating lymphocytes, normal colonic mucosa, cancer-associated fibroblasts, clinicopathological data and the immunoregulatory molecules of patients diagnosed with colorectal cancer. Cancer Immunology, Immunotherapy, 2021, 70, 2681-2700.	2.0	13
1524	The impact of molecular profile on the lymphatic spread pattern in stage III colon cancer. Cancer Science, 2021, 112, 1545-1555.	1.7	2
1525	Molecular features and gene expression signature of metastatic colorectal cancer (Review). Oncology Reports, 2021, 45, .	1.2	31
1526	Implications for the colorectal surgeon following the 100Â000 Genomes Project. Colorectal Disease, 2021, 23, 1049-1058.	0.7	4
1527	Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer. Journal of Clinical Investigation, 2021, 131, .	3.9	11

#	ARTICLE	IF	CITATIONS
1528	A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2021, 27, 2470-2480.	3.2	51
1529	Genetic architectures of proximal and distal colorectal cancer are partly distinct. Gut, 2021, 70, 1325-1334.	6.1	44
1530	HERVs establish a distinct molecular subtype in stage II/III colorectal cancer with poor outcome. Npj Genomic Medicine, 2021, 6, 13.	1.7	17
1532	Advances in CpG Island Methylator Phenotype Colorectal Cancer Therapies. Frontiers in Oncology, 2021, 11, 629390.	1.3	11
1533	The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization. Diagnostics, 2021, 11, 339.	1.3	46
1534	Postâ€translational Wnt receptor regulation: Is the fog slowly clearing?. BioEssays, 2021, 43, e2000297.	1.2	10
1535	In Vitro Suppression of T Cell Proliferation Is a Conserved Function of Primary and Immortalized Human Cancer-Associated Fibroblasts. International Journal of Molecular Sciences, 2021, 22, 1827.	1.8	11
1536	Colorectal Cancer-Associated Smad4 R361 Hotspot Mutations Boost Wnt/Î²-Catenin Signaling through Enhanced Smad4â€"LEF1 Binding. Molecular Cancer Research, 2021, 19, 823-833.	1.5	4
1537	Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer. Molecular Cancer, 2021, 20, 29.	7.9	139
1538	Dual inhibition of TGFÎ² and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype. Medical Oncology, 2021, 38, 24.	1.2	7
1539	Another One Bites the Gut: Nuclear Receptor LRH-1 in Intestinal Regeneration and Cancer. Cancers, 2021, 13, 896.	1.7	3
1540	Radiogenomics in Colorectal Cancer. Cancers, 2021, 13, 973.	1.7	18
1541	Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatinâ€based or irinotecanâ€based therapy for colorectal cancer. Cancer Science, 2021, 112, 1567-1578.	1.7	5
1543	Advances in colon cancer research: in vitro and animal models. Current Opinion in Genetics and Development, 2021, 66, 50-56.	1.5	37
1544	Therapeutic Targeting of the Tumour Microenvironment in Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 2021, 22, 2067.	1.8	14
1545	Therapeutic targeting of the oncogenic Wnt signaling pathway for treating colorectal cancer and other colonic disorders. Advanced Drug Delivery Reviews, 2021, 169, 118-136.	6.6	58
1546	Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches. Expert Review of Gastroenterology and Hepatology, 2021, 15, 735-742.	1.4	14
1547	Subversion of Niche-Signalling Pathways in Colorectal Cancer: What Makes and Breaks the Intestinal Stem Cell. Cancers, 2021, 13, 1000.	1.7	20

#	Article	IF	Citations
1548	Differential immune signatures in the tumor microenvironment are associated with colon cancer racial disparities. Cancer Medicine, 2021, 10, 1805-1814.	1.3	17
1550	Understanding relevant immune mechanisms in gastrointestinal oncology. Journal of Oncology Pharmacy Practice, 2021, 27, 107815522199286.	0.5	0
1551	Prognostic Factor and Survival Benefit of Adjuvant Chemotherapy in Stage IIA Colon Cancer. Annals of Coloproctology, 2021, 37, 35-43.	0.5	8
1552	AKT3 Expression in Mesenchymal Colorectal Cancer Cells Drives Growth and Is Associated with Epithelial-Mesenchymal Transition. Cancers, 2021, 13, 801.	1.7	16
1553	Low Expression of miR-375 and miR-190b Differentiates Grade 3 Patients with Endometrial Cancer. Biomolecules, 2021, 11, 274.	1.8	2
1554	Clinical-grade whole-genome sequencing and 3â€² transcriptome analysis of colorectal cancer patients. Genome Medicine, 2021, 13, 33.	3.6	5
1555	The Distinctive Serum Metabolomes of Gastric, Esophageal and Colorectal Cancers. Cancers, 2021, 13, 720.	1.7	13
1557	TRIM Proteins in Colorectal Cancer: TRIM8 as a Promising Therapeutic Target in Chemo Resistance. Biomedicines, 2021, 9, 241.	1.4	12
1558	A tumor microenvironment-specific gene expression signature predicts chemotherapy resistance in colorectal cancer patients. Npj Precision Oncology, 2021, 5, 7.	2.3	29
1559	Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). Journal of Clinical Oncology, 2021, 39, 285-294.	0.8	169
1560	A novel epithelialâ€mesenchymal transition molecular signature predicts the oncological outcomes in colorectal cancer. Journal of Cellular and Molecular Medicine, 2021, 25, 3194-3204.	1.6	8
1561	Cytotoxic Efficacy and Resistance Mechanism of a TRAIL and VEGFA-Peptide Fusion Protein in Colorectal Cancer Models. International Journal of Molecular Sciences, 2021, 22, 3160.	1.8	2
1562	V600E and Non-V600E BRAF Mutations in Colorectal Cancer: Clinicopathologic Correlations in a Single Institution. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2021, 31, 43-49.	0.1	0
1563	Case Report: Two Cases of Metastatic Pancreatoblastoma in Adults: Efficacy of Folfirinox and Implication of the Wnt/Î²-Catenin Pathway in Genomic Analysis. Frontiers in Oncology, 2021, 11, 564506.	1.3	6
1564	Epigenetic Mechanisms Are Involved in the Oncogenic Properties of ZNF518B in Colorectal Cancer. Cancers, 2021, 13, 1433.	1.7	4
1565	ROLE OF PD-L1 ASSESSMENT IN THE ASPECT OF MOLECULAR-GENETIC CLASSIFICATION OF COLORECTAL CANCER. CURRENT STATE OF THE PROBLEM. Siberian Journal of Oncology, 2021, 20, 115-122.	0.1	0
1566	Emerging Trends for Radio-Immunotherapy in Rectal Cancer. Cancers, 2021, 13, 1374.	1.7	18
1567	Molecular Oncology in Management of Colorectal Cancer. Indian Journal of Surgical Oncology, 2021, 12, 169-180.	0.3	0

#	ARTICLE	IF	CITATIONS
1568	Deciphering the Role of Intestinal Crypt Cell Populations in Resistance to Chemotherapy. Cancer Research, 2021, 81, 2730-2744.	0.4	4
1569	Refining the Molecular Framework for Pancreatic Cancer with Single-cell and Spatial Technologies. Clinical Cancer Research, 2021, 27, 3825-3833.	3.2	8
1570	Increasing Embryonic Morphogen Nodal Expression Suggests Malignant Transformation in Colorectal Lesions and as a Potential Marker for CMS4 Subtype of Colorectal Cancer. Pathology and Oncology Research, 2021, 27, 587029.	0.9	2
1571	Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. European Journal of Cancer, 2021, 146, 145-154.	1.3	8
1572	Prognostic Cancer Gene Expression Signatures: Current Status and Challenges. Cells, 2021, 10, 648.	1.8	47
1573	Recent Advances in Our Knowledge of mCRC Tumor Biology and Genetics: A Focus on Targeted Therapy Development. OncoTargets and Therapy, 2021, Volume 14, 2121-2130.	1.0	8
1574	Tumorâ€‘infiltrating lymphocytes in tissue material combined with systemic lymphocyte inflammation in patients with colorectal cancer. Molecular and Clinical Oncology, 2021, 14, 97.	0.4	2
1575	Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer. Scientific Reports, 2021, 11, 6731.	1.6	5
1576	Signaling pathways in intestinal homeostasis and colorectal cancer: KRAS at centre stage. Cell Communication and Signaling, 2021, 19, 31.	2.7	19
1577	Investigation of clinicopathological characters and gene expression features in colorectal signetâ€‘ring cell carcinoma utilizing CMS classification. Molecular and Clinical Oncology, 2021, 14, 98.	0.4	2
1578	Resistance to Cell Death in Mucinous Colorectal Cancerâ€"A Review. Cancers, 2021, 13, 1389.	1.7	12
1579	Tumor microenvironment-associated gene C3 can predict the prognosis of colorectal adenocarcinoma: a study based on TCGA. Clinical and Translational Oncology, 2021, 23, 1923-1933.	1.2	5
1580	Using Theory To Extend the Scope of Azobenzene Drugs in Chemotherapy: Novel Combinations for a Specific Delivery. ChemMedChem, 2021, 16, 1765-1775.	1.6	2
1581	The impact of recent next generation sequencing and the need for a new classification in gastric cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2021, 50-51, 101730.	1.0	18
1582	LncRNA ILF3-AS1 Promotes the Progression of Colon Adenocarcinoma Cells Through the miR-619-5p/CAMK1D Axis. OncoTargets and Therapy, 2021, Volume 14, 1861-1872.	1.0	6
1583	On the limits of active module identification. Briefings in Bioinformatics, 2021, 22, .	3.2	30
1584	COMSUC: A web server for the identification of consensus molecular subtypes of cancer based on multiple methods and multi-omics data. PLoS Computational Biology, 2021, 17, e1008769.	1.5	2
1585	Prognostic significance and immune infiltration of microenvironment-related signatures in pancreatic cancer. Medicine (United States), 2021, 100, e24957.	0.4	3

#	Article	IF	Citations
1586	WNT5a in Colorectal Cancer: Research Progress and Challenges. Cancer Management and Research, 2021, Volume 13, 2483-2498.	0.9	6
1587	Tumor Microenvironment in Metastatic Colorectal Cancer: The Arbitrator in Patients' Outcome. Cancers, 2021, 13, 1130.	1.7	15
1588	Cancer-Associated Fibroblast-Induced Resistance to Chemotherapy and Radiotherapy in Gastrointestinal Cancers. Cancers, 2021, 13, 1172.	1.7	31
1589	Functional States in Tumor-Initiating Cell Differentiation in Human Colorectal Cancer. Cancers, 2021, 13, 1097.	1.7	11
1590	A Drastic Shift in Lipid Adducts in Colon Cancer Detected by MALDI-IMS Exposes Alterations in Specific K+ Channels. Cancers, 2021, 13, 1350.	1.7	4
1593	Microsatellite Instability in Colorectal Cancer Liquid Biopsy—Current Updates on Its Potential in Non-Invasive Detection, Prognosis and as a Predictive Marker. Diagnostics, 2021, 11, 544.	1.3	15
1594	Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency. Cancers, 2021, 13, 1149.	1.7	30
1595	Chemotherapy agents stimulate dendritic cells against human colon cancer cells through upregulation of the transporter associated with antigen processing. Scientific Reports, 2021, 11, 9080.	1.6	6
1596	Circular RNA in Chemonaive Lymph Node Negative Colon Cancer Patients. Cancers, 2021, 13, 1903.	1.7	1
1597	Identification of Epithelial-Mesenchymal Transition-Related lncRNAs that Associated With the Prognosis and Immune Microenvironment in Colorectal Cancer. Frontiers in Molecular Biosciences, 2021, 8, 633951.	1.6	9
1598	Clinicopathological and Molecular Features of Patients with Early and Late Recurrence after Curative Surgery for Colorectal Cancer. Cancers, 2021, 13, 1883.	1.7	10
1599	The Role of p53 Signaling in Colorectal Cancer. Cancers, 2021, 13, 2125.	1.7	106
1600	BH3 Mimetic Sensitivity of Colorectal Cancer Cell Lines in Correlation with Molecular Features Identifies Predictors of Response. International Journal of Molecular Sciences, 2021, 22, 3811.	1.8	3
1601	Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells. BMC Cancer, 2021, 21, 448.	1.1	8
1602	Current and Prospective Methods for Assessing Anti-Tumor Immunity in Colorectal Cancer. International Journal of Molecular Sciences, 2021, 22, 4802.	1.8	6
1603	The inflammatory pathogenesis of colorectal cancer. Nature Reviews Immunology, 2021, 21, 653-667.	10.6	270
1604	A modified protein marker panel to identify four consensus molecular subtypes in colorectal cancer using immunohistochemistry. Pathology Research and Practice, 2021, 220, 153379.	1.0	7
1605	Systemic therapy in addition to cytoreduction and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: recent insights from clinical studies and translational research. Journal of Gastrointestinal Oncology, 2021, 12, S206-S213.	0.6	5

#	ARTICLE	IF	CITATIONS
1606	Prognostic implications of an autophagy-based signature in colorectal cancer. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 7	0.4	9
1607	Colorectal Cancer and Immunity: From the Wet Lab to Individuals. Cancers, 2021, 13, 1713.	1.7	1
1608	Molecular Classification Based on Prognostic and Cell Cycle-Associated Genes in Patients With Colon Cancer. Frontiers in Oncology, 2021, 11, 636591.	1.3	7
1609	Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clinical Cancer Research, 2021, 27, 3039-3049.	3.2	28
1610	Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ. Nature Communications, 2021, 12, 2340.	5.8	43
1611	High-content, targeted RNA-seq screening in organoids for drug discovery in colorectal cancer. Cell Reports, 2021, 35, 109026.	2.9	35
1612	RAC1B modulates intestinal tumourigenesis via modulation of WNT and EGFR signalling pathways. Nature Communications, 2021, 12, 2335.	5.8	20
1614	Disease recurrence after colorectal cancer surgery in the modern era: a population-based study. International Journal of Colorectal Disease, 2021, 36, 2399-2410.	1.0	42
1615	RGL2 Drives the Metastatic Progression of Colorectal Cancer via Preventing the Protein Degradation of Î²-Catenin and KRAS. Cancers, 2021, 13, 1763.	1.7	6
1616	An Immune-Related Gene Pairs Signature Predicts Prognosis and Immune Heterogeneity in Glioblastoma. Frontiers in Oncology, 2021, 11, 592211.	1.3	1
1617	Routine Molecular Pathology Diagnostics in Precision Oncology. Deutsches A&#x0308;rzteblatt International, 2021, 118, .	0.6	2
1618	Mucinous Colorectal Cancer is Associated With Expression of the TIM-3 Immune Checkpoint Independently of Microsatellite Instability (MSI) Status. Annals of Surgical Oncology, 2021, 28, 7999-8006.	0.7	3
1619	Discovering the Mutational Profile of Early Colorectal Lesions: A Translational Impact. Cancers, 2021, 13, 2081.	1.7	2
1620	Comprehensive genomic analysis contrasting primary colorectal cancer and matched liver metastases. Oncology Letters, 2021, 21, 466.	0.8	12
1621	Multilevel prioritization of gene regulators associated with consensus molecular subtypes of colorectal cancer. Briefings in Bioinformatics, 2021, 22, .	3.2	4
1622	PD-L1 as a Prognostic Factor in Early-Stage Colon Carcinoma within the Immunohistochemical Molecular Subtype Classification. Cancers, 2021, 13, 1943.	1.7	13
1623	Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer. Clinical and Translational Medicine, 2021, 11, e401.	1.7	6
1624	Outcomes of young patients diagnosed with locally advanced rectal cancer. Journal of Gastrointestinal Oncology, 2021, 12, 592-601.	0.6	2

#	Article	IF	Citations
1625	Cancer-associated fibroblast-derived gene signatures determine prognosis in colon cancer patients. Molecular Cancer, 2021, 20, 73.	7.9	44
1626	Integrated approaches for precision oncology in colorectal cancer: The more you know, the better. Seminars in Cancer Biology, 2022, 84, 199-213.	4.3	35
1627	Weighted Gene Co-expression Network Analysis Identifies CALD1 as a Biomarker Related to M2 Macrophages Infiltration in Stage III and IV Mismatch Repair-Proficient Colorectal Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 649363.	1.6	10
1628	NEM-Tar: A Probabilistic Graphical Model for Cancer Regulatory Network Inference and Prioritization of Potential Therapeutic Targets From Multi-Omics Data. Frontiers in Genetics, 2021, 12, 608042.	1.1	1
1629	Significance of Plasma UCA1 for Predicting Colorectal Cancer and BRAF Mutation Status. Anticancer Research, 2021, 41, 1761-1769.	0.5	2
1630	The clinical relevance of gene expression based prognostic signatures in colorectal cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188513.	3.3	56
1631	Colon Fibroblasts and Inflammation: Sparring Partners in Colorectal Cancer Initiation?. Cancers, 2021, 13, 1749.	1.7	7
1632	Evolutionary genetic algorithm identifies <i>IL2RB</i> as a potential predictive biomarker for immune-checkpoint therapy in colorectal cancer. NAR Genomics and Bioinformatics, 2021, 3, lqab016.	1.5	10
1633	Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study. ESMO Open, 2021, 6, 100073.	2.0	12
1634	Actual survival after resection of primary colorectal cancer: results from a prospective multicenter study. World Journal of Surgical Oncology, 2021, 19, 96.	0.8	41
1635	Rational Treatment of Metastatic Colorectal Cancer: A Reverse Tale of Men, Mice, and Culture Dishes. Cancer Discovery, 2021, 11, 1644-1660.	7.7	11
1636	Natural Killer cells and monoclonal antibodies: Two partners for successful antibody dependent cytotoxicity against tumor cells. Critical Reviews in Oncology/Hematology, 2021, 160, 103261.	2.0	18
1637	Genomic Alteration Characterization in Colorectal Cancer Identifies a Prognostic and Metastasis Biomarker: FAM83A|IDO1. Frontiers in Oncology, 2021, 11, 632430.	1.3	32
1638	TOX Acts as a Tumor Suppressor by Inhibiting mTOR Signaling in Colorectal Cancer. Frontiers in Immunology, 2021, 12, 647540.	2.2	14
1639	Controlling for cellular heterogeneity using single-cell deconvolution of gene expression reveals novel markers of colorectal tumors exhibiting microsatellite instability. Oncotarget, 2021, 12, 767-782.	0.8	5
1640	Respiratory complex and tissue lineage drive recurrent mutations in tumour mtDNA. Nature Metabolism, 2021, 3, 558-570.	5.1	58
1641	The 2019 Incentive Award of the Okayama Medical Association in Cancer Research (2019 Hayashibara) Tj ETQq0 0 0 rgBT /Overlock 10	0.0	0
1642	Anchorâ€IMPACT: A standardized microfluidic platform for highâ€throughput antiangiogenic drug screening. Biotechnology and Bioengineering, 2021, 118, 2524-2535.	1.7	13

#	Article	IF	Citations
1643	The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer. British Journal of Cancer, 2021, 125, 240-246.	2.9	8
1644	The impact of primary tumor sidedness on survival in early‐onset colorectal cancer by stage: A National Veterans Affairs retrospective analysis. Cancer Medicine, 2021, 10, 2987-2995.	1.3	8
1645	Comparative Analysis of Patient-Matched PDOs Revealed a Reduction in OLFM4-Associated Clusters in Metastatic Lesions in Colorectal Cancer. Stem Cell Reports, 2021, 16, 954-967.	2.3	21
1646	Precision oncology in metastatic colorectal cancer â€" from biology to medicine. Nature Reviews Clinical Oncology, 2021, 18, 506-525.	12.5	113
1647	Primary tumor resection improves prognosis of unresectable carcinomas of the transverse colon including flexures with liver metastasis: a preliminary population-based analysis. BMC Cancer, 2021, 21, 503.	1.1	1
1650	Potential Impact of ALKBH5 and YTHDF1 on Tumor Immunity in Colon Adenocarcinoma. Frontiers in Oncology, 2021, 11, 670490.	1.3	20
1651	Molecular Pathways Associated with Kallikrein 6 Overexpression in Colorectal Cancer. Genes, 2021, 12, 749.	1.0	3
1652	Cancer-Associated Fibroblasts and Tumor-Associated Macrophages in Cancer and Cancer Immunotherapy. Frontiers in Oncology, 2021, 11, 668731.	1.3	55
1653	Immune Checkpoint Blockade in Lower Gastrointestinal Cancers: A Systematic Review. Annals of Surgical Oncology, 2021, 28, 7463-7473.	0.7	3
1654	Prognostic relevance and putative histogenetic role of cytokeratin 7 and MUC5AC expression in Crohnâ€™s disease-associated small bowel carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 667-678.	1.4	10
1655	Genomic and immunological features of microsatellite instability in colon cancer. Gene, 2021, 781, 145534.	1.0	5
1656	Lincp21-RNA as Predictive Response Marker for Preoperative Chemoradiotherapy in Rectal Cancer. Journal of Personalized Medicine, 2021, 11, 420.	1.1	6
1657	Claudin-Low Breast Cancer Inflammatory Signatures Support Polarization of M1-Like Macrophages with Protumoral Activity. Cancers, 2021, 13, 2248.	1.7	7
1658	Targeting BRAF and RAS in Colorectal Cancer. Cancers, 2021, 13, 2201.	1.7	29
1659	Firstâ€line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component. Cancer Medicine, 2021, 10, 3388-3402.	1.3	5
1661	Molecular Determinants of Gastrointestinal Cancers. Advances in Oncology, 2021, 1, 311-325.	0.1	0
1662	Prognostic Value of Tumor-Stroma Ratio in Rectal Cancer: A Systematic Review and Meta-analysis. Frontiers in Oncology, 2021, 11, 685570.	1.3	8
1664	Galectin-1 fosters an immunosuppressive microenvironment in colorectal cancer by reprogramming CD8[+] regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	58

#	ARTICLE	IF	CITATIONS
1665	HNF1A regulates colorectal cancer progression and drug resistance as a downstream of POU5F1. Scientific Reports, 2021, 11, 10363.	1.6	11
1666	Methylation Regulation of TLR3 on Immune Parameters in Lung Adenocarcinoma. Frontiers in Oncology, 2021, 11, 620200.	1.3	3
1667	Are Molecular Alterations Linked to Genetic Instability Worth to Be Included as Biomarkers for Directing or Excluding Melanoma Patients to Immunotherapy?. Frontiers in Oncology, 2021, 11, 666624.	1.3	5
1668	KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas. Cancers, 2021, 13, 2429.	1.7	18
1669	Irinotecan or Oxaliplatin: Which is the First Move for the Mate?. Current Medicinal Chemistry, 2021, 28, 3158-3172.	1.2	1
1670	A mutational signature for colorectal cancer prognosis prediction: Associated with immune cell infiltration. Clinical and Translational Medicine, 2021, 11, e414.	1.7	0
1671	Complete mesocolic excision versus conventional surgery for colon cancer: A systematic review and meta‐analysis. Colorectal Disease, 2021, 23, 1670-1686.	0.7	27
1672	It takes a village: microbiota, parainflammation, paligenosis and bystander effects in colorectal cancer initiation. DMM Disease Models and Mechanisms, 2021, 14, .	1.2	12
1673	A Comprehensive Overview of Colon Cancer- A Grim Reaper of the 21st Century. Current Medicinal Chemistry, 2021, 28, 2657-2696.	1.2	19
1674	Chromatin state dynamics confers specific therapeutic strategies in enhancer subtypes of colorectal cancer. Gut, 2022, 71, 938-949.	6.1	25
1675	Arid5a Promotes Immune Evasion by Augmenting Tryptophan Metabolism and Chemokine Expression. Cancer Immunology Research, 2021, 9, 862-876.	1.6	15
1676	Data Driven Mathematical Model of FOLFIRI Treatment for Colon Cancer. Cancers, 2021, 13, 2632.	1.7	14
1677	The ZEB2‐dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes *ERCC1* and *ERCC4* in colorectal cancer. Molecular Oncology, 2021, 15, 2065-2083.	2.1	18
1678	A Bayesian approach to comparing common models of life-course epidemiology. International Journal of Epidemiology, 2021, 50, 1660-1670.	0.9	6
1679	Phenotypic plasticity underlies local invasion and distant metastasis in colon cancer. ELife, 2021, 10, .	2.8	38
1680	Screening and Prognostic Value of Methylated Septin9 and its Association With Clinicopathological and Molecular Characteristics in Colorectal Cancer. Frontiers in Molecular Biosciences, 2021, 8, 568818.	1.6	6
1681	Mathematical modeling of multiple pathways in colorectal carcinogenesis using dynamical systems with Kronecker structure. PLoS Computational Biology, 2021, 17, e1008970.	1.5	11
1682	Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. Cancers, 2021, 13, 2638.	1.7	32

#	Article	IF	Citations
1683	Organoids and Colorectal Cancer. Cancers, 2021, 13, 2657.	1.7	26
1684	Therapeutic Targets and Tumor Microenvironment in Colorectal Cancer. Journal of Clinical Medicine, 2021, 10, 2295.	1.0	28
1685	Relationship between microsatellite status and immune microenvironment of colorectal cancer and its application to diagnosis and treatment. Journal of Clinical Laboratory Analysis, 2021, 35, e23810.	0.9	20
1687	lncRNA Profiles Enable Prognosis Prediction and Subtyping for Esophageal Squamous Cell Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 656554.	1.8	10
1688	Current status of cancer immunotherapy with immune checkpoint inhibitors. Journal of the Korean Medical Association, 2021, 64, 326-331.	0.1	1
1689	Advances in Treatment Selection for Patients with Metastatic Colorectal Cancer. Advances in Oncology, 2021, 1, 297-310.	0.1	0
1690	Identifying Novel Actionable Targets in Colon Cancer. Biomedicines, 2021, 9, 579.	1.4	13
1691	A New Oxaliplatin Resistance-Related Gene Signature With Strong Predicting Ability in Colon Cancer Identified by Comprehensive Profiling. Frontiers in Oncology, 2021, 11, 644956.	1.3	8
1692	Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes. International Journal of Molecular Sciences, 2021, 22, 5246.	1.8	9
1693	Engineering L7Ae for RNA-Only Delivery Kill Switch Targeting CMS2 Type Colorectal Cancer Cells. ACS Synthetic Biology, 2021, 10, 1095-1105.	1.9	10
1694	Clinical Implications of Colorectal Cancer Stem Cells in the Age of Single-Cell Omics and Targeted Therapies. Gastroenterology, 2021, 160, 1947-1960.	0.6	42
1695	Analysis of Survival Among Adults With Early-Onset Colorectal Cancer in the National Cancer Database. JAMA Network Open, 2021, 4, e2112539.	2.8	48
1696	Loss of mitochondrial aconitase promotes colorectal cancer progression via SCD1-mediated lipid remodeling. Molecular Metabolism, 2021, 48, 101203.	3.0	22
1697	Insulin-Like Growth Factor 2 mRNA-Binding Protein 1 (IGF2BP1) Is a Prognostic Biomarker and Associated with Chemotherapy Responsiveness in Colorectal Cancer. International Journal of Molecular Sciences, 2021, 22, 6940.	1.8	19
1698	Consensus molecular subtyping of colorectal cancers is influenced by goblet cell content. Cancer Genetics, 2021, 254-255, 34-39.	0.2	5
1699	Artificial intelligence in early drug discovery enabling precision medicine. Expert Opinion on Drug Discovery, 2021, 16, 991-1007.	2.5	35
1700	αSMA+ fibroblasts suppress Lgr5+ cancer stem cells and restrain colorectal cancer progression. Oncogene, 2021, 40, 4440-4452.	2.6	27
1701	Analyzing the Opportunities to Target DNA Double-Strand Breaks Repair and Replicative Stress Responses to Improve Therapeutic Index of Colorectal Cancer. Cancers, 2021, 13, 3130.	1.7	13

#	ARTICLE	IF	CITATIONS
1702	The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy. Current Drug Targets, 2021, 22, 1021-1033.	1.0	6
1703	Pre-clinical modelling of rectal cancer to develop novel radiotherapy-based treatment strategies. Oncology Reviews, 2021, 15, 511.	0.8	4
1704	Metabolic Reprogramming of Colorectal Cancer Cells and the Microenvironment: Implication for Therapy. International Journal of Molecular Sciences, 2021, 22, 6262.	1.8	53
1705	Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. European Journal of Cancer, 2021, 150, 133-142.	1.3	1
1706	Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies. Cancers, 2021, 13, 3063.	1.7	29
1708	Methylation-eQTL analysis in cancer research. Bioinformatics, 2021, 37, 4014-4022.	1.8	5
1709	Claudin-2 promotes colorectal cancer liver metastasis and is a biomarker of the replacement type growth pattern. Communications Biology, 2021, 4, 657.	2.0	32
1710	Oncogenic BRAF, unrestrained by TGFβ2-receptor signalling, drives right-sided colonic tumorigenesis. Nature Communications, 2021, 12, 3464.	5.8	33
1711	Enhanced triacylglycerol catabolism by carboxylesterase 1 promotes aggressive colorectal carcinoma. Journal of Clinical Investigation, 2021, 131, .	3.9	25
1712	Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer. Frontiers in Oncology, 2021, 11, 601722.	1.3	32
1713	The association between the adapted dietary inflammatory index and colorectal cancer recurrence and all-cause mortality. Clinical Nutrition, 2021, 40, 4436-4443.	2.3	10
1714	Differential genetic influences over colorectal cancer risk and gene expression in large bowel mucosa. International Journal of Cancer, 2021, 149, 1100-1108.	2.3	7
1715	A bird's eye view of fibroblast heterogeneity: A pan‐disease, pan‐cancer perspective. Immunological Reviews, 2021, 302, 299-320.	2.8	23
1716	Microbial Community Heterogeneity Within Colorectal Neoplasia and its Correlation With Colorectal Carcinogenesis. Gastroenterology, 2021, 160, 2395-2408.	0.6	74
1717	Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1726-1734.	1.1	0
1718	Insulin-Like Growth Factor 1 (IGF-1) Signaling in Glucose Metabolism in Colorectal Cancer. International Journal of Molecular Sciences, 2021, 22, 6434.	1.8	68
1719	A <scp>SMAD4</scp>‐modulated gene profile predicts disease‐free survival in stage <scp>II</scp> and <scp>III</scp> colorectal cancer. Cancer Reports, 2022, 5, e1423.	0.6	10
1720	Framing the potential of public frameshift peptides as immunotherapy targets in colon cancer. PLoS ONE, 2021, 16, e0251630.	1.1	5

#	Article	IF	Citations
1721	*BRAF* Mutations as Actionable Targets: A Paradigm Shift in the Management of Colorectal Cancer and Novel Avenues. JCO Oncology Practice, 2021, 17, 723-730.	1.4	20
1722	*14-3-3ƒ* Functions as an Intestinal Tumor Suppressor. Cancer Research, 2021, 81, 3621-3634.	0.4	8
1723	CHK1 inhibitor sensitizes resistant colorectal cancer stem cells to nortopsentin. IScience, 2021, 24, 102664.	1.9	31
1724	Beyond Microsatellite Instability: Intrinsic Disorder as a Potential Link Between Protein Short Tandem Repeats and Cancer. Frontiers in Bioinformatics, 2021, 1, .	1.0	1
1725	Gene Expression Profiles Associated with Radio-Responsiveness in Locally Advanced Rectal Cancer. Biology, 2021, 10, 500.	1.3	9
1726	Immune cell - produced ROS and their impact on tumor growth and metastasis. Redox Biology, 2021, 42, 101891.	3.9	72
1727	Genetic and biological hallmarks of colorectal cancer. Genes and Development, 2021, 35, 787-820.	2.7	159
1728	Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2022, 114, 503-516.	3.0	70
1729	Primary tumor side is associated with prognosis of colorectal cancer patients with brain metastases. ESMO Open, 2021, 6, 100168.	2.0	9
1730	Targeting cancer stem cells in refractory cancer. Regenerative Therapy, 2021, 17, 13-19.	1.4	9
1731	Preclinical models as patients' avatars for precision medicine in colorectal cancer: past and future challenges. Journal of Experimental and Clinical Cancer Research, 2021, 40, 185.	3.5	20
1732	Tribbles Pseudokinases in Colorectal Cancer. Cancers, 2021, 13, 2825.	1.7	8
1733	Treatment sequencing of metastatic colorectal cancer based on primary tumor location. Seminars in Oncology, 2021, 48, 119-129.	0.8	4
1734	HS3ST2 and Its Related Molecules as Potential Biomarkers for Predicting Lymph Node Metastasis in Patients with Colorectal Cancer. OncoTargets and Therapy, 2021, Volume 14, 3881-3894.	1.0	2
1735	Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer. International Journal of Molecular Sciences, 2021, 22, 6813.	1.8	20
1736	Analyzing microsatellite instability and gene mutation in circulating cell-free DNA to monitor colorectal cancer progression. Translational Cancer Research, 2021, 10, 2812-2821.	0.4	2
1737	Molecular genetic classification of colorectal cancer subtypes: current state of the problem. South Russian Journal of Cancer, 2021, 2, 50-56.	0.1	7
1738	KRAS mutant rectal cancer cells interact with surrounding fibroblasts to deplete the extracellular matrix. Molecular Oncology, 2021, 15, 2766-2781.	2.1	7

#	Article	IF	Citations
1739	A Prognosis Marker SLC2A3 Correlates With EMT and Immune Signature in Colorectal Cancer. Frontiers in Oncology, 2021, 11, 638099.	1.3	27
1740	PROGNOSTIC ROLE OF MOLECULAR SUBTYPES OF COLON CANCER. A CURRENT VIEW ON THE PROBLEM. Siberian Journal of Oncology, 2021, 20, 107-114.	0.1	2
1741	Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer. Current Treatment Options in Oncology, 2021, 22, 69.	1.3	16
1742	Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer. Clinical Cancer Research, 2021, 27, 4768-4780.	3.2	25
1743	Contribution of the microbiota and their secretory products to inflammation and colorectal cancer pathogenesis: the role of toll-like receptors. Carcinogenesis, 2021, 42, 1133-1142.	1.3	11
1744	Oncogenic KRAS creates an aspartate metabolism signature in colorectal cancer cells. FEBS Journal, 2021, 288, 6683-6699.	2.2	7
1746	Resectable Colorectal Cancer: Current Perceptions on the Correlation of Recurrence Risk, Microbiota and Detection of Genetic Mutations in Liquid Biopsies. Cancers, 2021, 13, 3522.	1.7	4
1747	The Evolving Field of Neoadjuvant Therapy in Locally-advanced Rectal Cancer: Evidence and Prospects. Clinical Colorectal Cancer, 2021, , .	1.0	6
1749	Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone. British Journal of Cancer, 2021, 125, 1080-1088.	2.9	10
1750	Organ preservation in rectal cancer: towards the norm rather than the exception. British Journal of Surgery, 2021, 108, 745-747.	0.1	4
1751	PD-1/PD-L1 immune checkpoint blockade-based combinational treatment: Immunotherapeutic amplification strategies against colorectal cancer. International Immunopharmacology, 2021, 96, 107607.	1.7	11
1752	Osteopontin as a Regulator of Colorectal Cancer Progression and Its Clinical Applications. Cancers, 2021, 13, 3793.	1.7	19
1753	Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era. International Journal of Molecular Sciences, 2021, 22, 7717.	1.8	7
1754	Colorectal Cancer: From Genetic Landscape to Targeted Therapy. Journal of Oncology, 2021, 2021, 1-17.	0.6	28
1755	Active elimination of intestinal cells drives oncogenic growth in organoids. Cell Reports, 2021, 36, 109307.	2.9	19
1756	Squalene epoxidase promotes colorectal cancer cell proliferation through accumulating calcitriol and activating CYP24A1â€mediated MAPK signaling. Cancer Communications, 2021, 41, 726-746.	3.7	32
1757	SPTAN1 Expression Predicts Treatment and Survival Outcomes in Colorectal Cancer. Cancers, 2021, 13, 3638.	1.7	2
1758	Multi-resolution characterization of molecular taxonomies in bulk and single-cell transcriptomics data. Nucleic Acids Research, 2021, 49, e98-e98.	6.5	4

#	Article	IF	Citations
1759	Targeting Metastatic Colorectal Cancer with Immune Oncological Therapies. Cancers, 2021, 13, 3566.	1.7	6
1760	Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread. Scientific Reports, 2021, 11, 15370.	1.6	2
1761	Clinical and Molecular Features in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Colorectal Cancer. Journal of Gastrointestinal Surgery, 2021, 25, 2649-2659.	0.9	2
1762	Cancer Genomic Profiling in Colorectal Cancer: Current Challenges in Subtyping Colorectal Cancers Based on Somatic and Germline Variants. Journal of the Anus, Rectum and Colon, 2021, 5, 213-228.	0.4	2
1763	Anticancer Drugs for Intra-Arterial Treatment of Colorectal Cancer Liver Metastases: In-Vitro Screening after Short Exposure Time. Pharmaceuticals, 2021, 14, 639.	1.7	6
1766	Tumour heterogeneity and evolutionary dynamics in colorectal cancer. Oncogenesis, 2021, 10, 53.	2.1	20
1767	Weighted Gene Co-expression Network Analysis Identified a Novel Thirteen-Gene Signature Associated With Progression, Prognosis, and Immune Microenvironment of Colon Adenocarcinoma Patients. Frontiers in Genetics, 2021, 12, 657658.	1.1	4
1768	<i>ASPM</i> is a Novel Candidate Gene Associated with Colorectal Cancer Cell Growth. DNA and Cell Biology, 2021, 40, 921-935.	0.9	7
1769	Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer. Cell Reports, 2021, 36, 109394.	2.9	41
1770	Effective Strategies to Predict Survival of Colorectal Peritoneal Metastases Patients Eligible for Cytoreductive Surgery and HIPEC. Cancer Management and Research, 2021, Volume 13, 5239-5249.	0.9	10
1771	An autophagy-related long non-coding RNA signature for patients with colorectal cancer. Physiology International, 2021, 108, 202-220.	0.8	2
1772	Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone. Cancer Treatment Reviews, 2021, 98, 102218.	3.4	33
1773	Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis. Cancer Prevention Research, 2021, 14, 851-862.	0.7	8
1774	The therapeutic and prognostic implications of immunobiology in colorectal cancer: a review. British Journal of Cancer, 2021, 125, 1341-1349.	2.9	21
1775	The Comparison of Fecal Microbiota in Left-Side and Right-Side Human Colorectal Cancer. European Surgical Research, 2021, 62, 248-254.	0.6	15
1776	We need to bring R0 <â‰1 to treat cancer too. Genome Medicine, 2021, 13, 120.	3.6	8
1777	Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer. Nature Communications, 2021, 12, 4441.	5.8	49
1778	Clinical Significance and Inflammatory Landscape of aNovel Recurrence-Associated Immune Signature in Stage II/III Colorectal Cancer. Frontiers in Immunology, 2021, 12, 702594.	2.2	36

#	ARTICLE	IF	CITATIONS
1779	Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer. Npj Genomic Medicine, 2021, 6, 59.	1.7	29
1780	Antigen presentation capability and AP-1 activation accompany methotrexate-induced colon cancer cell senescence in the context of aberrant Î²-catenin signaling. Mechanisms of Ageing and Development, 2021, 197, 111517.	2.2	3
1781	The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer. Cancers, 2021, 13, 3433.	1.7	67
1782	Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFNâ€"driven CCL5 and CXCL10. Journal of Experimental Medicine, 2021, 218, .	4.2	61
1783	Development and clinical validation of a novel six-gene signature for accurately predicting the recurrence risk of patients with stage II/III colorectal cancer. Cancer Cell International, 2021, 21, 359.	1.8	28
1784	Tumor Infiltrating Lymphocytes Target HLA-I Phosphopeptides Derived From Cancer Signaling in Colorectal Cancer. Frontiers in Immunology, 2021, 12, 723566.	2.2	14
1785	Targeting STAT3 Signaling Pathway in Colorectal Cancer. Biomedicines, 2021, 9, 1016.	1.4	36
1786	Deep learning-based gene selection in comprehensive gene analysis in pancreatic cancer. Scientific Reports, 2021, 11, 16521.	1.6	11
1787	Immune Responses Vary in Preinvasive Colorectal Lesions by Tumor Location and Histology. Cancer Prevention Research, 2021, 14, 885-892.	0.7	3
1788	Genetic and Epigenetic Characteristics of Inflammatory Bowel Diseaseâ€"Associated Colorectal Cancer. Gastroenterology, 2021, 161, 592-607.	0.6	81
1789	Core Circadian Clock Proteins as Biomarkers of Progression in Colorectal Cancer. Biomedicines, 2021, 9, 967.	1.4	5
1790	Prognostic Immunity and Therapeutic Sensitivity Analyses Based on Differential Genomic Instability-Associated LncRNAs in Left- and Right-Sided Colon Adenocarcinoma. Frontiers in Molecular Biosciences, 2021, 8, 668888.	1.6	6
1791	Cell Models for Chromosome 20q11.21 Amplification and Drug Sensitivities in Colorectal Cancer. Medicina (Lithuania), 2021, 57, 860.	0.8	2
1792	Transcriptome-wide <i>In Vitro</i> Effects of Aspirin on Patient-derived Normal Colon Organoids. Cancer Prevention Research, 2021, 14, 1089-1100.	0.7	12
1793	PLA2G4A promotes right-sided colorectal cancer progression by inducing CD39+Î³Î´ Treg polarization. JCI Insight, 2021, 6, .	2.3	26
1794	Comparative analysis of nuclear and mitochondrial DNA from tissue and liquid biopsies of colorectal cancer patients. Scientific Reports, 2021, 11, 16745.	1.6	13
1795	Deep learning from HE slides predicts the clinical benefit from adjuvant chemotherapy in hormone receptor-positive breast cancer patients. Scientific Reports, 2021, 11, 17363.	1.6	7
1796	Identification of three immune molecular subtypes associated with immune profiles, immune checkpoints, and clinical outcome in multiple myeloma. Cancer Medicine, 2021, 10, 7395-7403.	1.3	4

#	Article	IF	Citations
1798	Consensus molecular subtypes of primary colon tumors and their hepatic metastases. Future Science OA, 2021, 7, FSO722.	0.9	3
1799	TGF-β Signaling in Liver, Pancreas, and Gastrointestinal Diseases and Cancer. Gastroenterology, 2021, 161, 434-452.e15.	0.6	81
1800	Genomic Analysis Reveals Heterogeneity Between Lesions in Synchronous Primary Right-Sided and Left-Sided Colon Cancer. Frontiers in Molecular Biosciences, 2021, 8, 689466.	1.6	5
1801	Joint association and classification analysis of multi‐view data. Biometrics, 2022, 78, 1614-1625.	0.8	9
1803	Insights Into Systemic Sclerosis from Gene Expression Profiling. Current Treatment Options in Rheumatology, 2021, 7, 208-221.	0.6	0
1804	Daily practice in guideline adherence to adjuvant chemotherapy in stage III colon cancer and predictors of outcome. European Journal of Surgical Oncology, 2021, 47, 2060-2068.	0.5	3
1805	Advances in colorectal cancer genomics and transcriptomics drive early detection and prevention. International Journal of Biochemistry and Cell Biology, 2021, 137, 106032.	1.2	5
1806	The current understanding on the impact of KRAS on colorectal cancer. Biomedicine and Pharmacotherapy, 2021, 140, 111717.	2.5	60
1807	Adipose stem cell niche reprograms the colorectal cancer stem cell metastatic machinery. Nature Communications, 2021, 12, 5006.	5.8	38
1808	Mitogen‐activated protein kinase activity drives cell trajectories in colorectal cancer. EMBO Molecular Medicine, 2021, 13, e14123.	3.3	47
1809	<i>KRAS</i> mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine. Expert Opinion on Biological Therapy, 2021, 21, 1325-1334.	1.4	4
1810	The recurring features of molecular subtypes in distinct gastrointestinal malignancies—A systematic review. Critical Reviews in Oncology/Hematology, 2021, 164, 103428.	2.0	6
1811	Novel Methods of Risk Stratifying Patients for Metachronous, Pre-Malignant Colorectal Polyps: A Systematic Review. Critical Reviews in Oncology/Hematology, 2021, 164, 103421.	2.0	5
1812	A comprehensive analysis of SNPs and CNVs identifies novel markers associated with disease outcomes in colorectal cancer. Molecular Oncology, 2021, 15, 3329-3347.	2.1	9
1813	Learning the structure of Bayesian Networks via the bootstrap. Neurocomputing, 2021, 448, 48-59.	3.5	6
1814	Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases. JAMA Network Open, 2021, 4, e2118416.	2.8	62
1815	Intratumor morphologic and transcriptomic heterogeneity in V600EBRAF-mutated metastatic colorectal adenocarcinomas. ESMO Open, 2021, 6, 100211.	2.0	4
1816	The Ratio of Exhausted to Resident Infiltrating Lymphocytes Is Prognostic for Colorectal Cancer Patient Outcome. Cancer Immunology Research, 2021, 9, 1125-1140.	1.6	18

#	Article	IF	Citations
1818	Cell-based immunotherapy approaches for colorectal cancer: main achievements and challenges. Future Oncology, 2021, 17, 3253-3270.	1.1	3
1819	Cost-effective screening using a two-antibody panel for detecting mismatch repair deficiency in sporadic colorectal cancer. World Journal of Clinical Cases, 2021, 9, 6999-7008.	0.3	1
1820	Transcriptomic Analyses of the Adenoma-Carcinoma Sequence Identify Hallmarks Associated With the Onset of Colorectal Cancer. Frontiers in Oncology, 2021, 11, 704531.	1.3	12
1821	Activated macrophages promote invasion by early colorectal cancer via an interleukin 1Î²â€serum amyloid A1 axis. Cancer Science, 2021, 112, 4151-4165.	1.7	9
1822	Current Advances and Trends in <i>KRAS</i> Targeted Therapies for Colorectal Cancer. Molecular Cancer Research, 2022, 20, 30-44.	1.5	9
1823	Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. Annals of Oncology, 2021, 32, 959-967.	0.6	102
1824	Clinical Perspectives of Single-Cell RNA Sequencing. Biomolecules, 2021, 11, 1161.	1.8	11
1825	YY1 Silencing Induces 5-Fluorouracil-Resistance and BCL2L15 Downregulation in Colorectal Cancer Cells: Diagnostic and Prognostic Relevance. International Journal of Molecular Sciences, 2021, 22, 8481.	1.8	8
1826	Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer. Clinical Cancer Research, 2021, 27, 5979-5992.	3.2	5
1827	Novel therapeutic strategies: targeting epithelialâ€"mesenchymal transition in colorectal cancer. Lancet Oncology, The, 2021, 22, e358-e368.	5.1	133
1828	Determination of therapeutic agents efficiencies of microsatellite instability high colon cancer cells in postâ€metastatic liver biochip modeling. FASEB Journal, 2021, 35, e21834.	0.2	2
1829	Gastrointestinal cancer classification and prognostication from histology using deep learning: Systematic review. European Journal of Cancer, 2021, 155, 200-215.	1.3	70
1830	Bevacizumab-Induced Tumor Vasculature Normalization and Sequential Chemotherapy in Colorectal Cancer: An Interesting and Still Open Question. Frontiers in Oncology, 2021, 11, 751986.	1.3	3
1831	The necessity of intensive surveillance colonoscopy for patients with a remaining right colon after resection of colorectal cancer: a retrospective cohort study. Surgery Today, 2022, 52, 502-509.	0.7	1
1832	Perioperative Systemic Chemotherapy for Colorectal Liver Metastasis: Recent Updates. Cancers, 2021, 13, 4590.	1.7	7
1833	The Role of Cancer-Associated Fibroblasts in Cancer Invasion and Metastasis. Cancers, 2021, 13, 4720.	1.7	96
1835	Tumour-stroma ratio outperforms tumour budding as biomarker in colon cancer: a cohort study. International Journal of Colorectal Disease, 2021, 36, 2729-2737.	1.0	8
1836	In situ functional cell phenotyping reveals microdomain networks in colorectal cancer recurrence. Cell Reports Methods, 2021, 1, 100072.	1.4	3

#	ARTICLE	IF	CITATIONS
1837	Identification of immune-related subtypes of colorectal cancer to improve antitumor immunotherapy. Scientific Reports, 2021, 11, 19432.	1.6	6
1838	A panel of DNA methylation markers for the classification of consensus molecular subtypes 2 and 3 in patients with colorectal cancer. Molecular Oncology, 2021, 15, 3348-3362.	2.1	3
1839	Obesity and Inflammation: Colorectal Cancer Engines. Current Molecular Pharmacology, 2022, 15, 620-646.	0.7	14
1840	Sustainable Clinical Development of Adjuvant Chemotherapy for Colon Cancer. Annals of Gastroenterological Surgery, 2022, 6, 37-45.	1.2	9
1841	Utility of exome sequencing in routine care for metastatic colorectal cancer. Molecular and Clinical Oncology, 2021, 15, 229.	0.4	1
1842	High-Throughput 3D In Vitro Tumor Vasculature Model for Real-Time Monitoring of Immune Cell Infiltration and Cytotoxicity. Frontiers in Immunology, 2021, 12, 733317.	2.2	25
1843	Identification of prognostic spatial organization features in colorectal cancer microenvironment using deep learning on histopathology images. Medicine in Omics, 2021, 2, 100008.	0.6	6
1844	A Truncated NRIP1 Mutant Amplifies Microsatellite Instability of Colorectal Cancer by Regulating MSH2/MSH6 Expression, and Is a Prognostic Marker of Stage III Tumors. Cancers, 2021, 13, 4449.	1.7	5
1845	*KRAS* and *BRAF* Mutations in Stage II and III Colon Cancer: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2022, 114, 517-527.	3.0	34
1846	Characteristics of Early-Onset vs Late-Onset Colorectal Cancer. JAMA Surgery, 2021, 156, 865.	2.2	110
1847	Patients with mesenchymal tumours and high *Fusobacteriales* prevalence have worse prognosis in colorectal cancer (CRC). Gut, 2021, , gutjnl-2021-325193.	6.1	23
1848	Stereotactic and Robotic Minimally Invasive Thermal Ablation of Malignant Liver Tumors: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 713685.	1.3	15
1849	Implications of Intratumor Heterogeneity on Consensus Molecular Subtype (CMS) in Colorectal Cancer. Cancers, 2021, 13, 4923.	1.7	19
1850	Different Mechanism Involvement in the Formation of Colorectal Cancer; Mega Review. International Journal of Research and Review, 2021, 8, 558-573.	0.0	0
1852	Colorectal Tumour Mucosa Microbiome Is Enriched in Oral Pathogens and Defines Three Subtypes That Correlate with Markers of Tumour Progression. Cancers, 2021, 13, 4799.	1.7	8
1853	Artificial intelligence-enhanced drug design and development: Toward a computational precision medicine. Drug Discovery Today, 2022, 27, 215-222.	3.2	35
1854	Data integration in logic-based models of biological mechanisms. Current Opinion in Systems Biology, 2021, 28, 100386.	1.3	9
1855	Targeting OLFML3 in Colorectal Cancer Suppresses Tumor Growth and Angiogenesis, and Increases the Efficacy of Anti-PD1 Based Immunotherapy. Cancers, 2021, 13, 4625.	1.7	12

#	Article	IF	Citations
1856	Image-based assessment of extracellular mucin-to-tumor area predicts consensus molecular subtypes (CMS) in colorectal cancer. Modern Pathology, 2022, 35, 240-248.	2.9	9
1857	PKCÎ»/Î¹ inhibition activates an ULK2-mediated interferon response to repress tumorigenesis. Molecular Cell, 2021, 81, 4509-4526.e10.	4.5	12
1858	De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity. Genome Medicine, 2021, 13, 143.	3.6	10
1860	Spatially organized multicellular immune hubs in human colorectal cancer. Cell, 2021, 184, 4734-4752.e20.	13.5	256
1861	Neuromedin U induces an invasive phenotype in CRC cells expressing the NMUR2 receptor. Journal of Experimental and Clinical Cancer Research, 2021, 40, 283.	3.5	8
1862	CRISPR/Cas13-Based Platforms for a Potential Next-Generation Diagnosis of Colorectal Cancer through Exosomes Micro-RNA Detection: A Review. Cancers, 2021, 13, 4640.	1.7	15
1863	STABILITY INDICATING AND COST-EFFECTIVE ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF SOTORASIB BY USING RP-HPLC. International Journal of Applied Pharmaceutics, 0, , 154-159.	0.3	3
1864	Genomic Profiling Reveals the Molecular Landscape of Gastrointestinal Tract Cancers in Chinese Patients. Frontiers in Genetics, 2021, 12, 608742.	1.1	5
1865	The Colorectal Cancer Lipidome: Identification of a Robust Tumor-Specific Lipid Species Signature. Gastroenterology, 2021, 161, 910-923.e19.	0.6	63
1868	microRNAs: Small molecules with a large impact on colorectal cancer. Biotechnology and Applied Biochemistry, 2022, 69, 1893-1908.	1.4	10
1869	Medullary Carcinoma of the Gastrointestinal Tract: Report on Two Cases with Immunohistochemical and Molecular Features. Diagnostics, 2021, 11, 1775.	1.3	2
1870	A single-cell tumor immune atlas for precision oncology. Genome Research, 2021, 31, 1913-1926.	2.4	87
1871	Molecular Approach to Colorectal Carcinoma. Surgical Pathology Clinics, 2021, 14, 429-441.	0.7	4
1872	A Robust Prognostic Signature of Tumor Microenvironment in Colorectal Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2022, 37, 963-975.	0.7	2
1873	Tumor-Associated Microbiota in Proximal and Distal Colorectal Cancer and Their Relationships With Clinical Outcomes. Frontiers in Microbiology, 2021, 12, 727937.	1.5	18
1874	Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. The Lancet Gastroenterology and Hepatology, 2021, 6, 933-946.	3.7	73
1876	Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer. Cancers, 2021, 13, 4906.	1.7	18
1877	Global colorectal cancer burden in 2020 and projections to 2040. Translational Oncology, 2021, 14, 101174.	1.7	914

#	Article	IF	Citations
1878	Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial). European Journal of Cancer, 2021, 157, 71-80.	1.3	4
1879	Longitudinal change of genetic variations in cetuximab-treated metastatic colorectal cancer. Cancer Genetics, 2021, 258-259, 27-36.	0.2	2
1880	Colon cancer patients with mismatch repair deficiency are more likely to present as acute surgical cases. European Journal of Cancer, 2021, 157, 1-9.	1.3	2
1881	Adenoma to carcinoma: A portrait of molecular and immunological profiles of colorectal sporadic tumors. International Immunopharmacology, 2021, 100, 108168.	1.7	1
1882	Current status and future perspective of immune checkpoint inhibitors in colorectal cancer. Cancer Letters, 2021, 521, 119-129.	3.2	16
1883	Overexpression of transposable elements is associated with immune evasion and poor outcome in colorectal cancer. European Journal of Cancer, 2021, 157, 94-107.	1.3	12
1884	Dual blockade of macropinocytosis and asparagine bioavailability shows synergistic anti-tumor effects on KRAS-mutant colorectal cancer. Cancer Letters, 2021, 522, 129-141.	3.2	12
1885	Gut Microbiota and Colorectal Cancer. , 2022, , 357-357.		0
1886	Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain. BMC Cancer, 2021, 21, 64.	1.1	4
1887	Translation initiation and its relevance in colorectal cancer. FEBS Journal, 2021, 288, 6635-6651.	2.2	10
1888	Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab. Scientific Reports, 2021, 11, 865.	1.6	16
1889	Molecular characterization of colorectal cancer: A five-gene prognostic signature based on RNA-binding proteins. Saudi Journal of Gastroenterology, 2021, 27, 223.	0.5	5
1890	DNA mismatch repair in mammals. , 2021, , 323-347.		1
1891	Gutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer. Journal of Immunotherapy, 2021, 44, 49-62.	1.2	7
1892	Field carcinogenesis for risk stratification of colorectal cancer. Advances in Cancer Research, 2021, 151, 305-344.	1.9	6
1894	ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. Clinical Cancer Research, 2021, 27, 1663-1670.	3.2	30
1895	The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer. Nature Genetics, 2021, 53, 16-26.	9.4	114
1896	Therapeutic targeting of TGF-Î² in cancer: hacking a master switch of immune suppression. Clinical Science, 2021, 135, 35-52.	1.8	42

#	Article	IF	Citations
1897	Colorectal Cancer: A Model for the Study of Cancer Immunology. , 2021, , 15-30.		0
1898	A RAC-GEF network critical for early intestinal tumourigenesis. Nature Communications, 2021, 12, 56.	5.8	11
1899	Identification of a novel therapeutic candidate, NRK, in primary cancer-associated fibroblasts of lung adenocarcinoma microenvironment. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1049-1064.	1.2	6
1900	Comparison of long-term outcomes between Lynch sydrome and sporadic colorectal cancer: a propensity score matching analysis. BMC Cancer, 2021, 21, 45.	1.1	4
1901	Exploiting KRAS-mediated metabolic reprogramming as a therapeutic target. Nature Genetics, 2021, 53, 9-10.	9.4	6
1903	Fibroblast Subsets in Intestinal Homeostasis, Carcinogenesis, Tumor Progression, and Metastasis. Cancers, 2021, 13, 183.	1.7	12
1904	Early age onset colorectal cancer. Advances in Cancer Research, 2021, 151, 1-37.	1.9	15
1905	Tumor-Infiltrating Lymphoid Cells in Colorectal Cancer Patients with Varying Disease Stages and Microsatellite Instability-High/Stable Tumors. Vaccines, 2021, 9, 64.	2.1	11
1906	Cofilin-1, LIMK1 and SSH1 are differentially expressed in locally advanced colorectal cancer and according to consensus molecular subtypes. Cancer Cell International, 2021, 21, 69.	1.8	10
1907	LINC00483 Has a Potential Tumor-Suppressor Role in Colorectal Cancer Through Multiple Molecular Axes. Frontiers in Oncology, 2020, 10, 614455.	1.3	15
1908	Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening?. Cancer Treatment and Research Communications, 2021, 28, 100442.	0.7	14
1909	Role of Up-Front Primary Tumor Resection and Tumor Sidedness in the Survival of Synchronous Metastatic Colon Cancer Patients. Digestive Surgery, 2021, 38, 283-289.	0.6	1
1910	Epigenetic biomarkers of disease. , 2021, , 117-141.		0
1911	Epigenetic alterations in the gastrointestinal tract: Current and emerging use for biomarkers of cancer. Advances in Cancer Research, 2021, 151, 425-468.	1.9	20
1912	Immunotherapy in Colorectal Cancer: Current and Future Strategies. Journal of the Anus, Rectum and Colon, 2021, 5, 11-24.	0.4	59
1913	Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features. Nature Communications, 2021, 12, 574.	5.8	39
1914	Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer. International Journal of Cancer, 2017, 141, 1215-1221.	2.3	24
1915	Development of Gene Expression-Based Biomarkers on the nCounterÂ® Platform for Immuno-Oncology Applications. Methods in Molecular Biology, 2020, 2055, 273-300.	0.4	4

#	Article	IF	Citations
1916	Genetic Instability Markers in Cancer. Methods in Molecular Biology, 2020, 2055, 133-154.	0.4	2
1917	Cell-Free DNA in the Management of Colorectal Cancer. Recent Results in Cancer Research, 2020, 215, 253-261.	1.8	5
1918	Genetic Analysis of Circulating Tumour Cells. Recent Results in Cancer Research, 2020, 215, 57-76.	1.8	12
1919	Colorectal Carcinoma. , 2020, , 79-97.		4
1921	The Intestinal Tumour Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1226, 1-22.	0.8	10
1922	The Role of the Immune Infiltrate in Distinct Cancer Types and Its Clinical Implications. Cancer Treatment and Research, 2020, 180, 197-211.	0.2	4
1923	Development of NSCLC Precise Puncture Prototype Based on CT Images Using Augmented Reality Navigation. Advances in Intelligent Systems and Computing, 2018, , 538-544.	0.5	1
1924	Translational Research in Oncology. , 2020, , 261-311.		3
1925	Biomarkers in the Management of Peritoneal Metastases. , 2020, , 251-279.		2
1926	Molecular subtypes of pancreatic cancer. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 207-220.	8.2	573
1927	Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer. Nature Genetics, 2020, 52, 594-603.	9.4	380
1928	Prognostic relevance of programmed cell death 1 ligand 2 (PDCD1LG2/PD-L2) in patients with advanced stage colon carcinoma treated with chemotherapy. Scientific Reports, 2020, 10, 22330.	1.6	13
1929	IDO1+ Paneth cells promote immune escape of colorectal cancer. Communications Biology, 2020, 3, 252.	2.0	26
1930	Towards the routine use of *in silico* screenings for drug discovery using metabolic modelling. Biochemical Society Transactions, 2020, 48, 955-969.	1.6	13
1931	Serrated neoplasia in the colorectum: gut microbiota and molecular pathways. Gut Microbes, 2021, 13, 1-12.	4.3	12
1932	*De Novo* and Supervised Endophenotyping Using Network-Guided Ensemble Learning. Systems Medicine (New Rochelle, N Y), 2020, 3, 8-21.	1.4	9
1933	Comment on â€œSurvival After Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastasesâ€. Annals of Surgery, 2021, 274, e720-e721.	2.1	1
1962	Overexpression of sortilin is associated with 5â€FU resistance and poor prognosis in colorectal cancer. Journal of Cellular and Molecular Medicine, 2021, 25, 47-60.	1.6	14

#	Article	IF	Citations
1963	Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer. , 2020, 8, e000272.		43
1964	Gene Alterations of N6-Methyladenosine (m6A) Regulators in Colorectal Cancer: A TCGA Database Study. BioMed Research International, 2020, 2020, 1-13.	0.9	13
1965	Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome. Journal of Clinical Investigation, 2019, 129, 4464-4476.	3.9	64
1966	Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice. Journal of Clinical Investigation, 2020, 130, 1199-1216.	3.9	35
1967	TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. Journal of Clinical Investigation, 2018, 128, 3887-3905.	3.9	79
1968	Colon cancer modulation by a diabetic environment: A single institutional experience. PLoS ONE, 2017, 12, e0172300.	1.1	5
1969	Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS ONE, 2017, 12, e0173345.	1.1	65
1970	KRAS and BRAF somatic mutations in colonic polyps and the risk of metachronous neoplasia. PLoS ONE, 2017, 12, e0184937.	1.1	26
1971	Transcriptomic and proteomic intra-tumor heterogeneity of colorectal cancer varies depending on tumor location within the colorectum. PLoS ONE, 2020, 15, e0241148.	1.1	13
1972	Streptococcus gallolyticus subsp. gallolyticus promotes colorectal tumor development. PLoS Pathogens, 2017, 13, e1006440.	2.1	168
1973	Depressed Colorectal Cancer: A New Paradigm in Early Colorectal Cancer. Clinical and Translational Gastroenterology, 2020, 11, e00269.	1.3	7
1974	The Role of Nuclear Receptor Subfamily 1 Group H Member 4 (NR1H4) in Colon Cancer Cell Survival through the Regulation of c-Myc Stability. Molecules and Cells, 2020, 43, 459-468.	1.0	13
1975	Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) Might Be a More Promising Immune Biomarker in Colorectal Cancer. Oncologist, 2019, 24, 1534-1542.	1.9	15
1976	2019 WHO classification of gastric epithelial tumors, 5th edition. Arkhiv Patologii, 2020, 82, 58.	0.0	3
1977	Microsatellite instability in colorectal cancer. EXCLI Journal, 2018, 17, 159-168.	0.5	100
1978	Microsatellite instability as a unique characteristic of tumors and a predictor of response to immune therapy. Malignant Tumours, 2020, 9, 59-69.	0.1	11
1979	The gut microflora assay in patients with colorectal cancer: in feces or tissue samples?. Iranian Journal of Microbiology, 0, , .	0.8	12
1980	Systematic profiling of alternative splicing events and splicing factors in left- and right-sided colon cancer. Aging, 2019, 11, 8270-8293.	1.4	25

#	Article	IF	Citations
1981	A molecular sub-cluster of colon cancer cells with low VDR expression is sensitive to chemotherapy, BRAF inhibitors and PI3K-mTOR inhibitors treatment. Aging, 2019, 11, 8587-8603.	1.4	22
1982	Identification of an exosomal long non-coding RNAs panel for predicting recurrence risk in patients with colorectal cancer. Aging, 2020, 12, 6067-6088.	1.4	8
1983	Large variety in a panel of human colon cancer organoids in response to EZH2 inhibition. Oncotarget, 2016, 7, 69816-69828.	0.8	23
1984	CD133+CD24lo defines a 5-Fluorouracil-resistant colon cancer stem cell-like phenotype. Oncotarget, 2016, 7, 78698-78712.	0.8	41
1985	Genomic profiling of stage II and III colon cancers reveals *APC* mutations to be associated with survival in stage III colon cancer patients. Oncotarget, 2016, 7, 73876-73887.	0.8	9
1986	Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer. Oncotarget, 2016, 7, 78932-78945.	0.8	36
1987	Gankyrin sustains PI3K/GSK-3β/β-catenin signal activation and promotes colorectal cancer aggressiveness and progression. Oncotarget, 2016, 7, 81156-81171.	0.8	33
1988	Pan-organ transcriptome variation across 21 cancer types. Oncotarget, 2017, 8, 6809-6818.	0.8	6
1989	TRAP1 protein signature predicts outcome in human metastatic colorectal carcinoma. Oncotarget, 2017, 8, 21229-21240.	0.8	18
1990	SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains. Oncotarget, 2017, 8, 33779-33795.	0.8	70
1991	Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype. Oncotarget, 2017, 8, 39367-39381.	0.8	38
1992	Assessment of concordance between fresh-frozen and formalin-fixed paraffin embedded tumor DNA methylation using a targeted sequencing approach. Oncotarget, 2017, 8, 48126-48137.	0.8	12
1993	Application of *in vivo* imaging techniques to monitor therapeutic efficiency of PLX4720 in an experimental model of microsatellite instable colorectal cancer. Oncotarget, 2017, 8, 69756-69767.	0.8	10
1994	Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases. Oncotarget, 2017, 8, 76290-76304.	0.8	23
1995	Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment. Oncotarget, 2017, 8, 85526-85536.	0.8	21
1996	Downregulation of DNA repair proteins and increased DNA damage in hypoxic colon cancer cells is a therapeutically exploitable vulnerability. Oncotarget, 2017, 8, 86296-86311.	0.8	20
1997	Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer. Oncotarget, 2017, 8, 87837-87847.	0.8	49
1998	Combination of primary tumor location and mismatch repair status guides adjuvant chemotherapy in stage II colon cancer. Oncotarget, 2017, 8, 99136-99149.	0.8	9

#	ARTICLE	IF	CITATIONS
1999	Immunological landscape of consensus clusters in colorectal cancer. Oncotarget, 2017, 8, 105299-105311.	0.8	55
2000	Loss of p53-inducible long non-coding RNA LINC01021 increases chemosensitivity. Oncotarget, 2017, 8, 102783-102800.	0.8	13
2001	The transcriptional and mutational landscapes of lipid metabolism-related genes in colon cancer. Oncotarget, 2018, 9, 5919-5930.	0.8	28
2002	LRP1 expression in colon cancer predicts clinical outcome. Oncotarget, 2018, 9, 8849-8869.	0.8	28
2003	<i>Bcl-xL</i> as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in <i>BRAF</i>-mutant stage II and III colon cancer. Oncotarget, 2018, 9, 13834-13847.	0.8	9
2004	Macrophages induce â€œbuddingâ€•in aggressive human colon cancer subtypes by protease-mediated disruption of tight junctions. Oncotarget, 2018, 9, 19490-19507.	0.8	17
2005	Comprehensive identification of long noncoding RNAs in colorectal cancer. Oncotarget, 2018, 9, 27605-27629.	0.8	16
2006	Identification of different mutational profiles in cancers arising in specific colon segments by next generation sequencing. Oncotarget, 2018, 9, 23960-23974.	0.8	13
2007	Increased expression of the thyroid hormone nuclear receptor TRÎ±1 characterizes intestinal tumors with high Wnt activity. Oncotarget, 2018, 9, 30979-30996.	0.8	12
2008	Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content. Oncotarget, 2018, 9, 31502-31515.	0.8	21
2009	Genomic mechanisms of immune evasion in colorectal cancer: from discovery to clinical practice. Oncotarget, 2018, 9, 33743-33744.	0.8	3
2010	Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer. Oncotarget, 2018, 9, 35623-35638.	0.8	15
2011	Immune response characterization of endometrial cancer. Oncotarget, 2019, 10, 982-992.	0.8	13
2012	Fibroblast-derived Gremlin1 localises to epithelial cells at the base of the intestinal crypt. Oncotarget, 2019, 10, 4630-4639.	0.8	12
2013	Mutanome and expression of immune response genes in microsatellite stable colon cancer. Oncotarget, 2016, 7, 17711-17725.	0.8	6
2014	Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer. Oncotarget, 2016, 7, 36632-36644.	0.8	15
2015	Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. Journal of Cancer Metastasis and Treatment, 2018, 4, 12.	0.5	5
2016	Understanding the microbiome: a primer on the role of the microbiome in colorectal neoplasia. Annals of Gastroenterology, 2020, 33, 223-236.	0.4	6

#	ARTICLE	IF	CITATIONS
2017	The significance of tumor-associated immune response in molecular taxonomy, prognosis and therapy of colorectal cancer patients. Annals of Translational Medicine, 2016, 4, 271-271.	0.7	6
2018	Colorectal cancer genomics and designing rational trials. Annals of Translational Medicine, 2018, 6, 159-159.	0.7	19
2019	Review: KRAS mutations are influential in driving hepatic metastases and predicting outcome in colorectal cancer. Chinese Clinical Oncology, 2019, 8, 53-53.	0.4	8
2020	Update on bladder cancer molecular subtypes. Translational Andrology and Urology, 2020, 9, 2881-2889.	0.6	28
2021	Low-depth whole genome sequencing reveals copy number variations associated with higher pathologic grading and more aggressive subtypes of lung non-mucinous adenocarcinoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 334-346.	0.7	5
2022	COLON AND RECTAL CANCER ARE DIFFERENT TUMOR ENTITIES ACCORDING TO EPIDEMIOLOGY, CARCINOGENESIS, MOLECULAR- AND TUMOR BIOLOGY, PRIMARY AND SECONDARY PREVENTION: PRECLINICAL EVIDENCE. Siberian Journal of Oncology, 2018, 17, 88-98.	0.1	2
2023	Metastatic Colorectal Cancer: Prognostic and Predictive Factors. Current Medicinal Chemistry, 2020, 27, 2779-2791.	1.2	4
2024	Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor. Anticancer Research, 2017, 37, 239-248.	0.5	88
2025	Consensus molecular subtypes (CMS) in metastatic colorectal cancer - personalized medicine decision. Radiology and Oncology, 2020, 54, 272-277.	0.6	22
2026	Increased IL-33 and IL-17 in Colorectal Carcinoma Patients with Severe Disease. Serbian Journal of Experimental and Clinical Research, 2020, 21, 239-245.	0.2	2
2027	Evaluation of colorectal cancer subtypes and cell lines using deep learning. Life Science Alliance, 2019, 2, e201900517.	1.3	65
2028	The Role of Angiogenesis in Colorectal Polyps and Cancer, a Review. Medical Laboratory Journal, 2018, 12, 1-6.	0.1	8
2029	The Anticancer Activity and Mechanisms of Ginsenosides: An Updated Review. EFood, 2020, 1, 226-241.	1.7	20
2030	Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice. Pathologica, 2020, 112, 248-259.	1.3	35
2031	Kolorektale Karzinome: Die Lage des Primarius zählt. , 0, , .		2
2032	A randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment, 2017, 21, 1-86.	1.3	44
2033	Collagen Kinase Receptors as Potential Therapeutic Targets in Metastatic Colon Cancer. Frontiers in Oncology, 2020, 10, 125.	1.3	38
2034	Common and Differential Traits of the Membrane Lipidome of Colon Cancer Cell Lines and Their Secreted Vesicles: Impact on Studies Using Cell Lines. Cancers, 2020, 12, 1293.	1.7	19

#	ARTICLE	IF	CITATIONS
2035	Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements. International Journal of Molecular Sciences, 2021, 22, 130.	1.8	160
2036	Impact of Microsatellite Instability in Signet-Ring Cell and Mucinous Components in Patients With Colorectal Carcinoma. Annals of Coloproctology, 2016, 32, 45.	0.5	2
2037	Cancer-Associated Fibroblasts and Desmoplastic Reactions Related to Cancer Invasiveness in Patients With Colorectal Cancer. Annals of Coloproctology, 2019, 35, 36-46.	0.5	37
2038	Differences Regarding the Molecular Features and Gut Microbiota Between Right and Left Colon Cancer. Annals of Coloproctology, 2018, 34, 280-285.	0.5	44
2039	Laterality: Immunological Differences Between Right-Sided and Left-Sided Colon Cancer. Annals of Coloproctology, 2019, 35, 291-293.	0.5	6
2040	The Prognosis and Recurrence Pattern of Right- and Left-Sided Colon Cancer in Stage II, Stage III, and Liver Metastasis After Curative Resection. Annals of Coloproctology, 2021, 37, 326-336.	0.5	28
2041	<i>PNN</i> and <i>KCNQ1OT1</i> Can Predict the Efficacy of Adjuvant Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer Patients. Oncology Research, 2020, 28, 631-644.	0.6	10
2042	Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma. , 2020, 1, 53-70.		5
2043	Expression and role of nuclear receptor coregulators in colorectal cancer. World Journal of Gastroenterology, 2017, 23, 4480.	1.4	16
2044	Multiparametric analysis of colorectal cancer immune responses. World Journal of Gastroenterology, 2018, 24, 2995-3005.	1.4	16
2045	CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer. World Journal of Gastroenterology, 2018, 24, 4738-4749.	1.4	99
2046	Predicting systemic spread in early colorectal cancer: Can we do better?. World Journal of Gastroenterology, 2019, 25, 2887-2897.	1.4	19
2047	Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches. World Journal of Gastroenterology, 2019, 25, 3920-3928.	1.4	43
2048	Mouse models of colorectal cancer: Past, present and future perspectives. World Journal of Gastroenterology, 2020, 26, 1394-1426.	1.4	89
2049	High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer. International Journal of Oncology, 2020, 57, 237-248.	1.4	47
2050	Identification of colorectal cancers with defective DNA damage repair by immunohistochemical profiling of mismatch repair proteins, CDX2 and BRCA1. Molecular and Clinical Oncology, 2020, 13, 1-1.	0.4	5
2051	Immunohistochemicalâ€‘based molecular subtyping of colorectal carcinoma using maspin and markers of epithelialâ€‘mesenchymal transition. Oncology Letters, 2020, 19, 1487-1495.	0.8	21
2052	Effects of miR-135a-5p and miR-141 on proliferation, invasion and apoptosis of colorectal cancer SW620 cells. Oncology Letters, 2020, 20, 914-920.	0.8	8

#	ARTICLE	IF	CITATIONS
2053	Weighted gene coexpression analysis indicates that PLAGL2 and POFUT1 are related to the differential features of proximal and distal colorectal cancer. Oncology Reports, 2019, 42, 2473-2485.	1.2	7
2054	Nâ€‘glycosylation and receptor tyrosine kinase signaling affect claudinâ€‘3 levels in colorectal cancer cells. Oncology Reports, 2020, 44, 1649-1661.	1.2	7
2055	Right versus left-sided colon cancer: Is it time to consider these as different diseases?. AIMS Medical Science, 2018, 5, 303-315.	0.2	2
2056	Promoter methylation and Ile105val polymorphism of GSTP1 gene in the modulation of colorectal cancer risk in ethnic Kashmiri population. Indian Journal of Cancer, 2019, 56, 248.	0.2	2
2057	The role of transcription factor caudal-related homeobox transcription factor 2 in colorectal cancer. Tzu Chi Medical Journal, 2020, 32, 305.	0.4	3
2058	The Smad4/PTEN Expression Pattern Predicts Clinical Outcomes in Colorectal Adenocarcinoma. Journal of Pathology and Translational Medicine, 2018, 52, 37-44.	0.4	10
2059	Immune landscape and biomarkers for immuno-oncology in colorectal cancers. Journal of Pathology and Translational Medicine, 2020, 54, 351-360.	0.4	9
2060	A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer. Cancer Research and Treatment, 2020, 52, 1153-1161.	1.3	9
2061	Precision medicine for gastrointestinal cancer: Recent progress and future perspective. World Journal of Gastrointestinal Oncology, 2019, 12, 1-20.	0.8	31
2062	Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions. World Journal of Gastrointestinal Oncology, 2020, 12, 808-832.	0.8	59
2063	Circulating cytokeratin-positive cells and tumor budding in colorectal cancer. World Journal of Clinical Oncology, 2016, 7, 433.	0.9	3
2064	Recurrence-free survival as a putative surrogate for overall survival in phase III trials of curative-intent treatment of colorectal liver metastases: Systematic review. World Journal of Clinical Oncology, 2017, 8, 266.	0.9	8
2065	CNApp, a tool for the quantification of copy number alterations and integrative analysis revealing clinical implications. ELife, 2020, 9, .	2.8	48
2066	Dichotomous role of the human mitochondrial Na+/Ca2+/Li+ exchanger NCLX in colorectal cancer growth and metastasis. ELife, 2020, 9, .	2.8	39
2067	GeNNet: an integrated platform for unifying scientific workflows and graph databases for transcriptome data analysis. PeerJ, 2017, 5, e3509.	0.9	11
2068	Establishment of a 12-gene expression signature to predict colon cancer prognosis. PeerJ, 2018, 6, e4942.	0.9	30
2069	Prognostic Impact of Tumor Status, Nodal Status and Tumor Sidedness in Metastatic Colon Cancer. Cureus, 2020, 12, e11444.	0.2	2
2070	Advancing the Care of Pancreatic Cancer Patients: Moving Beyond Just Tumour Tissue. Biomarker Insights, 2021, 16, 117727192110498.	1.0	1

#	ARTICLE	IF	CITATIONS
2071	An Integrated Digital Pathology Platform for Tumors Using Artificial Intelligence Analysis. SSRN Electronic Journal, 0, , .	0.4	0
2073	Expression of TSP50, SERCA2 and IL-8 in Colorectal Adenoma and Carcinoma: Correlation to Clinicopathological Factors. Pathology and Oncology Research, 2021, 27, 1609990.	0.9	2
2075	Validation of genetic classifiers derived from mouse and human tumors to identify molecular subtypes of colorectal cancer. Human Pathology, 2022, 119, 1-14.	1.1	1
2076	Prognostic Factors for Post-Recurrence Survival in Stage II and III Colorectal Carcinoma Patients. Medicina (Lithuania), 2021, 57, 1108.	0.8	10
2077	Adipose stromal cells promote the transition of colorectal cancer cells toward a mesenchymal-like phenotype. Molecular and Cellular Oncology, 2021, 8, 1986343.	0.3	1
2078	The Therapeutic Potential of Tackling Tumor-Induced Dendritic Cell Dysfunction in Colorectal Cancer. Frontiers in Immunology, 2021, 12, 724883.	2.2	19
2079	Organ Specificity and Heterogeneity of Cancer-Associated Fibroblasts in Colorectal Cancer. International Journal of Molecular Sciences, 2021, 22, 10973.	1.8	12
2080	The Genomic Landscape of Serrated Lesion of the Colorectum: Similarities and Differences With Tubular and Tubulovillous Adenomas. Frontiers in Oncology, 2021, 11, 668466.	1.3	4
2081	Epithelialâ€Mesenchymal Transition in colorectal cancer: Annexin A2 is caught in the crosshairs. Journal of Cellular and Molecular Medicine, 2021, 25, 10774-10777.	1.6	5
2082	Antigen Presenting Cells from Tumor and Colon of Colorectal Cancer Patients Are Distinct in Activation and Functional Status, but Comparably Responsive to Activated T Cells. Cancers, 2021, 13, 5247.	1.7	3
2083	Development and validation of a weakly supervised deep learning framework to predict the status of molecular pathways and key mutations in colorectal cancer from routine histology images: a retrospective study. The Lancet Digital Health, 2021, 3, e763-e772.	5.9	128
2084	Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study. Cancer Immunology, Immunotherapy, 2022, 71, 1443-1451.	2.0	13
2085	Epithelial to Mesenchymal Transition: A Challenging Playground for Translational Research. Current Models and Focus on TWIST1 Relevance and Gastrointestinal Cancers. International Journal of Molecular Sciences, 2021, 22, 11469.	1.8	9
2086	Breast Cancer Consensus Subtypes: A system for subtyping breast cancer tumors based on gene expression. Npj Breast Cancer, 2021, 7, 136.	2.3	20
2087	Pilot Nanostring PanCancer pathway analysis of colon adenocarcinoma in a tertiary healthcare centre in Kerala, India. Ecancermedicalscience, 2021, 15, 1302.	0.6	3
2088	Genomic landscape of treatment refractory metastatic colorectal cancer. Acta OncolÃ³gica, 2021, 60, 1621-1628.	0.8	2
2089	Colonic Microbial Abundances Predict Adenoma Formers. Annals of Surgery, 2021, Publish Ahead of Print, .	2.1	3
2090	Lymph node status and its impact on the prognosis of leftâ€sided and rightâ€sided colon cancer: A SEER populationâ€based study. Cancer Medicine, 2021, 10, 8708-8719.	1.3	12

#	ARTICLE	IF	CITATIONS
2091	Identification and quantification of immune infiltration landscape on therapy and prognosis in left- and right-sided colon cancer. Cancer Immunology, Immunotherapy, 2022, 71, 1313-1330.	2.0	30
2092	Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype. Cell Death and Disease, 2021, 12, 978.	2.7	9
2093	Evolutionary patterns of chromosomal instability and mismatch repair deficiency in proximal and distal colorectal cancer. Colorectal Disease, 2022, 24, 157-176.	0.7	9
2094	Impact of the ileal microbiota on colon cancer. Seminars in Cancer Biology, 2022, 86, 955-966.	4.3	11
2096	Novel Immunological Approaches in the Treatment of Locally Advanced Rectal Cancer. Clinical Colorectal Cancer, 2022, 21, 3-9.	1.0	11
2097	IFITM1 expression determines extracellular vesicle uptake in colorectal cancer. Cellular and Molecular Life Sciences, 2021, 78, 7009-7024.	2.4	12
2098	Deubiquitinase OTUB2 exacerbates the progression of colorectal cancer by promoting PKM2 activity and glycolysis. Oncogene, 2022, 41, 46-56.	2.6	26
2099	A Microsatellite in the Coding Sequence of HLA-A/B Is a Mutation Hotspot in Colon Cancer With Microsatellite Instability. Gastroenterology, 2022, 162, 960-963.e3.	0.6	0
2100	Sidedness determines clinical characteristics and survival outcomes in medullary adenocarcinoma of the colon. Scientific Reports, 2021, 11, 20481.	1.6	1
2101	The role of PDGFRA as a therapeutic target in young colorectal cancer patients. Journal of Translational Medicine, 2021, 19, 446.	1.8	11
2102	Advances in Gastrointestinal Surgery. GI Surgery Annual, 2015, , 179-237.	0.0	0
2103	Graph Centrality Based Prediction of Cancer Genes. Springer Proceedings in Mathematics and Statistics, 2016, , 275-311.	0.1	0
2105	Reinstating endogenous antitumor immunity: The concept of therapeutic management of cancer. Forum of Clinical Oncology, 2016, 7, 4-16.	0.1	0
2108	Personalised Genomics and Molecular Profiles in Colorectal Cancer: Towards Precision Cancer Care. , 2017, , 261-285.		0
2109	Molecular and Cellular Mechanisms of Carcinogenesis in the Large Bowel. , 2017, , 65-82.		0
2110	The use of phenotype and genotype in the management of pT1 colorectal cancer. Journal of Public Health and Emergency, 0, 1, 28-28.	4.4	0
2116	Clinical laboratory and imaging evidence for effectiveness of agarose-agarose macrobeads containing stem-like cells derived from a mouse renal adenocarcinoma cell population (RMBs) in treatment-resistant, advanced metastatic colorectal cancer: Evaluation of a biological-systems approach to cancer therapy (U.S. FDA IND-BB 10091; NCT 02046174, NCT 01053013). Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 72-83.	0.7	3
2117	Notch Signaling in the Normal Intestine and Intestinal Cancer. , 2018, , 333-352.		0

#	ARTICLE	IF	CITATIONS
2118	Pathology of Tumor Angiogenesis. , 2018, , 1-22.		1
2119	Biomarker for the Treatment of Colorectal Cancer. Nihon Daicho Komonbyo Gakkai Zasshi, 2018, 71, 425-434.	0.1	0
2120	Recent Progress in First-Line Chemotherapy in Metastatic Colorectal Cancer. Nihon Daicho Komonbyo Gakkai Zasshi, 2018, 71, 371-379.	0.1	0
2127	Classifications molÃ©culaires et immunes des cancers colorectaux : implication pour la prise en charge clinique. Colon and Rectum, 2018, 12, 138-144.	0.0	0
2129	Prognostic markers for colorectal cancer. Oncotarget, 2018, 9, 33060-33061.	0.8	0
2134	Pathology of Tumor Angiogenesis. , 2019, , 253-274.		0
2135	Molecular Diagnostics and Genomic Profiling in Individualized Therapies of Gastrointestinal Cancers. , 2019, , 613-631.		0
2136	Surgery, Perioperative Treatment and Prognostic Factors Based on Genetic and Epigenetic Alterations in Colorectal Cancer. Juntendo Medical Journal, 2019, 65, 194-202.	0.1	0
2137	Advances in Gastrointestinal Surgery. GI Surgery Annual, 2019, , 233-269.	0.0	0
2138	Chemotherapy and Biologic Therapy in Rectal Cancer: An Update. , 2019, , 407-444.		0
2139	In silico Drug Repositioning Using Omics Data: The Potential and Pitfalls. , 2019, , 1-19.		0
2140	Colorectal Cancer Prevention. , 2019, , 473-509.		1
2141	Pushing the limits of liver surgery for colorectal liver metastases: Current state and future directions. World Journal of Gastrointestinal Surgery, 2019, 11, 34-40.	0.8	3
2144	Identification of the Altered Proteins Related to Colon Carcinogenesis by iTRAQ-based Quantitative Proteomic Analysis. Current Proteomics, 2019, 16, 297-306.	0.1	0
2146	Prognostic importance of primary tumor location in RAS mutant metastatic colorectal cancer. Dicle Medical Journal, 0, , .	0.2	1
2147	Eicosapentaenoic acid and/or aspirin for preventing colorectal adenomas during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: the seAFOod RCT. Efficacy and Mechanism Evaluation, 2019, 6, 1-154.	0.9	7
2153	Pancratistatin Inhibits the Growth of Colorectal Cancer Cells by Inducing Apoptosis, Autophagy, and G2/M Cell Cycle Arrest. Medical Science Monitor, 2019, 25, 6015-6022.	0.5	5
2154	Inflammation-based markers can predict the prognosis of geriatric patients with metastatic colorectal cancer receiving first-line chemotherapy. Translational Cancer Research, 2019, 8, 1137-1147.	0.4	6

#	ARTICLE	IF	CITATIONS
2156	PREDICTORS OF THERAPY RESPONSE AND EARLY RECURRENCE IN PATIENTS WITH POTENTIALLY RESECTABLE COLORECTAL LIVER METASTASES TREATED WITH BEVACIZUMAB AND FOLFOX4 AS A CONVERSION THERAPY. Acta Medica Medianae, 2019, , 72-79.	0.0	1
2157	An observational study of vascular endothelial growth factor inhibitors as second-line treatment for metastatic colorectal cancer treated with bevacizumab plus FOLFIRI beyond progression: the association with RAS mutation and tumor sidedness. Translational Cancer Research, 2019, 8, 2357-2370.	0.4	1
2158	Methylation of bone morphogenetic protein 2 is associated with poor prognosis in colorectal cancer. Oncology Letters, 2020, 19, 229-238.	0.8	5
2159	A novel cancer stem cell-based classification model for the tumorigenesis and development of colorectal cancer. Translational Cancer Research, 2019, 8, 2621-2623.	0.4	1
2161	Neoadjuvant Chemotherapy for Resectable Colorectal Cancer Liver Metastases: Indications and Results. , 2020, , 205-228.		0
2162	The Biology of Colorectal Liver Metastases. , 2020, , 7-20.		0
2163	Enhanced cancer subtyping via pan-transcriptomics data fusion, Monte-Carlo consensus clustering, and auto classifier creation. , 2019, , .		0
2165	Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging Paradigms. Journal of Immunotherapy and Precision Oncology, 2020, 3, 3-15.	0.6	3
2170	Current perspective on the treatment of advanced/metastatic colorectal cancer. Onkologie (Czech) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5(	0.0	0
2172	Clinicopathological Significance of BRAF V600E Mutation in Egyptian Colorectal Cancer Patients. Medical Journal of the University of Cairo Faculty of Medicine, 2020, 88, 991-997.	0.0	1
2173	Peritumoral activated hepatic stellate cells are associated with hepatic recurrence for resectable colorectal adenocarcinoma liver metastasis following resection. Oncology Letters, 2020, 20, 1-1.	0.8	0
2174	Molecular characteristics of colorectal hyperplastic polyp subgroups. Turkish Journal of Gastroenterology, 2020, 31, 573-580.	0.4	7
2175	Capturing tumour heterogeneity in pre- and post-chemotherapy colorectal cancer ascites-derived cells using single-cell RNA-sequencing. Bioscience Reports, 2021, 41, .	1.1	7
2176	Epithelial Wnt secretion drives the progression of inflammation-induced colon carcinoma in murine model. IScience, 2021, 24, 103369.	1.9	4
2177	APC and TP53 Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes. Cancers, 2021, 13, 5394.	1.7	7
2178	Disruption of Tumor Suppressors HNF4α/HNF1α Causes Tumorigenesis in Liver. Cancers, 2021, 13, 5357.	1.7	4
2179	Management of Colorectal Cancer with Synchronous Liver Metastases: An Inception Cohort Study (CoSMIC). Annals of Surgical Oncology, 2022, 29, 1939-1951.	0.7	10
2180	Tailored Systemic Therapy for Colorectal Cancer Liver Metastases. International Journal of Molecular Sciences, 2021, 22, 11780.	1.8	7

#	Article	IF	Citations
2181	Morphogen regulation of stem cell plasticity in intestinal regeneration and carcinogenesis. Developmental Dynamics, 2021, , .	0.8	3
2182	General insight into cancer: An overview of colorectal cancer (Review). Molecular and Clinical Oncology, 2021, 15, 271.	0.4	47
2183	Deciphering the Molecular Landscape of Appendiceal Mucinous Neoplasms for Diagnostic, Prognostic and Therapeutic Purposes. Annals of Surgical Oncology, 2020, 27, 1312-1313.	0.7	0
2185	Single-Cell Analysis May Shed New Lights on the Role of LncRNAs in Chemoresistance in Gastrointestinal Cancers. RNA Technologies, 2020, , 229-253.	0.2	1
2188	Multicohort and cross‑platform validation of a prognostic Wnt signature in colorectal cancer. Clinical and Translational Medicine, 2020, 10, e199.	1.7	1
2189	Increased Cytoplasmic Yes-associated Protein (YAP) Expression in Mismatch Repair Protein-Proficient Colorectal Cancer With High-grade Tumor Budding and Reduced Autophagy Activity. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 305-312.	0.6	5
2192	The Effect of Tumor Sideness and Mutational Status on First Line Treatment Response and Survival in The Patients with Metastatic Colorectal Cancer. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2020, 30, 197-206.	0.1	0
2193	DIAGNOSTICS, TREATMENT AND PROGNOSIS IN PATIENTS WITH COLORECTAL CANCER AND PERITONEAL CARCINOMATOSIS (review). Koloproktologia, 2020, 19, 131-149.	0.1	2
2194	Carcinomas of the Gastrointestinal Tract. , 2021, , 427-472.		0
2195	Oncolytic effects of the recombinant Newcastle disease virus, rAF-IL12, against colon cancer cells in vitro and in tumor-challenged NCr-Foxn1nu nude mice. PeerJ, 2020, 8, e9761.	0.9	8
2197	Mutational Characterization of Colorectal Cancer from Korean Patients with Targeted Sequencing. Journal of Cancer, 2021, 12, 7300-7310.	1.2	2
2198	A roadmap for medical treatment of metastatic CRC. , 2022, , 365-379.		0
2199	Early onset of CRC. , 2022, , 41-44.		0
2200	Immunology and immunotherapy in CRC. , 2022, , 435-453.		0
2201	CRC: A Darwinian model of cellular immunoselection. , 2022, , 529-541.		0
2202	Cartilage Oligomeric Matrix Protein, COMP may be a Better Prognostic Marker Than CEACAM5 and Correlates With Colon Cancer Molecular Subtypes, Tumor Aggressiveness and Overall Survival. Journal of Surgical Research, 2022, 270, 169-177.	0.8	4
2203	Immunology and Immunotherapy of Colorectal Cancer. , 2020, , 261-289.		1
2204	PDAC Subtypes/Stratification. Molecular and Translational Medicine, 2020, , 117-128.	0.4	1

#	ARTICLE	IF	CITATIONS
2205	Colorectal Cancer Genetics: An Overview of the Actionable Building Blocks. , 2020, , 29-71.		1
2206	Optimum patient selection for irinotecan-containing regimens in metastatic colorectal cancer: Literature review and lessons from clinical practice. Indian Journal of Cancer, 2020, 58, 5-16.	0.2	2
2207	Immune Targets in Colorectal Cancer. Diagnostics and Therapeutic Advances in GI Malignancies, 2020, , 205-230.	0.2	0
2208	Biomarkers in colon cancer and its clinical implications. Journal of Current Oncology, 2020, 3, 66.	0.2	1
2209	Decision making process in simultaneous laparoscopic resection of colorectal cancer and liver metastases. Review of literature. Acta Cirurgica Brasileira, 2020, 35, e202000308.	0.3	1
2213	Minimally invasive complete mesocolic excision for right colon cancer. Annals of Gastroenterological Surgery, 2020, 4, 234-242.	1.2	7
2214	The Unreasonable Effectiveness of Inverse Reinforcement Learning in Advancing Cancer Research. Proceedings of the AAAI Conference on Artificial Intelligence, 2020, 34, 437-445.	3.6	5
2215	Nonnegative matrix factorization–based bioinformatics analysis reveals that TPX2 and SELENBP1 are two predictors of the inner sub–consensuses of lung adenocarcinoma. Cancer Medicine, 2021, 10, 9058-9077.	1.3	7
2216	Genome-wide profiling in colorectal cancer identifies PHF19 and TBC1D16 as oncogenic super enhancers. Nature Communications, 2021, 12, 6407.	5.8	41
2217	AQP9 Is a Prognostic Factor for Kidney Cancer and a Promising Indicator for M2 TAM Polarization and CD8+ T-Cell Recruitment. Frontiers in Oncology, 2021, 11, 770565.	1.3	12
2218	Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Molecular Cancer, 2021, 20, 143.	7.9	117
2219	Stratification of chemotherapy-treated stage III colorectal cancer patients using multiplexed imaging and single-cell analysis of T-cell populations. Modern Pathology, 2022, 35, 564-576.	2.9	12
2220	The Immune Landscape of Colorectal Cancer. Cancers, 2021, 13, 5545.	1.7	14
2222	Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?. International Journal of Molecular Sciences, 2021, 22, 11941.	1.8	27
2223	KMT9 Controls Stemness and Growth of Colorectal Cancer. Cancer Research, 2022, 82, 210-220.	0.4	11
2224	The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer. Current Treatment Options in Oncology, 2021, 22, 113.	1.3	9
2231	Artificial intelligence for the study of colorectal cancer tissue slides. Artificial Intelligence in Gastroenterology, 2020, 1, 51-59.	0.2	0
2232	Pathologic Features of Colorectal Carcinomas. , 2021, , 455-480.		2

#	ARTICLE	IF	CITATIONS
2237	High SEMA4C expression promotes the epithelial-mesenchymal transition and predicts poor prognosis in colorectal carcinoma. Aging, 2020, 12, 21992-22018.	1.4	10
2238	Commentary: Pulmonary metastasectomy efficacy: A game of clones?. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, 503-510.	0.4	0
2239	Analysis of DNA methylation-driven genes for predicting the prognosis of patients with colorectal cancer. Aging, 2020, 12, 22814-22839.	1.4	3
2241	Consensus Molecular Subtypes of Colorectal Cancer and their Clinical Implications. International Biological and Biomedical Journal, 2017, 3, 105-111.	7.0	54
2242	How does inflammation drive mutagenesis in colorectal cancer?. Trends in Cancer Research, 2017, 12, 111-132.	1.6	4
2243	Patients with RAS wild-type right-sided unresectable liver-confined mCRC also benefit from cetuximab plus chemotherapy in first-line treatment. American Journal of Cancer Research, 2018, 8, 2337-2345.	1.4	5
2244	The gut microflora assay in patients with colorectal cancer: in feces or tissue samples?. Iranian Journal of Microbiology, 2019, 11, 1-6.	0.8	10
2245	Long non-coding RNA CASC2 induces apoptosis and autophagy in human colon cancer cells via modulation of TRIM16 expression. American Journal of Translational Research (discontinued), 2020, 12, 2695-2702.	0.0	3
2246	Three Data-Driven Phenotypes of Multiple Organ Dysfunction Syndrome Preserved from Early Childhood to Middle Adulthood. AMIA ... Annual Symposium proceedings, 2020, 2020, 1345-1353.	0.2	8
2247	The Unreasonable Effectiveness of Inverse Reinforcement Learning in Advancing Cancer Research. Proceedings of the AAAI Conference on Artificial Intelligence, 2020, 34, 437-445.	3.6	0
2248	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. Journal of the National Cancer Institute, 2022, 114, 819-828.	3.0	2
2249	Translational epigenetics in precision medicine of colorectal cancer. , 2022, , 19-41.		0
2250	Protein arginine N-methyltransferase 5 in colorectal carcinoma: Insights into mechanisms of pathogenesis and therapeutic strategies. Biomedicine and Pharmacotherapy, 2022, 145, 112368.	2.5	9
2251	Single-Cell RNA Sequencing Analysis of the Heterogeneity in Gene Regulatory Networks in Colorectal Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 765578.	1.8	4
2252	Modeling of Personalized Treatments in Colon Cancer Based on Preclinical Genomic and Drug Sensitivity Data. Cancers, 2021, 13, 6018.	1.7	3
2253	Proteasome inhibitors restore the STAT1 pathway and enhance the expression of MHC class I on human colon cancer cells. Journal of Biomedical Science, 2021, 28, 75.	2.6	7
2254	Stage Iâ€"IV Colorectal Cancer Prognosis Can Be Predicted by Type and Number of Intratumoral Macrophages and CLEVER-1+ Vessel Density. Cancers, 2021, 13, 5988.	1.7	4
2255	Consensus molecular subtypes of colorectal cancer in clinical practice: A translational approach. World Journal of Clinical Oncology, 2021, 12, 1000-1008.	0.9	24

#	ARTICLE	IF	CITATIONS
2256	Updates on Age to Start and Stop Colorectal Cancer Screening: Recommendations From the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2022, 162, 285-299.	0.6	89
2257	Current treatment and surveillance modalities are not sufficient for advanced stage III colon cancer: Result from a multicenter cohort analysis. Cancer Medicine, 2021, 10, 8924-8933.	1.3	5
2258	Novel Methylation Biomarkers for Colorectal Cancer Prognosis. Biomolecules, 2021, 11, 1722.	1.8	21
2259	Identification of Gene Co-Expression Networks Associated with Consensus Molecular Subtype-1 of Colorectal Cancer. Cancers, 2021, 13, 5824.	1.7	4
2260	A Portrait of Intratumoral Genomic and Transcriptomic Heterogeneity at Single-Cell Level in Colorectal Cancer. Medicina (Lithuania), 2021, 57, 1257.	0.8	5
2261	Cancer-associated fibroblasts in colorectal cancer. Clinical and Translational Oncology, 2022, 24, 757-769.	1.2	29
2262	The Impact of KRAS Mutation in Patients With Sporadic Nonampullary Duodenal Epithelial Tumors. Clinical and Translational Gastroenterology, 2021, 12, e00424.	1.3	1
2263	Patient Similarity in the Era of Precision Medicine: A Philosophical Analysis. Erkenntnis, 0, , 1.	0.6	1
2264	Stromal Cells Promote Matrix Deposition, Remodelling and an Immunosuppressive Tumour Microenvironment in a 3D Model of Colon Cancer. Cancers, 2021, 13, 5998.	1.7	8
2265	Identification of an Autophagy-Related Gene Signature for the Prediction of Prognosis in Early-Stage Colorectal Cancer. Frontiers in Genetics, 2021, 12, 755789.	1.1	4
2266	Comprehensive Analysis of Subtype-Specific Molecular Characteristics of Colon Cancer: Specific Genes, Driver Genes, Signaling Pathways, and Immunotherapy Responses. Frontiers in Cell and Developmental Biology, 2021, 9, 758776.	1.8	10
2267	p130Cas Is Correlated with EREG Expression and a Prognostic Factor Depending on Colorectal Cancer Stage and Localization Reducing FOLFIRI Efficacy. International Journal of Molecular Sciences, 2021, 22, 12364.	1.8	3
2268	Sporadic and Inherited Colorectal Cancer: How Epidemiology and Molecular Biology Guide Screening and Treatment. , 2022, , 397-412.		0
2269	Somatostatin and Its Receptor System in Colorectal Cancer. Biomedicines, 2021, 9, 1743.	1.4	7
2270	Disruption of Î²-Cateninâ€"Dependent Wnt Signaling in Colon Cancer Cells Remodels the Microenvironment to Promote Tumor Invasion. Molecular Cancer Research, 2022, 20, 468-484.	1.5	7
2271	Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?. Frontiers in Oncology, 2021, 11, 769305.	1.3	13
2272	Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer. Frontiers in Oncology, 2021, 11, 764618.	1.3	17
2273	Comprehensive analyses of microRNA and mRNA expression in colorectal serrated lesions and colorectal cancer with a MSI phenotype. Genes Chromosomes and Cancer, 2021, , .	1.5	3

#	Article	IF	Citations
2274	Neoadjuvant therapy in rectal cancer: An ongoing conundrum. ANZ Journal of Surgery, 2021, 91, 2251-2253.	0.3	0
2275	Post-polypectomy colonoscopy surveillance: Can we improve the diagnostic yield?. GastroenterologÃa Y HepatologÃa, 2022, 45, 474-487.	0.2	4
2276	A Novel Prognostic Biomarker Panel for Early-Stage Colon Carcinoma. Cancers, 2021, 13, 5909.	1.7	5
2277	Identification of Prognostic Biomarkers Originating From the Tumor Stroma of Betel Quid-Associated Oral Cancer Tissues. Frontiers in Oncology, 2021, 11, 769665.	1.3	5
2278	<i>TP53</i> Gain-of-Function and Nonâ€"Gain-of-Function Mutations Are Differentially Associated With Sidedness-Dependent Prognosis in Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2022, 40, 171-179.	0.8	33
2279	An overview and bibliometric analysis on the colorectal cancer therapy by magnetic functionalized nanoparticles for the responsive and targeted drug delivery. Journal of Nanobiotechnology, 2021, 19, 399.	4.2	33
2280	Exploration of the Key Proteins of High-Grade Intraepithelial Neoplasia to Adenocarcinoma Sequence Using In-Depth Quantitative Proteomics Analysis. Journal of Oncology, 2021, 2021, 1-13.	0.6	5
2281	CCL20 induces colorectal cancer neoplastic epithelial cell proliferation, migration, and further CCL20 production through autocrine HGF-c-Met and MSP-MSPR signaling pathways. Oncotarget, 2021, 12, 2323-2337.	0.8	5
2282	Updates on age to start and stop colorectal cancer screening: recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy, 2022, 95, 1-15.	0.5	10
2283	Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers. Cancers, 2021, 13, 5750.	1.7	4
2285	A Network-Centric Framework for the Evaluation of Mutual Exclusivity Tests on Cancer Drivers. Frontiers in Genetics, 2021, 12, 746495.	1.1	0
2286	Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer. Journal of Clinical Laboratory Analysis, 2022, 36, e24141.	0.9	12
2287	Adjuvant treatment of colon cancer with microsatellite instability â€" the state of the art. Critical Reviews in Oncology/Hematology, 2022, 169, 103537.	2.0	5
2288	Molecular subclassification of gastrointestinal cancers based on cancer stem cell traits. Experimental Hematology and Oncology, 2021, 10, 53.	2.0	5
2289	Lef1 restricts ectopic crypt formation and tumor cell growth in intestinal adenomas. Science Advances, 2021, 7, eabj0512.	4.7	6
2290	Circular RNA: A promising new star for the diagnosis and treatment of colorectal cancer. Cancer Medicine, 2021, 10, 8725-8740.	1.3	26
2291	Patientâ€derived organoids as a preclinical platform for precision medicine in colorectal cancer. Molecular Oncology, 2022, 16, 2396-2412.	2.1	17
2292	Survival Trends of Right- and Left-Sided Colon Cancer across Four Decades: A Norwegian Population-Based Study. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 342-351.	1.1	7

#	Article	IF	Citations
2293	Clinicopathological Features Combined With Immune Infiltration Could Well Distinguish Outcomes in Stage II and Stage III Colorectal Cancer: A Retrospective Study. Frontiers in Oncology, 2021, 11, 776997.	1.3	2
2294	Tumor evolution selectively inactivates the core microRNA machinery for immune evasion. Nature Communications, 2021, 12, 7003.	5.8	7
2296	Single-Cell Atlas of Infiltrating B Cells and Their Clinical Outcomes in Colorectal Cancer. SSRN Electronic Journal, 0, , .	0.4	0
2297	Synchronous resection of primary colorectal cancer with liver metastases: two birds with one stone?. British Journal of Surgery, 2022, 109, 303-305.	0.1	7
2298	Microsatellite instability in young patients with rectal cancer: molecular findings and treatment response. British Journal of Surgery, 2022, 109, 251-255.	0.1	9
2299	A Pan-Cancer Analysis of Tumor-Infiltrating B Cell Repertoires. Frontiers in Immunology, 2021, 12, 790119.	2.2	7
2300	Microenvironmental Metabolites in the Intestine: Messengers between Health and Disease. Metabolites, 2022, 12, 46.	1.3	4
2301	IndGOterm: a qualitative method for the identification of individually dysregulated GO terms in cancer. Briefings in Bioinformatics, 2022, 23, .	3.2	0
2302	Alternative RNA splicing in tumour heterogeneity, plasticity and therapy. DMM Disease Models and Mechanisms, 2022, 15, .	1.2	12
2303	Immune Landscape Refines the Classification of Colorectal Cancer With Heterogeneous Prognosis, Tumor Microenvironment and Distinct Sensitivity to Frontline Therapies. Frontiers in Cell and Developmental Biology, 2021, 9, 784199.	1.8	13
2305	Integrative analysis of CRISPR screening data uncovers new opportunities for optimizing cancer immunotherapy. Molecular Cancer, 2022, 21, 2.	7.9	14
2306	Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits. Communications Biology, 2022, 5, 41.	2.0	8
2307	Silencing ESRP1 expression promotes caspase-independent cell death via nuclear translocation of AIF in colon cancer cells. Cellular Signalling, 2022, 91, 110237.	1.7	6
2310	Immunotherapy of Rectal Cancer. , 2021, , 139-153.		0
2311	Systematic review and meta-analysis of tumour microsatellite-instability status as a predictor of response to fluorouracil-based adjuvant chemotherapy in colorectal cancer. International Journal of Colorectal Disease, 2022, 37, 35-46.	1.0	6
2312	Emerging Therapeutic Agents for Colorectal Cancer. Molecules, 2021, 26, 7463.	1.7	14
2313	Loss of Neuropilin-2 in Murine Mesenchymal-like Colon Cancer Organoids Causes Mesenchymal-to-Epithelial Transition and an Acquired Dependency on Insulin-Receptor Signaling and Autophagy. Cancers, 2022, 14, 671.	1.7	5
2314	Emerging Prospects for the Study of Colorectal Cancer Stem Cells using Patient-Derived Organoids. Current Cancer Drug Targets, 2022, 22, .	0.8	0

#	Article	IF	Citations
2315	HIPK2 Cooperates with KRAS Signaling and Associates with Colorectal Cancer Progression. Molecular Cancer Research, 2022, 20, 686-698.	1.5	5
2316	Biomarkers to Detect Early-Stage Colorectal Cancer. Biomedicines, 2022, 10, 255.	1.4	9
2317	Improvement in colorectal cancer outcomes over time is limited to patients with left-sided disease. Journal of Cancer Research and Clinical Oncology, 2022, 148, 3007-3014.	1.2	2
2318	Clinical Significance of the Duality of Wnt/Î²-Catenin Signaling in Human Hepatocellular Carcinoma. Cancers, 2022, 14, 444.	1.7	20
2319	Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer. European Journal of Cancer, 2022, 161, 90-98.	1.3	13
2320	Identification of an at-risk subpopulation with high immune infiltration based on the peroxisome pathway and TIM3 in colorectal cancer. BMC Cancer, 2022, 22, 44.	1.1	8
2321	Decellularized Colorectal Cancer Matrices as Bioactive Scaffolds for Studying Tumor-Stroma Interactions. Cancers, 2022, 14, 359.	1.7	10
2322	Comprehensive clinicopathologic, molecular, and immunologic characterization of colorectal carcinomas with loss of three intestinal markers, CDX2, SATB2, and KRT20. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 543-555.	1.4	5
2323	Clinicopathological significance of CBX3 in colorectal cancer: An intensive expression study based on formalinâ€fixed and paraffinâ€embedded tissues. Pathology International, 2022, , .	0.6	2
2324	^{68}Ga-FAPI-04 PET Provides Better Diagnostic Imaging for Malignant Colorectal Carcinomas Than ^{18}F-FDG PET. SSRN Electronic Journal, 0, , .	0.4	0
2325	Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists. Molecular Cancer Therapeutics, 2022, 21, 594-606.	1.9	1
2326	Current Approaches in Managing Colonic Serrated Polyps and Serrated Polyposis. Annual Review of Medicine, 2022, 73, 293-306.	5.0	9
2327	Identification of a prognostic signature in colorectal cancer using combinatorial algorithmâ€driven analysis. Journal of Pathology: Clinical Research, 2022, , .	1.3	1
2328	Genomic landscape of colorectal carcinogenesis. Journal of Cancer Research and Clinical Oncology, 2022, 148, 533-545.	1.2	13
2329	Loss of circadian gene Timeless induces EMT and tumor progression in colorectal cancer via Zeb1-dependent mechanism. Cell Death and Differentiation, 2022, 29, 1552-1568.	5.0	18
2330	Pervasive Conditional Selection of Driver Mutations and Modular Epistasis Networks in Cancer. SSRN Electronic Journal, 0, , .	0.4	0
2331	Squalene synthase predicts poor prognosis in stage Iâ€II colon adenocarcinoma and synergizes squalene epoxidase to promote tumor progression. Cancer Science, 2022, 113, 971-985.	1.7	9
2332	The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection. The Lancet Gastroenterology and Hepatology, 2022, 7, 262-274.	3.7	177

#	Article	IF	Citations
2333	Identification of a Subset of Stage I Colorectal Cancer Patients with High Recurrence Risk. Journal of the National Cancer Institute, 2022, , .	3.0	1
2334	Precision medicine to manage chronic immune-related conditions. , 2022, , 295-318.		1
2335	Precision medicine for metastatic colorectal cancer in clinical practice. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110727.	1.4	23
2336	Integrative analysis from multi-center studies identities a consensus machine learning-derived lncRNA signature for stage II/III colorectal cancer. EBioMedicine, 2022, 75, 103750.	2.7	73
2337	Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 2022, 19, 146-157.	0.7	7
2338	Rewired lipid metabolism as an actionable vulnerability of aggressive colorectal carcinoma. Molecular and Cellular Oncology, 2022, 9, 2024051.	0.3	3
2339	Targeting PELP1 Attenuates Angiogenesis and Enhances Chemotherapy Efficiency in Colorectal Cancer. Cancers, 2022, 14, 383.	1.7	4
2341	The Prognostic Value of FoxP3+ Tumour-Infiltrating Lymphocytes in Rectal Cancer Depends on Immune Phenotypes Defined by CD8+ Cytotoxic T Cell Density. Frontiers in Immunology, 2022, 13, 781222.	2.2	8
2342	Association Between Tumor Mutation Profile and Clinical Outcomes Among Hispanic-Latino Patients With Metastatic Colorectal Cancer. Frontiers in Oncology, 2021, 11, 772225.	1.3	5
2343	Immune translational control by CPEB4 regulates intestinal inflammation resolution and colorectal cancer development. IScience, 2022, 25, 103790.	1.9	4
2344	Robust nonparametric integrative analysis to decipher heterogeneity and commonality across subgroups using sparse boosting. Statistics in Medicine, 2022, 41, 1658-1687.	0.8	3
2345	SMAD4â€"201 transcript as a putative biomarker in colorectal cancer. BMC Cancer, 2022, 22, 72.	1.1	2
2346	Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data. Journal of Personalized Medicine, 2022, 12, 128.	1.1	6
2347	Predictive â€œomicâ€•biomarkers of drug response: Colorectal cancer as a model. , 2022, , 199-240.		2
2348	Canonical TGFÎ² signaling induces collective invasion in colorectal carcinogenesis through a Snail1- and Zeb1-independent partial EMT. Oncogene, 2022, 41, 1492-1506.	2.6	10
2349	Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2022, 23, 1133.	1.8	31
2350	The Role of RAB GTPases and Its Potential in Predicting Immunotherapy Response and Prognosis in Colorectal Cancer. Frontiers in Genetics, 2022, 13, 828373.	1.1	9
2351	Stemness Refines the Classification of Colorectal Cancer With Stratified Prognosis, Multi-Omics Landscape, Potential Mechanisms, and Treatment Options. Frontiers in Immunology, 2022, 13, 828330.	2.2	32

#	Article	IF	Citations
2353	A glycolysis-related two-gene risk model that can effectively predict the prognosis of patients with rectal cancer. Human Genomics, 2022, 16, 5.	1.4	7
2354	Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?. Critical Reviews in Oncology/Hematology, 2022, 170, 103597.	2.0	19
2355	Evaluating the Clinical Performance of a Dual-Target Stool DNA Test for Colorectal Cancer Detection. Journal of Molecular Diagnostics, 2022, 24, 131-143.	1.2	9
2356	Nanoparticle mediated targeting of toll-like receptors to treat colorectal cancer. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 172, 16-30.	2.0	4
2357	Alpha-fetoprotein can promote gastric cancer progression via upregulation of metastasis-associated colon cancer 1. Oncology Letters, 2022, 23, 84.	0.8	4
2358	Ferroptosis-associated molecular classification characterized by distinct tumor microenvironment profiles in colorectal cancer. International Journal of Biological Sciences, 2022, 18, 1773-1794.	2.6	12
2359	TSG-6 promotes Cancer Cell aggressiveness in a CD44-Dependent Manner and Reprograms Normal Fibroblasts to create a Pro-metastatic Microenvironment in Colorectal Cancer. International Journal of Biological Sciences, 2022, 18, 1677-1694.	2.6	17
2360	Use of Omics Technologies for the Detection of Colorectal Cancer Biomarkers. Cancers, 2022, 14, 817.	1.7	8
2361	Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies. Expert Opinion on Investigational Drugs, 2022, 31, 235-247.	1.9	3
2362	Reversing chemorefraction in colorectal cancer cells by controlling mucin secretion. ELife, 2022, 11, .	2.8	6
2363	The earliest events in <scp><i>BRAF</i></scp>-mutant colorectal cancer: exome sequencing of sessile serrated lesions with a tiny focus dysplasia or cancer reveals recurring mutations in two distinct progression pathways. Journal of Pathology, 2022, 257, 239-249.	2.1	5
2364	Contribution of Epithelial and Gut Microbiome Inflammatory Biomarkers to the Improvement of Colorectal Cancer Patients' Stratification. Frontiers in Oncology, 2021, 11, 811486.	1.3	3
2365	Inflammatory fibroblasts make rectal cancer resistant to radiation therapy. Cancer Cell, 2022, 40, 122-124.	7.7	2
2366	Links Between N6-Methyladenosine and Tumor Microenvironments in Colorectal Cancer. Frontiers in Cell and Developmental Biology, 2022, 10, 807129.	1.8	4
2367	Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer. Nature Cancer, 2022, 3, 219-231.	5.7	24
2368	Treatment Trends and Clinical Outcomes of Left-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer in the United States. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 268-275.	2.3	3
2369	Omega-3 polyunsaturated fatty acids: moving towards precision use for prevention and treatment of colorectal cancer. Gut, 2022, 71, 822-837.	6.1	13
2370	Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. Cancer Cell, 2022, 40, 168-184.e13.	7.7	117

#	ARTICLE	IF	CITATIONS
2371	ILâ€36 Î³ and ILâ€36Ra Reciprocally Regulate Colon Inflammation and Tumorigenesis by Modulating the Cellâ€"Matrix Adhesion Network and Wnt Signaling. Advanced Science, 2022, , 2103035.	5.6	12
2372	Intestinal stem cell dynamics in homeostasis and cancer. Trends in Cancer, 2022, 8, 416-425.	3.8	9
2373	Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer. Nature Communications, 2022, 13, 816.	5.8	192
2374	Association between Altered Oncogenic Signaling Pathways and Overall Survival of Patients with Metastatic Colorectal Cancer. Diagnostics, 2021, 11, 2308.	1.3	4
2375	Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers. , 2021, 9, e003414.		14
2376	MFmap: A semi-supervised generative model matching cell lines to tumours and cancer subtypes. PLoS ONE, 2021, 16, e0261183.	1.1	4
2377	Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps. Cell, 2021, 184, 6262-6280.e26.	13.5	125
2378	Characterizing and exploiting the many roles of aberrant H2B monoubiquitination in cancer pathogenesis. Seminars in Cancer Biology, 2022, 86, 782-798.	4.3	8
2379	Colorectal cancer-associated fibroblasts promote metastasis by up-regulating LRG1 through stromal IL-6/STAT3 signaling. Cell Death and Disease, 2022, 13, 16.	2.7	36
2380	Primary and metastatic peritoneal surface malignancies. Nature Reviews Disease Primers, 2021, 7, 91.	18.1	87
2381	The Origin and Contribution of Cancer-Associated Fibroblasts in Colorectal Carcinogenesis. Gastroenterology, 2022, 162, 890-906.	0.6	63
2382	Energy Balanceâ€"Related Factors and Risk of Colorectal Cancer Expressing Different Levels of Proteins Involved in the Warburg Effect. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 633-646.	1.1	6
2383	Metabolomics reveals that CAF-derived lipids promote colorectal cancer peritoneal metastasis by enhancing membrane fluidity. International Journal of Biological Sciences, 2022, 18, 1912-1932.	2.6	18
2384	Prognostic and Predictive Molecular Biomarkers in Advanced Colorectal Cancer. SSRN Electronic Journal, 0, , .	0.4	0
2385	Molecular Classifications of Gastrointestinal Tract Tumors. , 2022, , 943-977.		0
2386	Impact of microsatellite status in early-onset colonic cancer. British Journal of Surgery, 2022, 109, 632-636.	0.1	7
2387	Mapping Proteome Changes in Microsatellite Stable, Recurrent Colon Cancer Reveals a Significant Immune System Signature. Cancer Genomics and Proteomics, 2022, 19, 130-144.	1.0	0
2388	Colorectal Cancer in the Arab World. , 2022, , 363-379.		4

#	Article	IF	Citations
2389	Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity. British Journal of Cancer, 2022, 126, 1824-1833.	2.9	24
2390	Neutrophil extracellular traps drive epithelial–mesenchymal transition of human colon cancer. Journal of Pathology, 2022, 256, 455-467.	2.1	43
2391	Application Progress of Organoids in Colorectal Cancer. Frontiers in Cell and Developmental Biology, 2022, 10, 815067.	1.8	8
2393	The Current and Evolving Role of Immunotherapy in Metastatic Colorectal Cancer. Current Cancer Drug Targets, 2022, 22, 617-628.	0.8	3
2394	Discoidin Domain Receptor 1 Expression in Colon Cancer: Roles and Prognosis Impact. Cancers, 2022, 14, 928.	1.7	7
2395	Comprehensive analysis of negatively correlated miRNA-mRNA regulatory pairs associated with microsatellite instability in colorectal cancer. Cancer Biomarkers, 2022, , 1-13.	0.8	0
2397	Molecular Endoscopy for the Diagnosis and Therapeutic Monitoring of Colorectal Cancer. Frontiers in Oncology, 2022, 12, 835256.	1.3	1
2399	A retrospective analysis using deep-learning models for prediction of survival outcome and benefit of adjuvant chemotherapy in stage II/III colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1955-1963.	1.2	8
2400	Clinical significance of molecular subtypes of gastrointestinal tract adenocarcinoma. World Journal of Gastrointestinal Oncology, 2022, 14, 628-645.	0.8	6
2401	The putative oncogenic role of <i>WDTC1</i> in colorectal cancer. Carcinogenesis, 2022, , .	1.3	2
2402	Development of a miRNA–based classifier for detection of colorectal cancer molecular subtypes. Molecular Oncology, 2022, 16, 2693-2709.	2.1	6
2403	Ras Pathway Activation and MEKi Resistance Scores Predict the Efficiency of MEKi and SRCi Combination to Induce Apoptosis in Colorectal Cancer. Cancers, 2022, 14, 1451.	1.7	3
2404	Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by 68Ga-FAPI-PET imaging. British Journal of Cancer, 2022, 127, 145-155.	2.9	16
2405	Molecular Mechanisms of Tumor Immunomodulation in the Microenvironment of Colorectal Cancer. International Journal of Molecular Sciences, 2022, 23, 2782.	1.8	11
2406	The case for cancer-associated fibroblasts: essential elements in cancer drug discovery?. Future Drug Discovery, 0, , .	0.8	3
2407	Genome–wide analysis of <scp>mRNA</scp> and <scp>microRNA</scp> expression in colorectal cancer and adjacent normal mucosa. Journal of Pathology: Clinical Research, 2022, , .	1.3	0
2408	Natural History of Human Epidermal Growth Factor Receptor 2–Amplified and Human Epidermal Growth Factor Receptor 2 Wild-Type Refractory Metastatic Colorectal Cancer in US Clinical Practice. JCO Clinical Cancer Informatics, 2022, 6, e2100133.	1.0	0
2409	The Complete Loss of p53 Expression Uniquely Predicts Worse Prognosis in Colorectal Cancer. International Journal of Molecular Sciences, 2022, 23, 3252.	1.8	12

#	Article	IF	Citations
2410	Prognosis and Sensitivity of Adjuvant Chemotherapy in Mucinous Colorectal Adenocarcinoma without Distant Metastasis. Cancers, 2022, 14, 1297.	1.7	8
2411	Exploration of predictive biomarkers for postoperative recurrence of stage <scp>II</scp> / <scp>III</scp> colorectal cancer using genomic sequencing. Cancer Medicine, 2022, , .	1.3	2
2412	Construction of immune-related lncRNA signature to predict aggressiveness, immune landscape, and drug resistance of colon cancer. BMC Gastroenterology, 2022, 22, 127.	0.8	2
2413	Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR). Annals of Oncology, 2022, 33, 628-637.	0.6	15
2415	Update of gene expression/methylation and MiRNA profiling in colorectal cancer; application in diagnosis, prognosis, and targeted therapy. PLoS ONE, 2022, 17, e0265527.	1.1	1
2416	Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer. Molecular Biomedicine, 2022, 3, 10.	1.7	4
2417	Clinical Oncogenomics and Personalized Medicine in Colorectal Cancer for the Surgeon: What We Need to Know and What the Future Holds. SN Comprehensive Clinical Medicine, 2022, 4, 1.	0.3	0
2418	Chemoprevention for Colorectal Cancers: Are Chemopreventive Effects Different Between Left and Right Sided Colorectal Cancers?. Digestive Diseases and Sciences, 2022, , 1.	1.1	3
2419	Colorectal cancer carcinogenesis: From bench to bedside. World Journal of Gastrointestinal Oncology, 2022, 14, 654-663.	0.8	19
2420	The Regulatory Role of Neuropeptide Gene Glucagon in Colorectal Cancer: A Comprehensive Bioinformatic Analysis. Disease Markers, 2022, 2022, 1-17.	0.6	1
2421	Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer. JAMA Oncology, 2022, 8, 760.	3.4	35
2422	Elevated MACC1 Expression in Colorectal Cancer Is Driven by Chromosomal Instability and Is Associated with Molecular Subtype and Worse Patient Survival. Cancers, 2022, 14, 1749.	1.7	3
2423	Targeting STAT3 Signaling in COL1+ Fibroblasts Controls Colitis-Associated Cancer in Mice. Cancers, 2022, 14, 1472.	1.7	6
2424	Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer. OncoImmunology, 2022, 11, 2046931.	2.1	19
2425	In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies. , 2022, 10, e004032.		25
2426	Stem Cell Theory of Cancer: Implications for Drug Resistance and Chemosensitivity in Cancer Care. Cancers, 2022, 14, 1548.	1.7	8
2427	Integrated multi-omics analysis reveals miR-20a as a regulator for metabolic colorectal cancer. Heliyon, 2022, 8, e09068.	1.4	3
2428	Risk of first onset of colorectal cancer associated with alcohol consumption in Lynch syndrome: a multicenter cohort study. International Journal of Clinical Oncology, 2022, 27, 1051-1059.	1.0	4

#	Article	IF	Citations
2429	Parvimonas micra is associated with tumour immune profiles in molecular subtypes of colorectal cancer. Cancer Immunology, Immunotherapy, 2022, 71, 2565-2575.	2.0	10
2430	Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Antiâ€"PD-1 Therapy. Clinical Cancer Research, 2022, 28, 2110-2117.	3.2	30
2431	The Microbiome: the Link to Colorectal Cancer and Research Opportunities. Current Treatment Options in Oncology, 2022, 23, 631.	1.3	0
2432	classifieR a flexible interactive cloud-application for functional annotation of cancer transcriptomes. BMC Bioinformatics, 2022, 23, 114.	1.2	3
2433	Liver mesenchymal neoplasms: something old, something new. Pathology, 2022, 54, 225-235.	0.3	2
2434	Microbiota-dependent activation of the myeloid calcineurin-NFAT pathway inhibits B7H3- and B7H4-dependent anti-tumor immunity in colorectal cancer. Immunity, 2022, 55, 701-717.e7.	6.6	16
2435	Organoid screening reveals epigenetic vulnerabilities in human colorectal cancer. Nature Chemical Biology, 2022, 18, 605-614.	3.9	24
2437	A â€œconversionâ€deteriorationâ€double mutationâ€•theory for the evolution and progression of colorectal cancer. Cancer Medicine, 2022, , .	1.3	1
2438	An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy. BMC Cancer, 2022, 22, 256.	1.1	4
2439	The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer. Journal of Experimental and Clinical Cancer Research, 2022, 41, 113.	3.5	9
2440	Precision Oncology in Colorectal Cancers- Therapeutics and Beyond (CME article). International Journal of Cancer Care and Delivery, 2022, 2, .	0.0	0
2441	Toward Targeted Therapies in Oesophageal Cancers: An Overview. Cancers, 2022, 14, 1522.	1.7	3
2443	BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications. Critical Reviews in Oncology/Hematology, 2022, 172, 103647.	2.0	10
2444	Comprehensive cancer-oriented biobanking resource of human samples for studies of post-zygotic genetic variation involved in cancer predisposition. PLoS ONE, 2022, 17, e0266111.	1.1	4
2445	Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target. , 2022, 10, e004302.		20
2446	How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC. Clinical Immunology, 2022, 237, 108962.	1.4	16
2447	Circulating exosomal gastric cancer-associated long noncoding RNA1 as a noninvasive biomarker for predicting chemotherapy response and prognosis of advanced gastric cancer: A multi-cohort, multi-phase study. EBioMedicine, 2022, 78, 103971.	2.7	8
2448	ACO/ARO/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group. Clinical and Translational Radiation Oncology, 2022, 34, 99-106.	0.9	7

#	Article	IF	Citations
2449	Artificial intelligence for detection of microsatellite instability in colorectal cancerâ€"a multicentric analysis of a pre-screening tool for clinical application. ESMO Open, 2022, 7, 100400.	2.0	47
2450	Cause, Epidemiology, and Histology of Polyps and Pathways to Colorectal Cancer. Gastrointestinal Endoscopy Clinics of North America, 2022, 32, 177-194.	0.6	29
2451	Colorectal Cancer: The Contribution of CXCL12 and Its Receptors CXCR4 and CXCR7. Cancers, 2022, 14, 1810.	1.7	17
2452	Downregulation of KRAB zinc finger proteins in 5-fluorouracil resistant colorectal cancer cells. BMC Cancer, 2022, 22, 363.	1.1	9
2453	KCNQ1 and lymphovascular invasion are key features in a prognostic classifier for stage II and III colon cancer. BMC Cancer, 2022, 22, 372.	1.1	2
2454	Privacy preserving validation for multiomic prediction models. Briefings in Bioinformatics, 2022, , .	3.2	1
2455	Mucin phenotypes and clinicopathological features of colorectal adenocarcinomas: Correlation with colorectal adenocarcinoma with enteroblastic differentiation. Pathology Research and Practice, 2022, 232, 153840.	1.0	2
2456	Single-cell and spatial analysis reveal interaction of FAP+ fibroblasts and SPP1+ macrophages in colorectal cancer. Nature Communications, 2022, 13, 1742.	5.8	213
2457	Identification and Validation in a Novel Quantification System of Ferroptosis Patterns for the Prediction of Prognosis and Immunotherapy Response in Left- and Right-Sided Colon Cancer. Frontiers in Immunology, 2022, 13, 855849.	2.2	14
2458	Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer. Critical Reviews in Oncology/Hematology, 2022, 173, 103657.	2.0	6
2459	Synergistic antitumor activity of 5-fluorouracil and atosiban against microsatellite stable colorectal cancer through restoring GATA3. Biochemical Pharmacology, 2022, 199, 115025.	2.0	0
2460	Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update. Critical Reviews in Oncology/Hematology, 2022, 173, 103663.	2.0	27
2461	DNA methylation-based diagnostic, prognostic, and predictive biomarkers in colorectal cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188722.	3.3	45
2462	Updates on Age to Start and Stop Colorectal Cancer Screening: Recommendations From the U.S. Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2022, 117, 57-69.	0.2	14
2463	TATI, TAT-2, and CRP as Prognostic Factors in Colorectal Cancer. Oncology, 2022, 100, 22-30.	0.9	3
2464	Development of Machine Learning based Colorectal Cancer Subtype Classificator. , 2021, , .		0
2465	Pathological Features and Prognostication in Colorectal Cancer. Current Oncology, 2021, 28, 5356-5383.	0.9	48
2466	Role of tumour- associated neutrophils in tissue material and systemic neutrophil inflammation in colorectal cancer patients. Progress in Health Sciences, 2021, 11, 85-98.	0.1	0

#	ARTICLE	IF	CITATIONS
2467	Colorectal Cancer-Associated Microbiome Patterns and Signatures. Frontiers in Genetics, 2021, 12, 787176.	1.1	22
2468	A probabilistic model for pathway-guided gene set selection. , 2021, , .		0
2469	Insights into the Role of Matrix Metalloproteinases in Precancerous Conditions and in Colorectal Cancer. Cancers, 2021, 13, 6226.	1.7	24
2470	Molecular drivers of tumor progression in microsatellite stable APC mutation-negative colorectal cancers. Scientific Reports, 2021, 11, 23507.	1.6	3
2471	Machine learning revealed molecular classification of colorectal cancer with negative lymph node metastasis. Biomarkers, 2022, 27, 86-94.	0.9	3
2472	Treatment for Peritoneal Metastasis of Patients With Colorectal Cancer. Annals of Coloproctology, 2021, 37, 425-433.	0.5	21
2473	Identification of a novel immune signature for optimizing prognosis and treatment prediction in colorectal cancer. Aging, 2021, 13, 25518-25549.	1.4	3
2474	Dissecting the Oncogenic Roles of Keratin 17 in the Hallmarks of Cancer. Cancer Research, 2022, 82, 1159-1166.	0.4	15
2475	Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response. Nature Communications, 2021, 12, 7297.	5.8	25
2476	The Stroma Liquid Biopsy Panel Contains a Stromal-Epithelial Gene Signature Ratio That Is Associated with the Histologic Tumor-Stroma Ratio and Predicts Survival in Colon Cancer. Cancers, 2022, 14, 163.	1.7	4
2477	Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer. Cancers, 2021, 13, 6311.	1.7	30
2478	Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care. Molecular Oncology, 2022, 16, 2042-2056.	2.1	8
2479	Rpl24Bst mutation suppresses colorectal cancer by promoting eEF2 phosphorylation via eEF2K. ELife, 2021, 10, .	2.8	15
2480	Prognostic Factors of Colorectal Cancer: A Comparative Study on Patients With or Without Liver Metastasis. Frontiers in Oncology, 2021, 11, 626190.	1.3	4
2481	Cancerâ€associated stroma reveals prognostic biomarkers and novel insights into the tumour microenvironment of colorectal cancer and colorectal liver metastases. Cancer Medicine, 2022, 11, 492-506.	1.3	5
2482	Multifocal Organoid Capturing of Colon Cancer Reveals Pervasive Intratumoral Heterogenous Drug Responses. Advanced Science, 2022, 9, e2103360.	5.6	14
2483	A Gene-Based Machine Learning Classifier Associated to the Colorectal Adenomaâ€"Carcinoma Sequence. Biomedicines, 2021, 9, 1937.	1.4	5
2484	Colorectal cancer subtyping. Nature Reviews Cancer, 2022, 22, 68-69.	12.8	10

#	ARTICLE	IF	CITATIONS
2485	Multi-omic data integration applied to molecular tumor classification. , 2021, , .		1
2486	Peritoneal Metastasis: Current Status and Treatment Options. Cancers, 2022, 14, 60.	1.7	21
2487	Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme B. PLoS ONE, 2021, 16, e0262198.	1.1	4
2488	A Gene Signature Derived from the Loss of CDKN1A (p21) Is Associated with CMS4 Colorectal Cancer. Cancers, 2022, 14, 136.	1.7	3
2489	Identification of Subtypes and a Prognostic Gene Signature in Colon Cancer Using Cell Differentiation Trajectories. Frontiers in Cell and Developmental Biology, 2021, 9, 705537.	1.8	7
2490	SMAD4 mutations do not preclude epithelialâ€"mesenchymal transition in colorectal cancer. Oncogene, 2022, 41, 824-837.	2.6	12
2491	Synchronous biliary gallstones and colorectal cancer: A single center analysis. Experimental and Therapeutic Medicine, 2021, 23, 138.	0.8	1
2492	SSCS: A Stage Supervised Subtyping System for Colorectal Cancer. Biomedicines, 2021, 9, 1815.	1.4	2
2493	Artificial intelligence, molecular subtyping, biomarkers, and precision oncology. Emerging Topics in Life Sciences, 2021, 5, 747-756.	1.1	1
2494	Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance). Clinical Cancer Research, 2022, 28, 2779-2788.	3.2	11
2495	Patient-centered developments in colon- and rectal cancer with a multidisciplinary international team: From translational research to national guidelines. World Journal of Gastrointestinal Surgery, 2021, 13, 1597-1614.	0.8	3
2496	Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients. BMC Cancer, 2021, 21, 1332.	1.1	2
2497	SH2D4A downregulation due to loss of chromosome 8p is associated with poor prognosis and low T cell infiltration in colorectal cancer. British Journal of Cancer, 2022, 126, 917-926.	2.9	3
2498	Comprehensive Imaging Characterization of Colorectal Liver Metastases. Frontiers in Oncology, 2021, 11, 730854.	1.3	7
2500	A Novel Superpixel Approach to the Tumoral Microenvironment in Colorectal Cancer. Journal of Pathology Informatics, 2022, 13, 100009.	0.8	5
2501	Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer. BMC Cancer, 2022, 22, 394.	1.1	7
2502	DNA Repairâ€"Related Gene Signature in Predicting Prognosis of Colorectal Cancer Patients. Frontiers in Genetics, 2022, 13, 872238.	1.1	6
2503	Dissection of Immune Profiles in Microsatellite Stable and Low Microsatellite Instability Colon Adenocarcinoma by Multiomics Data Analysis. Journal of Oncology, 2022, 2022, 1-20.	0.6	0

#	Article	IF	Citations
2504	Deep learning-based prediction of molecular cancer biomarkers from tissue slides: A new tool for precision oncology. Clinical and Molecular Hepatology, 2022, , .	4.5	10
2505	Integrative analysis of mutated genes and mutational processes reveals novel mutational biomarkers in colorectal cancer. BMC Bioinformatics, 2022, 23, 138.	1.2	9
2508	Tumor–targeted fluorescence labeling systems for cancer diagnosis and treatment. Cancer Science, 2022, 113, 1919-1929.	1.7	3
2509	Identification of TPM2 and CNN1 as Novel Prognostic Markers in Functionally Characterized Human Colon Cancer-Associated Stromal Cells. Cancers, 2022, 14, 2024.	1.7	4
2510	Mechanobiology of Colorectal Cancer. Cancers, 2022, 14, 1945.	1.7	5
2511	The gut microbial metabolite formate exacerbates colorectal cancer progression. Nature Metabolism, 2022, 4, 458-475.	5.1	97
2512	Roles of ARID1A variations in colorectal cancer: a collaborative review. Molecular Medicine, 2022, 28, 42.	1.9	5
2513	Tumor microenvironment-aware, single-transcriptome prediction of microsatellite instability in colorectal cancer using meta-analysis. Scientific Reports, 2022, 12, 6283.	1.6	5
2514	Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series. European Journal of Cancer, 2022, 168, 34-40.	1.3	4
2585	CRISPR-Based Screening in Three-Dimensional Organoid Cultures to Identify TGF-β Pathway Regulators. Methods in Molecular Biology, 2022, 2488, 99-111.	0.4	2
2586	Comprehensive genetic characterization of rectal cancer in a large cohort of Japanese patients: differences according to tumor location. Journal of Gastroenterology, 2022, 57, 476-485.	2.3	2
2587	Colorectal cancer subtype identification from differential gene expression levels using minimalist deep learning. BioData Mining, 2022, 15, 12.	2.2	2
2588	Comparative molecular genomic analyses of a spontaneous rhesus macaque model of mismatch repair-deficient colorectal cancer. PLoS Genetics, 2022, 18, e1010163.	1.5	8
2589	Multi-OMICs data analysis identifies molecular features correlating with tumor immunity in colon cancer. Cancer Biomarkers, 2022, 33, 261-271.	0.8	3
2590	Diagnostic and therapeutic biomarkers in colorectal cancer: a review.. American Journal of Cancer Research, 2022, 12, 661-680.	1.4	0
2592	Evaluation of stromal cell infiltration in the tumor microenvironment enable prediction of treatment sensitivity and prognosis in colon cancer. Computational and Structural Biotechnology Journal, 2022, 20, 2153-2168.	1.9	9
2593	Association of microsatellite instability (MSI) status with the 5-year outcome and genetic ancestry in a large Brazilian cohort of colorectal cancer. European Journal of Human Genetics, 2022, 30, 824-832.	1.4	8
2594	Morphological Analyses of Colorectal Adenocarcinomas in Japanese Familial Adenomatous Polyposis Patients. Journal of the Anus, Rectum and Colon, 2022, 6, 121-128.	0.4	0

#	ARTICLE	IF	CITATIONS
2596	Patient-Derived Organoids of Colorectal Cancer: A Useful Tool for Personalized Medicine. Journal of Personalized Medicine, 2022, 12, 695.	1.1	3
2597	Predictive value of chromosome 18q11.2â€q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase <scp>III</scp>â€trial <scp>AGITGâ€MAX</scp>. International Journal of Cancer, 2022, 151, 1166-1174.	2.3	1
2598	Comprehensive profiling of 1015 patientsâ€™ exomes reveals genomic-clinical associations in colorectal cancer. Nature Communications, 2022, 13, 2342.	5.8	21
2599	Identification of a Novel Immune Landscape Signature for Predicting Prognosis and Response of Colon Cancer to Immunotherapy. Frontiers in Immunology, 2022, 13, 802665.	2.2	4
2600	The Synergistic Cooperation between TGF-Î² and Hypoxia in Cancer and Fibrosis. Biomolecules, 2022, 12, 635.	1.8	17
2601	Copy Number Alterations as Novel Biomarkers and Therapeutic Targets in Colorectal Cancer. Cancers, 2022, 14, 2223.	1.7	9
2602	Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer. Gut, 2022, 71, 2502-2517.	6.1	4
2603	Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine. Cancers, 2022, 14, 2241.	1.7	26
2604	The Evolving Treatment Landscape in <i>BRAF-V600E</i>â€"Mutated Metastatic Colorectal Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 254-263.	1.8	13
2605	Clinical management of metastatic colorectal cancer in the era of precision medicine. Ca-A Cancer Journal for Clinicians, 2022, 72, 372-401.	157.7	167
2606	Cancer-Associated Fibroblasts and Squamous Epithelial Cells Constitute a Unique Microenvironment in a Mouse Model of Inflammation-Induced Colon Cancer. Frontiers in Oncology, 2022, 12, .	1.3	6
2607	Assimilating Epigenetics and Transcriptomics for the Identification of Prognostic Novel Biomarkers and Imminent Targets in Colorectal Carcinoma with Therapeutic Potential. Current Molecular Medicine, 2023, 23, 784-798.	0.6	2
2608	Refining colorectal cancer classification and clinical stratification through a single-cell atlas. Genome Biology, 2022, 23, 113.	3.8	48
2609	Curcumin and NCLX inhibitors share anti-tumoral mechanisms in microsatellite-instability-driven colorectal cancer. Cellular and Molecular Life Sciences, 2022, 79, 284.	2.4	8
2610	A robust immune-related lncRNA signature for the prognosis of human colorectal cancer. Bioscience Reports, 2022, 42, .	1.1	2
2611	Tumor Purity in Preclinical Mouse Tumor Models. Cancer Research Communications, 2022, 2, 353-365.	0.7	4
2612	Consensus molecular subtype differences linking colon adenocarcinoma and obesity revealed by a cohort transcriptomic analysis. PLoS ONE, 2022, 17, e0268436.	1.1	3
2613	Transcriptome of sessile serrated adenoma/polyps is associated with <scp>MSI</scp>â€high colorectal cancer and decreased expression of <scp>CDX2</scp>. Cancer Medicine, 2022, 11, 5066-5078.	1.3	5

#	Article	IF	Citations
2614	Colorectal Cancer in Younger Adults. Hematology/Oncology Clinics of North America, 2022, 36, 449-470.	0.9	13
2615	Metastatic colorectal carcinoma-associated fibroblasts have immunosuppressive properties related to increased IGFBP2 expression. Cancer Letters, 2022, 540, 215737.	3.2	10
2617	TGF-Î²-Induced FLRT3 Attenuation Is Essential for Cancer-Associated Fibroblastâ€"Mediated Epithelialâ€"Mesenchymal Transition in Colorectal Cancer. Molecular Cancer Research, 2022, 20, 1247-1259.	1.5	16
2618	Clinical impact of primary tumor sidedness and sex on unresectable post-recurrence survival in resected pathological stage II-III colorectal cancers: a nationwide multicenter retrospective study. BMC Cancer, 2022, 22, 486.	1.1	3
2619	An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy. Biology Direct, 2022, 17, 10.	1.9	0
2620	A p300/GATA6 axis determines differentiation and Wnt dependency in pancreatic cancer models. Journal of Clinical Investigation, 2022, 132, .	3.9	13
2621	Immune Profile of BRAF-Mutated Metastatic Colorectal Tumors with Good Prognosis after Palliative Chemotherapy. Cancers, 2022, 14, 2383.	1.7	1
2622	Clinical Relevance of Myopenia and Myosteatosis in Colorectal Cancer. Journal of Clinical Medicine, 2022, 11, 2617.	1.0	7
2623	High-throughput single-Ñell sequencing in cancer research. Signal Transduction and Targeted Therapy, 2022, 7, 145.	7.1	39
2625	Apelin-driven endothelial cell migration sustains intestinal progenitor cells and tumor growth. , 2022, 1, 476-490.		13
2626	Antibiotic-impregnated external ventricular drainage for the management of post-hemorrhagic hydrocephalus in low birth weight premature infants following intraventricular hemorrhage. Child's Nervous System, 2022, 38, 1567-1572.	0.6	4
2627	Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients. Nature Communications, 2022, 13, 2800.	5.8	21
2628	DAB2IP down-regulates HSP90AA1 to inhibit the malignant biological behaviors of colorectal cancer. BMC Cancer, 2022, 22, 561.	1.1	13
2629	Bulk and single-cell transcriptome profiling reveal necroptosis-based molecular classification, tumor microenvironment infiltration characterization, and prognosis prediction in colorectal cancer. Journal of Translational Medicine, 2022, 20, 235.	1.8	7
2630	A pyroptosis-related prognosis model to predict survival in colorectal cancer patients.. International Journal of Clinical and Experimental Pathology, 2022, 15, 168-182.	0.5	0
2631	Two-Front War on Cancerâ€"Targeting TAM Receptors in Solid Tumour Therapy. Cancers, 2022, 14, 2488.	1.7	7
2632	Cross talk between acetylation and methylation regulators reveals histone modifier expression patterns posing prognostic and therapeutic implications on patients with colon cancer. Clinical Epigenetics, 2022, 14, .	1.8	5
2634	p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis. Nature Communications, 2022, 13, .	5.8	17

#	ARTICLE	IF	CITATIONS
2635	Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 1-12.	1.8	12
2636	Osteopontin (OPN/SPP1), a Mediator of Tumor Progression, Is Regulated by the Mesenchymal Transcription Factor Slug/SNAI2 in Colorectal Cancer (CRC). Cells, 2022, 11, 1808.	1.8	6
2637	Nitric-Oxide Synthase trafficking inducer (NOSTRIN) is an emerging negative regulator of colon cancer progression. BMC Cancer, 2022, 22, .	1.1	0
2638	Exploration of Different Hypoxia Patterns and Construction of a Hypoxia-Related Gene Prognostic Index in Colorectal Cancer. Frontiers in Immunology, 2022, 13, .	2.2	2
2639	Construction of a prognostic glycolysisâ€related lncRNA signature for patients with colorectal cancer. Cancer Medicine, 2023, 12, 930-948.	1.3	4
2640	Immunotherapy in colorectal cancer: an unmet need deserving of change. Lancet Oncology, The, 2022, 23, 830-831.	5.1	10
2641	Epithelial to mesenchymal transition influences fibroblast phenotype in colorectal cancer by altering miRâ€200 levels in extracellular vesicles. Journal of Extracellular Vesicles, 2022, 11, .	5.5	18
2642	Natural Products in Preventing Tumor Drug Resistance and Related Signaling Pathways. Molecules, 2022, 27, 3513.	1.7	12
2644	Transcriptional profiling of human VÎ´1 TÂcells reveals a pathogen-driven adaptive differentiation program. Cell Reports, 2022, 39, 110858.	2.9	13
2645	Engineered colorectal cancer tissue recapitulates key attributes of a patient-derived xenograft tumor line. Biofabrication, 2022, 14, 045001.	3.7	8
2646	Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science, 2022, 376, .	6.0	75
2647	Proteomic Profiling and Biomarker Discovery in Colorectal Liver Metastases. International Journal of Molecular Sciences, 2022, 23, 6091.	1.8	6
2648	Comprehensive Analysis of a Cancer-Immunity Cycleâ€"Based Signature for Predicting Prognosis and Immunotherapy Response in Patients With Colorectal Cancer. Frontiers in Immunology, 0, 13, .	2.2	10
2649	Translation of <scp>IDEA</scp> trial results into clinical practice: Analysis of the implementation of a new guideline for colon cancer. International Journal of Cancer, 2022, 151, 1270-1279.	2.3	5
2650	Identification and Characterization of Human Colorectal Cancer Cluster Predominantly Expressing EP3 Prostanoid Receptor Subtype. Biological and Pharmaceutical Bulletin, 2022, 45, 698-702.	0.6	1
2651	Integrative Analysis Revealed Stemness Features and a Novel Stemness-Related Classification in Colorectal Cancer Patients. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	2
2652	Colorectal Cancer Patientâ€Derived 2D and 3D Models Efficiently Recapitulate Interâ€and Intratumoral Heterogeneity. Advanced Science, 2022, 9, .	5.6	10
2653	Multivariate Risk Analysis of RAS, BRAF and EGFR Mutations Allelic Frequency and Coexistence as Colorectal Cancer Predictive Biomarkers. Cancers, 2022, 14, 2792.	1.7	2

#	Article	IF	Citations
2655	Postoperative circulating tumor DNA combined with consensus molecular subtypes can better predict outcomes in stage III colon cancers: A prospective cohort study. European Journal of Cancer, 2022, 169, 198-209.	1.3	9
2656	Colorectal adenosquamous carcinoma: Peculiar morphologic features and distinct immunoprofiles in squamous and glandular components. Pathology Research and Practice, 2022, 236, 153967.	1.0	2
2659	Characterizing the *KRAS* G12C mutation in metastatic colorectal cancer: a population-based cohort and assessment of expression differences in The Cancer Genome Atlas. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210979.	1.4	2
2660	Comprehensive Library of Drug Response and Pan-Omic Analysis Identified Therapeutic Candidates and Accompanying Prognostic Biomarkers for Asian Cholangiocarcinoma. SSRN Electronic Journal, 0, , .	0.4	0
2662	Transcriptome-wide prediction of prostate cancer gene expression from histopathology images using co-expression-based convolutional neural networks. Bioinformatics, 2022, 38, 3462-3469.	1.8	9
2664	CPDR: An R Package of Recommending Personalized Drugs for Cancer Patients by Reversing the Individualâ€™s Disease-Related Signature. Frontiers in Pharmacology, 0, 13, .	1.6	1
2665	MSI colorectal cancer, all you need to know. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101983.	0.7	8
2667	The drug-induced phenotypic landscape of colorectal cancer organoids. Nature Communications, 2022, 13, .	5.8	22
2669	Oncogenic Signalling of PEAK2 Pseudokinase in Colon Cancer. Cancers, 2022, 14, 2981.	1.7	1
2670	Post-polypectomy colonoscopy surveillance: Can we improve the diagnostic yield?. GastroenterologÃa Y HepatologÃa (English Edition), 2022, 45, 474-487.	0.0	0
2671	Adoptive NK Cell Transfer as a Treatment in Colorectal Cancer Patients: Analyses of Tumour Cell Determinants Correlating With Efficacy In Vitro and In Vivo. Frontiers in Immunology, 0, 13, .	2.2	7
2672	Alpha-2 Heremans Schmid Glycoprotein (AHSG) promotes the proliferation of bladder cancer cells by regulating the TGF-Î² signalling pathway. Bioengineered, 2022, 13, 14282-14298.	1.4	7
2673	Microsatellite instability testing in colorectal patients with Lynch syndrome: lessons learned from a case report and how to avoid such pitfalls. Personalized Medicine, 2022, 19, 277-286.	0.8	30
2674	Genes copy number variation in colorectal cancer patients as a marker of the disease clinical outcome and response to therapy. South Russian Journal of Cancer, 2022, 3, 52-64.	0.1	1
2675	<scp>DNA</scp> methylation biomarkers in colorectal cancer: Clinical applications for precision medicine. International Journal of Cancer, 2022, 151, 2068-2081.	2.3	14
2676	Colorectal cancer screening with fecal immunochemical testing: a community-based, cross-sectional study in average-risk individuals in Nigeria. The Lancet Global Health, 2022, 10, e1012-e1022.	2.9	6
2677	Colon cancer organoids using monoclonal organoids established in four different lesions of one cancer patient reveal tumor heterogeneity and different real-time responsiveness to anti-cancer drugs. Biomedicine and Pharmacotherapy, 2022, 152, 113260.	2.5	4
2678	Encorafenib plus cetuximab for the treatment of *BRAF-V600E*-mutated metastatic colorectal cancer. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482211106.	1.4	4

#	Article	IF	Citations
2679	<sup>68</sup>Ga-FAPI-04 PET Distinguishes Malignancy&nbsp;From&nbsp;<sup>18</sup>F-FDG-Avid&nbsp;Colorectal Lesions. SSRN Electronic Journal, 0, , .	0.4	0
2680	Caracterización molecular de pacientes con cáncer colorrectal. Biomedica, 2022, 42, 154-171.	0.3	1
2681	Somatic targeted mutation profiling of colorectal cancer precursor lesions. BMC Medical Genomics, 2022, 15, .	0.7	3
2682	Comprehensive Analysis of microRNA Expression During the Progression of Colorectal Tumors. Digestive Diseases and Sciences, 2023, 68, 813-823.	1.1	1
2683	Synaptotagmin 11 scaffolds MKK7â€"JNK signaling process to promote stem-like molecular subtype gastric cancer oncogenesis. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	7
2684	A Transcription Factor Signature Can Identify the CMS4 Subtype and Stratify the Prognostic Risk of Colorectal Cancer. Frontiers in Oncology, 0, 12, .	1.3	3
2685	ALOX12: A Novel Insight in Bevacizumab Response, Immunotherapy Effect, and Prognosis of Colorectal Cancer. Frontiers in Immunology, 0, 13, .	2.2	1
2686	Circulating and Tumor-Infiltrating Immune Checkpoint-Expressing CD8+ Treg/T Cell Subsets and Their Associations with Disease-Free Survival in Colorectal Cancer Patients. Cancers, 2022, 14, 3194.	1.7	8
2687	Artificial intelligence and machine learning in colorectal cancer. Artificial Intelligence in Gastrointestinal Endoscopy, 2022, 3, 31-43.	0.2	0
2688	Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer. Cancer Treatment Reviews, 2022, 109, 102433.	3.4	15
2689	Fusobacterium nucleatum and Malignant Tumors of the Digestive Tract: A Mechanistic Overview. Bioengineering, 2022, 9, 285.	1.6	2
2690	From Intestinal Epithelial Homeostasis to Colorectal Cancer: Autophagy Regulation in Cellular Stress. Antioxidants, 2022, 11, 1308.	2.2	2
2691	The NOTCH4-GATA4-IRG1 axis as a novel target in early-onset colorectal cancer. Cytokine and Growth Factor Reviews, 2022, 67, 25-34.	3.2	10
2692	Low cholesterol biosynthesis favors epithelialâ€toâ€mesenchymal transition maintenance and influences tumor molecular subtyping and diseaseâ€free survival in colon cancer patients. Cancer Communications, 0, , .	3.7	0
2693	GenomicSuperSignature facilitates interpretation of RNA-seq experiments through robust, efficient comparison to public databases. Nature Communications, 2022, 13, .	5.8	6
2694	An Orthotopic Patient-Derived Xenograft (PDX) Model Allows the Analysis of Metastasis-Associated Features in Colorectal Cancer. Frontiers in Oncology, 0, 12, .	1.3	10
2695	Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer. Nature Genetics, 2022, 54, 963-975.	9.4	106
2696	Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer. Targeted Oncology, 2022, 17, 483-492.	1.7	8

#	Article	IF	Citations
2697	Genomic and transcriptomic analysis of Korean colorectal cancer patients. Genes and Genomics, 2022, 44, 967-979.	0.5	2
2698	WNT signaling and cancer stemness. Essays in Biochemistry, 2022, 66, 319-331.	2.1	28
2699	Mitochondrial <scp>DNA</scp> mutations in ageing and cancer. Molecular Oncology, 2022, 16, 3276-3294.	2.1	18
2700	Computational estimation of quality and clinical relevance of cancer cell lines. Molecular Systems Biology, 2022, 18, .	3.2	12
2701	Natural Products from Actinobacteria as a Potential Source of New Therapies Against Colorectal Cancer: A Review. Frontiers in Pharmacology, 0, 13, .	1.6	12
2702	A RAS-Independent Biomarker Panel to Reliably Predict Response to MEK Inhibition in Colorectal Cancer. Cancers, 2022, 14, 3252.	1.7	1
2703	The emerging era of personalized medicine in advanced colorectal cancer. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 1411-1425.	1.4	6
2704	Cytokineâ€•and chemokineâ€•induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy. Cancer Communications, 2022, 42, 689-715.	3.7	41
2705	KIT promotes tumor stroma formation and counteracts tumor-suppressive TGFÎ² signaling in colorectal cancer. Cell Death and Disease, 2022, 13, .	2.7	4
2706	Identification of Endoplasmic Reticulum Stress-Related Subtypes, Infiltration Analysis of Tumor Microenvironment, and Construction of a Prognostic Model in Colorectal Cancer. Cancers, 2022, 14, 3326.	1.7	2
2707	Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data. Clinical Cancer Research, 2022, 28, 4056-4069.	3.2	14
2708	Impact of frailty on oncological outcomes in patients undergoing surgery for colorectal cancer â€" A systematic review and meta-analysis. Journal of the Royal College of Surgeons of Edinburgh, 2023, 21, 173-180.	0.8	3
2710	MRI data harmonization across sites using ComBat enhances classification of meningioma and glioma brain-tumors in dogs: a case study. F1000Research, 0, 11, 759.	0.8	0
2711	Tumor microenvironment involvement in colorectal cancer progression <i>via</i> Wnt/Î²-catenin pathway: Providing understanding of the complex mechanisms of chemoresistance. World Journal of Gastroenterology, 2022, 28, 3027-3046.	1.4	8
2712	Exploring immunotherapy in colorectal cancer. Journal of Hematology and Oncology, 2022, 15, .	6.9	104
2713	ATF2 loss promotes tumor invasion in colorectal cancer cells via upregulation of cancer driver TROP2. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	12
2714	Digital image analysis provides robust tissue microenvironment-based prognosticators in patients with stage I-IV colorectal cancer. Human Pathology, 2022, 128, 141-151.	1.1	4
2715	Characterization of Immune-Related Molecular Subtypes and a Prognostic Signature Correlating With the Response to Immunotherapy in Patients With Gastric Cancer. Frontiers in Immunology, 0, 13, .	2.2	0

#	ARTICLE	IF	CITATIONS
2716	Dynamic Co-Evolution of Cancer Cells and Cancer-Associated Fibroblasts: Role in Right- and Left-Sided Colon Cancer Progression and Its Clinical Relevance. Biology, 2022, 11, 1014.	1.3	2
2718	Integrated Bioinformatics Analysis of the Hub Genes Involved in Irinotecan Resistance in Colorectal Cancer. Biomedicines, 2022, 10, 1720.	1.4	3
2719	New Genetic Technologies in Diagnosis and Treatment of Cancer of Unknown Primary. Cancers, 2022, 14, 3429.	1.7	5
2720	New insights into the unique nature of colorectal cancer peritoneal metastasesâ€"rethinking HIPEC. British Journal of Cancer, 0, , .	2.9	0
2721	Neogambogic acid suppresses characteristics and growth of colorectal cancer stem cells by inhibition of DLK1 and Wnt/Î²-catenin pathway. European Journal of Pharmacology, 2022, 929, 175112.	1.7	1
2722	Prognostic and predictive molecular biomarkers in advanced colorectal cancer. , 2022, 236, 108239.		17
2723	Capturing the latent space of an Autoencoder for multi-omics integration and cancer subtyping. Computers in Biology and Medicine, 2022, 148, 105832.	3.9	7
2725	Epidemiology and risk factors for metastatic colorectal disease. , 2023, , 1-17.		0
2726	The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis. Pathology and Oncology Research, 0, 28, .	0.9	9
2727	Serial Analysis of Gene Mutations and Gene Expression during First-Line Chemotherapy against Metastatic Colorectal Cancer: Identification of Potentially Actionable Targets within the Multicenter Prospective Biomarker Study REVEAL. Cancers, 2022, 14, 3631.	1.7	3
2728	PU.1-driven Th9 Cells Promote Colorectal Cancer in Experimental Colitis Models Through Il-6 Effects in Intestinal Epithelial Cells. Journal of Crohn's and Colitis, 2022, 16, 1893-1910.	0.6	5
2729	Recent advances in targeting protein kinases and pseudokinases in cancer biology. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	4
2731	LncRNA profiles from Notch signaling: Implications for clinical management and tumor microenvironment of colorectal cancer. Frontiers in Immunology, 0, 13, .	2.2	3
2732	Transcriptomic and Cellular Content Analysis of Colorectal Cancer by Combining Multiple Independent Cohorts. Clinical and Translational Gastroenterology, 2023, 14, e00517.	1.3	3
2733	Patient-derived rectal cancer organoidsâ€"applications in basic and translational cancer research. Frontiers in Oncology, 0, 12, .	1.3	0
2734	Immune checkpoint inhibitors in metastatic colorectal cancer therapy (a review). ZaporoÅ¾skij Medicinskij Å½urnal, 2022, 24, 354-364.	0.0	0
2735	Anatomic location of colorectal cancer presents a new paradigm for its prognosis in African American patients. PLoS ONE, 2022, 17, e0271629.	1.1	4
2736	Regulation of the <scp> <i>THRA</i> </scp> gene, encoding the thyroid hormone nuclear receptor TRÎ±1, in intestinal lesions. Molecular Oncology, 0, , .	2.1	0

#	Article	IF	Citations
2737	Classification of colon adenocarcinoma based on immunological characterizations: Implications for prognosis and immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	4
2738	Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study. BMC Cancer, 2022, 22, .	1.1	3
2739	Metabolic balance in colorectal cancer is maintained by optimal Wnt signaling levels. Molecular Systems Biology, 2022, 18, .	3.2	3
2740	Comprehensive Analysis of Genomic and Expression Data Identified Potential Markers for Predicting Prognosis and Immune Response in CRC. Genetical Research, 2022, 2022, 1-12.	0.3	3
2741	High enhancer activity is an epigenetic feature of HPV negative atypical head and neck squamous cell carcinoma. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	1
2742	Consensus Molecular Subtypes Efficiently Classify Gastric Adenocarcinomas and Predict the Response to Anti-PD-1 Immunotherapy. Cancers, 2022, 14, 3740.	1.7	2
2743	Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene. Cancers, 2022, 14, 3718.	1.7	6
2744	Combinatorial treatment with statins and niclosamide prevents CRC dissemination by unhinging the MACC1-Î²-catenin-S100A4 axis of metastasis. Oncogene, 2022, 41, 4446-4458.	2.6	6
2745	Therapeutic Targeting of Cancer Stem Cells Prevents Resistance of Colorectal Cancer Cells to MEK Inhibition. ACS Pharmacology and Translational Science, 2022, 5, 724-734.	2.5	6
2746	A bioinformatics perspective on molecular classification of diffuse large B-cell lymphoma. Leukemia, 2022, 36, 2177-2179.	3.3	6
2747	Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6. Cancer Research, 2022, 82, 3335-3344.	0.4	14
2748	Singleâ€cell landscape and clinical outcomes of infiltrating B cells in colorectal cancer. Immunology, 2023, 168, 135-151.	2.0	25
2749	RNA editing facilitates the enhanced production of neoantigens during the simultaneous administration of oxaliplatin and radiotherapy in colorectal cancer. Scientific Reports, 2022, 12, .	1.6	2
2750	Cancer Stem Cells in Tumor Microenvironment of Adenocarcinoma of the Stomach, Colon, and Rectum. Cancers, 2022, 14, 3948.	1.7	2
2751	Histopathological Evaluation and Molecular Diagnostic Tests for Peritoneal Metastases with Unknown Primary Siteâ€"a Review. Indian Journal of Surgical Oncology, 0, , .	0.3	0
2752	Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer. Nature Medicine, 2022, 28, 1646-1655.	15.2	42
2753	Thyroid hormone signaling in the intestinal stem cells and their niche. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	2
2754	Guanylyl cyclase C as a diagnostic and therapeutic target in colorectal cancer. Personalized Medicine, 2022, 19, 457-472.	0.8	4

#	Article	IF	Citations
2755	Genome‐wide analysis of colorectal cancer based on gene‐based somatic copy number alterations during neoplastic progression within the same tumor. Cancer Medicine, 0, , .	1.3	1
2756	Molecular Basis of Extramural Vascular Invasion (EMVI) in Colorectal Carcinoma. Annals of Surgical Oncology, 0, , .	0.7	2
2757	Comprehensive exploration of tumor immune microenvironment feature and therapeutic response in colorectal cancer based on a novel immune-related long non-coding RNA prognostic signature. Frontiers in Genetics, 0, 13, .	1.1	0
2758	Hidden epithelial subtypes refine colorectal cancer classification. Nature Reviews Cancer, 2022, 22, 495-495.	12.8	0
2759	A proof of concept for targeting the PrPC - Amyloid Î² peptide interaction in basal prostate cancer and mesenchymal colon cancer. Oncogene, 2022, 41, 4397-4404.	2.6	3
2760	Transposon-activated POU5F1B promotes colorectal cancer growth and metastasis. Nature Communications, 2022, 13, .	5.8	7
2761	Identification of a Five-MiRNA Expression Assay to Aid Colorectal Cancer Diagnosis. Gastrointestinal Disorders, 2022, 4, 190-204.	0.4	1
2762	Utilising Proteomics and Organoid Cultures for Predicting Treatment Response in Colorectal Cancer. , 0, , .		0
2763	Hidden patterns of gene expression provide prognostic insight for colorectal cancer. Cancer Gene Therapy, 2023, 30, 11-21.	2.2	3
2764	WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAFV600E Mutant Metastatic Colorectal Cancer: A Multi-institutional Registry-based Study (BRACELET Study). Clinical Colorectal Cancer, 2022, , .	1.0	0
2765	Contribution of MMP14-expressing cancer-associated fibroblasts in the tumor immune microenvironment to progression of colorectal cancer. Frontiers in Oncology, 0, 12, .	1.3	5
2766	Risk Stratification for Breast Cancer Patient by Simultaneous Learning of Molecular Subtype and Survival Outcome Using Genetic Algorithm-Based Gene Set Selection. Cancers, 2022, 14, 4120.	1.7	0
2767	From Dukes-MAC Staging System to Molecular Classification: Evolving Concepts in Colorectal Cancer. International Journal of Molecular Sciences, 2022, 23, 9455.	1.8	7
2768	The immune phenotypes and different immune escape mechanisms in colorectal cancer. Frontiers in Immunology, 0, 13, .	2.2	5
2769	Tumor Organoid model and Its Pharmacological Applications in Tumorigenesis Prevention. Current Molecular Pharmacology, 2022, 15, .	0.7	3
2770	Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis. Cancers, 2022, 14, 4012.	1.7	10
2771	SHMT2-mediated mitochondrial serine metabolism drives 5-FU resistance by fueling nucleotide biosynthesis. Cell Reports, 2022, 40, 111233.	2.9	31
2772	Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). , 2022, 10, e005332.		18

#	Article	IF	Citations
2773	ETS1 governs pathological tissue-remodeling programs in disease-associated fibroblasts. Nature Immunology, 2022, 23, 1330-1341.	7.0	23
2774	Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement. , 2022, 33, 627-663.		0
2775	Pervasive conditional selection of driver mutations and modular epistasis networks in cancer. Cell Reports, 2022, 40, 111272.	2.9	4
2776	Immune cellular components and signaling pathways in the tumor microenvironment. Seminars in Cancer Biology, 2022, 86, 187-201.	4.3	18
2777	Molecular characterization of colorectal cancer related peritoneal metastatic disease. Nature Communications, 2022, 13, .	5.8	26
2778	Mechanisms and prospects of circular RNAs and their interacting signaling pathways in colorectal cancer. Frontiers in Oncology, 0, 12, .	1.3	5
2780	Fecal biomarkers: Non-invasive diagnosis of colorectal cancer. Frontiers in Oncology, 0, 12, .	1.3	5
2782	Long-term resistance to 5-fluorouracil promotes epithelialâ€"mesenchymal transition, apoptosis evasion, autophagy, and reduced proliferation rate in colon cancer cells. European Journal of Pharmacology, 2022, 933, 175253.	1.7	5
2783	N-glycosylation of CD82 at Asn157 is required for suppressing migration and invasion by reversing EMT via Wnt/Î²-catenin pathway in colon cancer. Biochemical and Biophysical Research Communications, 2022, 629, 121-127.	1.0	9
2784	Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment. European Journal of Cancer, 2022, 175, 136-157.	1.3	76
2785	Cancer Epigenetics. , 2023, , 697-714.		0
2786	A Label Retaining System to Capture Slow-Cycling Cancer Cells. Methods in Molecular Biology, 2022, , 85-92.	0.4	0
2787	Colorectal Cancer Cell Differentiation Trajectory Predicts Patient Immunotherapy Response and Prognosis. Cancer Control, 2022, 29, 107327482211213.	0.7	1
2788	Cancer Biomarkers in the Era of Systems Biology. , 2022, , 51-70.		2
2789	Association between microsatellite instability and tumor response to neoadjuvant chemoradiotherapy for rectal cancer. Annals of Surgical Treatment and Research, 2022, 103, 176.	0.4	3
2790	Cancer-associated fibroblasts as accomplices to confer therapeutic resistance in cancer. Cancer Drug Resistance (Alhambra, Calif), 0, 5, 889-901.	0.9	6
2791	Attention-Based Interpretable Regression ofÂGene Expression inÂHistology. Lecture Notes in Computer Science, 2022, , 44-60.	1.0	3
2792	The seen and the unseen: Molecular classification and image based-analysis of gastrointestinal cancers. Computational and Structural Biotechnology Journal, 2022, 20, 5065-5075.	1.9	0

#	ARTICLE	IF	CITATIONS
2793	*Csf1r* mediates enhancement of intestinal tumorigenesis caused by inactivation of *Mir34a*. International Journal of Biological Sciences, 2022, 18, 5415-5437.	2.6	3
2794	Genetic and epigenetic dependencies in colorectal cancer development. Gastroenterology Report, 2022, 10, .	0.6	19
2795	Complexity and Integration. European Studies in Philosophy of Science, 2022, , 65-88.	0.4	0
2796	Incorporating Intratumoral Heterogeneity intoÂWeakly-Supervised Deep Learning Models viaÂVariance Pooling. Lecture Notes in Computer Science, 2022, , 387-397.	1.0	1
2797	Heterogeneous Tumour Modeling Using PhysiCell andÂIts Implications inÂPrecision Medicine. Emergence, Complexity and Computation, 2022, , 157-189.	0.2	0
2798	Identification of Tissue Types and Gene Mutations From Histopathology Images for Advancing Colorectal Cancer Biology. IEEE Open Journal of Engineering in Medicine and Biology, 2022, 3, 115-123.	1.7	5
2799	Introduction to various types of cancers. , 2022, , 1-29.		2
2800	ä»Žå…¨çƒè¶‹åŠ¿çœ‹æˆ‘å›½ç»"ç´è‚ç™Œé˜²æŽ§ï¼šæŒ'æˆ˜ä¸Žç—ç•¥. Scientia Sinica Vitae, 2022, , .	0.1	0
2801	The RING finger protein family in health and disease. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	31
2802	Impact of classical and basal-like molecular subtypes on overall survival in resected pancreatic cancer in the SPACIOUS-2 multicentre study. British Journal of Surgery, 2022, 109, 1150-1155.	0.1	6
2803	Stage-dependent prognostic shift in mismatch repair-deficient tumors: Assessing patient outcomes in stage II and III colon cancer. Frontiers in Oncology, 0, 12, .	1.3	1
2804	Modeling Colorectal Cancer Progression Reveals Niche-Dependent Clonal Selection. Cancers, 2022, 14, 4260.	1.7	5
2805	Optimal Surgical Indications for Resectable Metastatic Colorectal Cancer with BRAF V600E Mutation. Japanese Journal of Gastroenterological Surgery, 2022, 55, 473-482.	0.0	0
2806	Defining the Immune Checkpoint Landscape in Human Colorectal Cancer Highlights the Relevance of the TIGIT/CD155 Axis for Optimizing Immunotherapy. Cancers, 2022, 14, 4261.	1.7	3
2807	Notch signaling mutations increase intra-tumor chemokine expression and predict response to immunotherapy in colorectal cancer. BMC Cancer, 2022, 22, .	1.1	7
2808	Emerging role of caldesmon in cancer: A potential biomarker for colorectal cancer and other cancers. World Journal of Gastrointestinal Oncology, 2022, 14, 1637-1653.	0.8	5
2809	Crosstalk of Oxidative Phosphorylation-Related Subtypes, Establishment of a Prognostic Signature and Immune Infiltration Characteristics in Colorectal Adenocarcinoma. Cancers, 2022, 14, 4503.	1.7	3
2810	Primary and secondary immune checkpoint inhibitors resistance in colorectal cancer: Key mechanisms and ways to overcome resistance. Cancer Treatment and Research Communications, 2022, 33, 100643.	0.7	3

#	Article	IF	Citations
2811	MAP7D2 reduces CD8+ cytotoxic T lymphocyte infiltration through MYH9-HMGB1 axis in colorectal cancer. Molecular Therapy, 2023, 31, 90-104.	3.7	3
2812	Smoking-induced microbial dysbiosis in health and disease. Clinical Science, 2022, 136, 1371-1387.	1.8	11
2814	Towards precision oncology with patient-derived xenografts. Nature Reviews Clinical Oncology, 2022, 19, 719-732.	12.5	33
2815	Genomic landscape of colorectal carcinoma in sub-Saharan Africa. Journal of Clinical Pathology, 2023, 76, 5-10.	1.0	2
2818	Identification and validation of an inflammation-related lncRNAs signature for improving outcomes of patients in colorectal cancer. Frontiers in Genetics, 0, 13, .	1.1	1
2819	Applications of human organoids in the personalized treatment for digestive diseases. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	7
2820	miR-aculous new avenues for cancer immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	0
2821	Regulation of transforming growth factor-β signaling as a therapeutic approach to treating colorectal cancer. World Journal of Gastroenterology, 2022, 28, 4744-4761.	1.4	6
2822	Advances in the management of peritoneal malignancies. Nature Reviews Clinical Oncology, 2022, 19, 698-718.	12.5	20
2823	Association of Simultaneous vs Delayed Resection of Liver Metastasis With Complications and Survival Among Adults With Colorectal Cancer. JAMA Network Open, 2022, 5, e2231956.	2.8	6
2824	Towards label-efficient automatic diagnosis and analysis: a comprehensive survey of advanced deep learning-based weakly-supervised, semi-supervised and self-supervised techniques in histopathological image analysis. Physics in Medicine and Biology, 2022, 67, 20TR01.	1.6	17
2825	Predicting prognosis and immunotherapy response among colorectal cancer patients based on a tumor immune microenvironment-related lncRNA signature. Frontiers in Genetics, 0, 13, .	1.1	0
2826	Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study. Cancers, 2022, 14, 4346.	1.7	4
2827	GITR Ligation Improves Anti-PD1-Mediated Restoration of Human MMR-Proficient Colorectal Carcinoma Tumor-Derived T Cells. Cellular and Molecular Gastroenterology and Hepatology, 2023, 15, 77-97.	2.3	5
2828	Comprehensive drug response profiling and pan-omic analysis identified therapeutic candidates and prognostic biomarkers for Asian cholangiocarcinoma. IScience, 2022, 25, 105182.	1.9	2
2829	From organoids to bedside: Advances in modeling, decoding and targeting of colorectal cancer. International Journal of Cancer, 2023, 152, 1304-1313.	2.3	4
2831	NSABP FCâ€6: Surgical conversion rate in colorectal cancer patients with unresectable, KRAS wildâ€type liver metastases receiving mFOLFOX7 plus cetuximab. Journal of Surgical Oncology, 0, , .	0.8	0
2832	Immune depletion of the methylated phenotype of colon cancer is closely related to resistance to immune checkpoint inhibitors. Frontiers in Immunology, 0, 13, .	2.2	2

#	Article	IF	Citations
2833	Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis. Cancers, 2022, 14, 4340.	1.7	1
2834	Detection of Experimental Colorectal Peritoneal Metastases by a Novel PDGFRÎ²-Targeting Nanobody. Cancers, 2022, 14, 4348.	1.7	2
2835	Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: A proof-of-concept study. Frontiers in Oncology, 0, 12, .	1.3	10
2837	Patientâ€Derived Organoids from Colorectal Cancer with Paired Liver Metastasis Reveal Tumor Heterogeneity and Predict Response to Chemotherapy. Advanced Science, 2022, 9, .	5.6	41
2838	Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer. World Journal of Gastrointestinal Oncology, 2022, 14, 1654-1664.	0.8	1
2839	Molecular actions of exosomes and their theragnostics in colorectal cancer: current findings and limitations. Cellular Oncology (Dordrecht), 2022, 45, 1043-1052.	2.1	2
2840	Colorectal cancer: Metabolic interactions reshape the tumor microenvironment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188797.	3.3	24
2842	Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals potential therapeutic strategies. Nature Communications, 2022, 13, .	5.8	18
2843	Mismatch repair deficiency in rectal cancer: an evolving scenario. Annals of Translational Medicine, 2022, 10, 951-951.	0.7	0
2844	Removing unwanted variation from large-scale RNA sequencing data with PRPS. Nature Biotechnology, 2023, 41, 82-95.	9.4	20
2845	Neoantigens and their clinical applications in human gastrointestinal cancers. World Journal of Surgical Oncology, 2022, 20, .	0.8	1
2846	Identification of Novel Molecular Subgroups in Esophageal Adenocarcinoma to Predict Response to Neo-Adjuvant Therapies. Cancers, 2022, 14, 4498.	1.7	2
2848	Classification of colorectal cancer based on gene sequencing data with XGBoost model: An application of public health informatics. Cukurova Medical Journal, 2022, 47, 1179-1186.	0.1	0
2849	Cancer-Associated Fibroblasts: The Origin, Biological Characteristics and Role in Cancerâ€"A Glance on Colorectal Cancer. Cancers, 2022, 14, 4394.	1.7	9
2850	Genetic and microenvironmental intra-tumor heterogeneity impacts colorectal cancer evolution and metastatic development. Communications Biology, 2022, 5, .	2.0	13
2851	Targeting the splicing isoforms of spleen tyrosine kinase affects the viability of colorectal cancer cells. PLoS ONE, 2022, 17, e0274390.	1.1	2
2852	A prognostic sixâ€gene expression riskâ€score derived from proteomic profiling of the metastatic colorectal cancer secretome. Journal of Pathology: Clinical Research, 2022, 8, 495-508.	1.3	3
2853	TBX21 Methylation as a Potential Regulator of Immune Suppression in CMS1 Subtype Colorectal Cancer. Cancers, 2022, 14, 4594.	1.7	0

#	Article	IF	Citations
2854	Comprehensive analysis of the prognostic signature and tumor microenvironment infiltration characteristics of cuproptosis-related lncRNAs for patients with colon adenocarcinoma. Frontiers in Oncology, 0, 12, .	1.3	6
2855	Modulation of tumor environment in colorectal cancer – could gut microbiota be a key player?. , 0, 1, .		1
2856	The role of autophagy in colorectal cancer: Impact on pathogenesis and implications in therapy. Frontiers in Medicine, 0, 9, .	1.2	6
2857	The clinical value of C-reactive protein and its association with tumour location in patients undergoing curative surgery for colorectal cancer – a ScotScan collaborative study. Acta Oncológica, 2022, 61, 1248-1255.	0.8	3
2858	The Prognostic Utilities of DNA Mismatch Repair Status and KRAS and BRAF Mutation in Korean Colorectal Cancer Patients: The KASID Multicenter Study. Oncology, 2023, 101, 49-58.	0.9	2
2859	COLONOMICS - integrative omics data of one hundred paired normal-tumoral samples from colon cancer patients. Scientific Data, 2022, 9, .	2.4	3
2860	CINSARC signature outperforms gold-standard TNM staging and consensus molecular subtypes for clinical outcome in stage II–III colorectal carcinoma. Modern Pathology, 2022, 35, 2002-2010.	2.9	4
2862	An Aspirin a Day: New Pharmacological Developments and Cancer Chemoprevention. Annual Review of Pharmacology and Toxicology, 2023, 63, 165-186.	4.2	14
2864	Adjuvant Chemotherapy for Colorectal Cancer in the Era of Genomic Medicine. Nihon Daicho Komonbyo Gakkai Zasshi, 2022, 75, 468-472.	0.1	0
2865	Epigenome-Wide Study Identifies Epigenetic Outliers in Normal Mucosa of Patients with Colorectal Cancer. Cancer Prevention Research, 2022, 15, 755-766.	0.7	1
2866	Molecular analyses of peritoneal metastasis from colorectal cancer. Journal of the Korean Medical Association, 2022, 65, 586-593.	0.1	1
2867	Current Immune Checkpoint Inhibitor Genetic Biomarker Exploration in Gastrointestinal Tumors. Cancers, 2022, 14, 4804.	1.7	0
2868	GPER Agonist G1 Prevents Wnt-Induced JUN Upregulation in HT29 Colorectal Cancer Cells. International Journal of Molecular Sciences, 2022, 23, 12581.	1.8	4
2869	Identification and validation of immunotherapy for four novel clusters of colorectal cancer based on the tumor microenvironment. Frontiers in Immunology, 0, 13, .	2.2	9
2870	Molecular Classification of Colorectal Cancer by microRNA Profiling: Correlation with the Consensus Molecular Subtypes (CMS) and Validation of miR-30b Targets. Cancers, 2022, 14, 5175.	1.7	3
2872	The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice. Frontiers in Oncology, 0, 12, .	1.3	2
2873	Differential Expression in the Tumor Microenvironment of mRNAs Closely Associated with Colorectal Cancer Metastasis. Annals of Surgical Oncology, 0, , .	0.7	0
2874	Molecular Subtypes Based on Cuproptosis-Related Genes and Tumor Microenvironment Infiltration Characterization in Colorectal Cancer. Journal of Oncology, 2022, 2022, 1-19.	0.6	2

#	ARTICLE	IF	CITATIONS
2875	Establishment and evaluation of module-based immune-associated gene signature to predict overall survival in patients of colon adenocarcinoma. Journal of Biomedical Science, 2022, 29, .	2.6	3
2876	Amino acid metabolism-based molecular classification of colon adenocarcinomavia in silico analysis. Frontiers in Immunology, 0, 13, .	2.2	1
2877	Insulin-like growth factor 2 receptor is a key immune-related gene that is correlated with a poor prognosis in patients with triple-negative breast cancer: A bioinformatics analysis. Frontiers in Oncology, 0, 12, .	1.3	2
2878	Phenotypic plasticity and genetic control in colorectal cancer evolution. Nature, 2022, 611, 744-753.	13.7	58
2880	Left-sided colorectal cancer distinct in indigenous African patients compared to other ethnic groups in South Africa. BMC Cancer, 2022, 22, .	1.1	1
2881	Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective. Cancers, 2022, 14, 4828.	1.7	11
2882	Identification of Prognostic Gene Signatures by Developing a scRNA-Seq-Based Integration Approach to Predict Recurrence and Chemotherapy Benefit in Stage IIâ€"III Colorectal Cancer. International Journal of Molecular Sciences, 2022, 23, 12460.	1.8	1
2884	Correlation of Immunological and Histopathological Features with Gene Expression-Based Classifiers in Colon Cancer Patients. International Journal of Molecular Sciences, 2022, 23, 12707.	1.8	0
2885	Decoding the colorectal cancer ecosystem emphasizes the cooperative role of cancer cells, TAMs and CAFsin tumor progression. Journal of Translational Medicine, 2022, 20, .	1.8	2
2886	SMAD4 Loss Induces c-MYCâ€"Mediated NLE1 Upregulation to Support Protein Biosynthesis, Colorectal Cancer Growth, and Metastasis. Cancer Research, 2022, 82, 4604-4623.	0.4	5
2888	Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in <i>KRASG12C</i>-mutant Colorectal Cancer. Molecular Cancer Therapeutics, 2023, 22, 135-149.	1.9	2
2889	Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis. BMC Gastroenterology, 2022, 22, .	0.8	12
2890	Use of Personalized Biomarkers in Metastatic Colorectal Cancer and the Impact of AI. Cancers, 2022, 14, 4834.	1.7	0
2891	Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated <i>SPP1</i>+ Macrophages and Fibroblasts. Clinical Cancer Research, 2023, 29, 244-260.	3.2	30
2892	Endoscopic polypectomy for malignant polyps: Should tumor location (right versus left side) guide clinical decisions?. Surgery, 2023, 173, 674-680.	1.0	0
2894	Personalized targeted therapy prescription in colorectal cancer using algorithmic analysis of RNA sequencing data. BMC Cancer, 2022, 22, .	1.1	5
2895	Characterization of sialylation-related long noncoding RNAs to develop a novel signature for predicting prognosis, immune landscape, and chemotherapy response in colorectal cancer. Frontiers in Immunology, 0, 13, .	2.2	8
2896	Molecular Pathogenesis of Colorectal Cancer: Impact of Oncogenic Targets Regulated by Tumor Suppressive miR-139-3p. International Journal of Molecular Sciences, 2022, 23, 11616.	1.8	8

#	Article	IF	Citations
2897	Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer. PLoS ONE, 2022, 17, e0273566.	1.1	0
2898	A local tumor microenvironment acquired super-enhancer induces an oncogenic driver in colorectal carcinoma. Nature Communications, 2022, 13, .	5.8	9
2899	Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers. Frontiers in Oncology, 0, 12, .	1.3	1
2900	Overview of predictive and prognostic biomarkers and their importance in developing a clinical pharmacology treatment plan in colorectal cancer patients. Expert Review of Clinical Pharmacology, 0, , 1-10.	1.3	0
2901	Prognostic impact of mitofusin 2 expression in colon cancer. Translational Cancer Research, 2022, 11, 3610-3619.	0.4	2
2902	Targeting Asparagine Synthetase in Tumorgenicity Using Patient-Derived Tumor-Initiating Cells. Cells, 2022, 11, 3273.	1.8	4
2903	Emerging target discovery and drug repurposing opportunities in chordoma. Frontiers in Oncology, 0, 12, .	1.3	3
2904	Tumor microenvironment: barrier or opportunity towards effective cancer therapy. Journal of Biomedical Science, 2022, 29, .	2.6	67
2905	Molecular Analyses in Peritoneal Metastasis from Colorectal Cancer: A Review-An English Version. Journal of the Anus, Rectum and Colon, 2022, 6, 197-202.	0.4	3
2907	Loss of primary cilia promotes inflammation and carcinogenesis. EMBO Reports, 2022, 23, .	2.0	6
2908	Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nature Medicine, 2022, 28, 2171-2182.	15.2	131
2910	Loss of bone morphogenetic protein signaling in fibroblasts results in CXCL12-driven serrated polyp development. Journal of Gastroenterology, 2023, 58, 25-43.	2.3	3
2911	Advances in Genomic Profiling of Colorectal Cancer Using Nature-Inspired Computing Techniques. Studies in Computational Intelligence, 2023, , 63-87.	0.7	1
2912	Molecular subtypes of leiomyosarcoma: Moving toward a consensus. Clinical and Translational Discovery, 2022, 2, .	0.2	3
2913	Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications. Journal of Hematology and Oncology, 2022, 15, .	6.9	60
2914	Novel prognostic implications of complement activation in the tumour microenvironment for de novo metastatic BRAF V600E mutant colorectal cancer. British Journal of Cancer, 0, , .	2.9	1
2915	Metabolism and Colorectal Cancer. Annual Review of Pathology: Mechanisms of Disease, 2023, 18, 467-492.	9.6	30
2916	Predictive value of tumor-infiltrating lymphocytes detected by flow cytometry in colorectal cancer. International Immunopharmacology, 2022, 113, 109286.	1.7	2

#	Article	IF	Citations
2917	Advances in immunotherapy for MMR proficient colorectal cancer. Cancer Treatment Reviews, 2022, 111, 102480.	3.4	11
2918	Tumour break load is a biologically relevant feature of genomic instability with prognostic value in colorectal cancer. European Journal of Cancer, 2022, 177, 94-102.	1.3	2
2919	Type I and II interferon signaling in colorectal cancer liver metastasis. Cytokine, 2023, 161, 156075.	1.4	2
2920	The Role of DNA Methylation and DNA Methyltransferases in Cancer. Advances in Experimental Medicine and Biology, 2022, , 317-348.	0.8	7
2921	A largeâ€scale targeted proteomics of plasma extracellular vesicles shows utility for prognosis prediction subtyping in colorectal cancer. Cancer Medicine, 2023, 12, 7616-7626.	1.3	6
2922	Chemokine switch regulated by TGF-Î²1 in cancer-associated fibroblast subsets determines the efficacy of chemo-immunotherapy. OncoImmunology, 2022, 11, .	2.1	7
2923	Developing a taxonomy for colorectal cancer. ELife, 0, 11, .	2.8	0
2924	Expression pattern of secretoryâ€cellâ€related transcriptional signatures in colon adenocarcinomas defines tumor microenvironment characteristics and correlates with clinical outcomes. Molecular Oncology, 2023, 17, 499-517.	2.1	1
2925	Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC. Pharmaceutics, 2022, 14, 2468.	2.0	1
2926	Axin1 Protects Colon Carcinogenesis by an Immune-Mediated Effect. Cellular and Molecular Gastroenterology and Hepatology, 2023, 15, 689-715.	2.3	8
2927	Molecular subtyping of esophageal squamous cell carcinoma by large-scale transcriptional profiling: Characterization, therapeutic targets, and prognostic value. Frontiers in Genetics, 0, 13, .	1.1	1
2928	Gene interaction perturbation network deciphers a high-resolution taxonomy in colorectal cancer. ELife, 0, 11, .	2.8	10
2929	Immune-related keratitis is a rare complication associated with nivolumab treatment in a patient with advanced colorectal cancer: A case report. Frontiers in Oncology, 0, 12, .	1.3	6
2930	Identification of BGN and THBS2 as metastasisâ€specific biomarkers and poor survival key regulators in human colon cancer by integrated analysis. Clinical and Translational Medicine, 2022, 12, .	1.7	11
2931	The Association of R-Loop Binding Proteins Subtypes with CIN Implicates Therapeutic Strategies in Colorectal Cancer. Cancers, 2022, 14, 5607.	1.7	0
2932	Metastatic recurrence in colorectal cancer arises from residual EMP1+ cells. Nature, 2022, 611, 603-613.	13.7	50
2933	Alternative splicing downstream of EMT enhances phenotypic plasticity and malignant behavior in colon cancer. ELife, 0, 11, .	2.8	5
2934	The prognostic value and immunological role of angiogenesis-related patterns in colon adenocarcinoma. Frontiers in Oncology, 0, 12, .	1.3	1

#	Article	IF	Citations
2937	Modulatory Effect of Chlorogenic Acid and Coffee Extracts on Wnt/Î²-Catenin Pathway in Colorectal Cancer Cells. Nutrients, 2022, 14, 4880.	1.7	9
2938	Cancer-Associated Fibroblasts in Inflammation and Antitumor Immunity. Clinical Cancer Research, 2023, 29, 1009-1016.	3.2	22
2939	In vivo phosphorus magnetic resonance spectroscopic imaging of the whole human liver at 7â€‰T using a phosphorus wholeâ€body transmit coil and 16â€channel receive array: Repeatability and effects of principal component analysisâ€based denoising. NMR in Biomedicine, 2023, 36, .	1.6	2
2940	Cancer-Associated Fibroblasts and Their Role in Cancer Progression. , 2022, , .		0
2941	MAST: a hybrid Multi-Agent Spatio-Temporal model of tumor microenvironment informed using a data-driven approach. Bioinformatics Advances, 2022, 2, .	0.9	3
2942	Enhancing Local Context ofÂHistology Features inÂVision Transformers. Lecture Notes in Computer Science, 2022, , 154-163.	1.0	3
2943	Prediction of immunotherapy efficacy and immunomodulatory role of hypoxia in colorectal cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211383.	1.4	4
2944	BST2 induced macrophage M2 polarization to promote the progression of colorectal cancer. International Journal of Biological Sciences, 2023, 19, 331-345.	2.6	12
2946	The landscape of cancer-associated fibroblasts in colorectal cancer liver metastases. Theranostics, 2022, 12, 7624-7639.	4.6	7
2947	Treatment Options in BRAF-mutant Metastatic Colorectal Cancer. Touch Reviews in Oncology & Haematology, 2022, 18, 103.	0.1	0
2948	State-of-the-Art Integration of Multiple Kinase Inhibitors in the Treatment of Gastrointestinal Cancers. European Medical Journal Oncology, 0, , 38-46.	0.0	0
2949	<i>Ex vivo</i> explant model of adenoma and colorectal cancer to explore mechanisms of action and patient response to cancer prevention therapies. Mutagenesis, 2022, 37, 227-237.	1.0	2
2950	Identification of immune subtypes and their prognosis and molecular implications in colorectal cancer. PLoS ONE, 2022, 17, e0278114.	1.1	0
2951	Utilizing Patient-Derived Organoids in the Management of Colorectal Cancer with Peritoneal Metastases: A Review of Current Literature. Journal of Gastrointestinal Cancer, 2023, 54, 712-719.	0.6	3
2952	Predictive biomarkers of colon cancer immunotherapy: Present and future. Frontiers in Immunology, 0, 13, .	2.2	30
2953	TGF-Î² Signaling in Metastatic Colorectal Cancer (mCRC): From Underlying Mechanism to Potential Applications in Clinical Development. International Journal of Molecular Sciences, 2022, 23, 14436.	1.8	13
2954	Biomarkers in the development of individualized treatment regimens for colorectal cancer. Frontiers in Medicine, 0, 9, .	1.2	3
2955	Tumour Colonisation of Parvimonas micra Is Associated with Decreased Survival in Colorectal Cancer Patients. Cancers, 2022, 14, 5937.	1.7	9

#	Article	IF	Citations
2957	Breast Cancer Dataset, Classification and Detection Using Deep Learning. Healthcare (Switzerland), 2022, 10, 2395.	1.0	10
2958	Exploration and validation of a combined immune and metabolism gene signature for prognosis prediction of colorectal cancer. Frontiers in Endocrinology, 0, 13, .	1.5	3
2959	Transcriptomic and immunophenotypic profiling reveals molecular and immunological hallmarks of colorectal cancer tumourigenesis. Gut, 2023, 72, 1326-1339.	6.1	15
2960	Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer. Frontiers in Immunology, 0, 13, .	2.2	1
2961	Mechanisms of colorectal liver metastasis development. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	7
2962	Comprehensive microRNA analysis across genome-edited colorectal cancer organoid models reveals miR-24 as a candidate regulator of cell survival. BMC Genomics, 2022, 23, .	1.2	2
2963	Case report: Complete pathologic response with first-line immunotherapy combination in a young adult with massive liver dissemination of mismatch repair–deficient metastatic colorectal cancer: Immunological and molecular profiling. Frontiers in Oncology, 0, 12, .	1.3	0
2964	The Glasgow Microenvironment Score and risk and site of recurrence in TNM I–III colorectal cancer. British Journal of Cancer, 0, , .	2.9	0
2965	Prognostic significance of p16, p21, and Ki67 expression at the invasive front of colorectal cancers. Pathology International, 0, , .	0.6	0
2967	Consensus molecular subtyping improves the clinical usefulness of canonical tumor markers for colorectal cancer. Biomedical Research, 2022, 43, 201-209.	0.3	2
2968	Patient-derived xenograft model in colorectal cancer basic and translational research. Animal Models and Experimental Medicine, 2023, 6, 26-40.	1.3	4
2969	Transcriptomic and functional analyses reveal a tumour-promoting role for the IL-36 receptor in colon cancer and crosstalk between IL-36 signalling and the IL-17/IL-23 axis. British Journal of Cancer, 2023, 128, 735-747.	2.9	7
2970	Application of machine learning in the prediction of deficient mismatch repair in patients with colorectal cancer based on routine preoperative characterization. Frontiers in Oncology, 0, 12, .	1.3	2
2971	Anti-Programmed Cell Death-1 Antibody and Dasatinib Combination Therapy Exhibits Efficacy in Metastatic Colorectal Cancer Mouse Models. Cancers, 2022, 14, 6146.	1.7	3
2972	Delineating the molecular landscape of different histopathological growth patterns in colorectal cancer liver metastases. Frontiers in Immunology, 0, 13, .	2.2	2
2974	CT-based radiogenomic analysis dissects intratumor heterogeneity and predicts prognosis of colorectal cancer: a multi-institutional retrospective study. Journal of Translational Medicine, 2022, 20, .	1.8	2
2975	Hyaluronan driven by epithelial aPKC deficiency remodels the microenvironment and creates a vulnerability in mesenchymal colorectal cancer. Cancer Cell, 2023, 41, 252-271.e9.	7.7	9
2976	An integrated analysis of the cancer genome atlas data discovers a hierarchical association structure across thirty three cancer types. , 2022, 1, e0000151.		0

#	Article	IF	Citations
2977	CpG Site-Based Signature Predicts Survival of Colorectal Cancer. Biomedicines, 2022, 10, 3163.	1.4	3
2978	SPATA2 and CYLD inhibit T cell infiltration into colorectal cancer via regulation of IFN-Î³/STAT1 axis. Frontiers in Oncology, 0, 12, .	1.3	0
2979	AS-CMC: a pan-cancer database of alternative splicing for molecular classification of cancer. Scientific Reports, 2022, 12, .	1.6	5
2980	ALG8 Fuels Stemness Through Glycosylation of the WNT/Beta-Catenin Signaling Pathway in Colon Cancer. DNA and Cell Biology, 2022, 41, 1075-1083.	0.9	1
2981	VPS9D1-AS1 overexpression amplifies intratumoral TGF-Î² signaling and promotes tumor cell escape from CD8+ T cell killing in colorectal cancer. ELife, 0, 11, .	2.8	10
2982	Epithelial TGFÎ² engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features. Nature Communications, 2022, 13, .	5.8	2
2983	Neuromedin U secreted by colorectal cancer cells promotes a tumour-supporting microenvironment. Cell Communication and Signaling, 2022, 20, .	2.7	2
2985	Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT. Efficacy and Mechanism Evaluation, 2022, 9, 1-92.	0.9	1
2987	Improved Delineation of Colorectal Cancer Molecular Subtypes and Functional Profiles with a 62-Gene Panel. Molecular Cancer Research, 2023, 21, 240-252.	1.5	0
2988	Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab. , 2022, 10, e005660.		6
2989	A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy. International Journal of Molecular Sciences, 2023, 24, 118.	1.8	2
2990	Role of <scp>PCIF1</scp>â€mediated 5â€²â€cap <scp>N6</scp>â€methyladeonsine <scp>mRNA</scp> methylation in colorectal cancer and <scp>antiâ€PD</scp>â€1 immunotherapy. EMBO Journal, 2023, 42, .	3.5	14
2991	An epithelialâ€"mesenchymal transition-related prognostic model for colorectal cancer based on weighted gene co-expression network analysis. Journal of International Medical Research, 2022, 50, 030006052211406.	0.4	0
2993	A new natural killer cell-specific gene signature predicting recurrence in colorectal cancer patients. Frontiers in Immunology, 0, 13, .	2.2	0
2994	Identification of Aging and Young Subtypes for Predicting Colorectal Cancer Prognosis and Immunotherapy Responses. International Journal of Molecular Sciences, 2023, 24, 1516.	1.8	1
2995	An immune, stroma, and epithelialâ€"mesenchymal transitionâ€related signature for predicting recurrence and chemotherapy benefit in stage IIâ€"III colorectal cancer. Cancer Medicine, 2023, 12, 8924-8936.	1.3	2
2996	Transcriptomic Profiling Reveals an Enhancer RNA Signature for Recurrence Prediction in Colorectal Cancer. Genes, 2023, 14, 137.	1.0	0
2998	Oncotherapeutic Strategies in Early Onset Colorectal Cancer. Cancers, 2023, 15, 552.	1.7	4

#	Article	IF	Citations
2999	Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer. Cancers, 2023, 15, 418.	1.7	7
3000	MetaFunc: Taxonomic and Functional Analyses of High Throughput Sequencing for Microbiomes. Gut Microbiome, 0, , 1-41.	0.8	2
3001	DNA methylation-based patterns for early diagnostic prediction and prognostic evaluation in colorectal cancer patients with high tumor mutation burden. Frontiers in Oncology, 0, 12, .	1.3	2
3002	Intimate communications within the tumor microenvironment: stromal factors function as an orchestra. Journal of Biomedical Science, 2023, 30, .	2.6	15
3004	Sertaconazole nitrate targets IDO1 and regulates the MAPK signaling pathway to induce autophagy and apoptosis in CRC cells. European Journal of Pharmacology, 2023, 942, 175515.	1.7	5
3005	Relationship between prognostic impact of N3 lymph node metastasis at the root of the feeding artery and location of colon cancer. Langenbeck's Archives of Surgery, 2023, 408, .	0.8	0
3006	Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 755-767.	1.5	3
3007	Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-Î², in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial. Oncologist, 2023, 28, e124-e127.	1.9	6
3008	Histopathological Growth Pattern in Colorectal Liver Metastasis and The Tumor Immune Microenvironment. Cancers, 2023, 15, 181.	1.7	5
3009	Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer. Cancers, 2023, 15, 183.	1.7	5
3010	BMX, a specific HDAC8 inhibitor, with TMZ for advanced CRC therapy: a novel synergic effect to elicit p53-, Î²-catenin- and MGMT-dependent apoptotic cell death. Cell Communication and Signaling, 2022, 20, .	2.7	3
3011	Artificial intelligence applications in predicting the behavior of gastrointestinal cancers in pathology. Artificial Intelligence in Gastroenterology, 0, 3, 142-162.	0.2	0
3012	The Cytokine Network in Colorectal Cancer: Implications for New Treatment Strategies. Cells, 2023, 12, 138.	1.8	15
3013	Integrative Clinical and DNA Methylation Analyses in a Population-Based Cohort Identifies CDH17 and LRP2 as Risk Recurrence Factors in Stage II Colon Cancer. Cancers, 2023, 15, 158.	1.7	5
3014	Noncanonical Wnt signaling promotes colon tumor growth, chemoresistance and tumor fibroblast activation. EMBO Reports, 2023, 24, .	2.0	7
3016	Seeking therapeutic synergy in BRAF mutant colorectal cancer. Nature Medicine, 0, , .	15.2	4
3017	Big Data in Gastroenterology Research. International Journal of Molecular Sciences, 2023, 24, 2458.	1.8	6
3020	Ferroptosis in colorectal cancer: a future target?. British Journal of Cancer, 2023, 128, 1439-1451.	2.9	12

#	ARTICLE	IF	CITATIONS
3021	Panomics reveals patient individuality as the major driver of colorectal cancer progression. Journal of Translational Medicine, 2023, 21, .	1.8	2
3023	What is precision medicine in oncology?. , 2023, , 1-30.		0
3024	MIMESIS: minimal DNA-methylation signatures to quantify and classify tumor signals in tissue and cell-free DNA samples. Briefings in Bioinformatics, 2023, 24, .	3.2	0
3025	Advances of Wnt Signalling Pathway in Colorectal Cancer. Cells, 2023, 12, 447.	1.8	12
3026	Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. Nature Medicine, 2023, 29, 458-466.	15.2	28
3027	PHB2 promotes colorectal cancer cell proliferation and tumorigenesis through NDUFS1-mediated oxidative phosphorylation. Cell Death and Disease, 2023, 14, .	2.7	10
3029	Transcriptomic Analyses of Pretreatment Tumor Biopsy Samples, Response to Neoadjuvant Chemoradiotherapy, and Survival in Patients With Advanced Rectal Cancer. JAMA Network Open, 2023, 6, e2252140.	2.8	8
3030	Enrichment of oral-derived bacteria in inflamed colorectal tumors and distinct associations of Fusobacterium in the mesenchymal subtype. Cell Reports Medicine, 2023, 4, 100920.	3.3	9
3031	Therapeutic landscape and future direction of metastatic colorectal cancer. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 306-322.	8.2	33
3033	Immunohistochemical Expression Analysis of Caldesmon Isoforms in Colorectal Carcinoma Reveals Interesting Correlations with Tumor Characteristics. International Journal of Molecular Sciences, 2023, 24, 2275.	1.8	5
3034	Aberrant N-glycosylation in cancer: MGAT5 and β1,6-GlcNAc branched N-glycans as critical regulators of tumor development and progression. Cellular Oncology (Dordrecht), 2023, 46, 481-501.	2.1	3
3035	Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma. Cancers, 2023, 15, 863.	1.7	6
3036	MmCMS: mouse models' consensus molecular subtypes of colorectal cancer. British Journal of Cancer, 2023, 128, 1333-1343.	2.9	6
3037	Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer. Frontiers in Oncology, 0, 13, .	1.3	13
3039	A Novel Molecular Analysis Approach in Colorectal Cancer Suggests New Treatment Opportunities. Cancers, 2023, 15, 1104.	1.7	1
3040	Reduced expression of alanyl aminopeptidase is a robust biomarker of non-familial adenomatous polyposis and non-hereditary nonpolyposis colorectal cancer syndrome early-onset colorectal cancer. Cancer Medicine, 2023, 12, 10091-10104.	1.3	3
3041	Determinants of Lymph Node Yield and Involvement in Resectable Colon Cancer: A Study of Anatomical, Pathological, and Fresh, Nonfixed Specimen Dissection. Indian Journal of Surgery, 2023, 85, 1177-1183.	0.2	1
3042	microRNA-627-5p inhibits colorectal cancer cell proliferation, migration and invasion by targeting Wnt2. World Journal of Gastrointestinal Oncology, 0, 15, 318-331.	0.8	1

#	ARTICLE	IF	CITATIONS
3043	Metabolic reprogramming in colorectal cancer: regulatory networks and therapy. Cell and Bioscience, 2023, 13, .	2.1	9
3044	Neoadjuvant Immune Checkpoint Inhibitor Therapy for Patients With Microsatellite Instability-High Colorectal Cancer: Shedding Light on the Future. JCO Oncology Practice, 2023, 19, 251-259.	1.4	5
3045	Identification of a novel Immune-Related prognostic model for patients with colorectal cancer based on 3 subtypes. Immunobiology, 2023, 228, 152352.	0.8	0
3046	Dissected subgroups predict the risk of recurrence of stage II colorectal cancer and select rational treatment. Frontiers in Immunology, 0, 14, .	2.2	2
3047	RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status. Oncogene, 2023, 42, 1649-1660.	2.6	6
3048	PUREE: accurate pan-cancer tumor purity estimation from gene expression data. Communications Biology, 2023, 6, .	2.0	3
3049	Early assessment of circulating exosomal lncRNA-GC1 for monitoring neoadjuvant chemotherapy response in gastric cancer. International Journal of Surgery, 0, Publish Ahead of Print, .	1.1	0
3051	The effects of chemotherapy, primary tumor location and histological subtype on the survival of stage III colon cancer patients. BMC Gastroenterology, 2023, 23, .	0.8	2
3052	Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human *BRAF*V600E-Mutant Colorectal Cancer. Clinical Cancer Research, 2023, 29, 2299-2309.	3.2	3
3053	European expert panel consensus on the clinical management of BRAF-mutant metastatic colorectal cancer. Cancer Treatment Reviews, 2023, 115, 102541.	3.4	3
3054	TGF-Î² signaling pathway: Therapeutic targeting and potential for anti-cancer immunity. European Journal of Pharmacology, 2023, 947, 175678.	1.7	12
3055	Generation of colon cancerâ€"derived tumor-infiltrating T cells (TILs) for adoptive cell therapy. Cytotherapy, 2023, 25, 537-547.	0.3	1
3056	Predicting gene mutation status via artificial intelligence technologies based on multimodal integration (MMI) to advance precision oncology. Seminars in Cancer Biology, 2023, 91, 1-15.	4.3	12
3057	Oncomicrobial Community Profiling Identifies Clinicomolecular and Prognostic Subtypes of Colorectal Cancer. Gastroenterology, 2023, 165, 104-120.	0.6	15
3058	Prognostic Role of Circulating Tumor Cell Trajectories in Metastatic Colorectal Cancer. Cells, 2023, 12, 1172.	1.8	3
3059	Microsatellite Instability: A Review of Molecular Epidemiology and Implications for Immune Checkpoint Inhibitor Therapy. Cancers, 2023, 15, 2288.	1.7	2
3060	Incidence and clinical significance of 491 known fusion genes in a large cohort of Japanese patients with colorectal cancer. International Journal of Clinical Oncology, 0, , .	1.0	0
3061	Implications of Tumor Immune Microenvironment and Molecular Markers for Cancer Immunotherapy. , 2022, , 1-34.		0

#	ARTICLE	IF	CITATIONS
3062	Opportunities on the horizon for the management of early colon cancer. Critical Reviews in Oncology/Hematology, 2023, 183, 103918.	2.0	2
3063	The molecular biology of peritoneal metastatic disease. EMBO Molecular Medicine, 2023, 15, .	3.3	7
3064	A<i>PRRX1</i>Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases. Cancer Research Communications, 2023, 3, 235-244.	0.7	0
3065	Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape. Cancers, 2023, 15, 1022.	1.7	6
3066	Alterations in Natural Killer Cells in Colorectal Cancer Patients with Stroma AReactive Invasion Front Areas (SARIFA). Cancers, 2023, 15, 994.	1.7	7
3067	Targeting Cbl-b in cancer immunotherapy. , 2023, 11, e006007.		14
3068	TET1 and TDG Suppress Inflammatory Response in Intestinal Tumorigenesis: Implications for Colorectal Tumors With the CpG Island Methylator Phenotype. Gastroenterology, 2023, 164, 921-936.e1.	0.6	4
3069	Robust correlation estimation and UMAP assisted topological analysis of omics data for disease subtyping. Computers in Biology and Medicine, 2023, 155, 106640.	3.9	3
3070	Characterization of the immune cell landscape in CRC: Clinical implications of tumour-infiltrating leukocytes in early- and late-stage CRC. Frontiers in Immunology, 0, 13, .	2.2	6
3071	The KRAS-Mutant Consensus Molecular Subtype 3 Reveals an Immunosuppressive Tumor Microenvironment in Colorectal Cancer. Cancers, 2023, 15, 1098.	1.7	8
3072	Targeted O-glycoproteomics for the development of diagnostic markers for advanced colorectal cancer. Frontiers in Oncology, 0, 13, .	1.3	1
3073	Early-Onset Cancer in the Gastrointestinal Tract Is on the Riseâ€"Evidence and Implications. Cancer Discovery, 2023, 13, 538-551.	7.7	24
3074	Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy. Nature Communications, 2023, 14, .	5.8	15
3075	Effects of KMT2D mutation and its exon 39 mutation on the immune microenvironment and drug sensitivity in colorectal adenocarcinoma. Heliyon, 2023, 9, e13629.	1.4	0
3076	Extracellular Vesicles in Colorectal Cancer: From Tumor Growth and Metastasis to Biomarkers and Nanomedications. Cancers, 2023, 15, 1107.	1.7	12
3077	Bulk and singleâ€cell spatial transcriptomic analysis reveals cuproptosisâ€related molecular subtypes characterized by distinct tumour microenvironment infiltrates in colorectal cancer. Clinical and Translational Discovery, 2023, 3, .	0.2	0
3078	Prevalent Pseudoprogression and Pseudoresidue in Patients With Rectal Cancer Treated With Neoadjuvant Immune Checkpoint Inhibitors. Journal of the National Comprehensive Cancer Network: JNCCN, 2023, 21, 133-142.e3.	2.3	5
3079	Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling. Cancer Research Communications, 2023, 3, 404-419.	0.7	1

#	Article	IF	Citations
3081	Development of a Novel Anti-CD44 Variant 6 Monoclonal Antibody C44Mab-9 for Multiple Applications against Colorectal Carcinomas. International Journal of Molecular Sciences, 2023, 24, 4007.	1.8	13
3083	Long non-coding RNA signature in colorectal cancer: research progression and clinical application. Cancer Cell International, 2023, 23, .	1.8	3
3084	Extracellular matrix-based gene signature for predicting prognosis in colon cancer and immune microenvironment. Translational Cancer Research, 2023, 12, 321-339.	0.4	1
3085	Aldolase B attenuates clear cell renal cell carcinoma progression by inhibiting CtBP2. Frontiers of Medicine, 0, , .	1.5	1
3087	Cancer Research in Adenocarcinoma, Adenoma, Adenomatous Polyposis Coli, and Colitis-Associated Neoplasia: A Special Issue. Cancers, 2023, 15, 1328.	1.7	0
3088	Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients. Frontiers in Oncology, 0, 13, .	1.3	0
3089	Mapping Immune Correlates and Surfaceome Genes in BRAF Mutated Colorectal Cancers. Current Oncology, 2023, 30, 2569-2581.	0.9	1
3090	Developing an m5C regulatorâ€"mediated RNA methylation modification signature to predict prognosis and immunotherapy efficacy in rectal cancer. Frontiers in Immunology, 0, 14, .	2.2	0
3091	An integrated multiomics analysis of rectal cancer patients identified <scp>POU2F3</scp> as a putative druggable target and entinostat as a cytotoxic enhancer of 5â€fluorouracil. International Journal of Cancer, 0, , .	2.3	0
3092	Feasibility of [18F]FSPG PET for Early Response Assessment to Combined Blockade of EGFR and Glutamine Metabolism in Wild-Type KRAS Colorectal Cancer. Tomography, 2023, 9, 497-508.	0.8	5
3093	Evaluation of Systemic Treatments of Small Intestinal Adenocarcinomas. JAMA Network Open, 2023, 6, e230631.	2.8	5
3094	Immune Microenvironment in Sporadic Early-Onset versus Average-Onset Colorectal Cancer. Cancers, 2023, 15, 1457.	1.7	1
3095	Efficacy and safety of preoperative immunotherapy in patients with mismatch repair-deficient or microsatellite instability-high gastrointestinal malignancies. World Journal of Gastrointestinal Surgery, 0, 15, 222-233.	0.8	0
3096	RTP4 silencing provokes tumor-intrinsic resistance to immune checkpoint blockade in colorectal cancer. Journal of Gastroenterology, 2023, 58, 540-553.	2.3	1
3097	Mimicking Tumor Cell Heterogeneity of Colorectal Cancer in a Patient-derived Organoid-Fibroblast Model. Cellular and Molecular Gastroenterology and Hepatology, 2023, 15, 1391-1419.	2.3	7
3098	Subtype-specific kinase dependency regulates growth and metastasis of poor-prognosis mesenchymal colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2023, 42, .	3.5	0
3099	Phenotypic subtypes predict outcomes in colorectal cancer. Acta OncolÃ³gica, 2023, 62, 245-252.	0.8	1
3100	Comprehensive analysis of the prognosis, tumor microenvironment, and immunotherapy response of SDHs in colon adenocarcinoma. Frontiers in Immunology, 0, 14, .	2.2	1

#	ARTICLE	IF	CITATIONS
3101	Up-regulated Circular RNAs in Colorectal Cancer: New Entities for Therapy and Tools for Identification of Therapeutic Targets. Cancer Genomics and Proteomics, 2023, 20, 132-153.	1.0	0
3102	Non-steroidal anti-inflammatory drugs and biomarkers: A new paradigm in colorectal cancer. Frontiers in Medicine, 0, 10, .	1.2	3
3103	Fusobacterium nucleatum induces a tumor microenvironment with diminished adaptive immunity against colorectal cancers. Frontiers in Cellular and Infection Microbiology, 0, 13, .	1.8	5
3104	Higher Neutrophil-to-Lymphocyte Ratio (NLR) Is a Preoperative Inflammation Biomarker of Poor Prognosis in HIV-Infected Patients with Colorectal Cancer: A Retrospective Study. Canadian Journal of Gastroenterology and Hepatology, 2023, 2023, 1-14.	0.8	2
3105	Lymphatic Invasion of Plakoglobin-Dependent Tumor Cell Clusters Drives Formation of Polyclonal Lung Metastases in Colon Cancer. Gastroenterology, 2023, 165, 429-444.e15.	0.6	2
3106	B7H4 Expression Is More Frequent in MSS Status Colorectal Cancer and Is Negatively Associated with Tumour Infiltrating Lymphocytes. Cells, 2023, 12, 861.	1.8	4
3107	The role of stromal BMP/CXCL12 signaling axis in serrated polyp development. Journal of Gastroenterology, 2023, 58, 429-430.	2.3	0
3108	Identifying and clinically validating biomarkers for immunotherapy in colorectal cancer. Expert Review of Molecular Diagnostics, 2023, 23, 231-241.	1.5	1
3109	Real�€world treatment and outcomes of patients with metastatic <scp>BRAF</scp> mutant colorectal cancer. Cancer Medicine, 2023, 12, 10473-10484.	1.3	5
3110	Aberrant HMGA2 Expression Sustains Genome Instability That Promotes Metastasis and Therapeutic Resistance in Colorectal Cancer. Cancers, 2023, 15, 1735.	1.7	1
3113	Genetic heterogeneity of colorectal cancer and the microbiome. World Journal of Gastrointestinal Oncology, 0, 15, 443-463.	0.8	1
3114	Integrated multi-omics approach to distinct molecular characterization and classification of early-onset colorectal cancer. Cell Reports Medicine, 2023, 4, 100974.	3.3	5
3115	Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. Annals of Oncology, 2023, 34, 543-552.	0.6	15
3117	The current understanding of the immune landscape relative to radiotherapy across tumor types. Frontiers in Immunology, 0, 14, .	2.2	5
3118	MOPA: An integrative multi-omics pathway analysis method for measuring omics activity. PLoS ONE, 2023, 18, e0278272.	1.1	1
3119	NKG2D Fine-Tunes the Local Inflammatory Response in Colorectal Cancer. Cancers, 2023, 15, 1792.	1.7	1
3120	Optimisation Models for Pathway Activity Inference in Cancer. Cancers, 2023, 15, 1787.	1.7	1
3121	Pipeline for characterizing alternative mechanisms (PCAM) based on bi-clustering to study colorectal cancer heterogeneity. Computational and Structural Biotechnology Journal, 2023, 21, 2160-2171.	1.9	0

#	Article	IF	Citations
3122	Phenotypic Heterogeneity Analysis of APC-Mutant Colon Cancer by Proteomics and Phosphoproteomics Identifies RAI14 as a Key Prognostic Determinant in East Asians and Westerners. Molecular and Cellular Proteomics, 2023, 22, 100532.	2.5	7
3123	Differential CMS-Related Expression of Cell Surface Carbonic Anhydrases IX and XII in Colorectal Cancer Modelsâ€"Implications for Therapy. International Journal of Molecular Sciences, 2023, 24, 5797.	1.8	3
3124	The Gut Microbiome, Microsatellite Status and the Response to Immunotherapy in Colorectal Cancer. International Journal of Molecular Sciences, 2023, 24, 5767.	1.8	4
3125	Identification of immunotherapy and chemotherapy-related molecular subtypes in colon cancer by integrated multi-omics data analysis. Frontiers in Immunology, 0, 14, .	2.2	3
3126	USP10 Regulates ZEB1 Ubiquitination and Protein Stability to Inhibit ZEB1-Mediated Colorectal Cancer Metastasis. Molecular Cancer Research, 2023, 21, 578-590.	1.5	3
3127	Application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer. Frontiers in Endocrinology, 0, 14, .	1.5	4
3128	Subcellular Epithelial HMGB1 Expression Is Associated with Colorectal Neoplastic Progression, Male Sex, Mismatch Repair Protein Expression, Lymph Node Positivity, and an â€˜Immune Coldâ€™ Phenotype Associated with Poor Survival. Cancers, 2023, 15, 1865.	1.7	2
3129	Prioritizing prognostic-associated subpopulations and individualized recurrence risk signatures from single-cell transcriptomes of colorectal cancer. Briefings in Bioinformatics, 2023, 24, .	3.2	2
3130	Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo. PLoS ONE, 2023, 18, e0281063.	1.1	2
3131	The Immune Landscape and Molecular Subtypes of Pediatric Crohnâ€™s Disease: Results from In Silico Analysis. Journal of Personalized Medicine, 2023, 13, 571.	1.1	0
3132	The Role of WNT Pathway Mutations in Cancer Development and an Overview of Therapeutic Options. Cells, 2023, 12, 990.	1.8	6
3133	Exploration of bioactive compounds from <i>Mangifera indica</i> (Mango) as probable inhibitors of thymidylate synthase and nuclear factor kappa-B (NF-Îšb) in colorectal cancer management. ChemistrySelect, 2022, .	0.7	0
3135	An Immune-Related Gene Signature for Determining Tumor Prognosis Based on Machine Learning. , 2023, , 1-18.		0
3136	Immunotherapy in Gastrointestinal Malignancies. , 2023, , 1-23.		0
3137	Targeting HDAC2-Mediated Immune Regulation to Overcome Therapeutic Resistance in Mutant Colorectal Cancer. Cancers, 2023, 15, 1960.	1.7	2
3138	An immunometabolism subtyping system identifies S100A9+ macrophage as an immune therapeutic target in colorectal cancer based on multiomics analysis. Cell Reports Medicine, 2023, 4, 100987.	3.3	5
3141	Application of nanotechnology in reversing therapeutic resistance and controlling metastasis of colorectal cancer. World Journal of Gastroenterology, 0, 29, 1911-1941.	1.4	0
3142	Metabolically Active Zones Involving Fatty Acid Elongation Delineated by DESI-MSI Correlate with Pathological and Prognostic Features of Colorectal Cancer. Metabolites, 2023, 13, 508.	1.3	2

#	Article	IF	Citations
3143	Neuroglobin plays as tumor suppressor by disrupting the stability of GPR35 in colorectal cancer. Clinical Epigenetics, 2023, 15, .	1.8	2
3144	Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinoma. Journal of Experimental and Clinical Cancer Research, 2023, 42, .	3.5	3
3145	<scp>COL19A1</scp> is a predictive biomarker for the responsiveness of esophageal squamous cell carcinoma patients to immune checkpoint therapy. Thoracic Cancer, 2023, 14, 1294-1305.	0.8	2
3146	Metabolic shift underlies tumor progression and immune evasion in Sâ€nitrosoglutathione reductaseâ€deficient cancer. Journal of Pathology, 2023, 260, 261-275.	2.1	1
3147	Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK) Tj ETQq0 0 0 rgBT /Overlock 1		
3148	Fibroblast Activation Protein Inhibitor-PET Imaging in Colorectal Cancer. PET Clinics, 2023, , .	1.5	0
3150	TGFÎ² and the Tumor Microenvironment in Colorectal Cancer. Cells, 2023, 12, 1139.	1.8	1
3151	Identification of the Prognostic Biomarkers CBX6 and CBX7 in Bladder Cancer. Diagnostics, 2023, 13, 1393.	1.3	4
3152	Molecular and Sociodemographic Colorectal Cancer Disparities in Latinos Living in Puerto Rico. Genes, 2023, 14, 894.	1.0	0
3153	Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	35
3154	Accelerating the understanding of cancer biology through the lens of genomics. Cell, 2023, 186, 1755-1771.	13.5	9
3155	Histopathology images predict multi-omics aberrations and prognoses in colorectal cancer patients. Nature Communications, 2023, 14, .	5.8	23
3156	Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases. Cancer Research, 2023, 83, 1329-1344.	0.4	4
3157	Trichostatin A inhibits expression of the human SLC2A5 gene via SNAI1/SNAI2 transcription factors and sensitizes colon cancer cells to platinum compounds. European Journal of Pharmacology, 2023, 949, 175728.	1.7	2
3158	MCâ€KV: A Prognosisâ€Oriented Classifier Based on Semiâ€Supervised Learning for Molecular Subtyping of Colorectal Cancer. Advanced Theory and Simulations, 2023, 6, .	1.3	0
3159	Molecular subtyping in colorectal cancer: A bridge to personalized therapy (Review). Oncology Letters, 2023, 25, .	0.8	3
3160	The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers. Cancers, 2023, 15, 2375.	1.7	5
3161	Information about immune cell proportions and tumor stage improves the prediction of recurrence in patients with colorectal cancer. Patterns, 2023, , 100736.	3.1	0

#	Article	IF	Citations
3162	Single-cell multi-omics sequencing and its application in tumor heterogeneity. Briefings in Functional Genomics, 2023, 22, 313-328.	1.3	2
3163	Targeting Myc-driven stress addiction in colorectal cancer. Drug Resistance Updates, 2023, 69, 100963.	6.5	4
3164	Machine Learning Predicts the Oxidative Stress Subtypes Provide an Innovative Insight into Colorectal Cancer. Oxidative Medicine and Cellular Longevity, 2023, 2023, 1-12.	1.9	1
3165	A Novel Anti-CD44 Variant 9 Monoclonal Antibody C44Mab-1 Was Developed for Immunohistochemical Analyses against Colorectal Cancers. Current Issues in Molecular Biology, 2023, 45, 3658-3673.	1.0	8
3167	Functional Proteomic Profiling Analysis in Four Major Types of Gastrointestinal Cancers. Biomolecules, 2023, 13, 701.	1.8	1
3168	Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy. Cancers, 2023, 15, 2389.	1.7	6
3169	Late-stage MC38 tumours recapitulate features of human colorectal cancer â€" implications for appropriate timepoint selection in preclinical studies. Frontiers in Immunology, 0, 14, .	2.2	0
3200	Iron metabolism in colorectal cancer: a balancing act. Cellular Oncology (Dordrecht), 2023, 46, 1545-1558.	2.1	5
3210	The current status and prospect of immunotherapy in colorectal cancer. Clinical and Translational Oncology, 2024, 26, 39-51.	1.2	4
3237	Molecular pathology of colorectal cancer. Memo - Magazine of European Medical Oncology, 2023, 16, 116-121.	0.3	0
3238	Applications of single-cell RNA sequencing in drug discovery and development. Nature Reviews Drug Discovery, 2023, 22, 496-520.	21.5	31
3266	Epidemiology and Prevention. I-3. Pathologic and Molecular Characteristics of Colorectal Cancer. , 2023, , 233-237.		0
3273	Desorption electrospray ionization mass spectrometry imaging (DESI-MSI) in disease diagnosis: an overview. Analytical Methods, 2023, 15, 3768-3784.	1.3	5
3294	Pathology of Digestive System Malignancies. , 2023, , 259-273.		0
3306	Potential effects of gut microbiota on host cancers: focus on immunity, DNA damage, cellular pathways, and anticancer therapy. ISME Journal, 2023, 17, 1535-1551.	4.4	6
3312	Colorectal cancer heterogeneity and targeted therapy: clinical implications, challenges, and solutions for treatment resistance. , 2023, , 207-221.		0
3344	Metabolic profiling stratifies colorectal cancer and reveals adenosylhomocysteinase as a therapeutic target. Nature Metabolism, 2023, 5, 1303-1318.	5.1	5
3346	Recent Advancements in the Inhibition of Metastasis of Colorectal Cancer Using Anticancer Compounds. , 2023, , 1-32.		0

#	ARTICLE	IF	CITATIONS
3347	The circadian clock circuitry deconvolutes colorectal cancer and lung adenocarcinoma heterogeneity in a dynamic time-related framework. Cancer Gene Therapy, 2023, 30, 1323-1329.	2.2	0
3353	Molecular testing in colorectal cancer. , 2024, , 339-358.		0
3367	Tumor Heterogeneity in Breast Cancer Progression. , 2023, , 1-26.		0
3405	PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies. Cancer Immunology, Immunotherapy, 2023, 72, 3875-3893.	2.0	4
3416	Complete pathologic response after laparoscopic hepatectomy following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high colon cancer liver metastasis consisting of poorly differentiated adenocarcinoma with squamous differentiation: A case report. Clinical Journal of Gastroenterology, 2024, 17, 57-64.	0.4	1
3418	Molecular mechanisms in colitis-associated colorectal cancer. Oncogenesis, 2023, 12, .	2.1	3
3430	Personalizing adjuvant therapy for patients with colorectal cancer. Nature Reviews Clinical Oncology, 2024, 21, 67-79.	12.5	1
3438	Vitamin D and colorectal cancer. , 2024, , 859-899.		0
3452	Histopathologie der Mukosa-FrÃ¼hneoplasien: Morphologische Karzinogenese im GI-Trakt. , 2023, , 29-51.		0
3460	Microbiota-based biomarkers and therapeutics for cancer management. Nature Reviews Gastroenterology and Hepatology, 0, , .	8.2	1
3469	Visualizing and Subtyping Tumor Ecosystem. , 2023, , 609-636.		0
3517	Fighting colorectal cancer and its drug resistance with the resources of the flora of Africa. Advances in Botanical Research, 2024, , .	0.5	0
3533	Omics-based molecular classifications empowering in precision oncology. Cellular Oncology (Dordrecht), 0, , .	2.1	0
3538	Molecular pathological classification of colorectal cancerâ€"an update. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2024, 484, 273-285.	1.4	1
3544	Clusterin: a marker and mediator of chemoresistance in colorectal cancer. Cancer and Metastasis Reviews, 2024, 43, 379-391.	2.7	0